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Abstract 
In plants, the enzyme norcoclaurine synthase (NCS) catalyses the formation of (S)-
norcoclaurine via the Pictet–Spengler condensation of dopamine and 4-
hydroxyphenylacetaldehyde (4-HPAA). (S)-Norcoclaurine is the precursor to all 
benzylisoquinoline alkaloids (BIAs), a diverse group of over 2500 natural products.  
The aim of this project was to elucidate the mechanism of NCS in order to enable the 
rational engineering of NCS activity. Variants of NCS were screened for activities with 
various substrates, forming novel tetrahydroisoquinolines (THIQs). NCS was combined 
with other enzymes in biocatalytic cascades to produce THIQs. 
Initially, an N-terminally truncated NCS from Thalictrum flavum (Δ19TfNCS) was 
expressed. Problems with the purification of Δ19TfNCS led to the use of a different 
truncate, Δ29TfNCS. This enzyme and variants were expressed and purified. The 
effect of mutations on the activity, kinetics and substrate specificity of Δ29TfNCS led to 
the conclusion that NCS operates with a ‘dopamine-first’ mechanism. Computational 
analysis, including molecular dynamics and docking experiments, supported this 
conclusion. Furthermore, rational engineering of substrate specificity was 
demonstrated. 
Next, the biocatalytic potential of NCS was investigated. Biotransformation conditions, 
such as enzyme or lysate loading, were optimised before demonstrative examples of 
milligram scale biotransformations were performed. Then, NCS and a transaminase 
were combined in a one-pot ‘triangular’ biocatalytic cascade to produce chiral BIAs. An 
additional chemical step led to the one-pot formation of chiral 
tetrahydroprotoberberines (berbines). The cascades were demonstrated on a milligram 
preparative scale. 
Methods for screening NCS mutants were examined: various enzyme preparations, 
reaction conditions and reporter systems were tested and evaluated. Subsequently, 
NCS mutants were screened for activities with numerous amines and aldehydes. NCS 
activity was identified with some α-substituted aldehydes and ketones. Selected 
mutants demonstrated an increase in activity compared to wild-type for these unusual 
substrates. Notably, high conversions were revealed for cyclohexanone derivatives. A 
number of resulting cyclohexane-spiro-THIQs were characterised. 
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 Chapter 1: Introduction 1
1.1 Background 
1.1.1 Secondary metabolism and evolution 
Secondary, or specialised, metabolites are chemicals produced by organisms that are 
not required for their immediate survival. Sessile organisms produce large varieties and 
quantities of these chemicals in order to interact with their environment and increase 
organismal fitness.1 In plants, these compounds have varied roles including pest and 
pathogen defense and UV protection.2 These compounds have considerable practical 
applications ranging from medicine to fragrance, but the majority of secondary 
metabolites remain uncharacterised. 
Recently, the notion of classical deterministic metabolic pathways in secondary 
metabolism has given way to an increasing appreciation of a metabolic networks, in 
which promiscuous enzymes catalyse transformations on multiple substrates in order 
to produce a cocktail of metabolites.1 There may be an advantage for sessile 
organisms to producing mixtures of chemicals, especially in situations in which the 
environment is changing. The classical pathways may evolve when particular 
metabolites have a clear evolutionary advantage, and enzymes gain ‘specialising’ 
mutations, reducing promiscuity. 
Enzyme promiscuity is considered crucial for the evolution of secondary metabolic 
pathways. Secondary metabolic pathways often have a ‘signature’ enzyme which has 
been recruited from primary metabolism via gene duplication.2,3 Duplication allows the 
enzyme to drift and gain novel activity (neofunctionalisation) or may enable an existing 
promiscuous activity to increase (subfunctionalisation).4 This signature enzyme defines 
the main structure of a particular secondary metabolite class. Subsequently, tailoring 
enzymes such as cytochrome P450s (CYPs), transferases and dehydrogenases are 
recruited via a similar duplication process; these enzymes form a metabolic network, 
capable of producing a variety of chemicals with potential fitness benefits. Individual 
metabolites providing distinctly beneficial effects will presumably lead to the reduction 
in the network-like character and an increase in pathway character as enzyme 
specificity increases. In a number of cases, these genes become clustered on the 
genome, potentially improving the ability of the organism to regulate the pathway.2 
The chemical innovation possible with evolution is exemplified by plant secondary 
metabolism. Furthermore, secondary metabolism provides numerous examples of 
enzyme evolution and promiscuity. It is possible that the enzymes of secondary 
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metabolism have different properties to typical primary metabolism enzymes—they 
may have evolved to be more promiscuous.3,5 Whilst the chemicals produced by 
secondary metabolism provide a rich resource for medicine and other industries, the 
enzymes found in secondary metabolism can teach us much about molecular evolution 
and chemical innovation.  
1.1.2 Benzylisoquinoline alkaloids (BIAs) 
The benzylisoquinoline alkaloids (BIAs) are a structurally diverse group of nitrogen 
containing secondary metabolites (alkaloids) found in plants.6 These compounds, 
which all contain a benzylisoquinoline moiety, provide defence against pathogens and 
herbivores.7 BIAs are mostly restricted to plants in the order Ranunculales (e.g. 
buttercup, poppy, barberry) and clade magnoliids (e.g. black pepper, magnolia, 
nutmeg), but their biosynthesis evolved monophyletically prior to the emergence of the 
eudicots (Fig. 1.1).7 
 
Fig. 1.1 The evolution of benzylisoquinoline alkaloid biosynthesis. The filled circle shows the 
hypothesised position of benzylisoquinoline alkaloid (BIA) evolution; the crosses show where BIA 
biosynthesis was lost. In orange are clades in which BIA biosynthesis is extant. All capitalised names are 
orders, all other clades are unranked. Basal eudicots are a polyphyletic group. 
There are over 2500 BIAs,8 including a number of molecules with significant and varied 
medicinal properties; examples of these bioactive BIAs include: morphine (analgesic),9 
noscapine (antitussive and anticancer)10 and berberine (anti-microbial)11 The BIAs can 
be separated into over 12 structural subgroups which are defined by C-C and C-O 
bonds added to the basic BIA structure at metabolic branch points.6 One of these 
subgroups is the morphinan alkaloids, which includes morphine and thebaine, and is 
defined by a cytochrome P450 (CYP) catalysed C-C bond formation.12 Other 
subgroups include the aporphine alkaloids, protoberberine alkaloids and the Bis-BIAs 
(Fig. 1.2). Different BIA producing species and strains produce these subgroups in 
varying proportions and purities.13,14  
Chloranthales
magnoliids
Canellales
Laurales
Magnoliales
Piperales
monocots
Ceratophyllales
eudicots
core eudicots
basal eudicots
Ranuncuales
angiosperms
basal angiosperms 
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Fig. 1.2 Benzylisoquinoline alkaloid biosynthesis. The major BIA branch points norcoclaurine, (S)-
reticuline, (R)-reticuline and (S)-scoulerine are depicted. Solid arrows represents single enzyme catalysed 
steps, dotted arrows represent multiple steps. Key enzymes are represented in italics: NCS (norcoclaurine 
synthase
15
), BerSyn (berbamunine synthase
16
), CorSyn (Corytuberine synthase
17
), SalSyn (Salutaridine 
synthase
12
), BBE (berberine bridge enzyme
18
) and REPI (reticuline epimerase
19
, also named STORR (S-
to-R-reticuline
20
) and DRS-DRR (1,2-dihydroreticuline synthase/reductase
21
)). Coloured backgrounds and 
underlined titles represent BIA subgroups. In grey is the general BIA family. BIA subgroups not mentioned: 
protopine, rhoeadine, isopavine, pavine and cularine. The exact branch point(s) for berbamunine and other 
bis-BIAs is not known. 
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1.1.3 The Pictet-Spengler reaction 
All plant BIAs have a common metabolic origin: (S)-norcoclaurine. This compound is 
the precursor to all BIAs; its formation is the first committed step into the BIA pathway. 
(S)-Norcoclaurine is formed via a Pictet-Spengler (PS) reaction between the tyrosine 
derivatives dopamine and 4-hydroxyphenylacetaldehyde (4-HPAA). The  
tetrahydroisoquinoline (THIQ) PS reaction was first observed over a century ago and 
was predicted to be involved in the biosynthesis of BIA natural products.22,23 The PS 
reaction can be seen as a combination of a Mannich reaction and a Friedel-Crafts 
electrophilic aromatic substitution. In an analogous fashion to the Mannich reaction, an 
amine and an aldehyde (or ketone) combine to form an electrophilic iminium cation 
(Schiff base), which is attacked by a nucleophile. As in the Friedel-Crafts reaction, the 
nucleophile is an aromatic group. The iminium electrophile undergoes an 
intramolecular attack from the electron rich aromatic ring system; final rearomatisation 
yields the product (Fig. 1.3).24 The PS reaction results in the formation of a C-N bond, a 
C-C bond and a chiral centre in a single reaction—this increase in molecular 
complexity in one synthetic transformation makes the reaction very useful for 
constructing complex molecules. This utility is shown by the fact that nature appears to 
have independently evolved use of the PS reaction for the formation of secondary 
metabolites in numerous cases (see section 1.7). 
 
Fig. 1.3 Tetrahydroisoquinoline Pictet-Spengler reaction. Electron donating substituents on the 
phenethylamine are possible, including groups to stabilise positive charge on the aromatic ring (e.g. the 3-
OH of the phenethylamine). If an aldehyde (or asymmetric ketone) is used  then the THIQ is chiral at 
position 1. Ketones are possible reactants but are typically less reactive than aldehydes. Mechanistically, a 
spirocyclic intermediate is also possible, but experimentally has been shown to not be involved in most 
cases.  
1.2 The benzylisoquinoline alkaloid Pictet-Spenglerase 
1.2.1 Norlaudanosoline synthase 
It was originally postulated that (S)-norlaudanosoline, not (S)-norcoclaurine, was the 
product of the initial BIA PS reaction.25,26 Feeding studies of radioactive 
norlaudanosoline provided evidence for its role.27 Also, racemic norlaudanosoline 
formation was observed in the spontaneous PS condensation between dopamine and 
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its corresponding aldehyde (3,4-dihydroxyphenylacetaldehyde, 3,4-DHPAA, 
DOPAL).28,29  
The BIA PS enzyme was first isolated from Eschscholzia tenuifolia in the early 1980s, 
and was originally annotated as a norlaudanosoline synthase.25,30 The enzyme, both in 
crude lysate and in its purified form, was shown to catalyse the condensation of 
dopamine with either 4-HPAA, forming norcoclaurine, or 3,4-DHPAA, forming 
norlaudanosoline. These reactions were catalysed with similar efficiency (Fig. 1.4).25,30 
The enzyme did not accept 3,4-dihydroxyphenylpyruvate, a postulated substrate.30 
 
Fig. 1.4 Activities of Pictet-Spenglerase extracted from E. tenuifolia
30
 
Later, radioactive feeding experiments showed that dopamine was not the precursor to 
the benzylic component of BIAs; this discovery led to a revision of the BIA pathway, 
and norcoclaurine was identified as the key intermediate. The hydroxylation of the 
aldehyde at the 3-position of the aromatic ring, was found to occur after the PS 
reaction, once the BIA skeleton had been formed. The natural activity and name of the 
BIA PS enzyme was correctly revised and the enzyme was re-annotated to (S)-
norcoclaurine synthase (NCS).26,31,32 
Despite predating subsequent NCS papers by almost twenty years, this early work on 
NCS (or norlaudanosoline synthase) conducted by Zenk’s group contains valuable 
information. Crucially, they identified that a background chemical reaction produces 
significant quantities of racemic product, and took this into careful consideration when 
purifying and analysing the protein.30 The enzyme was purified from E. tenuifolia plant 
cultures through a series of columns, and emerged as a 15 kDa monomer, with a pI of 
7.6. There was evidence for three other isoenzymes, with pIs of 4.6, 5.3 and 6.7. 
Based on recent work we can speculate that these may have been different N- and C-
terminal truncates. The enzyme was found to be most active at pH 7.4 for 4-HPAA and 
at pH 7.8 for 3,4-DHPAA. Activity dropped off gradually at more acidic pHs, but more 
sharply in basic conditions. Kinetic experiments showed dopamine Km = 1.5 mM, 3,4-
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DHPAA Km = 0.7 mM and 4-HPAA Km = 0.9 mM.
30 No evidence of dimerisation, co-
operation, product inhibition or substrate inhibition was observed.  
1.2.2 Norcoclaurine synthase  
The subsequent studies on NCS were carried out by Facchini and co-workers. In 2001 
Samanani and Facchini presented data from three partially characterised NCSs from 
Papaver somniferum, E. tenuifolia and Thalictrum flavum.33 Enzymes were not purified, 
but extracted from whole plant tissue. The NCSs showed different behaviour to the 
enzyme purified in prior studies. All three enzymes had the highest activity at around 
pH 6.5-7 and 50 °C. Dopamine kinetics were observed as being sigmoidal, suggesting 
cooperativity, whilst 4-HPAA showed typical Michaelis-Menten kinetics with Kms 
between 0.4-1 mM.33 
Next, T. flavum NCS (TfNCS) was purified and characterised further. Similar to Zenk’s 
work, 4 isoenzymes of NCS were identified; although in this instance NCS was 
characterised by SDS-PAGE as a 28 kDa dimer, with monomers of 15 kDa.15 Kinetic 
experiments of this pure protein supported previous data collected with the crude 
extracts;33 both experiments identified cooperativity with respect to dopamine. This 
work also indicated that NCS was inhibited by norlaudanosoline. The mechanistic 
conclusion from these studies was that NCS follows an iso-ordered bi-uni mechanism 
with 4-HPAA binding before dopamine. The difference in the kinetic parameters 
determined by Samamani and Facchini compared to those determined by Zenk and co-
workers may be partially accounted for by the use of different substrate saturating 
concentrations. The former used 280 μM of dopamine and 2 mM 4-HPAA; the latter 
used higher concentrations of approximately 5 mM for both substrates.15,30 
In 2004 the Facchini group isolated the gene encoding NCS from T. flavum. This was 
achieved by constructing primers based on the peptide sequence obtained by analysis 
of the purified plant enzyme, and using a polymerase chain reaction (PCR) to retrieve 
the complementary deoxyribonucleic acid (cDNA).34 The recombinant protein did not 
express in Escherichia coli in its full length form; N-terminal truncations (Δ10 or Δ19) 
were required for successful expression.  The enzyme showed a mass of 
approximately 32 kDa on SDS-PAGE analysis, possibly corresponding to a dimer. 
Kinetic parameters were performed on crude cell extracts and provided similar values 
to those obtained from the native purified enzyme.15 Computational analysis led to the 
identification of a 19 residue N-terminal sequence as a signal peptide for subcellular 
localisation.34 Although only a single NCS gene was isolated from T. flavum, Southern 
blot analysis showed that there are three to five NCS genes in the T. flavum genome. 
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1.3 PR-10 family 
1.3.1 PR-10/Bet v 1 
The gene encoding for TfNCS was found to have substantial homology to the Bet v 1 
allergen and pathogenesis related-10 (PR-10) protein families, found in a variety of 
plant species.34 It has particularly close identity (35%) with the postulated hypericin 
synthase HYP1 from St John’s wort (Hypericum perforatum).35 However, HYP1 activity 
has not been consistently observed and this protein’s function remains unclear.36–38 
NCS shows no homology to the other well characterised Pictet-Spenglerase from 
plants, strictosidine synthase (STR). 
Plant genes that are upregulated in times of stress are referred to as pathogenesis 
related (PR) genes. The PR-10 family share an evolutionarily origin and a structure: the 
Bet v 1 fold (Fig. 1.5).39 The Bet v 1 fold is named after the major birch pollen allergen 
(Bet v 1), which was the first protein of its type to have an elucidated structure.40 The 
Bet v 1 fold is distributed across all domains of life and is thus predicted to have an 
ancient origin in the last universal common ancestor.41 Aside from the plant Bet v 
1/PR10 family, the Bet v 1 superfamily includes families with diverse activities: lipid 
transfer (START family), hydroxylase activity, phosphatidylinositol transfer (PITP 
family), ATPase regulation (AHA1 family) and polyketide cyclase activity.41 Bet v 1 
superfamily members typically have a large, solvent-accessible hydrophobic cavity, 
which is able to bind bulky hydrophobic ligands. The diverse activities of Bet v 1 
superfamily members suggest this scaffold is evolutionarily tractable for the innovation 
of novel functions, including enzyme activities. 
 
Fig. 1.5 Phylogeny of NCS proteins. Schematic describing the superfamily/fold and family relationships 
of the NCS clade. The diagram is illustrative and not comprehensive, as there are at least six other sub-
classes in the PR-10/Bet v 1 family and other families in the Bet v 1 superfamily. 
The PR-10/Bet v 1 family can be split up into eleven subclasses.41 These include the 
classic PR-10s, the major pollen allergens (e.g. Bet v 1), the major latex proteins (MLP) 
and the NCS family.39 Despite fairly low sequence similarities, members of the PR-
10/Bet v 1 family are very similar structurally. They have a seven-stranded β-sheet 
PR10/Bet v 1Bet v 1
START
PITP
AHA1
NCS
Bet v 1
PR10
MLP
Superfamily Family Sub-classes
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which curves around a long C-terminal α-helix. Two small α-helices connect the first N-
terminal β-strand with the rest of the sheet (Fig. 1.6). Variations in the structure are 
typically localised to the α-helices. Compared to the rest of the sequence, the glycine 
rich loop L4 (between β-strands 2 and 3) is extremely well conserved and, despite the 
presence of glycines, the loop is surprisingly rigid in crystal structures.39 The activities 
of these proteins are very diverse, and include RNase, anti-pathogenic, membrane 
binding and ligand binding activities. The Bet v 1 and MLP subclass of PR-10 proteins 
display strongly allergenic properties. This human immune response has led to 
investigations into the epitopes and mechanism of the immune response. Recently an 
epitope from Bet v 1 was grafted onto Δ29TfNCS to enable elucidation of the amino 
acid constituents of the epitope.42 
 
Fig. 1.6 PR-10/Bet v 1 family structure. A. Schematic of Bet v 1 structural topology.
39
 B. Bet v 1 (light 
blue) and TfNCS (light green) structural alignment, with secondary structure elements labelled. Structural 
alignment and figure constructed in Chimera (UCSF). PDB accession codes: Bet v 1
40
, 1bv1; TfNCS
43
, 
2VNE-A.  
1.3.2 The NCS clade 
Sequence homology (using TfNCS) enabled the identification of two NCSs from opium 
poppy (Papaver somniferum), PsNCS1 and PsNCS2.7 These two NCSs have 86% 
identity with each other, and both have approximately 40% identity with the TfNCS 
homologue. These were shown to catalyse the NCS PS reaction. Other closely related 
PR-10 proteins, such as two others from P. somniferum, PsPR10-1 and PsPR10-2, did 
not catalyse the NCS reaction. From this study it was unclear whether active NCSs 
grouped together as a single clade phylogenetically. Further evidence for the NCS 
grouping was obtained through the testing of PR-10 proteins from Persian poppy (P. 
bracteatum) and Mexican prickly poppy (Argemone mexicana).44 The P. bracteatum 
protein (PbNCS) showed NCS activity (as does a closely related PsNCS345), but the A. 
mexicana PR-10 (AmPR10) did not. Phylogenetic analysis shows that the non-NCS 
proteins PsPR10-1, PsPR10-2 and AmPR10 are within the NCS clade but show no 
activity. The most likely explanation for this is that there was a monophyletic origin of 
NCS activity, but non-NCS PR-10 proteins within this clade subsequently lost activity. 
BA
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This is considered more likely than convergent evolution of NCS activity (and BIA 
metabolism) in closely related PR-10 proteins.7  
The Japanese gold thread plant (Coptis japonica) produces large quantities of 
berberine type BIAs. A library of expressed sequences tags from C. japonica was 
screened for NCS activity. Two proteins with NCS activity were identified: CjPR10A 
(later renamed to CjNCS2), and CjNCS1. The former is closely related to TfNCS, with 
62% identity. Interestingly, it was shown to accept 4-hydroxyphenylpyruvate as a 
substrate.46 The CjNCS1 enzyme is not a PR-10 and has homology to 2-oxo-glutarate 
dependent, iron binding enzymes. It was subsequently determined that this enzyme 
does not catalyse the NCS reaction, but perhaps caused increased background 
reaction, providing an explanation for the erroneous annotation.44 CjNCS1 actually has 
close homology with demethylation enzymes involved in BIA biosynthesis, so it is 
possible that the activity observed was a result of an equilibrium shift in the cell 
extracts. 
A further verification of the NCS monophyletic clade was the cloning and expression of 
putative NCS proteins from Arabidopsis thaliana.47 One of these was a PR-10 protein, 
though lacked the crucial NCS catalytic residues. The other four NCSs were 
homologous to CjNCS1. None of these proteins showed NCS activity. Although it is 
debated whether A. thaliana produces complex alkaloids, there remains no evidence 
for the presence of an NCS.48  
The recent progress with plant transcriptomic libraries has led to a significant increase 
in the availability of plant gene sequences.49,50 With these new resources and with the 
increasing fall in sequencing costs, the sequences of more NCSs will now become 
available. 
1.4 NCS structure and mechanism 
For an in depth discussion of structure and mechanism see section 4.1. 
1.4.1 Overall mechanism 
The mechanism of NCS was first investigated by Luk et al by examining the activity of 
the enzyme (Δ19TfNCS) with various substrate analogues.51 These analogues 
included methylated dopamine species: methylation of the 3-hydroxy abolished activity 
but methylation of the 4-hydroxyl did not (Fig. 1.7). This suggested cyclisation occurred 
via a σ-intermediate rather than a spirocyclic intermediate. Kinetic isotope effects 
investigated by the use of deuterated dopamine led to the identification of the reaction 
rate limiting steps. Overall the aromatic electrophilic addition was found to be rate 
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determining, whilst the subsequent rearomatisation step was shown to be partially rate 
determining and irreversible. Along with these mechanism determining experiments, a 
new method for determining kinetic rates was developed using circular-dichroism (CD) 
spectroscopy. The kinetic data obtained mostly supported previous work, though a 
much greater Km for dopamine was observed: around 400 μM compared to previous 
values of 2.5 μM. This discrepancy was likely due to the low ‘saturating’ concentrations 
of substrates in previous work.15,51 
 
Fig. 1.7 Outline of mechanism proposed by Luk et al
51
. (a) iminium ion formation, (b) aromatic 
electrophilic addition (rate determining), (c) rearomatisation (partially rate determining). The 3-hydroxy 
group on the phenethylamine is vital for the reaction progression. 
1.4.2 NMR investigation 
In order to investigate the enzyme mechanism more thoroughly, it was necessary to 
conduct structural studies of NCS. As a small protein (~20 kDa), NCS was thought to 
be amenable to nuclear magnetic resonance spectroscopy (NMR) analysis. Thus the 
first of the structural studies was an NMR study, conducted by Rosch and co-workers. 
Their initial attempts at recombinant expression of Δ19TfNCS led to the identification of 
2 isoforms of NCS present during purification. One of these was the expected 
Δ19TfNCS product, whilst the other was identified as a truncate: 10 N-terminal 
residues of Δ19TfNCS were being removed during the expression/purification process, 
forming Δ29TfNCS. A Δ29TfNCS construct was directly expressed to avoid this 
problem.52 This behaviour, upon purification, has not been reported by other groups 
who have expressed Δ19TfNCS.43,51,53 The expression of Δ29TfNCS is biologically 
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justified as the N-terminal extension is not part of the globular structure of the enzyme 
and it is likely to be part of a signal peptide, which may be cleaved in vivo. For a more 
in depth discussion of the N-terminal extension of NCS, see section 3.6. 
A homology model of Δ29TfNCS was built based on the Bet v 1 structure and data 
from the NCS NMR measurements.54 Aside from this model, the NMR study contained 
numerous valuable observations. Unlike observations from native NCS or Δ19TfNCS, 
Δ29TfNCS was shown to be monomeric in solution at concentrations of up to 1 mM. 
Monitoring chemical shifts during the titration of dopamine and a 4-HPAA substrate 
analogue (methyl 4-hydroxyphenylacetate) enabled the identification of substrate 
binding sites. Titration of the 4-HPAA substrate analogue led to significant shifts across 
the entire protein, pointing to a conformational change being triggered upon 4-HPAA 
binding.54 Titration of dopamine caused a change in shifts in two regions: around 
residues 97-100 and residues 178-183; though these residues were also affected by 
non-specific binding of a phenylalanine control. It was observed that dopamine did not 
bind to the protein after the 4-HPAA analogue was bound. This was at odds with 
previous indications from kinetic investigations that 4-HPAA bound to the enzyme prior 
to dopamine.34,51 The NMR data raised many questions about the enzyme mechanism, 
but the use of a 4-HPAA substrate analogue in place of the natural substrate 
undermined the significance of some of the results.  
1.4.3 X-ray structure and mechanism 
The X-ray structure of Δ19TfNCS was solved in 2008, in both its apo form and a holo 
form with two ligands. As predicted through sequence analysis and the NMR homology 
model, the protein has a Bet v 1 type fold, characteristic of plant phytohormone carriers 
(see section 1.3).43,55 Potentially important functional residues in the mostly 
hydrophobic active site were identified: Tyr-108, Glu-110, Lys-122 and Asp-141 (Fig. 
1.8). The holo structure contained both dopamine and an aldehyde analogue, 4-
hydroxybenzaldehyde (4-HBA), bound in the active site. 4-HBA was bound deep in the 
active site, the carbonyl group closely associated with Lys-122 (Fig. 1.8B). The 
dopamine was bound closer to the active site entrance. This supported a mechanism 
where the aldehyde binds to the enzyme prior to dopamine, a scheme originally 
proposed by the Facchini group based upon kinetic analyses.15,51 
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Fig. 1.8 Δ19TfNCS holo structure.
43
 A. Cartoon representation of NCS monomer. B. NCS active site (α3-
helix removed). Sticks show active site residues with predicted catalytic role. 4-HBA (4-
hydroxybenzaldehyde) and dopamine are ligands soaked into crystals. PDB accession number: 2VQ5 
subunit B. 
The observed binding modes of the ligands in the NCS active site led to the 
development of a mechanistic scheme (Fig. 1.9).56 Although the mechanism could 
account for substrate binding, imine formation and the final rearomatisation step, it 
failed to provide a basic residue to abstract the 3-hydroxy proton from dopamine, a 
step that was previously shown to be partially rate determining.51 The authors invoked 
the use of water as a base and Tyr-108 as a stabilising factor; but water is insufficiently 
basic to achieve this deprotonation, and no residue was proposed to interact with water 
to increase its basicity and enable a ‘domino’ deprotonation. In the next reaction step, 
the proposed Tyr-108 interaction does not seem to provide thermodynamic stabilisation 
to the intermediate quinolinone. The importance of Lys-122 was verified by the 
absence of activity in a K122A mutant. The mutations E110A and Y108F showed a fall 
in the kcat (turnover number) of the enzyme, and an increase in Kms (Michaelis 
constants), though the actual effect on the mechanism remained unclear. Both the 
kinetic experiments and the crystal structure of NCS provided no evidence of the 
cooperativity predicted in previous studies of NCS. Limitations of using these X-ray 
crystal structures as a basis of the enzyme mechanism derive from two features of the 
study. First, the protein was crystallised under acidic conditions (pH 4.5), conditions at 
which the enzyme is typically inactive. Second, 4-HBA has very different electronic 
properties to the natural substrate, 4-HPAA, and may interact with active site in a 
different fashion. For a more detailed discussion of the mechanism and crystal 
structure, see section 4.1. 
Tyr-108
Glu-110
Asp-141
Lys-122
4-HBA
Dopamine
A B
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Fig. 1.9 NCS mechanism proposed based on X-ray studies.
43,56
 (1) The aldehyde carbonyl is activated 
by Lys-122. Dopamine attacks the carbonyl and proton exchange with Lys-122 lead to the formation of the 
iminium ion (2). (3) Stabilised by Tyr-108, the electrophilic aromatic substitution occurs. (4) Glu-110 
removes the proton causing rearomatisation and product formation. 
1.4.4 Revision of mechanism 
Whilst structurally diverse aldehydes are accepted by NCS, the majority of 
modifications of the amine substrate are not tolerated.53,57 This behaviour seems at 
odds with the Ilari et al mechanism where the aldehyde is deeply buried in the active 
site, and the indispensable 3-hydroxy group of the dopamine is solvent exposed.43,56 In 
order to understand the binding modes and mechanism further, Pesnot et al conducted 
computational docking experiments.57 Reaction intermediates were docked into the 
active site of the Δ19TfNCS crystal structure and these revealed a binding mode where 
the dopamine portion of the intermediate is buried in the active site, whilst the aldehyde 
R-group is partially solvent exposed. Such a binding mode could account for the 
different substrate promiscuities of the enzyme towards the two substrates. A novel 
mechanism was elucidated based on the binding mode observed from the docking 
calculations (Fig. 1.10).57 For a full discussion and exploration of docking and 
mechanism see section 4. 
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Fig. 1.10 ‘Dopamine first’ mechanism.
57
 The two key steps of the novel mechanism are shown. LHS: 
electrophilic alkylation, catalysed by abstraction of the 3-hydroxy by Lys-122. RHS: rearomatisation of the 
quinolone intermediate, catalysed by Glu-110. Dotted lines show hydrophobic interactions. 
1.5 NCS biocatalysis and substrate scope 
1.5.1 Hypochlorite biocatalysis 
The tetrahydroisoquinoline (THIQ) moiety is feature of many bioactive natural products 
and synthetic drugs. A facile, stereoselective synthesis of THIQs would be of significant 
use to the fine chemical and pharmaceutical industries. The only gram scale synthesis 
using NCS was conducted with the natural substrates dopamine and 4-HPAA, using 
purified Δ19TfNCS as the catalyst.58 The method involved the oxidative 
decarboxylation of tyrosine by sodium hypochlorite to form 4-HPAA (Fig. 1.11). Upon 
completion of this reaction, dopamine, NCS and ascorbate were added to the reaction 
mixture. The in situ synthesis of 4-HPAA prevented the need to isolate and purify the 
aldehyde—it is a reactive compound, prone to oxidation and thus difficult to purify. The 
ascorbate prevented the autoxidation of dopamine, allowing concentrations to reach 10 
mM. The use of activated carbon for extraction enabled the separation of unreacted 
dopamine and 4-HPAA from the norcoclaurine product, precluding extensive 
purification. The conversion was achieved with an enantiomeric excess (ee) of 93% 
and yield of 81%. Although the reaction was conducted in phosphate buffer, known to 
catalyse the racemic condensation of dopamine and 4-HPAA,59 the enzyme acted at 
greater rate than the background reaction, allowing a route to (S)-norcoclaurine as the 
major enantiomer. A similar hypochlorite procedure was used to generate halogenated 
aldehydes in situ and these were successfully turned over (with dopamine) by 
Δ19TfNCS.60 
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Fig. 1.11 Mechanism of aldehyde formation from amino acids by hypochlorite.  
 
1.5.2 Substrate diversity  
The catalytic versatility of NCS was first demonstrated in two papers published in 2012. 
One of these papers, by the group of O’Connor, was a screen of Δ19TfNCS with a 
number of different aldehydes.53 A high-pressure liquid chromatography (HPLC) assay 
detecting a reduction in dopamine concentration was used, and product formation was 
confirmed by mass spectrometry (MS) analysis and verified standards, however, ees 
were not determined. Many different substituted phenylacetaldehyde substrates were 
turned over by the enzyme (Fig. 1.12). A number of aliphatic acetaldehydes were also 
accepted, though α-substituted aldehydes were not. Perhaps the most significant result 
of the study was the tolerance of the enzyme for 1-napthylacetaldehyde, a large 
substrate. This is notable because the mechanism proposed based on the X-ray 
structure would require both the 1-naphthyl acetaldehyde and dopamine bound in the 
active site simultaneously, which seems unlikely considering the comparative sizes of 
the active site and the substrates.43,53 
The substrate promiscuity of NCS was explored by Pesnot et al. using CjNCS2.57 
Reactions were screened using a novel fluorescamine based assay, which enabled the 
rapid monitoring of dopamine consumption. Results from amine screens confirmed the 
importance of the 3-hydroxy group, although some substitutions on the ethyl portion of 
the amine were tolerated.51 For the aldehyde substrate it was shown that, in a similar 
fashion to Δ19TfNCS, substitutions on the aromatic group were mostly tolerated by the 
enzyme; α-substituted aldehydes were not. The long chain aliphatic aldehyde heptanal 
was also shown to be turned over by the enzyme, a substrate very different to the 
natural substrate 4-HPAA (Fig. 1.12). Furthermore, the conversion of dopamine and 
hydrocinnamaldehyde by NCS to form 1-phenethyl-THIQ indicates that NCS or a 
homologue may be involved in the biosynthesis of phenethyl-THIQ alkaloids such as 
colchicine and dysoxyline.61 
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Fig. 1.12 Substrate tolerance of NCS. Various aldehydes accepted by CjNCS2
57
 and Δ19TfNCS
53
. 
Aromatic acetaldehydes were mostly accepted. Notable aldehydes accepted here included the large indole 
and naphthyl ring systems, as well as a number of aliphatic groups. For CjNCS2, conversions were 
measured by tracking consumption of dopamine with a fluorescamine assay. Conversions measured with 
loss of fluorescence: high = >80%, medium = 40-80%, trace = 10-25%, no conversions = <10%. For 
Δ19TfNCS conversions were measured by tracking consumption of dopamine with HPLC  
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The in-depth study of the substrate tolerance of CjNCS2 also included 4 representative 
milligram scale biotransformations.57 The reactions involved the incubation of 
substrates with CjNCS2 in HEPES buffer (4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid). Product isolation was achieved by preparative-HPLC. Three of the 
reactions involved the use of unnatural substrates. The products were fully 
characterised by NMR and Mosher’s acid analysis, proving for the first time the 
absolute (S)-stereochemistry of the NCS product. Exceptional ees were accounted for 
by the use of HEPES  buffer rather than phosphate buffer. 
1.6 Synthetic biology approaches towards BIAs 
Whole cell conversions are a particularly attractive method for industrial 
biotransformations. Fermentative multistep chemical conversions can be achieved 
through the expression of multiple biocatalytic enzymes, often a biosynthetic pathway, 
in a single micro-organism. The development of these sophisticated biocatalysts is a 
major goal of synthetic biology; achievements thus far include the fermentative 
production of biofuels62 and drug precursors63. The BIA pathway has attracted some 
interest within this field: the pathway is diverse and modular, many enzymes are 
characterised and the products have biomedical interest. Most notably the pathway 
includes morphine, which is an iconic target for synthetic efforts due to its historical 
significance, structural intricacy and continued medical importance. 
1.6.1 Approaches without NCS 
A number of synthetic biology approaches to BIAs use a BIA feedstock, rather than 
having the BIA structure made in situ by NCS. 
The Smolke group used the yeast Saccharomyces cerevisiae as a host, and focussed 
their initial efforts on the pathways downstream of the formation of the THIQ skeleton 
by NCS. In one example rac-norlaudanosine was administered to a transgenic yeast 
and conversion to reticuline, sanguinarine and berberine precursors was 
demonstrated.64 Co-expression of CYP2D6, a cytochrome P450 from human liver with 
broad substrate tolerance, was proposed to convert reticuline to salutaridine, the first 
morphinan alkaloid and a precursor to morphine. Although the enzyme seemed to 
accept reticuline as a substrate and catalysed the formation of a new C-C bond, the 
product was not fully characterised and was likely to be a mixture of numerous 
cyclisation products. Some subsequent work from the group focussed on developing 
yeast strains for the tailoring of thebaine, a morphinan alkaloid, into various natural and 
semi-synthetic morphinan alkaloids.65 
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The biosynthetic pathway from norcoclaurine to dihydrosanguinarine, a 
benzophenanthridine alkaloid, was successfully incorporated into S. cerevisiae first by 
Facchini, Martin and co-workers,66 and later by Smolke and co-workers.67 In both 
studies norlaudanosoline was used as a racemic feedstock. At the time of the former 
study, it was thought that the three enzymes converting norcoclaurine/ 
norlaudanosoline to reticuline were not enantioselective and therefore would produce 
racemic (R,S)-reticuline. With this expectation in mind, the formation of morphine in 
yeast was attempted using a metabolic short-cut in which the key intermediate (R)-
reticuline would be produced directly from (R)-norlaudanosoline. This contrasts with the 
plant biosynthetic pathway where (R)-reticuline is formed from (S)-reticuline via an 
epimerisation. However, in the investigation, the formation of (R)-reticuline from rac-
norlaudanosoline was not observed, and the three reticuline forming enzymes were 
revealed to be enantioselective, specific only to (S)-isomers.68 This attempt to form 
morphine via a metabolic short-cut was not altogether unsuccessful, however, given 
that it resulted in the formation of codeine from (R)-reticuline.68 Notably, this was the 
first verified demonstration of the CYP catalysed morphinan C-C bond forming step in 
yeast. 
This metabolic short-cut was attempted as the plant enzyme(s) converting (S)-reticuline 
to (R)-reticuline had yet to be discovered. This missing enzyme, the final unknown step 
in the morphine biosynthesis pathway, was reported in 2015 in three separate 
publications by independent research groups.19–21 Accordingly, the enzyme was given 
three different names: STORR (S-to-R-reticuline),20 REPI (reticuline epimerase)19 and 
DRS-DRR (1,2-dihydroreticuline synthase/reductase).21 The enzyme is a fusion protein 
between a CYP, which oxidises (S)-reticuline to 1,2-dihydroreticuline, and a reductase, 
which stereoselectively reduces 1,2-dihydroreticuline to (R)-reticuline. It has already 
been incorporated successfully into transgenic yeast capable of the de novo production 
of morphinan alkaloids (see below, section 1.6.2).21 
1.6.2 Approaches using NCS 
The NCS catalysed PS step is the entry point to the BIA pathway. It is the key branch 
point between primary and BIA secondary metabolism. In plants, this step is controlled 
by cellular and subcellular localisation, and probably involves substrate channelling.69 
There is also a very high rate of spontaneous PS condensation between dopamine and 
aldehydes; this has been observed on many occasions23,28,70,71 and is probably due 
primarily to the presence of phosphate in cells and tissues.59 These factors have 
created some difficulties in generating microbial in vivo NCS activity. 
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The initial work in incorporating NCS into microbial systems was conducted by Sato 
and co-workers. They initially utilised E. coli as a host, and first attempted to 
incorporate a pathway beginning with dopamine. The biosynthesis of 4-HPAA from 
tyrosine was not fully characterised, so an alternative was constructed: 3,4-DHPAA 
was formed from dopamine by the action of a microbial monoamine oxidase (MAO), 
and this aldehyde was used in the Pictet-Spengler reaction instead of 4-HPAA, in a two 
enzyme one substrate ‘triangular’ scheme (Fig. 1.13, see also section 5.4). The 
formation of racemic norlaudanosoline from dopamine and MAO had been observed 
previously.29,70 Furthermore, the use of norlaudanosoline rather than norcoclaurine is a 
feature of some synthetic biology approaches to BIA formation (probably due to its 
cost) and is reminiscent of the original annotation of norlaudanosoline as the product of 
NCS.25,30 In the initial E. coli work, non-enzymatic condensation in vivo between 
dopamine and 3,4-DHPAA led to the production of racemic reticuline.72 However, in 
vitro the same enzymes were shown to produce (S)-reticuline specifically. The rationale 
for this is that the environment of the cell is rich is in phosphate, which catalysed the 
non-enzymatic Pictet-Spengler reaction.59 Upon lysis and dilution, the enzyme activity 
was observed above the background reaction. 
 
Fig. 1.13 Two enzyme, one substrate ‘triangular’ synthetic scheme. Monoamine oxidase converted a 
portion of dopamine to 3,4-DHPAA before cyclisation of dopamine and 3,4-DHPAA by NCS to form (S)-
norlaudanosoline. Subsequent enzymatic steps led to the production of reticuline. 
An extension to this work incorporated dopamine biosynthesis into the E. coli system, 
creating a system where (S)-reticuline was formed from glucose.73 Interestingly, when 
the NCS enzyme was omitted from the system entirely, there was no effect on the in 
vivo production of (S)-reticuline. The explanation for this is that there is a high rate of 
chemical PS condensation, forming rac-norlaudanosoline in relatively large quantities. 
The enzymes downstream of NCS are enantioselective and thus form the single (S)-
reticuline isomer. Although it is unclear why in the previous study this enzyme 
enantioselectivity was not observed,72 the finding is in accordance with the later 
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observation that (R)-reticuline cannot be formed from rac-norlaudanosoline with the 
same enzymes.68 Further optimisation of this system suggested that NCS expression 
levels were important for the (S)-reticuline yield, but the studies failed to fully verify that 
NCS was active in vivo.74,75 Using a stepwise fermentation method, with one strain 
producing dopamine from glucose and a second strain expressing MAO, a system for 
producing rac-norlaudanosoline was developed; here the NCS was omitted completely 
and racemic products were formed.71 
In 2015 the first fully verified case of in vivo NCS activity in microbes was 
demonstrated.45 Dueber, Martin and co-workers constructed a S. cerevisiae strain able 
to produce (S)-reticuline from glucose, with NCS catalysing the key PS step. They used 
the plant biosynthetic pathway, with (S)-norcoclaurine as the intermediate. Although the 
production of (S)-reticuline from glucose was achieved previously in E. coli,73 there was 
no verification that NCS was active. In this S. cerevisiae system, NCS stereoselective 
activity was verified through chiral HPLC and by the fact that without NCS (or other 
downstream enzymes) no norcoclaurine was detected (despite the presence of 
dopamine and 4-HPAA). The NCS used in this system was a newly detected PsNCS3, 
which is very similar in sequence to PbNCS (90% identity).44 Interestingly the (S)-
norcoclaurine concentration was 228-fold lower than the dopamine concentration, 
suggesting that the NCS catalysed step is very inefficient. 
In a similar project conducted by Smolke and co-workers in which (S)-reticuline was 
produced from glucose in S. cerevisiae, the NCS enzymes CjNCS, TfNCS and PsNCS 
were shown to have in vivo activity.76 It was proposed that low concentrations of 
dopamine present reduced the background reaction. Activity was verified by comparing 
production with strains lacking the NCS enzyme. The variant TfNCS had very low 
activity, only approximately 5 times greater than the background. The variants PsNCS 
and CjNCS had higher activity, with over 13-fold and 15-fold greater production of 
norcoclaurine than the background respectively.76 This glucose to (S)-reticuline 
pathway was combined with the newly discovered DRS-DRR enzyme and downstream 
morphinan related enzymes to form a yeast strain capable of producing opioids in a 
fermentative fashion.21 This was a milestone for synthetic biology and a significant step 
forward to the fermentative production of morphine. All the enzymes needed to achieve 
this are known and show activity in yeast. However, low titres of pathway intermediates 
and low enzyme conversions, especially in the final steps of the pathway, remain 
challenges that must be overcome before the microbial production of morphine can be 
finally achieved.21,65 
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1.7 Other Pictet-Spenglerases 
There are over five known Pictet-Spenglerase enzymes, including NCS, and all 
contribute to secondary metabolism. The PS reaction is irreversible, causes a 
significant increase in molecular complexity and does not require any co-factors.. 
These factors have contributed towards its repeated evolution in secondary 
metabolism. There are also a number of secondary metabolite pathways with 
postulated PS reactions where an enzyme has not been identified. 
 
1.7.1 Strictosidine synthase 
The best characterised Pictet-Spenglerase, other than NCS, is strictosidine synthase 
(STR; EC 4.3.3.2), which catalyses the formation of 3-α-(S)-strictosidine from 
tryptamine and secologanin.77 The activities of at least three different STRs have been 
verified.78 The reaction it catalyses is the first committed step into the monoterpene 
indole alkaloids, a structurally diverse group of alkaloids that includes quinine, 
strychnine and vinblastine (Fig. 1.14). The reaction mechanism is different to NCS: no 
base is required to trigger the Friedel-Crafts step.79 For more analysis of the STR 
reaction mechanism, see section 4.1.1. Modulation of STR activity has been achieved 
by mutations based upon the understanding of the binding modes of the substrates,80 
and by circular permutation.81 The enzyme has also been found to turn over a variety of 
substrates, including an unusual substrate enabling the formation of a piperazino-
indole structure (Fig. 1.14B).82,83 
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Fig. 1.14 A. Examples of monoterpene-indole alkaloids. B. Reaction catalysed by STR. STR 
catalyses the first committed step into the monoterpene indole alkaloids. In the dashed box is the unusual 
piperazino-indole structure also formed by this enzyme. 
 
1.7.2 Fungal Pictet-Spenglerase 
A remarkable study found that a fungi (Chaetomium globsum), which resides in the 
Calico grouper fish (Epinephelus drummondhayi) gut, generated a diverse range of 
indole alkaloids via a PS reaction.84 The typically “silent” fungal Pictet-Spenglerase 
(FPS) gene was switched on with the addition of 1-methyl-L-trytophan (1-MT). The 1-
MT then acted as a substrate for the FPS, combining in situ with the fungal dialdehyde 
flavipin. The enzyme products were then extensively modified by fungal enzymes, 
thereby triggering the formation of a gamut of “unnatural natural products” (Fig. 1.15). 
The Pictet-Spenglerase in question was annotated as STR-like; alignment between this 
FPS and Rauvolfia serpentina Strictosidine synthase showed 33% similarity. The 
automated annotation of the FPS places it within the SGL subgroup of the N6P 
superfamily. The Strictosidine Synthase-like (SSL) enzymes are found in a different 
subgroup. Phylogenetic evaluation of the N6P superfamily suggested only SSL 
enzymes have PS activity,78 yet this study of FPS suggests that the PS STR-like 
activity may actually be more widely spread than previously considered. 
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Fig. 1.15 Observed products of fungal Pictet-Spenglerase and tailoring enzymes. 
 
1.7.3 Ipecacuanha alkaloids 
The Ipecacuanha alkaloid (tetrahydroisoquinoline-monoterpene alkaloid) structure 
consists of the arylethylamine from the BIAs, dopamine, and the aldehyde from the 
indole alkaloids, secologanin. The reaction catalysed is more similar to the NCS 
reaction than the STR reaction, because it is the arylethylamine substrate that plays 
the larger role in the reaction mechanistically. Two Pictet-Spenglerase enzymes were 
identified from cell-free extracts of Alangium lamarckii: deacetylipecoside synthase 
(DIS, EC 4.3.3.4) and deacetylisoipecoside synthase (DIIS, EC 4.3.3.3). Both use 
dopamine and secologanin to make (1R)-deacetylipecoside and (1S)-
deacetylisopecoside respectively, which spontaneously convert to demethyalangiside 
and demethyisoalaniside (Fig. 1.16).85 DIS was purified from A. lamarckii and was 
shown to be a 30 kDa monomer with an optimum activity at pH 7.5 and 45 °C. It 
exhibited a high substrate specificity to dopamine; Kms for dopamine and secologanin 
were 0.7 mM and 0.9 mM respectively.86 The enzyme was inhibited by a number of 
Ipecacuanha alkaloids. Although only compared to STR at the time, DIS has properties 
more comparable to NCS. In order to evaluate the similarity of these enzymes the 
sequence of DIS must be elucidated. The fact that NCS can turn over a wide variety of 
aldehydes means that, until the DIS or DIIS enzyme sequences are determined, it 
remains possible that this PS reaction can be catalysed by an NCS type enzyme. 
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Incidentally, the ipecacuanha alkaloid pathway gives rise to the only known BIA that is 
not derived via the typical BIA pathway (Fig. 1.16). The compound bharatamine, a 
racemic protoberberine, is formed through the oxidation and reorganisation of the 
secologanin portion of deacetyl(iso)ipecoside.87 
 
Fig. 1.16 Pictet-Spengler reaction catalysed by DIS and DIIS. The enzymes catalyse the first committed 
steps into the Ipecacuanha alkaloids. The compound bharatamine superficially appears to be from the BIA 
protoberberine biosynthesis pathway but is in fact an ipecacuanha alkaloid. 
1.7.4 THIQ antitumour antibiotics 
Tetrahydroisoquinoline (THIQ) antibiotics such as saframycin share a key structural 
motif with many plant alkaloids, but are derived from non-ribosomal peptides (NRPs). A 
key structural distinction between plant derived THIQs and the NRP derived THIQs, 
isolated from bacteria and invertebrates, is that the latter have an ortho-hydroxyl or 
ketone (position 8) and an absence of a meta-hydroxyl (position 6) (Fig. 1.17). The 
Pictet-Spenglerase domain responsible for this ortho-cyclisation has been partially 
characterised; it was isolated from Streptomyces lavendulae.88 The Saframycin C non-
ribosomal peptide synthetase (SfmC) condensation domain has been shown to have 
Pictet-Spenglerase activity, catalysing the condensation of an enzyme bound tyrosine-
like arylethylamine with an aldehyde containing a long hydrophobic chain (Fig. 1.17). 
The regioselectivity of the cyclisation is an ortho-cyclisation, in contrast to the NCS 
para-cyclisation. This enzyme was also shown to be able to catalyse pyrrolidine 
formation via a Mannich-type reaction.89 
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Fig. 1.17 Action of SfmC. SfmC catalyses an ortho directed Pictet-Spengler condensation in the 
biosynthesis of tetrahydroisoquinoline antibiotics in Streptomyces. Saframycin undergoes two iterative 
Pictet-Spengler condensations, the second being spontaneous. SfmC can also catalyse the formation of 
pyrrolidines. 
 
1.7.5 β-Carboline 
The β-carboline alkaloids are distributed throughout nature; they are found in higher 
plants, fungi, actinomycetes and marine sponges. The β-carboline Pictet-Spenglerase 
McbB was obtained from the actinomycete Marinaactinospora thermotolerans.90 
Carbon-13 labelling of substrates led to the identification of oxaloacetaldehyde as the 
aldehyde substrate, which is derived from oxaloacetic acid, found in the citric acid 
cycle. The arylethylamine was found to be the amino acid tryptophan (Fig. 1.18). 
Mutagenesis of Glu-97 in McbB knocked out activity completely, suggesting it has a 
key mechanistic role in the enzyme. It is likely that it acts a base, catalysing the 
rearomatisation and formation of the product. Although the enzyme has a similar 
mechanism to STR, it is structurally and evolutionarily distinct.91 Originally, the variety 
of products observed indicated that McbB may have decarboxylase and oxidase 
activity, as well as the characterised Pictet-Spenglerase activity, but these steps have 
been found to be spontaneous and non-enzymatic. Furthermore, rational site directed 
mutagenesis of McbB has increased its capacity to accept bulky aldehydes.91 
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Fig. 1.18 Pictet-Spengler reaction for the formation of β-carboline alkaloids. The reactions here are 
catalysed by McbB. McbB has Pictet-Spengler activity; decarboxylation and oxidation occur 
spontaneously, which leads to the formation of a variety of products, including 1-acetyl-β-carboline, shown 
here. 
1.8 Chemical and biocatalytic routes to THIQs 
The THIQ moiety is a privileged scaffold in organic chemistry as it is found in numerous 
natural and artificial bioactive molecules.92 Accordingly, there have been numerous 
chemical and biocatalytic methods developed for the synthesis of these compounds.  
 
1.8.1 Chemical THIQ formation 
There are many chemical methods for the synthesis of THIQs. The two key reactions 
for the formation of THIQs are the Pictet-Spengler reaction and the Bischler-Napieralski 
reaction. The Bischler-Napieralski reaction forms a cyclic imine (dihydroisoquinoline) 
from an amide intermediate and typically uses POCl3 as a dehydrating agent. The 
imine can then be reduced to yield the THIQ (Fig. 1.19). Traditionally the Bischler-
Napieralski reaction was considered to use milder reaction conditions than the PS 
reaction, in which high temperatures and acid conditions were required. This prevented 
the use of unstable amines and aldehydes in the PS reaction. 
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Fig. 1.19 Bischler-Napieralski reaction. Reaction mechanism with POCl3. Optional reduction step yields 
THIQs. Other dehydrating agents can be used in place of POCl3, such as PCl5, SOCl2 and ZnCl2. 
In 2010 Stambuli and co-workers established calcium hexafluoroisopropoxide as a PS 
catalyst for the formation of THIQs.93 This catalyst was able to catalyse the conversion 
of unactivated ketones as well as aldehydes. Subsequently a biomimetic PS reaction 
using phosphate buffer was discovered by the groups of Hailes and Ward.59 This mild, 
water based synthesis is applicable to a wide range of substrates. The major product of 
this phosphate reaction is the para-product, with the ortho-product present in small 
quantities.94 The key requirement of both these PS THIQ reactions is that the 
arylethylamine has a 3-hydroxy group (or amine). This substrate requirement is 
therefore similar to the NCS reaction, and the reaction mechanisms may be 
comparable. 
A further development of the phosphate catalysed PS reaction was the establishment 
of an organocatalytic reaction using BINOL derived chiral phosphate ligands.95 The use 
of a hydrophobic chiral phosphate meant that the reactions had to be conducted in 
toluene, not water. The ligands only provided modest stereoselectivity compared to 
enzymes, the maximum ee being 86%. Crystallisation was used to further improve the 
product ees. 
1.8.2 Monoamine oxidase 
There are a number of synthetic biocatalytic routes to chiral BIAs and THIQs that do 
not involve a Pictet-Spenglerase enzyme, however all require the formation of a 
racemic THIQ or a 1,2-dihydroisoquinoline prior to the enzyme catalysed step.96 A 
deracemisation cascade developed by the Turner group used monoamine oxidase 
(MAO) and a mild reducing agent to form a chiral amine starting from either a racemate 
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or an imine. Enantioselective MAOs can be used catalyse the oxidation of a specific 
amine enantiomer to an imine using molecular oxygen. The imine produced can be 
reduced back to the amine (by a mild borane reducing agent) and over a number of 
redox cycles there will be a considerable enrichment of a single amine enantiomer. An 
evolved variant of MAO from Aspergillus niger, MAO-N-5, was used to deracemise the 
THIQ crispine A, providing an ee of 97%.97 Another MAO variant, D11, was used for 
the deracemisation of a number of N-methylated BIAs (Fig. 1.20).98 
 
Fig. 1.20 MAO deracemisation method. Preparative scale deracemisation of rac-BIAs to (S)-BIAs. MAO-
N can oxidise (R)-BIA but not (S)-BIA. With non-chiral reduction but enantiospecific oxidation, the 
population of (S)-BIA becomes enriched. The starting material is the racemic THIQ. 
 
1.8.3 Berberine bridge enzyme 
The berberine bridge enzyme (BBE) is a flavin dependent enzyme that catalyses the 
establishment of a C-C bond in the BIAs between an N-methyl group and the benzyl 
group.18 It forms the protoberberine subgroup of the BIAs, which includes the 
compounds scoulerine, berberine and palmatine. The enzyme is enantioselective, so 
will only turn-over the (S)-isomer of a racemic N-methylated BIAs. This means that it 
can perform kinetic resolution if a racemate is used, and the maximum yield of the 
reaction can only be 50%. BBE has been used for the biocatalytic formation of 
protoberberine alkaloids (Fig. 1.21).99–101 The use of some fluorinated substrates has 
been reported to result in a change in the enzyme regioselectivity.102 Combination of 
the MAO deracemisation cascade (section 1.8.2) with the BBE enzyme enables 
conversions to reach 100%.103 
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Fig. 1.21 Berberine bridge enzyme activity. A representative substrate of BBE. Catalase is typically 
used to break down hydrogen peroxide co-product. Only the (S)-enantiomer is turned over by the enzyme 
so maximum yield from a racemic BIA is 50%, unless a deracemisation step is incorporated (e.g. MAO). 
 
1.8.4 Imine reductases 
Recently, a new enzyme class has shown great potential in the biocatalytic formation of 
chiral alkaloids.104 Imine reductases (IRED) catalyse the stereoselective reduction of 
imines to amines with NADPH. They have been found with complementary 
stereoselectivity,105 thereby enabling the formation of both enantiomers from the same 
starting material. Some IREDs have been shown to be able to form THIQs,106 although 
accurately predicting the stereoselectivity with novel substrates is currently not possible 
(Fig. 1.22). IREDs have advantages over the MAO system as a single enzyme is 
required rather than a coupled reducing agent and enzyme, though co-factor recycling 
is still required. However, for MAO, BBE and IRED methods the main structure of the 
molecule must be constructed prior to the biocatalytic step. Pictet-Spenglerases by 
comparison have the advantage that the key bond forming steps are enzymatic. 
 
Fig. 1.22 Observed activity of an IRED. These enzymes show potential for the synthesis of chiral THIQs. 
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1.9 Aims 
The overall aim of the project was to explore the biocatalytic utility of NCS.  
1.9.1 Initial state of the project 
At the beginning of this project, Dr Thomas Pesnot (Hailes group) and Dr Markus 
Gershater (Ward Group) were working on the chemical and enzymatic THIQ PS 
reaction. Dr Pesnot was primarily focussed on the chemical aspects of the reaction, 
while Dr Gershater was generating and testing different NCSs. The phosphate 
catalysed THIQ PS reaction had recently been discovered, and was being used to 
synthesise a variety of THIQs.59 The biomimetic chemical syntheses of THIQs was 
later continued by Dr Eleanor Lamming. The THIQ products produced were 
investigated for antimicrobial activity.94 
A number of synthetic genes for different NCSs had been obtained. Good activity was 
observed with CjNCS2, and the enzyme’s substrate scope was subsequently 
examined.57 In order to rapidly screen NCS activities with numerous compounds, a 
novel fluorescamine-based assay was developed. This end-point assay measured 
consumption of dopamine by NCS and led to the observation that numerous aldehydes 
are accepted by CjNCS2 (see section 1.5.2). This substrate scope could not be 
rationalised with the enzyme mechanism derived by the X-ray crystal structure,58 and 
consequently substrate docking was used to propose a novel ‘dopamine-first’ 
mechanism (see section 1.4.4). Less progress had been made with the TfNCS protein, 
but activity had been tentatively verified. Around the same time of the investigation into 
the CjNCS2 substrate scope, the TfNCS substrate scope was investigated by the 
O’Connor group and shown to be similar (see section 1.5.2).53 
1.9.2 Enzyme mechanism 
The first aim of the project was to use mutations to verify the enzyme mechanism. 
There are two proposed mechanisms for NCS, and it was hoped the activity of certain 
mutations would discriminate between the two mechanisms and reveal which was the 
most accurate. The enzyme TfNCS would be used for this investigation, because a 
crystal structure was available and therefore mutations could be selected in a 
deterministic manner. Furthermore, the X-ray structure of TfNCS formed the basis of 
both mechanisms (through the holo structure and computational docking) and therefore 
this was the ideal NCS to examine the enzyme mechanism.  
Two types of mutations were proposed. Mechanistic mutations would probe residues 
involved in the enzyme mechanism: the residues Tyr-108, Glu-110, Lys-122 and Asp-
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141 would be targeted. The second set of mutations would target residues more 
involved in aldehyde substrate binding. This latter set of mutations could potentially 
distinguish between the two mechanisms as the proposed aldehyde binding residues 
are very different in each mechanism. These mutants would be tested with a variety of 
aldehydes to identify how different mutations affect the activity with different aldehydes. 
Selected mutations and substrates would then be investigated more thoroughly, using 
enzyme kinetics experiments. The change in kcat or Km revealed in kinetics could 
provide insight into the origin of activity changes. For mutations at aldehyde binding 
sites, it was expected that the Km for the aldehyde would change, but the Km for 
dopamine would remain mostly unchanged.  
1.9.3 Enzyme engineering 
In the process of understanding the enzyme mechanism via mutations, it was hoped 
that a number of variants with modified substrate specificities could be identified. 
Furthermore, verification of the enzyme mechanism would allow the undertaking of a 
considerable enzyme engineering effort. This enzyme engineering would begin with 
rational site-directed mutagenesis with the aim of modifying substrate 
specificity/tolerance. 
The target for novel activities would initially be the modification and expansion of the 
aldehyde substrate scope. A range of aldehydes are already known to be accepted by 
NCS and expansion and improvement of these activities is achievable (see section 
1.5.2).53,57 The α-substituted, aliphatic and bulky aldehydes would be of particular 
interest. Subsequent effort would focus on the NCS amine tolerance, though this would 
likely to be more challenging as few amines are accepted. Key compounds to target 
would be substituted phenethylamines, including 3-aminophenethylamines and N/O 
methylated amines, and more diverse compounds such as phenylpropylamines 
(forming 7-membered ring products) and even phenethylalcohols (forming 
isochromans) (Fig. 1.23). More extreme modifications such as switching regioselectivity 
or stereoselectivity may also be considered. 
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Fig. 1.23 Target amine substrates for enzyme engineering. Dopamine is the natural substrate. 3,4-
dihyroxyphenylethanol is not an amine, but replaces an amine in the NCS reaction scheme. 
Initially mutations would be rationally designed based on the mechanism and effected 
by site-directed mutagenesis. Depending on the project progression, saturation 
mutagenesis and more sophisticated direct evolution methods may be used.107–111 The 
screening method would vary depending on the library size. Individual mutants can be 
purified and screened with fluorescamine detection. Hits can be verified with HPLC. For 
larger libraries purification may be inconvenient, and the fluorescamine assay may be 
inappropriate if protein purity and concentration cannot be controlled. In this instance, 
different screening methods may need to be developed and used.  
Finally, once interesting mutants and substrates have been identified, preparative scale 
biotransformations will be performed. Novel products will be purified and characterised 
via typical chemistry analytic techniques such as NMR spectroscopy and mass 
spectrometry. The compounds may also be investigated for antibiotic activity, either in-
house or by collaborators. 
1.9.4 Multi-enzyme cascades 
Depending on progress, it may be possible to combine NCS with other enzymes or 
chemicals to develop in vitro cascade reactions. These will generate chiral THIQs of 
interest. The nature of these cascades will depend greatly on the enzymes available. 
Enzymes will be combined with NCS in order to generate substrates (e.g. dopamine 
and aldehydes) or to modify THIQ reaction products. The Hailes and Ward labs have 
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considerable experience with transaminases and transketolases and these would 
especially be targeted for use in multi-enzyme cascades. The use of alcohol 
dehydrogenases and CYPs will also be considered (see section 5.4). 
Finally, the use of NCS in vivo could be investigated. If successful, enzymes could be 
incorporated into in vivo pathways to mimic the natural plant biosynthesis pathway in E. 
coli. The use of different enzymes may enable novel biosynthesis pathways to be 
developed for the generation of novel chiral THIQs. 
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 Chapter 2: Materials and methods 2
2.1 Genes and primers 
2.1.1 Δ19TfNCS 
A plasmid containing the C-terminal hexahistidine tagged (His-tag) gene of Δ19TfNCS 
was prepared by Dr Markus Gershater. Originally, synthesised genes were inserted 
into the pET29a(+) vector by restriction and subsequent ligation using the restriction 
enzymes NdeI and HindIII (Fig. 2.1).* 
CATATGCAAAAACTCATTCTCACAGGTCGGCCCTTTCTCCACCACCAAGGGATAAT
AAACCAAGTATCTACGGTCACGAAAGTAATTCATCATGAGCTGGAAGTTGCAGCAT
CAGCAGATGATATATGGACCGTTTATTCGTGGCCGGGGCTGGCTAAGCATCTGCC
GGACCTGCTCCCGGGGGCATTTGAAAAGTTGGAAATCATTGGTGATGGCGGTGTT
GGTACGATCCTTGACATGACGTTTGTACCGGGTGAATTTCCGCATGAATACAAGG
AGAAGTTTATATTAGTCGATAATGAGCATAGATTAAAGAAGGTACAGATGATTGAG
GGCGGTTATCTCGACCTGGGCGTAACGTACTACATGGACACGATCCATGTTGTTC
CGACCGGTAAAGATTCATGTGTTATTAAATCGTCAACCGAGTACCATGTAAAACCG
GAGTTTGTCAAAATCGTTGAACCGCTGATCACGACGGGTCCGTTAGCAGCTATGG
CAGACGCTATCTCAAAACTGGTTCTTGAACACAAATCGAAATCGAACTCAGATGAA
ATTGAGGCTGCAATAATAACGGTCCATCATCACCACCATCACTGATAGGAAGCTT 
 
Fig. 2.1 Δ19TfNCS (s6), pQR1024. DNA sense strand 5`-3`. Bold text shows start and stop codons. Italics 
shows restriction endonuclease recognition sites NdeI and HindIII used for cloning. Underlined is the 3’/C-
terminal His-tag.* 
All Δ19TfNCS mutants were constructed using QuikChange® Lightening mutagenesis 
kit (Agilent, Santa Clara, CA, USA) and mutagenesis primers (purchased from 
Eurofins, Luxembourg) (Table 2.1). Standard QuikChange® Lightening recommended 
parameters and conditions were used for primer design and experimental conditions. 
All plasmid sequences were verified by Sanger sequencing provided at the UCL 
Wolfson Institute for Biomedical Research. 
  
                                               
* The cloning of Δ19TfNCS was conducted by Dr Markus Gershater 
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Table 2.1 Primer sequences for Δ19TfNCS (s6) mutations. Nucleotide sequences numbered from start 
of NdeI site.  
Amino acid 
variant 
DNA mutation Primer sequences (5` to 3`) 
L76A c175g, t176c tctgccggacctggccccgggggcattt 
aaatgcccccggggccaggtccggcaga 
A79F g184t, c185t, a186t gccggacctgctcccggggttttttgaaaagttggaaatcat 
atgatttccaacttttcaaaaaaccccgggagcaggtccggc 
A79I g184a, c185t, 
a186t 
gccggacctgctcccggggatttttgaaaagttggaaatcat 
atgatttccaacttttcaaaaatccccgggagcaggtccggc 
F80L t187c, t189g gacctgctcccgggggcactggaaaagttggaaatcattg 
caatgatttccaacttttccagtgcccccgggagcaggtc 
M97F a238t, g240c gttggtacgatccttgacttcacgtttgtaccgggtgaa 
ttcacccggtacaaacgtgaagtcaaggatcgtaccaac 
M97L a238c tggtacgatccttgacctgacgtttgtaccggg 
cccggtacaaacgtcaggtcaaggatcgtacca 
F99L t244c, t246g acgatccttgacatgacgctggtaccgggtgaatttccg 
cggaaattcacccggtaccagcgtcatgtcaaggatcgt 
Y108F a272t ataaacttctccttgaattcatgcggaaattcacccgg 
ccgggtgaatttccgcatgaattcaaggagaagtttat 
E110D g279c tcattatcgactaatataaacttgtccttgtattcatgcggaaattc 
gaatttccgcatgaatacaaggacaagtttatattagtcgataatga 
E110Q g277c attatcgactaatataaacttctgcttgtattcatgcggaaattcac 
gtgaatttccgcatgaatacaagcagaagtttatattagtcgataat 
D141E c372g acatggatcgtctccatgtagtacgttacgccc 
gggcgtaacgtactacatggagacgatccatgt 
D141N g370a gaacaacatggatcgtgttcatgtagtacgttacgcc 
ggcgtaacgtactacatgaacacgatccatgttgttc 
A182F g493t, c494t cgacgggtccgttagcatttatggcagacgctatct 
agatagcgtctgccataaatgctaacggacccgtcg 
A182I g493a, c494t cgacgggtccgttagcaattatggcagacgctatct 
agatagcgtctgccataattgctaacggacccgtcg 
M183F a496t, g498t tgagatagcgtctgcaaaagctgctaacggacccg 
cgggtccgttagcagcttttgcagacgctatctca 
M183L a496c gcgtctgccagagctgctaacggacccgt 
acgggtccgttagcagctctggcagacgc 
F80Aa t187g, t188c tttccaacttttcagctgcccccgggagcaggtcc 
ggacctgctcccgggggcagctgaaaagttggaaa 
F80Ha t187g gatttccaacttttcaactgcccccgggagcagg 
cctgctcccgggggcagttgaaaagttggaaatc 
F80Va t187c, t188a tttccaacttttcatgtgcccccgggagcaggtcc 
ggacctgctcccgggggcacatgaaaagttggaaa 
a 
These mutants were produced during this project but were not examined. 
 
2.1.2 Δ29TfNCS 
The plasmid containing the gene for C-terminal hexahistidine tagged Δ29TfNCS was 
purchased from DNA2.0 (Menlo Park, CA, USA) (Fig. 2.2). The nucleotide sequences 
were designed using DNA2.0 codon optimisation algorithms for optimum expression in 
E. coli.112 The synthesised genes were provided cloned into a pJ411 expression vector. 
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GTTTAACTTTTAGGAGGTAAAACATATGTTGCATCACCAGGGTATCATCAATCAAG
TTAGCACCGTCACGAAAGTAATTCATCACGAGCTGGAAGTTGCGGCATCCGCTGA
CGACATTTGGACCGTGTACAGCTGGCCGGGTCTGGCGAAGCACTTGCCGGATCT
GCTGCCTGGCGCGTTCGAAAAACTGGAGATTATCGGCGATGGCGGTGTTGGTAC
GATTCTGGACATGACCTTTGTCCCGGGTGAATTCCCGCACGAGTATAAAGAGAAA
TTCATCCTGGTTGATAACGAACATCGTCTGAAGAAGGTGCAGATGATCGAAGGCG
GCTATCTGGACCTGGGTGTGACGTATTACATGGACACGATTCACGTTGTGCCGAC
CGGTAAAGACAGCTGCGTCATCAAGAGCAGCACTGAGTACCACGTCAAGCCGGA
GTTTGTGAAGATTGTTGAGCCGCTGATCACCACCGGTCCACTGGCAGCCATGGCA
GATGCCATTAGCAAGTTGGTCCTGGAACATAAATCTAAAAGCAACTCCGATGAAAT
TGAGGCGGCGATCATCACCGTGCTGGAGCATCACCACCACCATCACTGATAAAA
GCTTCCCC 
Fig. 2.2 Δ29TfNCS, pQR1046: DNA sense strand 5`-3`. Bold text shows start and stop codons. Italics 
shows restriction endonuclease recognition sites NdeI and HindIII . Underlined at the 5’ is the Shine-
Dalgarno sequence and at the 3’/C-terminus the His-tag. Sequence codon optimised for expression in E. 
coli by DNA2.0. 
A number of Δ29TfNCS mutants were purchased from DNA2.0 and provided in the 
same format. These were the variants: L76A, L76V, A79F, A79I, F80L, Y108F, E110D, 
E110Q, D141E and D141N. All other Δ29TfNCS mutants were constructed using 
QuikChange® Lightening mutagenesis kit (Agilent, Santa Clara, CA, USA) and 
mutagenesis primers (purchased from Eurofins, Luxembourg) (Table 2.2). Standard 
QuikChange® Lightening recommended parameters and conditions were used for 
primer design and experimental conditions unless noted. All plasmid sequences were 
verified by Sanger sequencing provided by Source BioScience. 
Table 2.2 Primer sequences for Δ29TfNCS mutations. Nucleotide sequence numbered from AUG start 
codon. 
Amino acid 
variant 
DNA mutation Primer sequences (5` to 3`) 
M97FLIVa,b a205n, g207c attctggacntcacctttgtcccgggtgaattcccgcac 
ctaccgccacaaccatgctaagacctgnagtggaaacag 
F112La t250c, c252g aagagaaactgatcctggttgataacgaacatcgtctgaagaagg 
gggcccacttaagggcgtgctcatatttctctttgactaggacca 
F112K t250a, t251a, 
c252g 
gaattcccgcacgagtataaagagaaaaagatcctggttgataacgaacatc 
gatgttcgttatcaaccaggatctttttctctttatactcgtgcgggaattc 
K122F a283t, a284t, 
g285t 
gccttcgatcatctgcaccttaaacagacgatgttcgttatcaac 
gttgataacgaacatcgtctgtttaaggtgcagatgatcgaaggc 
K122L a283c, a283c, 
a284t 
cttcgatcatctgcaccttcagcagacgatgttcgttatcaa 
ttgataacgaacatcgtctgctgaaggtgcagatgatcgaag 
A69K g121a, c122a ccggcaagtgcttcttcagacccggccagc 
gctggccgggtctgaagaagcacttgccgg 
L72K t130a, t131a gtctggcgaagcacaagccggatctgctgc 
gcagcagatccggcttgtgcttcgccagac 
I85K t170a, t171g aacaccgccatcgccgatcttctccagtttttcgaacg 
cgttcgaaaaactggagaagatcggcgatggcggtgtt 
L95K c199a, t200a aaggtcatgtccttaatcgtaccaacaccgccatcgc 
gcgatggcggtgttggtacgattaaggacatgacctt 
M126K 
(K122L)c 
t293a agccgccttcgatcttctgcaccttcagc 
gctgaaggtgcagaagatcgaaggcggct 
M183K t464a cggtccactggcagccaaggcagatgc 
gcatctgccttggctgccagtggaccg 
a 
These primers were designed with 3` overhangs to minimise primer-primer annealing. 
b
 The degenerate codon NTC was used, encoding for Phe, Leu, Ile and Val. 
c
 This primer pair is specific 
 
for the K122L variant. 
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2.1.3 CjNCS2 
A plasmid containing the C-terminal hexahistidine tagged gene of CjNCS2 was 
provided by Dr Thomas Pesnot. Originally, synthesised genes were inserted into the 
pET29a(+) vector by restriction and subsequent ligation using the restriction enzymes 
NdeI and HindIII (Fig. 2.3).* 
CATATGCGTATGGAAGTGGTGTTGGTGGTGTTCCTGATGTTCATCGGCACAATCA
ACTGTGAACGCCTGATCTTCAACGGCCGGCCCTTGTTGCATCGGGTAACCAAAGA
AGAAACCGTAATGCTGTATCATGAATTGGAAGTAGCGGCGAGCGCTGATGAAGTT
TGGAGCGTAGAAGGCTCACCGGAACTGGGGCTGCATCTGCCGGACCTGTTGCCG
GCGGGCATCTTTGCGAAATTTGAAATTACCGGCGATGGCGGCGAAGGCTCAATCT
TGGACATGACCTTCCCTCCGGGCCAATTTCCGCATCATTACCGCGAAAAATTCGTT
TTCTTCGATCATAAAAACCGGTACAAATTGGTAGAACAAATCGATGGCGATTTTTT
CGATTTGGGCGTGACCTACTATATGGATACCATCCGGGTGGTGGCTACCGGGCC
GGATAGCTGTGTAATCAAAAGCACCACCGAATACCATGTTAAACCGGAATTTGCTA
AAATCGTAAAACCGCTGATTGACACCGTGCCGTTGGCGATCATGAGCGAAGCTAT
TGCGAAAGTGGTGTTGGAAAATAAACATAAAAGCAGCGAACATCATCATCATCATC
ATTAATAGAAGCTT 
 
Fig. 2.3 CjNCS2, pQR1025. DNA sense strand 5`-3`. Bold text shows start and stop codons. Italics shows 
restriction endonuclease recognition sites NdeI and HindIII used for cloning . Underlined at the 3’/C-
terminus the His-tag.* 
The plasmid containing the gene for C-terminal hexahistidine tagged Δ21CjNCS2 was 
purchased from DNA2.0 (Menlo Park, CA, USA) (Fig. 2.4). The nucleotide sequences 
were designed using DNA2.0 codon optimisation algorithms for optimum expression in 
E. coli.112 The synthesised genes were provided cloned into a pJ411 expression vector. 
 
ATGCTGATTTTCAATGGTCGTCCGCTGCTGCACCGTGTTACGAAAGAAGAAACCG
TTATGCTGTACCATGAGTTGGAAGTGGCGGCGAGCGCCGACGAAGTCTGGAGCG
TCGAGGGTAGCCCGGAGCTGGGCCTGCATCTGCCGGATCTGCTGCCGGCTGGTA
TTTTCGCAAAATTCGAGATCACGGGCGATGGCGGCGAAGGTAGCATTTTGGATAT
GACCTTTCCGCCAGGTCAATTTCCGCACCATTATCGTGAGAAGTTTGTGTTCTTTG
ATCACAAGAACCGCTACAAACTGGTGGAGCAGATCGATGGTGACTTCTTCGACCT
GGGTGTGACCTACTATATGGACACGATCCGCGTCGTGGCGACTGGCCCTGACAG
CTGCGTTATCAAGTCTACCACCGAATATCACGTTAAACCGGAGTTTGCGAAGATTG
TCAAGCCGCTGATTGACACCGTGCCGCTGGCCATCATGTCCGAGGCGATCGCAA
AAGTTGTTCTGGAAAACAAACACAAGAGCAGCGAGCATCACCATCACCACCACTA
ACTCGAG 
 
Fig. 2.4 Δ21CjNCS2. DNA sense strand 5`-3`. Bold text shows start and stop codons. Underlined at the 
3’/C-terminus the His-tag. Sequence codon optimised for expression in E. coli by DNA2.0. 
  
                                               
* The cloning of CjNCS2 was conducted by Dr Markus Gershater and Dr Thomas Pesnot 
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2.1.4 NCS plasmid list 
Table 2.3 Complete list of NCS plasmids generated in this study. All these plasmids are stored both as 
the pure plasmid DNA and as BL21(DE3) glycerol stocks. 
pQR Vector NCS gene Mutation(s) His Tag Source Method 
1024 pET29a(+)
a
 Δ19TfNCS WT C-terminal M. Gershater - 
1721 pET29a(+) Δ19TfNCS L76A C-terminal This study SDM
f
 
1722 pET29a(+) Δ19TfNCS A79F C-terminal This study SDM 
1723 pET29a(+) Δ19TfNCS A79I C-terminal This study SDM 
1724 pET29a(+) Δ19TfNCS F80L C-terminal This study SDM 
1725 pET29a(+) Δ19TfNCS M97F C-terminal This study SDM 
1726 pET29a(+) Δ19TfNCS M97L C-terminal This study SDM 
1727 pET29a(+) Δ19TfNCS F99L C-terminal This study SDM 
1728 pET29a(+) Δ19TfNCS Y108F C-terminal This study SDM 
1729 pET29a(+) Δ19TfNCS E110D C-terminal This study SDM 
1730 pET29a(+) Δ19TfNCS E110Q C-terminal This study SDM 
1731 pET29a(+) Δ19TfNCS D141E C-terminal This study SDM 
1732 pET29a(+) Δ19TfNCS D141N C-terminal This study SDM 
1733 pET29a(+) Δ19TfNCS A182F C-terminal This study SDM 
1734 pET29a(+) Δ19TfNCS A182I C-terminal This study SDM 
1735 pET29a(+) Δ19TfNCS M183F C-terminal This study SDM 
1736 pET29a(+) Δ19TfNCS M183L C-terminal This study SDM 
1737 pET29a(+) Δ19TfNCS F80A C-terminal This study SDM 
1738 pET29a(+) Δ19TfNCS F80H C-terminal This study SDM 
1739 pET29a(+) Δ19TfNCS F80V C-terminal This study SDM 
1046 pJ411
b
 Δ29TfNCS WT C-terminal This study GS
g
 
1831 pJ411 Δ29TfNCS L76A C-terminal This study GS 
1045 pJ411 Δ29TfNCS L76V C-terminal This study GS 
1832 pJ411 Δ29TfNCS A79F C-terminal This study GS 
1047 pJ411 Δ29TfNCS A79I C-terminal This study GS 
1833 pJ411 Δ29TfNCS F80L C-terminal This study GS 
1834 pJ411 Δ29TfNCS Y108F C-terminal This study GS 
1835 pJ411 Δ29TfNCS E110D C-terminal This study GS 
1836 pJ411 Δ29TfNCS E110Q C-terminal This study GS 
1837 pJ411 Δ29TfNCS D141E C-terminal This study GS 
1838 pJ411 Δ29TfNCS D141N C-terminal This study GS 
1839 pJ411 Δ29TfNCS M97F C-terminal This study SDM 
1840 pJ411 Δ29TfNCS M97L C-terminal This study SDM 
1841 pJ411 Δ29TfNCS M97V C-terminal This study SDM 
1842 pJ411 Δ29TfNCS F112L C-terminal This study SDM 
1843 pJ411 Δ29TfNCS F112K C-terminal This study SDM 
1844 pJ411 Δ29TfNCS K122L C-terminal This study SDM 
1845 pJ411 Δ29TfNCS K122F C-terminal This study SDM 
1846 pJ411 Δ29TfNCS K122L A69K C-terminal This study SDM 
1847 pJ411 Δ29TfNCS K122L L72K C-terminal This study SDM 
1848 pJ411 Δ29TfNCS K122L I85K C-terminal This study SDM 
1849 pJ411 Δ29TfNCS 122L F112K C-terminal This study SDM 
1850 pJ411 Δ29TfNCS K122L L95K C-terminal This study SDM 
1851 pJ411 Δ29TfNCS 122L M126K C-terminal This study SDM 
1852 pJ411 Δ29TfNCS 122L M183K C-terminal This study SDM 
1853 pJ411 Δ29TfNCS 122F F112K C-terminal This study SDM 
1025 pET29a(+)
a
 CjNCS2 WT C-terminal T. Pesnot
e
 - 
1854 pJ411 Δ21CjNCS WT C-terminal This study GS 
1855 
pNic28-
BSa4 
Δ29TfNCS WT N-term-TeV
d
 This study LIC
h
 
1856 pD451-SR
b
 
ΔN33C196 
TfNCS
c
 
WT N-term-TeV
d
 This study GS 
a
 Gene inserted between NdeI and HindIII sites by Dr Markus Gershater. Genes are codon optimised for 
E. coli. 
b
 pJ411 and pD451-SR vectors are from DNA2.0. Both have: kanamycin resistance, high copy 
pUC origins, T7 IPTG inducible promoters and strong RBSs. 
c
 TfNCS sequence from 1-33 and from 
196-210 removed. 
d
 N-terminal HisTag with linker and TeV protease cleavage site: 
MHHHHHHSSGVDLGTENLYFQ^S. 
e
 See Pesnot et al. 
f
 Site-directed mutagenesis (SDM). 
g
 Gene 
synthesis (GS) from DNA2.0, with E. coli codon optimisation. 
h
 Ligation independent cloning, performed 
by Dr Altin Sula 
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TfNCS              MMKME-VVFVFLMLLGTINCQKLILTGRPFLHHQGIINQVSTVTKVIHHELEVAASADDI   59 
Δ19TfNCS           -------------------MQKLILTGRPFLHHQGIINQVSTVTKVIHHELEVAASADDI   41 
Δ29TfNCS           -----------------------------MLHHQGIINQVSTVTKVIHHELEVAASADDI   31 
ΔN33C196TfNCS      ---------------------------------MGIINQVSTVTKVIHHELEVAASADDI   27 
CjNCS2             -MRMEVVLVVFLMFIGTINCERLIFNGRPLLHRVTK-----EETVMLYHELEVAASADEV   54 
Δ21CjNCS2          ---------------------MLIFNGRPLLHRVTK-----EETVMLYHELEVAASADEV   34 
                                                              * :::**********:: 
 
TfNCS              WTVYSWPGLAKHLPDLLP-GAFEKLEIIGDGGVGTILDMTFVPGEFPHEYKEKFILVDNE  118 
Δ19TfNCS           WTVYSWPGLAKHLPDLLP-GAFEKLEIIGDGGVGTILDMTFVPGEFPHEYKEKFILVDNE  100 
Δ29TfNCS           WTVYSWPGLAKHLPDLLP-GAFEKLEIIGDGGVGTILDMTFVPGEFPHEYKEKFILVDNE  90 
ΔN33C196TfNCS      WTVYSWPGLAKHLPDLLP-GAFEKLEIIGDGGVGTILDMTFVPGEFPHEYKEKFILVDNE  86 
CjNCS2             WSVEGSPELGLHLPDLLPAGIFAKFEITGDGGEGSILDMTFPPGQFPHHYREKFVFFDHK  114 
Δ21CjNCS2          WSVEGSPELGLHLPDLLPAGIFAKFEITGDGGEGSILDMTFPPGQFPHHYREKFVFFDHK  94 
                   *:* . * *. ******* * * *:** **** *:****** **:***.*:***::.*.: 
 
TfNCS              HRLKKVQMIEGGYLDLGVTYYMDTIHVVPTGKDSCVIKSSTEYHVKPEFVKIVEPLITTG  178 
Δ19TfNCS           HRLKKVQMIEGGYLDLGVTYYMDTIHVVPTGKDSCVIKSSTEYHVKPEFVKIVEPLITTG  160 
Δ29TfNCS           HRLKKVQMIEGGYLDLGVTYYMDTIHVVPTGKDSCVIKSSTEYHVKPEFVKIVEPLITTG  150 
ΔN33C196TfNCS      HRLKKVQMIEGGYLDLGVTYYMDTIHVVPTGKDSCVIKSSTEYHVKPEFVKIVEPLITTG  146 
CjNCS2             NRYKLVEQIDGDFFDLGVTYYMDTIRVVATGPDSCVIKSTTEYHVKPEFAKIVKPLIDTV  174 
Δ21CjNCS2          NRYKLVEQIDGDFFDLGVTYYMDTIRVVATGPDSCVIKSTTEYHVKPEFAKIVKPLIDTV  154 
                   .* * *: *:* ::***********:** ** *******:*********.***:*** *  
 
TfNCS              PLAAMADAISKLVLEHKSKSNSDEIEAAIITV------  210 
Δ19TfNCS           PLAAMADAISKLVLEHKSKSNSDEIEAAIITVHHHHHH  198 
Δ29TfNCS           PLAAMADAISKLVLEHKSKSNSDEIEAAIITVHHHHHH  188 
ΔN33C196TfNCS      PLAAMADAISKLVLEHKS--------------------  164 
CjNCS2             PLAIMSEAIAKVVLENKHKSSE----------HHHHHH  202 
Δ21CjNCS2          PLAIMSEAIAKVVLENKHKSSE----------HHHHHH  182 
 
Fig. 2.5 Multiple sequence alignments of NCSs used in this study. Allignment constructed with Clustal 
omega.
113
 Symbols: “.” = conservation between groups of weakly similar properties, “:” = conservation 
between groups of strongly similar properties, and “*” = fully conserved residue. Important conserved 
residues emboldened: Tyr-108, Glu-110, Lys-122 and Asp-141 (numbered by TfNCS from N-terminus). 
TfNCS sequence from Saminami et al
34
. Δ19TfNCS: pQR1024, Δ29TfNCS: pQR1046, ΔN33C196TfNCS: 
pQR1855, CjNCS2: pQR1025 and Δ21CjNCS2: pQR1854 (see Table 2.3). 
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2.1.5 Transaminases 
Transaminase (TAm) genes were amplified by PCR from genomic DNA and cloned into 
pET29a(+) plasmids by previous members of the Ward group.* Ten TAms from the 
Ward group TAm library and expressed from BL21 (DE3) cells. 
Table 2.4 Transaminases used in this study. All enzymes obtained from the Ward group TAm library.  
TAm Organism Uniprot entry name Gene name First reported 
BSU_09260 Bacillus subtilis YHXA_BACSU yhxA This thesis 
CV_2025 Chromobacterium violaceum Q7NWG4_CHRVO CV_2025 Kaulmann et al
114
 
Dgeo_1416 Deinococcus geothermalis Q1IYH3_DEIGD argD/lysJ This thesis 
KPN_00255 Klebsiella pneumoniae A6T537_KLEP7 gabT This thesis 
PP_0596 Pseudomonas putida Q88Q98_PSEPK PP_0596 This thesis 
PP_3718 Pseudomonas putida Q88GK3_PSEPK PP_3718 This thesis 
SaV_2612 Streptomyces avermitilis Q82JZ2_STRAW SAV_2612 This thesis 
SaV_4551 Streptomyces avermitilis Q82ER2_STRAW SaV_4551 This thesis 
VF_JS17 Vibrio fluvialis F2XBU9_VIBFL JS17 Shin et al
115
 
 
SAV_4551       MTPQPNPQVG-----AAVKAADRAHVFH---SWSAQELIDPLAVAGAEGSYFWDYDGRRY 52 
PP0596         ---MNMPETGPA---GIASQLKLDAHWMPYTANRNF-QRDPRLIVAAEGNYLVDDHGRKI 53 
CV_2025        MQKQRTT--------SQWRELDAAHHLHPFTDTASLNQAGARVMTRGEGVYLWDSEGNKI 52 
VF_JS17        ---MNKP--------QSWEARAETYSLYGFTDMPSLHQRGTVVVTHGEGPYIVDVNGRRY 49 
BSU09260       MEMMGMEN---IQQNQGLKQKDEQFVWH---AMKGAHQADSLIAQKAEGAWVTDTDGRRY 54 
PP3718         ---MATPSKAFAIAHDPLVEADKAHYMHGYHVFDEHREQGALNIVAGEGAYIRDTHGNRF 57 
SAV_2612       ---MGNP---IAVSKDL-SRTAYDHLWMHFTRMSSYENAPVPTIVRGEGTYIYDDKGKRY 53 
Dgeo_1416      ---MTGTKTK----ASKWLDAE-------LRYDSGVYNKHQVVMVRGQGATVWDETGRAY 46 
KPN_00255      ---MNSNKAM----MA---RRS-------DAVPRGVGQIHPIFAERAENCRVWDVEGREY 43 
                                                             .:   . *  *.   
SAV_4551       LDFTSGLVFTNIGYQHPKVVAAIQEQAASLTTFAPAF--AVEARSEAARLIAERTPGD-L 109 
PP0596         FDALSGLWTCGAGHTRKEIADAVTRQLSTLDYSPAF-QFGHPLSFQLAEKIAELVPGN-L 111 
CV_2025        IDGMAGLWCVNVGYGRKDFAEAARRQMEELPFYNTFFKTTHPAVVELSSLLAEVTPAG-F 111 
VF_JS17        LDANSGLWNMVAGFDHKGLIDAAKAQYERFPGYHAFFGRMSDQTVMLSEKLVEVSPFD-S 108 
BSU09260       LDAMSGLWCVNIGYGRKELAEAAYEQLKELPYYPLTQ--SHAPAIQLAEKLNEWLGGD-Y 111 
PP3718         LDAVGGMWCTNIGLGREEMALAIVDQVRQLAYSNPFSDMANDVAIELCQKLAQLAPGD-L 116 
SAV_2612       LDGLSGLFVVQAGHGRTELAETAFKQAQELAFFPVW-SYAHPKAVELAERLANYAPGD-L 111 
Dgeo_1416      IDCVAGYGVANIGHCHPDVVKAIQEQAARLIVMPQT--LPNDKRAEFLTELVGVLPQG-L 103 
KPN_00255      LDFAGGIAVLNTGHLHPQVVAAVEDQLKKLSHTCFQ-VLAYEPYLALCEKMNQKVPGDFA 102 
               :*  .*      *  :  .  :   *   :                    :          
 
SAV_4551       DKIFFTNGGADAIEHAVRMARIH------TGRPKVLSAYRSYHGGTQQAVNITGDPRRWA 163 
PP0596         NHVFYTNSGSECADTALKMVRAYWRLKGQATKTKIIGRARGYHGVNIAGTSLGGVNGNRK 171 
CV_2025        DRVFYTNSGSESVDTMIRMVRRYWDVQGKPEKKTLIGRWNGYHGSTIGGASLGGMKYMHE 171 
VF_JS17        GRVFYTNSGSEANDTMVKMLWFLHAAEGKPQKRKILTRWNAYHGVTAVSASMTGKPYNSV 168 
BSU09260       -VIFFSNSGSEANETAFKIARQYHLQNGDHSRYKFISRYRAYHGNTLGALSATGQAQRKY 170 
PP3718         NHVFLTTGGSTAVDTAYRLIQYYQNCRGKPHKKHIIARYNAYHGSTTLTMSIGNKAADRV 176 
SAV_2612       NKVFFTTGGGEAVETAWKLAKQYFKLQGKPTKYKVISRAVAYHGTPQGALSITGLPALKA 171 
Dgeo_1416      ERVFLCNSGTEAMEAAKKFAITA------TGRSRFVSMKRGFSGRSLGALAFTWE----- 152 
KPN_00255      KKTLLVTTGSEAVENAVKIARAA------TGRSGAIAFTGAYHGRTHYTLSLTGKVNPYS 156 
                  :  . *  . :   ::            :   :    .: *                 
                                               
* Cloning of previously unreported transaminases conducted by previous Ward group members, 
including Julio Rubéns Martínez-Torres 
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SAV_4551       --SDSASAGVVHFWAPYLYRSRFYAETEQQECER-ALEHLET-TIAFEGPGTIAAIVLET 219 
PP0596         -MFGQLLDV-DHLPHTVLPVNAFSKGLPEEGGIA-LADEMLK-LIELHDASNIAAVIVEP 227 
CV_2025        -QGDLPIPGMAHIEQPWWYKHGKDM-TPDEFGVV-AARWLEE-KILEIGADKVAAFVGEP 227 
VF_JS17        --FGLPLPGFVHLTCPHYWRYGEEGETEEQFVAR-LARELEE-TIQREGADTIAGFFAEP 224 
BSU09260       -KYEPLSQGFLHAAPPDIYRNPDDADTLES------ANEIDR-IMTWELSETIAGVIMEP 222 
PP3718         PEFDYHHDLIHHVSNPNPYRAPDDMDEA-EFLDF-LVAEFED-KILSLGADNVAAFFAEP 233 
SAV_2612       P-FEPLVPGAHKVPNTNIYRAPLFGDDPEAFGRW-AADQIEQ-QILFEGPETVAAVFLEP 228 
Dgeo_1416      ----------------PKYREPFGEAVDNKHVDFVTYGNIDE--LRAAVTDQTAAVILEP 194 
KPN_00255      -------AGMG-LMPGHVYRALYPCALHGVSDD-EAIASIHRIFKNDAAPEDIAAIIIEP 207 
                                                      :             *... *  
 
SAV_4551       VPGTAGIMVPPPGYLAGVRELCDKYGIVFVLDEVMAGFGRTGEWFAAD-LFDVTPDLMTF 278 
PP0596         LAGSAGVLPPPKGYLKRLREICTQHNILLIFDEVITGFGRMGAMTGSE-AFGVTPDLMCI 286 
CV_2025        IQGAGGVIVPPATYWPEIERICRKYDVLLVADEVICGFGRTGEWFGHQ-HFGFQPDLFTA 286 
VF_JS17        VMGAGGVIPPAKGYFQAILPILRKYDIPVISDEVICGFGRTGNTWGCV-TYDFTPDAIIS 283 
BSU09260       IITGGGILMPPDGYMKKVEDICRRHGALLICDEVICGFGRTGEPFGFM-HYGVKPDIITM 281 
PP3718         IMGSGGVIIPPEGYFQRMWQLCQTYDILFVADEVVTSFGRLGTFFASEELFGVTPDIITT 293 
SAV_2612       VQNAGGCFPPPPGYFQRVREICDQYDVLLVSDEVICAFGRLGTMFACD-KFGYVPDMITC 287 
Dgeo_1416      VQGEGGVRPVTPEFIRAAREITREKGALLILDEIQTGFCRTGKMFAAE-HFGVVPDGMTL 253 
KPN_00255      VQGEGGFYAASPAFMQRLRALCDEHGIMLIADEVQSGAGRTGTLFAME-QMGVAADITTF 266 
               :   .*       :      :       .: **:  .  * *   .         *     
 
SAV_4551       AKGVNSGYVPLGGVAISGKIAETFG-------KRAYPGGLTYSGHPLACAAAVATINVMA 331 
PP0596         AKQVTNGAIPMGAVIASSEIYQTFMNQPTPEYAVEFPHGYTYSAHPVACAAGLAALDLLQ 346 
CV_2025        AKGLSSGYLPIGAVFVGKRVAE----GL--IAGGDFNHGFTYSGHPVCAAVAHANVAALR 340 
VF_JS17        SKNLTAGFFPMGAVILGPELSKRLETAI--EAIEEFPHGFTASGHPVGCAIALKAIDVVM 341 
BSU09260       AKGITSAYLPLSATAVKRDIFEAYQ-GE--APYDRFRHVNTFGGSPAACALALKNLQIME 338 
PP3718         AKGLTSAYLPLGACIFSERIWQVIA-EP--GKGRCFTHGFTYSGHPVCCTAALKNIEIIE 350 
SAV_2612       AKGMTSGYSPIGACIVSDRIAEPFY-K----GDNTFLHGYTFGGHPVSAAVGVANLDLFE 342 
Dgeo_1416      AKAMAGG-VPVGAFAMTAEVADRMPAG---------GHGTTFGGNPLAMAAGIAAIRAMK 303 
KPN_00255      AKSIAGG-FPLAGVTGRAEVMDAIAPG---------GLGGTYAGNPIACAAALAVLQIFE 316 
               :* :  .  *:..      : .                  * .. *   : .   :  .  
 
SAV_4551       EEGVVENAANLGARVIEPGLRELAERHPSVGEVRGVGMFWALELVKDRETREPLVPYNAA 391 
PP0596         KENLVQSAAEL-APHFEKLLHG-VKGTKNIVDIRNYGLAGAIQIAARDGDAIVRPY---- 400 
CV_2025        DEGIVQRVKDDIGPYMQKRWRETFSRFEHVDDVRGVGMVQAFTLVKNKAKRELFPDFGEI 400 
VF_JS17        NEGLAENVRRL-APRFEERLKH-IAERPNIGEYRGIGFMWALEAVKDKASKTPFDGNLSV 399 
BSU09260       DEQLIQRSRDL-GAKLLGELQA-LREHPAVGDVRGKGLLIGIELVKDKLTKEPADAAKVN 396 
PP3718         REQLLDHVNDV-GSYLEQRLQS-LRDLPLVGDVRCMKLMACVEFVANKASKALFADEVNI 408 
SAV_2612       REGLNQHVLDN-ESAFLTTLQK-LHDLPIVGDVRGNGFFYGIELVKDKATKETFTDEESE 400 
Dgeo_1416      NEKMAEQAREK-GAYFMERLRAI--RSPKIREVRGLGLMIGVELKEKSAPY--------- 351 
KPN_00255      QENLLEKANQL-GDTLRQGLLAIAEDHPEIGDVRGLGAMIAIELFEEGDHSRPNA----- 370 
                * : :         :             : : *       .                   
 
SAV_4551       GEA----NAPMAAFGAAAKANGLWPFINMNRTHVVPPCNVTEAEAKEGLAALDAALSVAD 447 
PP0596         -----EAAMKLWKAGFYVRFGGDT-------LQFGPTFNTKPQELDRLFDAVGETLNLID 448 
CV_2025        GTL---CRDIFFRNNLIMRACGDH-------IVSAPPLVMTRAEVDEMLAVAERCLEEFE 450 
VF_JS17        SER---IANTCTDLGLICRPLGQS-------VVLCPPFILTEAQMDEMFDKLEKALDKVF 449 
BSU09260       Q-----VVAACKEKGLIIGKNGDTVAGYNNVIQLAPPFCLTEEDLSFIVKTVKESFQTI- 450 
PP3718         GER---IHSKAQEKGLLVRP----I---MHLNVMSPPLIITHAQVDEIVETLRQCIIETA 458 
SAV_2612       RVLYGFVSKKLFEYGLYCRA----DDRGDPVIQLSPPLISNQSTFDEIESIIRQVLTEAW 456 
Dgeo_1416      ------IAALEHEEGVLTLAATP------LVVRFLPPLTISREQIDQVVAAFERVLERVN 399 
KPN_00255      -RLTADIVARARDKGLILLSCGPY----YNVLRILVPLTIEEAQIEQGLKIIADCFSEAK 425 
                                                            .         :     
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SAV_4551       EYTV------------ 451 
PP0596         ---------------- 448 
CV_2025        QTLKARGLA------- 459 
VF_JS17        AEVA------------ 453 
BSU09260       ---------------- 450 
PP3718         RELTALGLYQGR---- 470 
SAV_2612       TKL------------- 459 
Dgeo_1416      PRAIPNQELREDKQTE 415 
KPN_00255      QA-------------- 427 
 
Fig. 2.6 Multiple sequence alignment of transaminases used in this study. Allignment constructed 
with Clustal omega.
113
 Symbols: “.” = conservation between groups of weakly similar properties, “:” = 
conservation between groups of strongly similar properties, and “*” = fully conserved residue.  
 
2.1.6 E. coli genotypes 
Top-10® and XL10 Gold cells were used interchangeably in site directed mutagenesis 
procedures and for producing large quantities of plasmid DNA for further use. 
Top-10® (Invitrogen): F– mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 nupG 
recA1 araD139 Δ(ara-leu)7697 galE15 galK16 rpsL(StrR) endA1 λ- 
XL10 Gold (Stratagene): endA1 glnV44 recA1 thi-1 gyrA96 relA1 lac Hte Δ(mcrA)183 
Δ(mcrCB-hsdSMR-mrr)173 tetR F'[proAB lacIqZΔM15 Tn10(TetR Amy CmR)] 
BL21 (DE3) cells (NEB) were used for protein expression. 
BL21 (DE3): F– ompT gal dcm lon hsdSB(rB
- mB
-) λ(DE3 [lacI lacUV5-T7 gene 1 ind1 
sam7 nin5]) 
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2.2 Computational tools 
2.2.1 Statistics and plotting 
Data were plotted in Microsoft Excel, R or QtGrace. Fitting conducted in R using the 
nonlinear least squares function using the default Gauss-Newton algorithm or the “port” 
algorithm. When standard deviations were available fitting was typically conducted with 
weights equal to inverse variance (1/σ2). All fitted parameters have p ≤ 0.05 unless 
mentioned. For Michalis-Menten or hyperbolic curves equation used was 𝑦 =
𝑉𝑥
𝐾+𝑥
, with 
gradient equal to 
𝑉𝐾
(𝐾+𝑥)2
. Exponential curves were: 𝑦 = 𝐶 − 𝐶𝑒−𝐿𝑥 and with the gradient 
𝐿𝐶𝑒−𝐿𝑥. Substrate inhibition/Haldane curves: 𝑦 =
𝑉𝑥
𝐾𝑚+𝑥+
𝑥2
𝐾𝑖
. 
2.2.2 Molecular dynamics (MD) 
Simulations were conducted in GROMACS using the Charmm27 forcefield.116,117 
Each subunit of 2VQ5 was prepared by removing waters and ligands. The N- and C-
termini were truncated, with the protein starting at Ser-40 and ending at Lys-197. The 
protein subunits were placed in a cube, then water (tip3p) and counter ions were 
added. The systems were energy minimised (Fmax < 250 kJ.mol
-1.nm-1). This was 
followed by NVT equilibration (100 ps) and NPT equilibration (100 ps). Three 
simulations for each subunit ran for 100 ns, at 300 K. The Phe-112 conformation was 
determined by calculating the angle between the Cα and Cζ of Phe-112 and the Cα of 
His-106. A value for this angle was calculated for every tenth frame. Data from MD 
simulations plotted with QtGrace. For more details, see Appendix A, section 8. 
2.2.3 Molecular docking 
Docking was conducted according to the protocol developed by Dr Thomas Pesnot.57 
Potential reaction intermediates were energy optimised using MM2 energy 
minimisation (ChemBio3D, CambridgeSoft) and docked in the active site of subunit A 
from the TfNCS crystal structure 2VQ5 (after removal of ligands)43. Docking was 
performed using AutoDock Vina (exhaustiveness = 8).118 The lowest free energy 
clusters were then visualised and their structure analysed. Unless noted otherwise, 
only the top ranked binding modes were used in this investigation. 
2.2.4 pKa predictions 
PROPKA 3.1 (http://propka.ki.ku.dk/) was used to predict pKas of residues in the 
enzyme active site.119 The TfNCS enzyme structure model was obtained from crystal 
structure 2VQ5 subunit A.43 Protein-ligand structures derived from docking calculations 
were also analysed in this manner. 
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2.2.5 Structural depiction and analysis 
The Δ19TfNCS X-ray crystal structures 2VNE and 2VQ5 were used.43 Depiction was 
achieved with Chimera (UCSF). Depiction of small molecules was achieved with 
ChemBioDraw (CambridgeSoft). The Δ19TfNCS sequence was submitted into 
Betascan (http://groups.csail.mit.edu/cb/betascan/) and analysed.120 The online tool 
scored sequences for pairwise β-strand formation and single strand formation. Residue 
conformations and Ramachandran angles of X-ray crystal structures were analysed 
using MOLPROBITY.121 Alternative conformations of side chains and ligands were 
explored using Coot and resulting density maps were refined with PHENIX.122 
2.3 Protein preparation 
Analysis of proteins was achieved by using SDS-PAGE (BioRad), typically with 12% 
polyacrylamide gels unless noted otherwise. Gels were stained using Imperial Protein 
Stain (ThermoScientific) or Instant blue (Expedeon). Protein purity and running mass 
on SDS-PAGE were measured with AlphaView software (ProteinSimple). 
2.3.1 NCS expression 
Plasmids containing NCS genes were transformed into E. coli BL21(DE3) cells by a 
standard heat-shock protocol. The transformed cells were stored as glycerol stocks at -
80 °C. An aliquot from a frozen glycerol stock of plasmid containing E. coli BL21(DE3) 
was inoculated into 20 mL of terrific broth (TB) medium (containing 50 µg.mL-1 
kanamycin) (Miller, Merck Millipore). Starter cultures were incubated 16 h at 37 °C, 
shaking at 250 revolutions per minute (rpm). This overnight culture was transferred into 
fresh media (4% v.v-1, TB with 50 µg.mL-1 kanamycin). These expression cultures were 
incubated for 2 hours at 37 °C, followed by 1 hour at 25 °C, whilst shaking at 250 rpm. 
Expression was induced by the addition of isopropyl β-D-1-thiogalactopyranoside 
(IPTG, final concentration 500 μM). Cultures were incubated for a further 3 hours at 25 
°C prior to harvesting, whilst shaking at 250 rpm. Cells were harvested by 
centrifugation at 10,000  g for 10 mins at 4 °C. Supernatant was removed and the cell 
pellets were stored at -20 °C until purification. 
2.3.2 NCS purification 
Optimum purification conditions for NCS proteins were explored using an automated 
ÄKTA purifier system and 5 mL HisTrap columns (GE Healthcare, Buckinghamshire, 
UK). Once the correct purification conditions were found, purification was performed on 
the bench-top in the process described below. 
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Cell pellets were thawed and suspended in BugBuster (10% culture volume) (Merck 
Millipore, Darmstadt, Germany). If necessary, the cells were homogenised by 
sonication. The insoluble portion of the lysate was pelleted by centrifugation at 10,000 
 g for 30 minutes at 4 °C. The supernatant was removed and filtered through a glass 
fibre prefilter and 0.2 µm cellulose acetate syringe filter (Sartorius Stedim Biotech, 
Göttingen, Germany). An empty and clean PD-10 column (GE) was charged with Ni-
Sepharose HP resin (2 mL, GE). The column was washed with distilled water (10 mL), 
followed by binding buffer (0.1 M HEPES, 20 mM imidazole, 100 mM NaCl, pH 7.5; 10 
mL). The filtered supernatant was passed through the Ni-Sepharose column, and the 
column was then washed with binding buffer (10 mL) followed by wash buffer (0.1 M 
HEPES, 40 mM imidazole, 100 mM NaCl, pH 7.5; 20 mL) or until no protein could be 
detected coming off the column by a standard Bradford’s assay. The bound protein 
was then eluted with elution buffer (0.1 M HEPES, 500 mM imidazole, 100 mM NaCl, 
pH 7.5; 5 mL). The eluant containing pure enzyme was buffer exchanged into assay 
buffer (50 or 100 mM HEPES pH 7.5), using a PD-10 column. 
Protein purity was established by SDS-PAGE (12% w.v-1 polyacrylamide). If sufficiently 
pure, protein concentration was determined using absorbance at 280 nm on a 
NanoDrop® 2000C (with molar absorbance calculated from Expasy ProtParam123). For 
storage, glycerol was added (10% v.v-1), the protein was divided into small samples 
(50-500 μL) and then flash-frozen in liquid nitrogen. The purified protein was stored at -
80 °C. For Δ29TfNCS, the yield of purified protein from culture  was approximately 100 
mg.L-1. 
2.3.3 Desalted lysate preparation 
Desalted lysate was prepared for biotransformation reactions by the following protocol: 
Cell pellets were thawed and suspended in BugBuster (10% culture volume). If 
necessary, lysate was sonicated until mixture became homogenous. The insoluble 
portion of the lysate was pelleted by centrifugation at 10,000  g for 45 mins at 4 °C. 
Lysate was buffer exchanged into assay buffer 0.1 M HEPES pH 7.5 using PD-10 
columns (GE). The HEPES-lysate elution was used immediately in biotransformations. 
2.3.4 Transaminases 
Transaminase expression: The Ward group have a library of TAm enzymes all 
expressed from the pET29a(+) vector in BL21(DE3) and stored as glycerol stocks. 
Selected enzymes from this library were plated out on LB-agar (Miller, Merck Millipore) 
plates with kanamycin (100 µg.mL-1). Single colonies from these plates were used to 
inoculate 5 mL 2xYT media (Sigma) and these were grown for 16 hours at 37 °C with 
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250 rpm orbital shaking. 300 µL of these overnight cultures were used to inoculate 75 
mL of 2xYT media. These were incubated (37 °C, 250 rpm) until OD600 = 0.8. Cultures 
were then induced with IPTG (500 µM) and incubated at 30 °C for 8 hours. The cells 
were then harvested by centrifugation (10,000  g, 10 mins) and the cell pellets stored 
at -80 °C. 
Transaminase lysate preparation: TAm cell pellets were resuspended in lysis buffer 
(10% culture volume, 0.1 M potassium phosphate, 1 mM PLP, pH 7.5) and 
homogenised by sonication (10 s intervals, 5 cycles). The insoluble portion of the lysate 
was pelleted by centrifugation (10,000  g, 30 mins). The supernatant was flash frozen 
in liquid nitrogen and stored at -80 °C.  
CV2025 preparation for one-pot two-enzyme cascade: The transaminase from 
Chromobacterium violaceum, CV2025, was expressed in 2xYT using the general TAm 
method described above. The CV2025 pellets were resuspended in lysis buffer (50 mM 
HEPES, 10 mM PLP, pH 7.5) and homogenised by sonication (10 s intervals, 5 cycles). 
The insoluble portion of the lysate was pelleted by centrifugation (10,000  g, 30 mins). 
The supernatant was flash frozen in liquid nitrogen and stored at -80 °C.  
2.4 Analytical methods 
2.4.1 HPLC 
Analytical HPLC: Methods were performed with a HPLC system consisting of a LC 
Packing FAMOS Autosampler, a Dionex P680 HPLC Pump, a Dionex TCC-100 
Column oven and a Dionex UVD170U Ultraviolet detector.  
Method 1, achiral: Analytic reverse phase analysis method was used for 
achiral quantitative analyses. Separation was achieved with a HiChrom ACE 
C18-5 (150  4.6 mm) column and a 1 mL.min-1 gradient of H2O (0.1% TFA) 
and acetonitrile 90:10 to 30:70 over 5 minutes at 30 °C (Fig. 2.7). Injection 
volumes were 20 µL. Product was detected via UV absorbance at 280 nm. 
Product retention times and concentrations were determined by chemically 
verified standards (see section 2.8). All non-chiral analytical HPLC analysis 
used this method.  
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Fig. 2.7 Analytical HPLC method.  
Method 2, chiral: Chiral separation was achieved with a Supelco Astec 
Chirobiotic T column and an isocratic mobile phase 20 mM NH4OAc pH 
4:MeOH (70:30) mobile phase at 0.2 mL.min-1 and 30 °C. Injection volumes 
were 5 µL. Compounds were detected by UV absorbance at 230 nm. Product 
retention times and concentrations were determined by chemically verified 
standards. 
Method 3, chiral: Chiral separation was achieved with a Supelco Astec 
Chirobiotic T2 column and an isocratic MeOH (0.1% TFA, 0.2% TEA) mobile 
phase at 1 mL.min-1 and 30 °C. Injection volumes were 5 µL. Compounds were 
detected by UV absorbance at 230 nm. Product retention times and 
concentrations were determined by chemically verified standards. 
Prep HPLC: Preparative HPLC was performed on a Varian Prostar instrument 
equipped with a UV-visible detector. Elutions were monitored at 280 nm and collected 
manually. 
Method 4: DiscoveryBIO wide Pore C18-10 column (25  2.12 cm), gradient: 
5% to 40% of acetonitrile/water (0.1% TFA). 
Method 5: Ascentis C18 150 x 21.2 mm, 5 µm. Gradient 5-20% of 
acetonitrile/water (0.1% TFA). 
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2.4.2 Chemical characterisation 
1H and 13C NMR spectra were recorded at 298 K at the field indicated using Bruker 
Avance 500 and Avance 600 machines. Coupling constants were measured in Hertz 
(Hz) and referenced to the deuterated solvent used. High resolution mass spectra 
(electrospray ionisation) performed with Waters Autosampler Manager 2777C 
connected to Waters LCT Premier XE, with positive ion detection, or a Q-TOF Aqilent 
6510. 
2.4.3 Plate readers 
Purpald® assays were read on a Tecan Safire2 plate reader. Absorbance spectra were 
recorded between 350 and 600 nm, with a step of 1 nm. Three reads were taken per 
well, each 1 ms apart. Typically absorbance at 522 nm was used for the aldehyde-
Purpald® complex. 
 
Fluorescamine assays were recorded on a BMG LABTECH CLARIOstar platereader. 
The gain was adjusted to highest well. Excitation wavelength: 390 nm with 15 nm 
bandwidth. Emission wavelenfth: 480 nm with 20 nm bandwidth. 
2.4.4 Circular dichroism (CD) 
CD spectroscopy performed on an AVIV 400, using Hellma QS quartz cuvettes. CD 
signal of standards were recorded by measuring 1 minute time-courses and averaging 
signal. All samples and reactions maintained at 37 °C. Dynode voltage was maintained 
below 500 V. 
2.5 Enzyme assays 
This refers to the methods used in section 4. 
2.5.1 General 
Reactions were typically conducted using 20 or 80 µg.mL-1 of purified enzyme in 50 mM 
HEPES, with varying concentrations of dopamine and aldehydes, in a total volume of 
100 µL. Reaction components were equilibrated at 37 °C and the reaction was started 
by the addition of enzyme to a substrate mixture. Typically the aldehyde stock solutions 
were made using acetonitrile (MeCN), as the hydrophobic aldehydes used were 
insoluble in water. Stock solutions were generally made at 10x concentration, thus all 
reactions contained 10% v.v-1 MeCN, unless noted. The reaction was incubated at 37 
°C and terminated by the addition of 20 µL of 1 M HCl. Reactions were performed in 
triplicate; all errors are standard deviations. The background reactions were recorded 
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by performing the reaction in HEPES buffer without enzyme and this was subtracted 
from the enzymatic reactions. 
2.5.2 Conversions 
Reactions were conducted with 80 µg.mL-1 enzyme, 10 mM dopamine and 10 mM 
aldehyde. Reactions were conducted with 50 mM HEPES pH 7.5 and 10% v.v-1 MeCN 
unless noted otherwise. Reactions were performed for 1 hour, and were analysed by 
analytical HPLC method 1 and chiral HPLC method 3.  
2.5.3 Initial rates 
The method described here is used in the main section on the enzyme mechanism 
(section 4.3). Reactions were performed with an enzyme concentration of 20 µg.mL-
1.Reactions were conducted with 50 mM HEPES pH 7.5 and 10% v.v-1 MeCN unless 
noted otherwise. Initial rates were determined by measuring the conversion after 30 
seconds, within the linear phase of the reaction. Initial rates were determined with 10 
mM of one substrate and 2.5 mM of the other. Reactions were analysed by analytical 
HPLC method 1. 
2.5.4 Kinetics 
To determine kinetic parameters, initial rates (see section 2.5.3) were measured with 
varying substrate concentrations. Dopamine concentrations were varied between 500 
µM and 20 mM in the presence of 2.5 mM aldehyde. Aldehyde concentrations were 
varied between 250 µM and 15 mM in the presence of 2.5 mM dopamine. The 
concentrations of substrates that were not varied during the assays were kept below 
saturating levels (typically 2.5 mM) to limit the non-enzymatic reaction. Similarly, higher 
concentrations of the varying substrates were not used as the increased background 
reactions led to increased errors. The kinetic data were calculated by fitting initial rates 
to a Michaelis-Menten or Substrate Inhibition equation using the non-linear least-
squares analysis in the R software environment (see section 2.2.1). 
2.5.5 Melting temperatures 
Enzyme melting and aggregation temperatures were determined using an Avacta 
Optim 1000 (Avacta Analytical Ltd., York, UK). Runs were performed in triplicate. Tm is 
calculated by observing changes in the intrinsic protein fluorescence spectrum; Tagg is 
calculated by changes in light scattering intensity.  
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2.6 Biotransformations 
2.6.1 Demonstrative biotransformations 
Biotransformations (see section 5) could be performed with a variety of substrates and 
enzyme preparations. Two demonstrative examples appear below. HPLC retention 
times and results are shown in a table below (Table 2.5). Compounds were identified 
by NMR and mass spectrometry.  
Hexanal and purified L76V- Δ29TfNCS: Substrate solutions of dopamine-HCl (38 mg, 
0.20 mmol) in water (2 mL) and hexanal (30 mg, 0.30 mmol) in MeCN (2 mL) were 
prepared. Purified L76V- Δ29TfNCS was prepared as described above (section 2.3.2). 
The reaction mixtures were prepared by the addition of the dopamine solution (2 mL, 
100 mM, 0.20 mmol), the hexanal solution (2 mL, 150 mM, 0.30 mmol) and purified 
enzyme (1.0 mg.mL-1, 2 mL) to water (14 mL). The final reaction mixtures (20 mL) 
contained 10 mM dopamine, 15 mM hexanal and approximately 0.1 mg.mL-1 purified 
enzyme. The reaction was incubated at 37 °C for 3 hours before being quenched by 
the addition of 1M HCl (2 mL). The mixture was centrifuged (10,000  g for 30 mins) to 
remove protein precipitate and then filtered before being concentrated under reduced 
pressure. Samples were taken at this point and analysed by HPLC methods 1 and 3 to 
determine ee and conversion yields. The product was purified via preparative-HPLC 
using method 5. Solvent was removed under reduced pressure and the product 
washed with MeOH to remove excess TFA, yielding the previously unreported (S)-1-
pentyl-1,2,3,4-tetrahydro-isoquinoline-6,7-diol as the TFA salt  (40 mg, 57%, >98% 
ee)6. 
(S)-1-Pentyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol (TFA salt)6 
 
1H NMR (500 MHz; CD3OD) δ  = 0.93 (3H, t, J = 7.1 Hz, (CH2)3CH3), 1.38–1.50 (6H, m, 
CH2)3CH3 ), 1.87 (1H, m, CHCHH), 2.01 (1H, m, CHCHH), 2.86–3.00 (2H, m, 4-H2), 
3.29–3.34 (1H, m, 3-HH), 3.50 (1H, m, 3-HH), 4.34 (1H, dd, J = 8.3 and 5.0 Hz, 1-H), 
6.60 (1H, s, 5-H), 6.64 (1H, s, 8-H); 13C NMR (125 MHz; CD3OD) δ 14.3, 23.5, 25.7, 
26.1, 32.7, 35.1, 41.0, 56.7, 113.9, 116.2, 118.3 (q, 1JCF 295 Hz, CF3), 123.7, 124.3, 
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145.9, 146.7, 163.2 (br, CF3CO2); m/z [HRMS ES+] found [M+H]
+ 236.1639. C14H22NO2 
requires 236.1651. 
B: Phenylacetaldehyde and CjNCS2 lysate: Substrate solutions of dopamine-HCl 
(38 mg, 0.20 mmol) in water (2 mL) and phenylacetaldehyde (36 mg, 0.30 mmol) in 
MeCN (2 mL), and were prepared. HEPES-lysate of CjNCS2 was prepared as 
described as in section 2.3.3. The reaction mixtures were prepared by the addition of 
the dopamine solution (2 mL, 0.20 mmol), the phenylacetaldehyde solution (2 mL, 0.30 
mmol) and HEPES-lysate (7 mL) to water (9 mL). The final reaction mixtures (20 mL) 
contained 10 mM dopamine and 15 mM phenylacetaldehyde. The reaction was 
incubated at 37 °C for 1 hour before being quenched by the addition of 1M HCl (2 mL). 
The mixture was centrifuged (10,000  g for 30 mins) to remove protein precipitate and 
then filtered. Samples were taken at this point and analysed by HPLC methods 1 and 3 
to determine ee and conversion yields. The product was purified via preparative-HPLC 
using method 5. Solvent was removed under reduced pressure and the product 
washed with MeOH to remove excess TFA, yielding (S)-1-benzyl-1,2,3,4-
tetrahydroisoquinoline-6,7-diol as the TFA salt (33 mg, 45%, >97% ee) with 
spectroscopic data consistent that previously reported.6 
Table 2.5 HPLC retention times for biotransformations to give (1S)-1-pentyl-1,2,3,4-tetrahydro-
isoquinoline-6,7-diol and (1S)-1-benzyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol. 
Product Pentyl Benzyl 
Analysis HPLC 
method 
RT (min) Yield RT (min) Yield 
Conversion 1 5.9 70% 5.5 81% 
ee 3 12.7 (S) 
15.9 (R) 
>98% 12.0 (S) 
16.8 (R) 
>97% 
Purified 5 32.0 57% 18.4 45% 
 
2.6.2 Triangular cascades 
These following methods relate to section 5.4. 
Transaminase screen 
Transaminases were screened for activity with dopamine and pyruvate through the 
formation of rac-norlaudanosoline. The reaction conditions: 50 mM dopamine, 25 mM 
pyruvate, 1 mM PLP, 10% v.v-1 TAm lysate. The reactions (50 µL) were incubated at 
37 °C with 500 rpm orbital rotation. The reactions were quenched by addition of 10 µL 
1M HCl. Reactions were quenched after 30 mins, 1, 2 and 4 hours. The insoluble 
portions of the reactions were removed by centrifugation and the soluble fractions were 
analysed by analytic HPLC (method 1) and compared to chemically verified standards. 
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One-pot two-enzyme cascade for the synthesis of (S)-norlaudanosoline 
Reactions were conducted to screen for optimum conditions. The reactions (100 µL) 
contained dopamine, pyruvate, purified Δ29TfNCS and CV2025 lysate in varying 
concentrations. Conditions were: either 20 or 50 mM dopamine (and 10 mM or 25 mM 
sodium pyruvate respectively), 0.1 or 0.5 mg.mL-1 NCS, 10, 20 or 30% CV2025 lysate. 
Reactions were quenched with 20 µL 1 M HCl. Reactions were incubated at 37 °C with 
500 rpm orbital rotation and were quenched after 3 hours. Each condition was 
performed in triplicate. The insoluble material was removed by centrifugation and the 
reaction were analysed by analytical and chiral HPLC (methods 1 and 2). 
One-pot two-enzyme cascade for the synthesis of (S)-1-(3-Hydroxybenzyl)-
1,2,3,4-tetrahydro-isoquinolin-6-ol 
Reaction components 3-hydroxyphenethylamine (20 mM), pyruvate (10 mM), CV2025 
lysate (20% v.v-1) and Δ29TfNCS (0.5 mg.mL-1) were combined (total volume 100 µL) 
and incubated at 37 °C with 500 rpm shaking for 3 hours. Reactions were quenched 
with 1M HCl (20 µL), centrifuged and then analysed by analytical and chiral HPLC 
(methods 1 and 3).  
One-pot two-enzyme chemoenzymatic cascade for the synthesis of 
tetrahydroprotoberberines 
First, synthesis of (S)-norlaudanosoline was achieved with conditions determined 
previously: reactions (100 µL) consisting of dopamine (20 mM), pyruvate (10 mM), 
Δ29TfNCS (0.5 mg.mL-1) and  CV2025 lysate (20% v.v-1) were incubated at 37 °C with 
500 rpm shaking for 3 hours. To these reactions was added 100 µL of 
formaldehyde/phosphate solution (40 mM formaldehyde, 1 M sodium phosphate, pH 6) 
and the reactions were incubated for 30 minutes at 37 °C and with 500 rpm shaking. 
Reactions were centrifuged to remove insoluble matter and then analysed by analytical 
and chiral HPLC (methods 1 and 2). 
  
70 
 
Preparatory scale enzyme cascade reactions 
(S)-1-(3,4-Dihydroxybenzyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol 
 
Dopamine (0.5 mmole, 94.5 mg), pyruvate (0.25 mmole, 27.5 mg), CV2025 lysate 
(5 mL) and Δ29TfNCS (12.5 mg) were combined with water to a total volume of 25 
mL. The reaction was stirred at 37 °C, checking reaction progress by HPLC analysis 
(method 1). Once the reaction had completed (86% conversion, 2 hours), the reaction 
was quenched by the addition of HCl (1M, 5 mL). Insoluble material was removed 
through centrifugation and ultrafiltration, and the mixture was concentrated in vacuo. 
The product was purified by preparative-HPLC (method 4) for characterisation 
purposes (TFA salt, 63 mg, 62% isolated yield).  1H NMR and chiral HPLC (method 4) 
confirmed the product was the expected (S)-1-(3,4-dihydroxybenzyl)-1,2,3,4-
tetrahydroisoquinoline-6,7-diol (>95% ee). See section 2.8.5 for synthesis and 
characterisation of chemical standards. See Appendix B (section 9) for NMR spectra. 
(S)-6,8,13,13a-tetrahydro-5H-isoquinolino[3,2-a]isoquinoline-2,3,10,11-tetraol 
 
Dopamine (0.5 mmole, 94.5 mg), pyruvate (0.25 mmole, 27.5 mg), CV2025 lysate 
(5 mL) and Δ29TfNCS (12.5 mg) were combined with water to a total volume of 25 
mL. The reaction was stirred at 37 °C for 2 hours. Formaldehyde (40 mM in 1M 
phosphate pH 6, 25 mL) was added to the reaction and it was stirred at 37 °C for 30 
minutes (47% conversion). Insoluble material was removed through centrifugation and 
ultrafiltration, and the mixture was concentrated in vacuo. The product was purified by 
preparative-HPLC (method 4) for characterisation (TFA salt, 43 mg, 42% isolated 
yield).  1H NMR and chiral HPLC (method 2) confirmed the product was the expected 
(S)-6,8,13,13a-tetrahydro-5H-isoquinolino[3,2-a]isoquinoline-2,3,10,11-tetraol 
(>95% ee). See section 2.8.5 for synthesis and characterisation of chemical standards. 
See Appendix B (section 9) for NMR spectra. 
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2.6.3 Spiro-THIQs 
Refers to Section 6.6. 
Enzyme preparation: A Δ29TfNCS variant was expressed as described in section 
2.3.1. The frozen cell pellet was thawed and resuspended in 50 mM HEPES buffer pH 
7.5 (10% volume of original culture). The suspension was sonicated (10 s ON, 10 s 
OFF) until homogenous. The insoluble portion of the lysate was pelleted by 
centrifugation at 10,000  g for 30 minutes at 4 °C. The supernatant was removed and 
filtered through a glass fibre prefilter and 0.2 µm cellulose acetate syringe filter. 
Reaction conditions: Reactions were conducted in 5 mL volumes and contained: 20% 
v.v-1 lysate, 5 mM ascorbic acid, 10 mM substituted cyclohexanone (CH), 15 mM 
dopamine, 10% v.v-1 DMSO and 50 mM HEPES pH 7.5. The components were mixed, 
with the lysate added last. The reaction was incubates for 6 hours at 37 ˚C, shaking at 
250 rpm. The reactions were stored at -20 ˚C until further processing. 
Extraction procedure: The reaction was diluted to 10 mL with water. The solution was 
extracted with ethyl acetate (3 x 20 mL). The fractions were pooled and washed with 
brine (3 x 20 mL). The organic layer was dried with magnesium sulfate, filtered and the 
solvent removed in vacuo. The material was resuspended in 20 mL of a 1:1 mixture of 
dichloromethane (DCM) and 0.1 M HCl. The DCM layer was extracted with 0.1 M HCl 
(2 x 10 mL). The aqueous layers were combined and water was removed in vacuo by a 
rotary evaporator until 5 mL remained. Then the final compound was freeze dried to 
yield the product as a solid hydrochloride salt (Table 2.6). 
Table 2.6 Purification of cyclohexanone derived spiro-THIQ products 
Cyclohexanone 
Substrate 
Purified mass 
(mg) 
Yield 
% Appearance 
4-methyl 7.3 51 Grey solid 
4-phenyl 10.0 58 White solid 
4-tert-butyl 5.4 33 White solid 
3-methyl (racemate) 8.5 60 Yellow solid 
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Characterisation data: 
4-Methylcyclohexane-spiro-THIQ 
(1s,4s)-4-methyl-3',4'-dihydro-2'H-spiro[cyclohexane-1,1'-isoquinoline]-6',7'-diol 
 
1H NMR (600 MHz; CD3OD): δ = 1.04 (3H, d, J 6.5 Hz, Mej), 1.31 (2H, m, Hg), 1.65 
(1H, m, Hi), 1.78 (1H, app. d, J 14.3 Hz, Hh), 2.05-2.10 (4H, m, He and Hf), 2.96 (2H, t, J 
6.3 Hz, Hc), 3.41 (2H, t, J 6.3 Hz, Hd), 6.56 (1H, s, Ha), 6.73 (1H, s, Hb); 
13C NMR (150 
MHz; CD3OD): δ = 22.2 (5’), 26.2 (4), 30.1 (3’), 32.4 (4’), 36.9 (2’), 38.7 (3), 60.6 (1), 
113.2 (8), 116.1 (5), 123.1 (8a), 129.5 (4a), 146.1(6/7), 146.5 (6/7); m/z [HRMS ES+] 
found [M+H]+ 248.1650. C15H22NO2 requires 248.1651. 
For NMR spectra, see Appendix B (section 9). 
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4-Phenylcyclohexane-spiro-THIQ 
(1s,4s)-4-phenyl-3',4'-dihydro-2'H-spiro[cyclohexane-1,1'-isoquinoline]-6',7'-diol 
 
1H NMR (600 MHz; CD3OD): δ = 1.84 (2H, m, Hg), 1.97 (2H, d, J 14.6 Hz, Hh), 2.21 
(2H, d, J 14.9 Hz, He), 2.28 (2H, m, Hf), 2.83 (1H, tt, J 12.3 and 3.4 Hz, Hi), 3.00 (2H, t, 
J 6.3 Hz, Hc), 3.49 (2H, t, J 6.3 Hz, Hd), 6.59 (1H, s, Ha), 6.83 (1H, s, Hb), 7.20 (1H, tt, J 
7.3 and 1.2 Hz, Hl), 7.31 (2H, m, Hk), 7.36 (2H, app. d, J 7.9 Hz, Hj); 
13C NMR (150 
MHz; CD3OD): δ = 26.3 (4), 29.5 (3’), 37.3 (2’), 38.8 (3), 44.0 (4’), 60.6 (1), 113.3 (8), 
116.1 (5), 123.2 (8a), 127.5 (8’), 127.9 (7’), 129.3 (4a), 129.6 (6’), 146.2 (6/7), 146.6 
(6/7), 146.9 (5’); m/z [HRMS ES+] found [M+H]+ 310.1808. C20H24NO2 requires 
310.1807. 
For NMR spectra, see Appendix B (section 9). 
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4-Tert-butylcyclohexane-spiro-THIQ 
(1s,4s)-4-(tert-butyl)-3',4'-dihydro-2'H-spiro[cyclohexane-1,1'-isoquinoline]-6',7'-
diol 
 
1H NMR (600 MHz; CD3OD): δ = 0.96 (9H, s, Hj), 1.28-1.40 (3H, m, Hi and Hg), 1.87 
(2H, app. d, J 13.0 Hz, Hh), 2.05 (2H, m, J 13.4 and 15.0 Hz, Hf) 2.13 (2H, d, J 15.0 Hz, 
He), 2.96 (2H, t, J 6.3 Hz, Hc), 3.42 (2H, t, 6.3 Hz, Hd), 6.57 (1H, s, Ha), 6.73 (1H, s, Hb); 
13C NMR (150 MHz; CD3OD): δ = 23.2 (3’), 26.3 (4), 27.9 (6’), 33.3 (5’), 37.7 (2’), 38.9 
(3), 48.4 (4’), 60.8 (1), 113.3 (8), 116.0 (5), 123.3 (8a), 129.4 (4a), 146.0 (6/7), 146.5 
(6/7); m/z [HRMS ES+] found [M+H]+ 290.2120. C18H28NO2 requires 290.2120. 
For NMR spectra, see Appendix B (section 9). 
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Rac-3-methylcyclohexane-spiro-THIQ 
(1S,3S)-3-methyl-3',4'-dihydro-2'H-spiro[cyclohexane-1,1'-isoquinoline]-6',7'-diol 
(1R,3R)-3-methyl-3',4'-dihydro-2'H-spiro[cyclohexane-1,1'-isoquinoline]-6',7'-diol 
 
1H NMR (600 MHz; CD3OD): δ = 1.00 (3H, d, J 6.32 Hz, Meh), 1.13 (1H, dq, J 3.7 and 
12.6 Hz, Hi),1.61-1.69 (2H, m, Hf and Hk), 1.74 (1H, br m, Hg), 1.85 (2H, m, Hj and Hl), 
1.93 (1H, dt, J 4.3 and 14.4 Hz, Hn), 2.04 (2H, m, He and Hm), 2.96 (2H, dt, J 2.3 and 
6.2 Hz, Hc), 3.41 (2H, m, J 4.3 and 6.2 Hz, Hd), 6.57 (1H, s, Ha), 6.73 (1H, s, Hb); 
13C 
NMR (150 MHz; CD3OD): δ = 21.6 (5’), 22.5 (7’), 26.2 (4), 28.3 (3’), 34.1 (4’), 36.3 (6’), 
38.7 (3), 45.3 (2’), 61.7 (1), 113.3 (8), 116.1 (5), 123.0 (4a), 129.6 (5a), 146.1 (6/7), 
145.5 (6/7); m/z [HRMS ES+] found [M+H]+ 248.1649. C15H22NO2 requires 248.1651. 
HSQC 1H (600 MHz; CD3OD): δ = 1.60-1.68 (t, Hf), 1.60-1.69 (q, Hk), 1.74 (br m, Hg), 
1.81-1.87 (d, Hl), 1.83-1.88 (d, Hj), 1.93 (dt, Hn), 2.00-2.05 (d, He), 2.03-2.07 (d, Hm). 
For NMR spectra and further analysis, see Appendix B (section 9). 
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2.7 Screening protocols  
Refers to section 6. 
2.7.1 Fluorescamine methods 
Dopamine (100 μM), aldehyde (1 mM) and purified enzyme (25 μg.mL-1) were 
incubated for 1-3 h at 37 ˚C. Fluorescamine (10 mM in MeCN, 25% volume of the 
reaction) was added, the mixture was incubated for 5 minutes, and then the 
fluorescence was read on a plate reader (see section 2.4.3). 
2.7.2 Purpald® progress curve 
Mixtures containing 10 μL dopamine (100 mM) and 10 μL aldehyde (100 mM) and 80 
μL desalted lysate (0.1 mg.mL-1) in 0.1 M HEPES buffer (pH 7.5) were prepared. After 
10 minutes 40 μL of the reaction mixture was added to 40 μL Purpald® (100 mg.mL-1 in 
1N NaOH) and 40 μL was added to 10 μL 1M HCl. 40 μL of the acid quenched mixture 
was diluted with 100 μL H2O and analysed by HPLC by method 1. After 30 minutes the 
absorbance of the Purpald® mixtures were read according to the plate reading method 
described above (section 2.4.3). Concentration of aldehyde was determined by 
absorbance at 522 nm and quantified by comparison with standards.  
2.7.3 Full micro-scale screening protocol 
An aliquot from a frozen glycerol stock of plasmid containing E. coli BL21(DE3) was 
inoculated into 20 mL of TB medium (containing 50 µg.mL-1 kanamycin). Starter 
cultures were incubated overnight at 37 °C, shaking at 250 rpm. 24 µL of starter culture 
was used to inoculate 600 µL TB medium (containing 50 µg.mL-1 kanamycin) in deep-
well microtitre plates. The expression cultures were incubated for 2 hours at 37 °C 
followed by 1 hour at 25 °C, whilst shaking at 1,100 rpm. Expression was induced by 
the addition of 6 µL of 50 mM IPTG. Cultures were incubated for a further 3 hours at 25 
°C prior to harvesting, whilst shaking at 250 rpm. Cells were harvested by 
centrifugation at 4,000  g for 10 mins at 4 °C. Supernatant was removed and the cells 
stored at -20 °C until purification. Cell pellets were thawed and suspended in 
BugBuster (60 µL). Lysate was transferred to U-bottomed microtitre plates. The 
insoluble portion of the lysate was pelleted by centrifugation at 4,000  g for 10 mins at 
4 °C. 50 µL of the supernatant was desalted using a Zeba desalting plate (>7 kDa MW, 
prepared according to manufacturer’s instructions (ThermoFisher, Massachusetts, 
USA). Purpald® (10 mg.mL-1 in 1N NaOH), dopamine (100 mM in water) and aldehyde 
(100 mM in MeCN) stocks were prepared. 5 µL of dopamine stock and 5 µL of 
aldehyde stock were added to 40 µL of lysate (substrate final concentration of 10 mM). 
Reaction was mixed and incubated at 37 °C. After 10 minutes, 50 µL Purpald® solution 
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was added to quench the reaction. After 30 minutes incubation at room temperature, 
the absorbance of each mixture was recorded using the Purpald® plate reading method 
(see section 2.4.3). 
 
2.8 Chemicals and syntheses 
All reagents were obtained from commercial sources (Sigma-Aldrich, St. Louis, MO, 
USA) and used as received unless otherwise stated. Non-commercially available 
compounds were provided by Dr Thomas Pesnot and Dr Eleanor Lamming. 
2.8.1 Aldehydes 
4-hydroxyphenylacetaldehyde (4-HPAA), 3,4-dihydroxyphenylacetaldehyde (3,4-
DHPAA) and  3,4-methylenedioxyphenylacetaldehyde were synthesised by Dr Eleanor 
Lamming and Dr Thomas Pesnot as previously described.57,59,94 
2.8.2 Amines 
Syntheses of 3-hydroxyphenethylamine and 2-bromo,5-hydroxyphenylethylamine have 
been previously described.57,94 3,4-dihydroxyphenylpropylamine, N-methyl-3-hydroxy-
phenethylamine, 4,N-dimethyl-dopamine, and 3,5-dihydroxy-phenethylamine were 
synthesised by Dr Eleanor Lamming. 
2.8.3 Benzylisoquinoline alkaloids (BIAs) 
These compounds were used as analytical HPLC standards. Norcoclaurine, 1-(3-
hydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol (3-hydroxbenzaldehyde 
product),  1-(2,6-dimethylhept-5-en-1-yl)-1,2,3,4-tetrahydro-isoquinoline-6,7-diol 
(citronellal product), 1-(3,4-methylenedioxybenzyl)-1,2,3,4-tetrahydroisoquinoline-6,7-
diol (methylene-dioxy-phenylacetaldehyde product) and 1-benzyl-1,2,3,4-
tetrahydroisoquinoline-6,7-diol (phenylacetaldehyde product) syntheses have been 
described previously.59,94 The characterisation of the novel hexanal product (Pentyl-
1,2,3,4-tetrahydroisoquinoline-6,7-diol) is described above (section 2.6.1). Compounds 
norlaudanosoline and 1-(3-Hydroxybenzyl)-1,2,3,4-tetrahydroisoquinolin-6-ol (from 
triangular cascade, section 5.4.8) were synthesised by Dr Eleanor Lamming according 
to the standard phosphate method and are described below.59 Racemic 
tetrahydroprotoberberines (THPBs) were synthesised and characterised by Dr Tom 
Pesnot and are described below, section 2.8.5. 
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2.8.4 Chemical syntheses of BIAs  
These syntheses were performed by Dr Eleanor Lamming, but have been included for 
completeness. 
Synthesis of norlaudanosoline 
 (3,4-Dihydroxyphenyl)acetaldehyde* 
 
(3,4-Dihydroxyphenyl)acetaldehyde (3,4-DHPAA) was prepared by the Parikh-Doering 
oxidation of 4-(2-hydroxyethyl)benzene-1,2-diol124 (500 mg, 3.24 mmol). To a solution 
of 4-(2-hydroxyethyl)benzene-1,2-diol (1 eq.) in DMSO/CH2Cl2 (15 mL) was added 
N,N-diisopropylethylamine (2.5 eq.) followed by a solution of SO3.pyridine (2.5 eq.) in a 
1:1 mixture of DMSO/CH2Cl2 (10 mL), added over 30 min at -15 ºC. The mixture was 
stirred for 1 h at -15 ºC and quenched by the addition of ice-cold water (50 mL). The 
aqueous layer was extracted with CH2Cl2 (3  50 mL) and the organic layers were 
combined and concentrated under reduced pressure. The crude material was purified 
using flash silica chromatography (60% EtOAc in hexane) to give (3,4-
dihydroxyphenyl)acetaldehyde as a pale yellow oil (212 mg, 43%).57,125 Rf 0.15 
(EtOAc:hexane, 1:1); 1H NMR (600 MHz; CDCl3) δ = 3.59 (2H, d, J = 2.4 Hz, CH2), 
5.51 (1H, br s, OH), 5.76 (1H, br s, OH), 6.64 (1H, dd, J = 8.0 and 2.0 Hz, 6-H), 6.70 
(1H, d, J = 2.0 Hz, 2-H), 6.85 (1H, d, J = 8.0 Hz, 5-H), 9.69 (1H, t, J 2.4 Hz, CHO); 13C 
NMR (150 MHz; CDCl3) δ = 49.9, 115.9, 116.6, 122.3, 124.2, 143.1, 144.0, 200.6; m/z 
[HRMS ES+] found [M]+ 152.04679. C8H8O3 requires 152.04680. 
 Norlaudanosoline* 
 
Norlaudanosoline/tetrahydropapaveroline was prepared by a biomimetic Pictet-
Spengler reaction. Dopamine.HCl (75 mg, 0.39 mmol) and (3,4-
dihydroxyphenyl)acetaldehyde (40 mg, 0.26 mmol) were added to 6 mL of a 1:1 
                                               
*This synthesis was conducted by Dr Eleanor Lamming 
*This synthesis was conducted by Dr Eleanor Lamming 
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mixture of acetonitrile/potassium phosphate buffer (0.1 M solution at pH 6). The 
resulting solution was stirred at 50 ºC for 12 h. The crude product was concentrated in 
vacuo, then purified by preparative-HPLC (method 4, rt (retention time) 11.5 min). 
Fractions containing the desired product were combined, concentrated and co-
evaporated with methanol (3  20 mL) to give 1-(3,4-dihydroxybenzyl)-1,2,3,4-
tetrahydroisoquinoline-6,7-diol as a colourless oil (46 mg, 61%).126 1H NMR (600 
MHz; CD3OD) δ = 2.86–3.02 (3H, m, 4-H2 and NCHCHH), 3.23 (1H, app. quintet, J = 
6.0 Hz, 3-HH), 3.30‒3.36 (1H, m, NCHCHH), 3.44 (1H, app. quintet, J = 5.9 Hz, 3-HH), 
4.54 (1H, dd, J = 8.8 and 5.6 Hz, 1-H), 6.61‒6.65 (3H, m, 5-H, 8-H and 6'-H), 6.74 (1H, 
d, J = 1.7 Hz, 2'-H), 6.78 (1H, d, J = 8.0 Hz, 5'-H); 13C NMR (150 MHz; CD3OD) δ = 
25.7, 40.7, 40.9, 57.9, 114.0, 116.1, 116.9, 117.4, 121.8, 123.6, 123.8, 127.7, 145.8, 
146.1, 146.6, 146.8; m/z [HRMS ES+] found [M+H]+ 288.1236. C16H18NO4 requires 
288.1233. 
Synthesis of 1-(3-hydroxybenzyl)-1,2,3,4-tetrahydro-isoquinolin-6-ol 
2-(3-Hydroxyphenyl)ethylamine hydrobromide* 
 
The reaction was performed under anhydrous conditions. A solution of 1 M boron 
tribromide in CH2Cl2 (10.2 mL, 10.2 mmol) was added to a stirred solution of 2-(3-
methoxyphenyl)ethan-1-amine (0.700 g, 4.63 mmol) in CH2Cl2 (20 mL) at -78 
oC under 
Ar.  The reaction was warmed to room temperature and stirred for 24 h.  The reaction 
was then cooled to 0 oC and quenched by addition of methanol (40 mL).  The solution 
was stirred at room temperature for 3 h.  The solution was concentrated in vacuo to 
give a brown oil.  Further methanol (20 mL) was added, and solvent evaporated.  This 
was repeated until no white fumes were observed upon addition of methanol, to give 2-
(3-hydroxyphenyl)ethylamine as a pale brown solid as the hydrobromide salt which was 
used without further purification (0.899 g, 89%).127 m.p. 102-104 oC; 1H NMR (600 
MHz; CD3OD) δ = 2.88 (2H, t, J = 8.0 Hz, CH2CH2N), 3.15 (2H, t, J = 8.0 Hz, CH2N), 
6.68-6.72 (2H, m, 2-H and 4-H), 6.73 (1H, d, J = 7.5 Hz, 6-H), 7.16 (1H, t, J = 7.5 Hz, 
5-H); 13C NMR (150 MHz; CD3OD) δ = 34.5, 41.9, 115.2, 116.6, 120.7, 131.0, 139.3, 
159.1; m/z [HRMS ES+] found [M+H]+ found 138.091213. C8H11ON requires 
138.09189.  
                                               
* This synthesis was conducted by Dr Eleanor Lamming 
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2-(3-Hydroxyphenyl)acetaldehyde* 
 
2-(3-Hydroxyphenyl)acetaldehyde was prepared by Parikh-Doering oxidation of 2-(3-
hydroxylphenyl)ethanol (500 mg, 3.62 mmol). To a solution of 2-(3-
hydroxylphenyl)ethanol (1 eq.) in DMSO/CH2Cl2 (15 mL) was added N,N-
diisopropylethylamine (2.5 eq.) followed by a solution of SO3.pyridine (2.5 eq.) in a 1:1 
mixture of DMSO/CH2Cl2 (10 mL) added over 30 min at -15 ºC. The mixture was stirred 
for 1 h at -15 ºC and quenched by the addition of ice-cold water (50 mL). The aqueous 
layer was extracted with CH2Cl2 (3  50 mL) and the organic layers were combined and 
concentrated under reduced pressure. The crude material was purified using silica 
flash chromatography (eluent 20% EtOAc in hexane). Fractions containing the desired 
product were combined and concentrated under reduced pressure. Purification by flash 
silica chromatography (15% EtOAc in hexane) yielded 2-(3-
hydroxyphenyl)acetaldehyde as a pale yellow oil (100 mg, 20%).128 Rf 0.47 
(EtOAc:hexane, 1:1); 1H NMR (500 MHz; CDCl3) δ = 3.64 (2H, d, J = 2.4 Hz, CH2), 
5.46 (1H, br s, OH), 6.69 (1H, t, J = 2.0 Hz, 2-H), 6.75‒6.79 (2H, m, 4-H and 6-H), 7.23 
(1H, t, J = 6.4 Hz, 5-H), 9.73 (1H, t, J = 2.4 Hz, CHO); 13C NMR (125 MHz; CDCl3) δ = 
50.4, 114.6, 116.6, 122.0, 130.3, 133.4, 156.3, 199.8; m/z [HRMS ES+] found [M]+ 
136.05206. C8H8O2 requires 136.05188.  
1-(3-Hydroxybenzyl)-1,2,3,4-tetrahydroisoquinolin-6-ol* 
 
A solution of 2-(3-hydroxyphenyl)acetaldehyde (27.2 mg, 0.200 mmol) in acetonitrile (2 
mL) was added to a solution of 2-(3-hydroxyphenyl)ethylamine (35.0 mg, 0.160 mmol) 
in potassium phosphate buffer (2 mL, 0.1 M, pH 6).  The solution was stirred at 50 oC 
for 17 h.  The reaction was concentrated and purified by preparative-HPLC (method 5, 
rt = 30 min).  Fractions containing the desired product were combined, concentrated 
and co-evaporated with methanol (3 x 10 mL), to give 1-(3-Hydroxybenzyl)-1,2,3,4-
                                               
* This synthesis was conducted by Dr Eleanor Lamming 
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tetrahydro-isoquinolin-6-ol as a pale yellow oil (15.0 mg, 37%).  1H NMR (CD3OD; 600 
MHz) δ = 2.96-3.03 (2H, m, 4-HH and NCHCHH) 3.05-3.12 (1H, m, 4-HH), 3.26-3.31 
(1H, m, 3-HH), 3.40-3.45 (1H, m, NCHCHH), 3.46-3.52 (1H, m, 3-HH), 4.66-4.70 (1H, 
m, 1-H), 6.65 (1H, s, 5-H), 6.68 (1H, d, J = 8.5 Hz, 7-H), 6.73-6.80 (3H, m, 2`-H, 6`-H, 
4`-H), 7.03 (1H, d, J = 8.5 Hz, 8-H), 7.12 (1H, t, J = 7.5 Hz, 5`-H); 13C NMR (150 MHz; 
CD3OD) δ = 24.9, 39.1, 39.6, 56.2, 114.1 (2 x signals), 114.5, 115.8, 119.9, 122.0, 
127.5, 129.7, 132.4, 136.4, 157.0, 157.7); m/z [HRMS ES+] found [M+H]+ 256.133461. 
C16H18O2N requires 256.13375. 
2.8.5 Chemical syntheses of THPBs 
These syntheses were performed by Dr Thomas Pesnot, but have been included for 
completeness. 
Synthesis of 6,8,13,13a-tetrahydro-5H-isoquinolino[3,2-a]isoquinoline-
2,3,10,11-tetraol, and 6,8,13,13a-tetrahydro-5H-isoquinolino[3,2-a]isoquinoline-
2,3,9,10-tetraol* 
 
Norlaudanosoline (30 mg, 100 µmol) and formaldehyde (15 µL, 0.20 mmol) were 
added to a 1:1 mixture of acetonitrile/potassium phosphate buffer (0.5 M solution at pH 
6, 3 mL). The solution was stirred at 40 ºC for 0.5 h. The crude product was purified by 
preparative-HPLC (method 4) and fractions containing the desired product were 
combined, concentrated and co-evaporated with methanol (3  20 mL). Two products 
were isolated 6,8,13,13a-tetrahydro-5H-isoquinolino[3,2-a]isoquinoline-2,3,10,11-
tetraol129 (22.6 mg, 72%, RT (retention time) 11.6 min) and 6,8,13,13a-tetrahydro-5H-
isoquinolino[3,2-a]isoquinoline-2,3,9,10-tetraol129 (5.3 mg, 17% RT 12.6 min).  
Major regioisomer 6,8,13,13a-tetrahydro-5H-isoquinolino[3,2-a]isoquinoline-
2,3,10,11-tetraol: 1H NMR (600 MHz; CD3OD) δ = 2.88‒3.03 (2H, m, 5-HH and 13-
HH), 3.12‒3.23 (1H, m, 5-HH), 3.48 (1H, td, J = 12.3 and 4.5 Hz, 6-HH), 3.58‒3.66 
(1H, m, 13-HH), 3.75‒3.82 (1H, m, 6-HH), 4.38-4.50 (2H, m, 8-H2), 4.67 (1H, dd, J = 
11.9 and 4.6 Hz, 13a-H), 6.62 (1H, s, 9-H), 6.64 (1H, s, 4-H), 6.71 (1H, br.s, 12-H), 
                                               
* This synthesis was conducted by Dr Thomas Pesnot 
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6.79 (1H, br.s, 1-H); 13C NMR (150 MHz; CD3OD) δ = 24.8, 32.7, 51.0, 55.1, 60.5, 
111.3, 111.7, 114.4, 114.5, 117.6, 117.9, 121.6, 122.3, 144.7, 144.8, 145.4, 145.6; m/z 
[HRMS ES+] found [M+H]+ 300.1228. C17H18NO4 requires 300.1236.  
Minor regioisomer 6,8,13,13a-tetrahydro-5H-isoquinolino[3,2-a]isoquinoline-
2,3,9,10-tetraol: 1H NMR (600 MHz; CD3OD) δ = 2.93 (1H, br.d, J = 16.8 Hz, 5-HH), 
3.02 (1H, dd, J = 16.8 and 12.3 Hz, 13-HH), 3.16-3.25 (1H, m, 5-HH), 3.53 (1H, td, J = 
12.2 and 4.7 Hz, 6-HH), 3.67 (1H, dd, J = 16.8 and 4.0 Hz, 13-HH), 3.88 (1H, dd, J = 
12.2 and 4.6 Hz, 6-HH), 4.31 (1H, d, J = 15.7 Hz, 8-HH), 4.66 (1H, dd, J = 12.3 and 4.0 
Hz, 13a-H), 4.73 (1H, d, J = 15.7 Hz, 8-HH), 6.65 (1H, s, 4-H), 6.67 (1H, d, J = 8.2 Hz, 
12-H), 6.77-6.82 (2H, m, 1-H and 11-H); 13C NMR (150 MHz; CD3OD) δ = 26.5, 34.3, 
52.7, 53.4, 61.7, 112.9, 115.9, 166.4, 120.3, 123.3, 123.5, 123.6, 123.8, 143.1, 144.6, 
146.5, 146.9; m/z [HRMS ES+] found [M+H]+ 300.1219. C17H18NO4 requires 300.1236.  
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 Chapter 3: Expression and purification of TfNCS 3
3.1 Introduction 
The enzyme Δ19TfNCS was selected to investigate the mechanism of NCS because it 
is the most studied enzyme in the literature. It was the first NCS to be isolated15 and 
subsequently the first to be cloned and recombinantly expressed.34 It has been 
examined with regards to its mechanism,51 its substrate scope53 and its structure.43,55 
The availability of Δ19TfNCS X-ray structures was the crucial factor in selecting the 
enzyme, because mutations and their effect on mechanism can only be fully 
understood in a structural context. 
Samanami et al originally obtained the cDNA for the TfNCS gene from Thalictrum 
flavum cell cultures, using PCR with degenerate primers based on the peptide 
sequence of the isolated enzyme.34 However, the full length gene did not produce 
recombinant protein. Genes encoding for N-terminal truncates of 10 and 19 residues 
(and a C-terminal His-Tag) both produced detectable and active recombinant NCS. 
Comparison with related PR-10 proteins revealed unique N- and C-terminal extensions 
on TfNCS. A 19 residue N-terminal signal peptide was predicted from the sequence 
which led to the original decision to use Δ19TfNCS for mechanistic and structural 
studies.34 
3.2 Expression of Δ19TfNCS 
3.2.1 ‘Dimer’ observation 
A gene encoding a C-terminal His-tagged Δ19TfNCS was obtained and cloned into a 
pET29a vector (see section 2.1.1).* Recombinant expression and purification of 
Δ19TfNCS appeared to provide a 44 kDa protein, with approximately 80% purity (Fig. 
3.1A). This protein was approximately double the expected size of Δ19TfNCS (22.1 
kDa), and was initially proposed to be a dimer form of the enzyme. However, 
incubation of the dimer with increasing concentrations of DTT failed to result in the 
observation of any monomer species by SDS-PAGE, perhaps suggesting a particularly 
tight dimer association (Fig. 3.1B).  
                                               
* The cloning of Δ19TfNCS was performed by Dr Markus Gershater 
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Fig. 3.1 Purification of 44 kDa protein. A: Purification of 44 kDa protein from Δ19TfNCS expressing 
cells. Lane 1: lysate; 2: wash 20mM imidazole; 3: elution 250 mM imidazole. The 44 kDa protein (marked 
with arrow) was obtained with approximately 80% purity. These fractions were used for initial Δ19TfNCS 
activity assays (see Fig. 3.2). B: Treatment of 44 kDa protein fraction with DTT. Lane 1: 0 M DTT; 2: 0.2 M 
DTT; 3: 0.5 M DTT. 44 kDa protein of interest marked with arrow. Gradient gel (4-20%) used. 
 
The elution fraction containing this protein was shown to exhibit Pictet-Spengler activity 
(Fig. 3.2). For example, approximately 10% conversion was observed with wild-type 
(WT) enzyme over 3 hours (0.45 mg.mL-1, 1 mM dopamine, 1.5 mM 4-HPAA). Although 
it was not possible to directly compare this with previously measured specific activities 
or kinetic parameters, the low conversions suggested orders-of-magnitude lower 
activity than expected. Variants of Δ19TfNCS were produced by site-directed-
mutagenesis with the intention of examining the substrate binding and mechanism of 
the enzyme. These demonstrated a diverse range of activities. The mutations Y108F, 
E110D/Q, D141N and M183F/L removed nearly all enzyme activity. L76A, F80L, F99L 
and A182F seemed to cause a relative shift in substrate specificity. The mutation A79I 
appeared to cause an increase in activity. However, despite these promising 
preliminary results, attempts to repeat the purification and assays of Δ19TfNCS and its 
variants proved unsuccessful. 
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Fig. 3.2 Δ19TfNCS activities (44 kDa fraction). Reaction conditions: 1 mM dopamine, 1.5 mM aldehyde. 
Final protein concentration varied between 0.05 – 0.75 mg.mL
-1
 (approximately 80% of this is the 44 kDa 
protein). Solid bars: 4-HPAA, white bars: heptanal. Product peak area is raw HPLC data and does not 
account for differences in absorbance in different products. Values are the mean of two measurements, 
error bars are standard deviations. 
 
Expression of an empty vector control revealed a 44 kDa protein that bound to the 
nickel column at concentrations greater than 40 mM imidazole (Fig. 3.3A). This 
suggested that the 44 kDa NCS ‘dimer’ was merely a native E. coli His-rich protein. 
The most likely candidate for this protein was ODO2, component E2 of the 
dihydrolipoamide succinyl transferase, which has previously been shown to bind to His-
trap columns and only elute at imidazole concentrations of approximately 50 mM.130 
The addition of a wash step with higher imidazole concentrations (up to 50 mM) 
removed this contaminant from the Δ19TfNCS enzyme preparation (Fig. 3.3B, Lane 7). 
Furthermore, it became apparent that the Δ19TfNCS bound to the column with high 
affinity; the use of 250 mM imidazole was insufficient to remove the majority of the 
protein from the column and 500 mM was required (Fig. 3.3B, Lane 8). The origin of 
NCS activity observed in the fractions containing mostly the 44 kDa protein was likely 
to be small contaminating quantities of monomeric Δ19TfNCS, not detectable by SDS-
PAGE. 
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Fig. 3.3 Purification of monomeric Δ19TfNCS. A: Purification of 44 kDa His-rich protein from empty pET 
vector control. His-trap media was washed with 40 mM imidazole wash buffer (not shown). The major 
component of elution with 50 mM EDTA was a 44 kDa protein (marked by arrow). B: Purification of 
Δ19TfNCS (L76V). Lane 1: Supernatant; 2-4: column flow through; 5-6: Wash (20-30 mM imidazole); 7: 
Wash (40-50 mM imidazole); 8: Elution (500mM imidazole). The His-rich 44 kDa protein (Lane 7, marked 
with an arrow) elutes from the column at 40-50 mM. Monomeric Δ19TfNCS elutes at high imidazole 
concentrations (lane 8); there appears to be two closely running bands (marked with arrows). 
 
3.2.2 Evidence of cleavage in vivo 
A more thorough exploration of the purification conditions of Δ19TfNCS led to the 
identification of two isoforms of NCS; these bound to the nickel column more tightly 
than the 44 kDa protein and eluted from the column at a higher imidazole concentration 
(>250 mM imidazole) (Fig. 3.3B, Lane 8; Fig. 3.4). These forms seemed to correspond 
to the Δ19TfNCS monomer and the N-terminal truncate Δ29TfNCS, the latter 
previously identified through N-terminal sequencing by Berkner et al.52 Cleavage of 
recombinant Δ19TfNCS in E. coli was not affected by the presence of protease 
inhibitors. However, it was not clear what conditions cause the cleavage event to occur: 
a number of research groups have expressed recombinant Δ19TfNCS in BL21(DE3) 
without reporting purification problems or this cleavage event.43,51,53 
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Fig. 3.4 Δ19TfNCS in situ cleavage. A: Δ19TfNCS purification. His-Trap column washed with 50 mM 
imidazole (not shown). Lanes 1-4: Elutions with increasing imidazole concentrations (100-500 mM). His-
rich 44 kDa protein observed (lane 1 and 2, marked with an arrow). Possible Δ19TfNCS observed in lane 
2, marked with arrow. Possible Δ29TfNCS observed in lane 4, marked with arrow. Gradient gel (4-20%) 
used. B: Verification of two eluents with different sizes. Lane 1 is identical to fraction 2 from (A); lane 3 is 
fraction 4 from (A); lane 2 is mixture of fractions. Lane 1 is Δ19TfNCS (22.1 kDa but runs as 25.0 kDa); 
lane 3 is Δ29TfNCS (21.2 kDa but runs as 23.5 kDa). 
3.2.3 Δ19TfNCS aggregation 
In Δ19TfNCS expressing cells, significant Pictet-Spengler activity was observed in the 
insoluble fraction after cell lysis (Fig. 3.5A). SDS-PAGE analysis of the insoluble 
fraction showed the presence of monomeric Δ19TfNCS (Fig. 3.5B). It was notable that 
the insoluble protein did not form an inactive precipitate, but an active oligomer.  
 
Fig. 3.5 Activity in the Δ19TfNCS insoluble fraction. A: Pictet-Spengler activity in Δ19TfNCS lysate 
before and after centrifugation. Activity is present in the insoluble fraction. Solid bars: non-boiled samples; 
clear bars: boiled controls. After centrifugation, the insoluble fraction was resuspended in HEPES buffer for 
use in assay. Activity in the supernatant control is a result of the non-enzymatic chemical rate. Values are 
the mean of two measurements, error bars are standard deviations; data is from HPLC peak area. B: SDS-
PAGE analysis of Δ19TfNCS insoluble fraction: Lane 1: Lysate; 2: Pellet. Δ19TfNCS monomer is enriched 
in the pellet (arrow). 
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A resuspension of the insoluble Δ19TfNCS oligomer with lysozyme and BugBuster 
produced a solution that demonstrated norcoclaurine synthase activity. This activity 
was removed through centrifugation, showing that the original precipitation was not 
caused by inefficient lysis of the E. coli but was indeed insoluble NCS. If insufficient 
lysis was occurring, then the second lysozyme/BugBuster step would leave fully 
soluble NCS that would not be removed by centrifugation. Further resuspension and 
filtration of the precipitate led to complete loss of Δ19TfNCS, indicating that the protein 
remained insoluble in particles greater than 0.2 µm (Fig. 3.6). It is worth noting that 
conditions required for SDS-PAGE preparation (50 mM DTT, 95 °C 5 mins) was 
sufficient to break any oligomers into Δ19TfNCS monomers. 
 
Fig. 3.6 Purification of Δ19TfNCS insoluble oligomers. SDS-PAGE analysis of purification of insoluble 
oligomers. Lane 1: Pellet; 2: supernatant; 3: post-lysozyme supernatant; 4: post-lysozyme pellet; 5: post-
lysozyme pellet resuspension; 6: post-lysozyme pellet resuspension filtered. Lysozyme highlighted in lane 
3; Δ19TfNCS insoluble monomer highlighted in lane 4 and 5. 
 
3.3 Expression and purification of Δ29TfNCS 
To eliminate problems associated with expressing Δ19TfNCS, a gene encoding 
Δ29TfNCS was obtained.52 The Δ29TfNCS protein was highly over-expressed and 
soluble. The enzyme was purified to 99% purity with bench-top affinity chromatography 
alone (Fig. 3.7). A wash step with 40 mM imidazole was sufficient to remove all native 
E. coli His-rich proteins and 500 mM imidazole was used to elute the protein. This 
enzyme was active and was used for subsequent investigations. In a similar manner to 
the Δ29TfNCS obtained via in situ cleavage (Fig. 3.4), the 21.2 kDa protein was 
observed at around 23.5 kDa on the SDS-PAGE gel.  
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Fig. 3.7 Δ29TfNCS purification. LHS Lane 1: lysate; 2: pellet; 3: flow-through; 4-5: 20 mM imidazole 
wash; 6-8: 40 mM imidazole wash; RHS Lane 1-8: 500 mM imidazole elution. Native 45 kDa protein 
highlighted in LHS lane 5; overexpressed Δ29TfNCS monomer highlighted in LHS lane 8. 
3.4 CjNCS2 expression 
Following on from the work conducted by Pesnot et al, CjNCS2 was expressed and 
purified for use in biotransformations.57 The gene for CjNCS2 used has no N-terminal 
truncation and therefore contains the entire N-terminal signal peptide (Table 3.1). 
Unlike TfNCS, however, this peptide does not preclude purification of the active 
monomer (Fig. 3.8).34  
 
Fig. 3.8 CjNCS2 expression. SDS-PAGE analysis of CjNCS2 purification. Lane 1: Cell lysate; 2-3:Flow-
through; 4-5: 30 mM imidazole; 6-7: 100 mM imidazole; 8-11: 200 mM imidazole. CjNCS2 highlighted in 
Lane 1. Potential N-terminal cleaved CjNCS2 highlighted in lane 5. CjNCS2 and 44 kDa His-rich protein 
highlighted in lanes 8-11. 
CjNCS2 precipitated at high concentrations, behaviour seen with Δ19TfNCS but not 
Δ29TfNCS. Also, the pelleted insoluble fraction after cell lysis contained considerable 
quantities of the protein monomer (Fig. 3.9; Lane 1). It is possible that it is the N-
terminal extension of CjNCS2 that causes these purification characteristics. Despite 
this, CjNCS2 monomer purified sufficiently well for application in biotransformations. 
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Fig. 3.9 CjNCS2 pellet. SDS-PAGE analysis of CjNCS2 purification. Lane 1: pellet (insoluble fraction); 2: 
Lysate; 3: Flow-through; 4: Purified CjNCS2. Monomeric CjNCS2 is highlighted (seen in Lanes 1 and 4). 
 
3.5 N-terminal truncates of CjNCS2 have been recently examined 
by the Sato group.61 The Δ10CjNCS2, Δ19CjNCS2 and 
Δ29CjNCS2 proteins appeared to express better than CjNCS2, 
but Δ19CjNCS2 and Δ29CjNCS2 showed increased insolubility. 
The protein Δ42CjNCS2 did not appear to express. The 
Δ29CjNCS2 enzyme was shown to have the highest activity 
compared to the other proteins and was then tested with a 
number of different substrates. This study further highlights 
the importance of using truncations when expressing 
eukaryotic proteins in E. coli. Δ19TfNCS structural analysis  
The effect of residues 19 to 28 on the behaviour of recombinant NCS was 
demonstrated by the differences between Δ19TfNCS and Δ29TfNCS. The former was 
largely insoluble (though remains active) and was cleaved within E. coli. The latter was 
soluble and highly expressed.  
The X-ray crystal structures of Δ19TfNCS provide interesting insight into how the 
residues 19-28 may affect the behaviour of the protein. In the crystal structures from 
Ilari et al these residues appear to mediate the formation of the crystallographic 
tetramer.43 The tetramers feature 2 asymmetric units, each containing a single dimer. 
The dimer interaction is stabilised by the presence of a β-strand between the two 
monomers; this causes the formation of a continuous β-sheet through the length of the 
dimer (Fig. 3.10). The β-strand in question is the N-terminal sequence from a monomer 
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in the other symmetry related dimer (Fig. 3.10A). This interaction leads to stable, tight 
tetrameric packing, and ultimately to a dense network of interconnected β-sheets 
stretching through 2 dimensions of the crystal (Fig. 3.10B). 
 
Fig. 3.10 Δ19TfNCS crystal structure packing. A: Cartoon representation of asymmetric units in 
2VQ5
43
. Red and blue cartoons show subunits A. Cyan and yellow show subunits B. Note the subunit A N-
terminal β-strand that mediates the interaction between subunits A and B in the adjacent dimer. B: 
Cartoon representation of crystal packing interactions across four crystallographic unit cells (expanded in y 
and z dimensions). β-sheets are coloured blue, loops and helices are white with outlines. Notice the 
continuous β-sheets formed across unit cells in the crystal due to the N-terminal β-strand. 
Computational analysis of the Δ19TfNCS sequence demonstrates that the N-terminal 
residues have a strong tendency toward forming β-strands. Betascan analysis shows a 
strong probability of β-strand formation in this region: it strongly predicts a β-strand 
involving residues 3 to 8 (Fig. 3.11).120 As this N-terminal β-strand is not part of the 
general globular fold, it is highly probably that it will form β-strand interactions in a 
promiscuous manner, such as with other monomers to form oligomers.  
It is possible that the N-terminal β-strands mediate the polymerisation of recombinant 
Δ19TfNCS to form an insoluble, active precipitates. The oligomer may exist as a 
‘beads-on-a-string’ type structure: a long continuous amyloid-like β-sheet running 
through its length, monomers connected via the N-terminal β-strand, NCS active sites 
on each surface. This would be a similar structure to that observed in the crystal 
structure packing (Fig. 3.10B). For biotechnological applications of NCS, these active 
oligomers may be of some use as they are essentially immobilised enzymes. It may 
even be possible to graft different enzymes onto the structure of such a structure, 
making it a more general tool for immobilising biocatalysts. Further characterisation of 
this insoluble Δ19TfNCS is required to understand its structure and potential 
application. 
A B
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Fig. 3.11 Betascan analysis of Δ19TfNCS. Heat-map of β-strand probabilities (odd residues 
exposed). Red shows high probability of β-strand formation, blue a low probability. Residues 2 to 8 of the 
expressed protein have a high probability of forming a β-strand (7 residues long). However, these residues 
do not form part of the globular structure of the protein and so may form promiscuous intermolecular 
connections. 
3.6 Discussion 
It is unclear what role the N-terminal sequence plays in the native enzyme and whether 
it remains attached to active NCS in planta. It is known from the original cDNA derived 
sequence that the native protein includes a longer N-terminal extension that acts as a 
signal peptide, causing relocation to an organelle within the plant. The first 19 residues 
at the N-terminus of TfNCS (and CjNCS2) are predicted to be a signal peptide by 
SignalP, an algorithm capable of predicting signal peptides (Table 3.1).131  The 
enzymes PsNCS1 and PsNCS2, active in Papaver somniferum, also have a similar N-
terminal extension, though, PbNCS from P. bracteatum does not.44 Signal peptides 
cause proteins to localise to the endoplasmic reticulum, often before transportation into 
a vesicle for secretion or for localisation into other membrane bound organelles.  
The crystal structure of Δ19TfNCS shows that a number of residues on the N- and C-
termini of the enzyme—that are not accounted for by signal peptide prediction—are not 
part of the main globular fold of the enzyme. At the N-terminal, the main globular fold of 
the protein only begins with the β-strand beginning at residue 42. In subunit A residues 
19-27 form the crystal packing mediating β-strand (see section 3.5), 28-33 are not 
present (disordered) and 36-41 form a small α-helix with limited contacts with the main 
fold. Residues 19-41 of subunit B are disordered and not visible in the crystal structure 
(Table 3.1). 
The situation at the C-terminal is similar; the globular fold ends around residue 193, but 
there are around 20 subsequent residues not present. In subunits A and B residues 
197-217 and 194-217 are disordered, respectively. Although it is common for the ends 
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of proteins to be disordered in crystal structures, in this instance significant lengths of 
the protein are unstructured and extend beyond the main fold. It is unlikely that these 
portions of the enzyme are required for activity, as the enzyme reaction requires no co-
factor recycling and there is little suggestion of any significant conformational changes 
occurring in catalysis.54 Instead these sequences may play a role in the localisation of 
NCS and its association with other proteins and membranes. 
By using an NCS-GFP fusion, with GFP fused to the C-terminus of PsNCS2, it was 
observed in P. somniferum that after expression NCS is transported to the central 
vacuole, via the endoplasmic reticulum.44 In general, vacuolar localisation is directed by 
a propeptide, which can be found either at the N- or C-terminus of the protein. When at 
the N-terminus, the vacuolar directing propeptide sequence typically sits between an N-
terminal signal peptide and the C-terminal protein sequence.132 There are 
approximately ten residues between the signal peptide and the globular NCS protein—
these residues are possibly the vacuolar-targeting propeptide. This would be an 
analogous case to the Berberine Bridge Enzyme (BBE), which has both a signal 
peptide and vacuolar sorting element on the N-terminus. BBE is localised to the same 
tissues and cellular compartments as NCS.18,44 It is notable that a different signal 
peptide prediction algorithm, SOSUIsignal, predicts the N-terminal peptide of TfNCS to 
extend for 27 residues: this prediction incorporates the proposed vacuolar localisation 
sequence (Table 3.1).133 The C-terminus of NCS may also have a sorting role: 
PsNCS1, PsNCS2 and PbNCS have significant C-terminal extensions of around 30 
residues beyond the predicted domain; TfNCS and CjNCS2 have shorter extensions of 
16 and 6 residues respectively.44  
This close association of NCS and other BIA enzymes with the membrane and 
membrane bound organelles suggests that there is a role for the transmembrane 
trafficking of pathway intermediates. This prediction has implications for NCS, its 
background reaction and attempts to use it in recombinant in vivo scenarios: in plants 
the substrates may be synthesised in close proximity to an enzyme that catalyses the 
next step, increasing the rate (through the increase in local concentration) and reducing 
the chance of background catalysis. 
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Table 3.1 Sequence and structural analysis of TfNCS N-terminus. Signal peptide prediction using 
SignalP
131
 and SOSUISIGNAL.
133
 X-ray structure analysis using subunits A and B of 2VQ5.
43
 Key for 
structure: n/p, electron density not present; α, α-helix; β, β-strand. For TfNCS SignalP predicts a 19 
residue signal peptide (for ER targeting). SOSUISIGNAL predicts a 27 residue signal peptide. The 8 
residue difference can be accounted for by vacuolar propeptide signal. X-ray structure analysis shows 
main globular fold only begins at residue 42. Prior to residue 42 much of the polypeptide is not present due 
to disorder. Subunit A forms an N-terminal β-strand interaction and a short α-helix prior to the main fold. 
Lines in table show N-terminal starting points of the truncates Δ19TfNCS and Δ29TfNCS. SignalP and 
SOSUISIGNAL are both signal peptide predictors but use different algorithms. 
TfNCS Peptide prediction X-ray 2VQ5 
Residue SignalP SOSUI A B 
1 M         
2 M     
  3 K     
  4 M     
  5 E     
  6 V     
  7 V     
  8 F     
  9 V     
  10 F     
  11 L     
  12 M     
  13 L     
  14 L     
  15 G     
  16 T     
  17 I     
  18 N     
  19 C         
20 Q     β n/p 
21 K     β n/p 
22 L     β n/p 
23 I     β n/p 
24 L     β n/p 
25 T     β n/p 
26 G     β n/p 
27 R     β n/p 
28 P     n/p n/p 
29 F     n/p n/p 
30 L     n/p n/p 
31 H     n/p n/p 
32 H     n/p n/p 
33 Q     n/p n/p 
34 G     loop n/p 
35 I     loop n/p 
36 I     α n/p 
37 N     α n/p 
38 Q     α n/p 
39 V     α n/p 
40 S     α loop 
41 T     loop loop 
42 V     Main fold 
43 T     Main fold 
44 K     Main fold 
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There is also a fascinating role for protein aggregation in the intracellular trafficking of 
enzymes. Aggregation is accepted to have a role in sorting proteins into vacuoles.134,135 
For example, secreted proteins may be in dense vesicles as aggregates prior to 
secretion.134 BIA enzymes are expected to be synthesised in companion cells before 
being secreted into sieve elements, so aggregation-sorting is one possible mechanism 
for this.136 The identification of the insoluble Δ19TfNCS certainly shows that the N-
terminal extension increases the aggregation propensity of the enzyme, and the 
observation of activity even raises the possibility that the enzyme could be an active 
oligomer in plants. The ideal experiments to elucidate the roles of the protein termini 
would be to introduce genes coding for fluorescently labelled fusion proteins with 
different peptide extensions on the C- and N-termini. The localisation of these proteins 
could then be followed visually. 
3.7 Summary 
The original enzyme intended for use, Δ19TfNCS was chosen as it is well studied and 
structural information is available. However, it was prone to aggregation and unsuitable 
for use. Removing 10 residues from the N-terminus was sufficient to correct expression 
and purification problems. The resulting enzyme Δ29TfNCS expressed with high yields, 
was soluble and was easy to purify. It was therefore an ideal enzyme to use in further 
mechanistic and biocatalytic studies. The N-terminus of NCS that effects enzyme 
solubility is likely to be involved in planta with cellular localisation and membrane 
association. 
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 Chapter 4: NCS Mechanism 4
4.1 Introduction 
4.1.1 The Pictet-Spengler reaction 
The Pictet-Spengler reaction involves the formation of an imine (Schiff base) followed 
by an electrophilic aromatic substitution. The two classic Pictet-Spengler reactions are 
tetrahydroisoquinoline (THIQ) synthesis and tetrahydro-β-carboline synthesis (Fig. 
4.1).24 In plants, these reactions are catalysed by NCS and strictosidine synthase 
(STR) respectively. 
 
Fig. 4.1 Two classic Pictet-Spengler reactions. Pictet-Spengler reaction between an aldehyde and a 
phenethylamine provides a tetrahydroisoquinoline. Chemically this can be catalysed by acids. A 3-hydroxy 
group on the amine allows catalysis by phosphate or NCS. The Pictet-Spengler condensation between an 
aldehyde and tryptamine leads to the formation of tetrahydro-β-carboline. This can also be catalysed by 
acid. In the plant indole alkaloid pathway this step is catalysed by strictosidine synthase (STR) using 
secologanin as the aldehyde.  
STR catalyses the Pictet-Spengler reaction between tryptamine and the terpene 
derived aldehyde secologanin. The product, strictosidine, is the precursor to all indole 
alkaloids. Maresh et al were able to define the mechanism of STR using methods 
including pH profiling, mutations, isotope effects, structural studies and theoretical 
calculations.79 The key enzymatic residue of the enzyme was determined to be Glu-
309, which catalyses both the formation of the Schiff base and the electrophilic 
aromatic substitution (Fig. 4.2). Through kinetic isotope effects, the final deprotonation 
step was identified as the rate limiting; this was the same in the chemical reaction, 
suggesting the enzyme does not significantly alter the reaction mechanism. Free 
energy calculations also ruled out the presence of a spiroindolenine intermediate.79  
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Fig. 4.2 Catalytic mechanism of strictosidine synthase. As proposed by Maresh et al.
79
 
In plants NCS catalyses the condensation of dopamine (3,4-dihydroxyphenethylamine) 
and 4-HPAA (4-hydroxyphenylacetaldehyde). Investigation by Luk et al into the 
mechanism of NCS—through the exploration of its substrate scope, kinetics and 
isotope effects—determined an overall mechanistic scheme for the enzyme (Fig. 4.3).51 
Turnover of 3-hydroxyphenylethylamine suggested the electronic effect of the 4-
hydroxyl group found on dopamine was not important, thus ruling out a spirocyclic 
intermediate. On the other hand the 3-hydroxy group was vital for catalysis. Isotope 
effects were not definitive: unlike in STR, the irreversible rearomatisation step was 
found to be only partially rate determining. The prior substrate binding, imine formation 
or the electrophilic addition played an unquantified rate limiting role. Furthermore, 
without structural information, no protein residues could be assigned any roles in the 
mechanism. 
Structural information on NCS was initially provided by an NMR study.54 A homology 
model of Δ29TfNCS was built based on NMR nuclear Overhauser effects (NOEs), 
chemical shifts and the Bet-v-1 structure. Observation of chemical shift perturbations 
from the titration of NCS with substrates led to the identification of a binding site 
centred on the residue Glu-103. However, relatively small chemical shift changes in 
titrations prevented assignment of catalytic roles to amino acid residues. 
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Fig. 4.3 Overall mechanism of NCS catalysis. As proposed by Luk et al.
51
  
4.1.2 HPAA-first mechanism  
Solution of the Δ19TfNCS crystal structure enabled the identification of the enzyme 
structure and active site residues (Fig. 4.4.43,55 The NCS active site is positioned in a 
catalytic tunnel and contains three charged and one polar reside: Tyr-108, Glu-110, 
Lys-122 and Asp-141 (Fig. 4.4B). The holo crystal structure contained dopamine and a 
non-productive aldehyde. An enzyme mechanism was proposed using evidence from 
the holo structure ligand binding modes,  with support from a number of active site 
mutations (Fig. 4.5).43,56 This mechanism involves the binding of 4-
hydroxyphenylacetaldehyde (HPAA) to the enzyme prior to dopamine (the HPAA-first 
mechanism); substrate binding order was previously proposed on the basis of kinetic 
analysis.15  
In the HPAA-first mechanism (Fig. 4.5), the aldehyde is activated by Lys-122, enabling 
nucleophilic attack from dopamine (step a). Loss of water, forming the iminium, is 
catalysed by the Lys-122 (b). Next, electrophilic addition and stabilisation of the 
resulting quinolinone intermediate is aided by Tyr-108 (d). Finally, rearomatisation is 
catalysed by Glu-110, forming the product (e). The behaviour of NCS mutants 
supported elements of this mechanism. The variant K122A eliminated activity, and the 
mutations Y108F and E110A reduced activity.43  
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Fig. 4.4 NCS X-ray structure. A. NCS globular structure. Δ19TfNCS holo crystal structure (2VQ5). 
Subunit A (blue) and subunit B (red) backbones depicted as cartoons. Bound ligands depicted as sticks. 
First ten N-terminal residues of subunit A removed. B. Active site cross section. Sections of the protein 
solvent accessible surface are shown and selective active site residues are represented by yellow sticks. 
Ligands are represented as purple sticks. Orientation of protein relative to overall structure seen in Fig. 
4.4A is similar to that observed for subunit B. Figure adapted from Lichman et al.
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There are a number of problems with the HPAA-first mechanism. Firstly, the 
intermediate iminium is proposed to undergo a rearrangement, which includes a cis-
trans isomerisation and the rotation of the entire aldehyde derived portion of the 
intermediate  (Fig. 4.5, step c). This step is vital for the subsequent rate-determining 
cyclisation and deprotonation, which ultimately establish the chirality of the product. 
However, there is no evidence for it; the holo crystal structure only provides evidence 
for the initial arrangement of the substrates. Such a large rearrangement seems 
unlikely to occur in the confines of the active site, especially with bulky aldehydes 
which have been shown to be accepted by the enzyme (see section 4.1.4). 
Subunit BSubunit A
A
B
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Fig. 4.5 HPAA-first mechanism. As proposed by Ilari et al
43
 and Bonamore et al
56
 on the basis of crystal 
structure information. 
The chemical basis of the mechanism also has limitations. No residue was proposed 
for interaction with the 3-hydroxy group in the electrophilic aromatic substitution steps. 
A partial positive charge is expected on the oxygen as the hydroxyl group stabilises the 
positive charge on the aromatic ring.51 To achieve this, a base is required to 
deprotonate or stabilise the 3-hydroxy group. In this mechanism, water was proposed 
to perform this role, with enzymatic stabilisation provided by Tyr-108 interaction with 
the 4-hydroxyl group (Fig. 4.5, steps d and e). However, water is not sufficiently basic 
to deprotonate this position (pKb = -1.7); a basic active site residue is necessary.138 It is 
possible that a residue may interact with the water to increase its basicity, in a ‘domino’ 
type mechanism. However, the only charged residue that is a reasonable position to 
interact with the water is Glu-103, which is not conserved in all NCSs. Finally, the H-
bond between the quinolinone and Tyr-108 would not provide the electrostatic 
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stabilisation to the intermediate as proposed, and cannot account for the successful 
reaction when the 4-hydroxy moiety is not present. 
4.1.3 X-ray structure 
The HPAA-first mechanism was based on and supported by the observed ligand 
binding modes in the holo NCS crystal structure (2VQ5), which had a resolution of 2.1 
Å.43,56 This structure was obtained by soaking NCS crystals in dopamine and 4-
hydroxybenzaldehyde (4-HBA), an electron deficient non-productive 4-HPAA analogue. 
Subunit A of the holo crystal structure is shown to bind 4-HBA in two different 
conformations, whilst subunit B binds both dopamine and 4-HBA simultaneously (Fig. 
4.4B, Fig. 4.6). 
The ligands modelled into the active site of the holo crystal structure do not fit the 
electron density convincingly (Fig. 4.6). The density observed in subunit A does not 
support the presence of two conformations of 4-HBA, as modelled. In subunit B, the 
methylene from dopamine does not fit the density, and there is no electron density in 
the area where the oxygen atoms must locate. Generally, the electron density appears 
to have insufficient definition to describe the identity of ligands present. This observed 
ambiguity may be a result of low occupancy or a heterogeneous sample. 
The difference in the binding behaviour of the two subunits was possibly a 
consequence of the different rotameric conformations of Phe-112 (Fig. 4.7A). Analysis 
of the NCS structure shows that whilst the Phe-112 in conformation A has favourable 
Ramachandran and rotamer angles, conformation B is less favoured: the residue is not 
in the favourable region of the Ramachandran plot, and the rotamer is unfavourable 
(analysis by MOLPROBITY).121 Interestingly, the unrefined electron density of subunit 
B may show that conformations A and B are both partially occupied in subunit B (Fig. 
4.7B). In the final published solution the density showing evidence of conformation A in 
subunit B was modelled as a water molecule.* 
                                               
* X-ray structure electron density analysis performed in collaboration with Dr Altin Sula and Prof 
Nicholas Keep 
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Fig. 4.6 Ligands in the NCS holo crystal structure. Electron density maps (blue, 2Fo - Fc, contoured at 
1σ) and difference map (red, 2mFo - DFc, contoured at 3 σ) of 2VQ5, with Lys-122 and ligands represented 
by sticks. Subunit A contains a 4-HBA molecule in two conformations. Subunit B contains a 4-HBA and 
dopamine ligand. Note that in both subunits the density does not fit around certain ligand atoms. Figure 
adapted from Lichman et al.
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Fig. 4.7 Rotamers of Phe-112. A. Structural alignment of subunits A (blue) and B (red). Side chains of 
Phe-112 and Lys-122 represented as sticks. Backbone represented as cartoon. B. Subunit B original Phe-
112 and water depicted in red. Remodelled Phe-112 side chain to fit water molecule density in blue 
(modelled with Coot and PHENIX). 2VQ5 Electron density maps (blue, 2Fo - Fc, contoured at 1σ) and 
difference map (red, 2mFo - DFc, contoured at 3 σ).* 
The differences in the subunits’ active sites may have been a knock-on effect from the 
tight crystal packing. The asymmetric dimer was held together by a non-native β-strand 
formed from the first nine N-terminal residues of subunit A in the adjacent dimer (see 
section 3.5). This N-terminal sequence is not necessary for enzyme activity, and is 
possibly part of a cleaved signal peptide.52,54  
Overall, the binding modes derived from the holo structure appear to be speculative on 
the basis of the observed electron density. This, in turn, adversely affects the reliability 
of the HPAA-first mechanism. 
4.1.4 Kinetic assays 
The Pictet-Spengler tetrahydroisoquinoline synthesis reaction can be catalysed by 
phosphate.59 Efficient catalysts for this reaction include inorganic phosphate (i.e. 
potassium or sodium salts) as well as organic phosphates such as uridine 
                                               
* X-ray structure electron density analysis performed in collaboration with Dr Altin Sula and Prof 
Nicholas Keep 
Subunit BSubunit A
A B
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monophosphate and glucose-1-phosphate. The phosphate catalyses reactions 
between phenylethylamines and aldehydes, but the amines must have a 3-hydroxy 
group for the reaction to proceed; this is similar to NCS substrate requirements.. The 
catalytic mechanism is currently unknown, but the phosphate is hypothesised to 
interact with the 3-hydroxy group at the aromatic cyclisation step, stabilising a build up 
of positive charge on the oxygen probably through deprotonation. The phosphate may 
also directly attack the imine, forming a covalent intermediate.  
Prior to the discovery of the phosphate mediated reaction, NCS assays were typically 
conducted in phosphate buffer43,51 or Tris (tris(hydroxymethyl)aminomethane) 
buffer.15,33,34 Although in all cases care was taken to account for the background 
reaction versus the enzymatic activity, the presence of phosphate and thus a high 
background reaction invalidates the observed kinetic parameters. The Pictet-Spengler 
reaction has multiple steps: hemiaminal formation, iminium formation, aromatic 
electrophilic addition and rearomatisation. Phosphate must be able to catalyse any of 
these steps, so although in phosphate NCS can raise conversions above background 
levels, its mechanistic contribution to this increase is unknown. Furthermore, the 
increased depletion of substrates by the phosphate reaction adversely affects enzyme 
time course assays. The reaction is also incompatible with Tris buffer as aldehydes can 
react with Tris to form oxazolidines, affecting the results (Fig. 4.8). 
 
Fig. 4.8 Reaction between Tris and aldehydes. 
The key difference between the enzyme reaction and the phosphate catalysed reaction 
is the stereoselectivity. In an effort to account for the background reaction and just 
observe enzymatic products, a circular dichroism (CD) spectroscopy method for 
measuring kinetic activity was developed.43,51 As only enantiomeric excesses are 
optically active, chiral enzyme products can be observed by CD spectroscopy, but 
racemic products cannot. Though it is true that in the NCS CD kinetics method any 
products detected by CD would be enzyme products, only the reaction step that 
establishes the chiral centre would actually need to be enzyme catalysed. 
In the NCS reaction, there are two factors which could influence chirality. First, the face 
of the pro-chiral iminium on which the aromatic electrophilic addition step occurs (which 
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itself is influenced by the iminium geometric isomer present). Second, a spatial 
preference for deprotonation in the final rearomatisation step. The electrophilic 
aromatic addition causes the formation of two chiral centres: the 1 position, which is 
maintained in the product, and the 8a position, which is deprotonated in the final 
reaction step. If this final irreversible deprotonation/rearomatisation step is 
enantioselective, then an enantiomeric excess may be formed in the product, 
regardless of the stereoselectivity of previous reversible steps (Fig. 4.9). The result of 
all this is that phosphate may catalyse three out of four steps in the reaction, and the 
enzyme only one step, and a CD signal would still be observed.  
 
Fig. 4.9 Origin of chirality in NCS reaction. Four quinolinone isomers can be formed by electrophilic 
aromatic addition, depending on the isomer of the iminium and the face of the iminium that is attacked. 
This step is reversible—so the final irreversible enantioselective deprotonation may also influence chirality 
of the final product. 
A further problem with the CD method was the establishment of the molar ellipticity 
constant used for calibration of the CD signal. A reaction with dopamine, 4-HPAA and 
NCS in phosphate buffer was observed to go to completion (as measured by proton 
NMR), the product was assumed to be entirely enzymatic (i.e. a single enantiomer) and 
so the CD signal of this product was used as a calibration. However, as this reaction 
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was performed in phosphate buffer, a significant proportion of this product was racemic 
and the result of non-enzymatic catalysis. This was demonstrated by the fact that the 
product was found to be racemic when purified. Any optical activity observed by CD 
was likely to be the result of a small enantiomeric enrichment caused by the presence 
of the enzyme. Overall, problems with the calibration constant and the presence of 
phosphate buffer in the reaction invalidate kinetic parameters determined with this 
sophisticated method. 
Kinetic assays conducted with these problematic methods led to the observation of 
positive cooperativity with respect to dopamine.15,33,34,51 This, coupled with 
chromatography data on the isolated plant enzyme,15 led to the prediction that NCS 
was dimeric in solution. However, investigations Δ29TfNCS by NMR and size-exclusion 
chromatography demonstrated that the enzyme is predominantly monomeric at 
concentrations around 10 µM.54 Kinetic assays (with Tris buffer) in the form of Hanes 
plots, with norlaudanosoline as a product inhibitor, led to the prediction that 4-HPAA 
binds to NCS prior to dopamine.15 This substrate binding order was supported by the 
X-ray holo structure43 but is not yet satisfactorily accounted for mechanistically. 
4.1.5 Substrate scope 
NCSs from Thalictrum flavum (TfNCS) and Coptis japonica (CjNCS2) have been 
shown to have a broad aldehyde substrate scope, enabling the enzymatic formation of 
diverse (S)-tetrahydroisoquinolines (THIQs).53,57,61 Both enzymes accepted most 
phenylacetaldehydes but did turn over α-substituted aldehydes well. Particularly 
notable was the turnover of a linear aliphatic aldehyde by CjNCS257 and the large 1-
napthylacetaldehyde by TfNCS,53 as these substrates have very different properties to 
the natural substrate 4-HPAA. In contrast to the aldehyde, little variation in dopamine 
structure was tolerated—the 3-hydroxy moiety is crucial for successful turnover. 
As previously described, the HPAA-first mechanism was proposed based on the 
arrangement of the substrates in subunit B (Fig. 4.5). A major drawback of the HPAA-
first mechanism (made evident by these substrate scope results) is that it cannot 
account for the fact that NCS reacts with a wide variety of aldehydes. First, the 
proposed interaction between Asp-141 and the phenol of 4-HPAA would not be 
possible with many aldehydes. Second, it is unlikely that the active site can incorporate 
large aldehydes (such as 1-napthylacetaldehyde53) and dopamine simultaneously and 
then rotate the intermediate in an important mechanistic step (Fig 5, step c).  
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4.1.6 Dopamine-first mechanism 
The inability of the HPAA-first mechanism to fully account for NCS activity was noted 
during the investigation into the CjNCS2 substrate scope.57 This led to a re-
examination of the enzyme mechanism through docking studies of reaction 
intermediates into the TfNCS crystal structure. Docking studies revealed novel binding 
modes of reaction intermediates. The lowest energy binding modes showed the 
dopamine portion of the reaction intermediates buried in the enzyme active site and the 
aldehyde R-group exposed to the solvent. This arrangement can account for the large 
variety of aldehydes accepted by the enzyme. It also accounts for low activity with 
substituted amines such as metaraminol, as the amine binds in a sterically hindered 
pocket.57 The docking investigation led to the proposal of a novel mechanism for the 
enzyme. In this mechanism the Lys-122 plays a key role as the base that deprotonates 
the 3-hydroxy group to trigger electrophilic aromatic addition. Glu-110 catalyses the 
rearomatisation step, and Asp-141 is proposed to interact with the charged nitrogen on 
the substrate and intermediates, holding them in place and providing electrostatic 
stabilisation (Fig. 4.10).  
 
Fig. 4.10 Dopamine-first mechanism. As proposed by Pesnot et al.
57
 The key feature of the mechanism 
is the arrangement of the intermediate so the aldehyde R-group can be partially solvent exposed. The 
residues Lys-122 and Glu-110 are proposed to be important in the mechanism. Dotted semi-circles show 
regions with hydrophobic residues.  
This ‘dopamine-first’ mechanism appears to account for the wide aldehyde substrate 
scope of NCS reaction more effectively than the HPAA-first mechanism. However, in 
order to more fully compare the two mechanisms, the enzyme must be examined more 
closely. Therefore, an investigation was conducted into the enzyme using 
computational and experimental methods, focussing on the effect of mutations on the 
mechanism and substrate specificity. 
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4.2 Computational analysis 
4.2.1 Molecular dynamics and Phe-112 
As described in section 4.1.3, the crystal structure 2VQ5 features two subunits, A and 
B that primarily differ in the nature of N-terminal interactions. The only significant 
difference in the active site of the two subunits is the conformation of the residue Phe-
112. In subunit A, the phenyl ring of the residue projects into the active site, whilst in 
subunit B it is situated behind Lys-122 (Fig. 4.7A). Structurally, this conformational 
difference has a number of implications. Firstly, the active site is larger in subunit B, as 
the Phe-112 phenyl is absent. Secondly, the position of Phe-112 in subunit B partially 
blocks a water channel that is present connecting Lys-122 to the solvent. The 
conformational organisation of the Phe-112 seems to affect substrate binding. In 
subunit A, with the smaller active site, it appears that a single molecule binds whereas 
in subunit B two molecules are bound: both dopamine and 4-HBA occupy the active 
site, in a stacked conformation (Fig. 4.4B). Analysis of the electron density of the 
ligands and the Phe-112 is described above (section 4.1.3). In order to investigate the 
influence of the residue using a different method, molecular dynamics simulations of 
NCS were performed. The crystal structure 2VQ5 was used as the starting point, and 
subunits A and B were investigated separately (see section 2.2.2 and Appendix A, 
section 8). 
For each subunit three separate molecular dynamics simulations of 100 ns were 
calculated. The behaviour of the Phe-112 residue was examined by tracking two 
separate angles. The rotation of the phenyl ring was tracked through the changing 
dihedral angle between the Cα, Cβ, Cγ and Cδ1 atoms (Fig. 4.11). Although there are 
two chemically identical Cδ atoms (so a 0° angle is identical to a 180° angle), by 
tracking the angle it was possible to follow the rotation of the side chain. The phenyl 
ring typically occupied a position of approximately 0° or 180°, which is expected for 
phenylalanine (Fig. 4.12). Notably the phenyl ring rotated at least once in all 
simulations (and at most eight times), suggesting that it was not packed tightly with 
other residues in the enzyme active site.  
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Fig. 4.11 Method for measuring Phe-112 rotation. The dihedral angle depicted was tracked to measure 
Phe-112 side chain rotation.  
The position of Phe-112 relative to the entire protein was monitored by the angle 
formed between the Phe-112 Cα, Cζ (at the tip of the phenyl ring) and the Cα of His-
106, which is on the same β-strand as Phe-112 but at the other end of the protein (Fig. 
4.13). For simulations of subunit A, this angle fluctuated around 65°. The Phe-112 did 
not change its position relative to the protein at any point in the 300 ns of subunit A 
simulations (Fig. 4.14). This must suggest, to some degree, that this Phe-112 
conformation is stable. Subunit B simulations showed very different characteristics. 
Firstly, the starting angle of Phe-112 was 110-130°. In all simulations the Phe-112 
conformation switched to the 65° conformation at some point, suggesting the 110-130° 
conformation is not stable (Fig. 4.14). For simulation 1 (yellow), this happened 
immediately (within 5 ns) and the residue remained in this position for the rest of the 
simulation (though rotated a number of times). In simulation 2 (blue) the Phe-112 
conformation decayed to 65° only after 70 ns, but remained there for the rest of the 
simulation. Simulation 3 (red) started similar to simulation 1 in that the residue 
immediately switched to the 65° conformation. However, in this simulation the side 
chain appeared slightly more unstable and there was brief reversion to the 110-130° 
conformation at 60-75 ns before switching again to 65°. 
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Fig. 4.12 Phe-112 rotation in simulations. A. Angle of dihedral over course of simulations (Fig. 4.11). 
B. Distribution of angles in simulation. Different colours depict different simulations, subunits were 
examined independently. Note how for all simulations the Phe-112 rotates, and typically occupies positions 
around 0˚ and 180˚. The exception is the red simulation of subunit B which also occupies a position around 
100 ˚. 
Overall the data show that Phe-112 was dynamic in the active site during the molecular 
dynamics simulations. The phenyl ring rotated and the rotamer conformation changed. 
Generally, it seems that the rotamer at 65° (observed in subunit A) is more stable than 
the rotamer at 110-130° (observed in subunit B). Although no switching from 65° to 
110-130° was observed in subunit A in these simulations, the observation of this switch 
in subunit B simulation 3 suggests that it is a possible transition—it is not a completely 
kinetically trapped conformation. This molecular dynamics simulation data adds to the 
evidence from the electron density analysis suggesting that the Phe-112 conformation 
and active site arrangement observed in the crystal structure subunit B is atypical.  
Overall, the simulations suggested that the Phe-112 conformation most prevalent in 
solution is that observed in subunit A. 
A
B
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Fig. 4.13 Method for measuring Phe-112 position. The Cα atoms on His-106 and the Cα and Cζ Phe-
112 are marked by black dots. The angle formed between them was recorded. Depicted are the subunits A 
(blue) and B (red) from the crystal structure. The angle for subunit A is approximately 65˚, the angle for 
subunit B around 120˚. 
 
Fig. 4.14 Position of Phe-112 residue in simulations. A. Value of angle (Fig. 4.13) over course of 
simulation. The thin lines are the values for this angle; the thick lines are a moving average (0.5 ns 
window). Different colours represent independent simulations. B. Distribution of angles in simulation. 
Note how for all simulations of subunit A the Phe-112 angle does not vary whilst in subunit B all 
simulations decay to 65 ˚. Figure adapted from Lichman et al.
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4.2.2 Molecular docking 
In order to explore the NCS enzyme mechanism, reaction intermediates were docked 
into the active site of TfNCS (2VQ5, subunit A) using AutoDock Vina (Fig. 4.15). This 
A
B
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work was a replication and extension of the docking experiments conducted by Pesnot 
et al.57 Subunit A was used for docking studies as it is a better candidate than subunit 
B on the basis of molecular dynamic simulations (see section 4.2.1). The holo crystal 
structure 2VQ5 (with ligands removed) was preferred to apo structure 2VNE on the 
basis of its superior resolution.  
The lowest energy docked structure of dopamine features the catechol portion of the 
substrate in close proximity with Lys-122, with the 3-hydroxy closest to the side chain 
amine (Fig. 4.16A, Table 4.1). The positively charged nitrogen on dopamine is near to 
the negatively charged carboxylic acid residues Glu-110 and Asp-141. The aldehyde 4-
HPAA binds in a similar manner, with the phenol group in close proximity to Lys-122, 
and the carbonyl near to the carboxylic acid residues (Fig. 4.16B, Table 4.1). This 
binding mode is different to that predicted in the HPAA-first mechanism; in this 
mechanism the aldehyde carbonyl binds to the Lys-122 (Fig. 4.5). 
 
Fig. 4.15 Structures of intermediates used in docking calculations. Figure adapted from Lichman et 
al.
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Two hemiaminal intermediates can be formed by the reaction between dopamine and 
4-HPAA. These are stereoisomers, with chirality at the hydroxyl group (Fig. 4.15). 
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Docking the (S)-hemiaminal provides a ‘dopamine first’ arrangement of the 
intermediate, with the dopamine catechol buried in the active site, close to Lys-122, in 
a similar manner to that observed with docking dopamine alone (Fig. 4.17A, Table 4.1). 
The charged nitrogen of the hemiaminal interacts with Glu-110 and Asp-141, whilst the 
hydroxyl group occupies a space between Glu-110 and Tyr-108, in the entrance to a 
water channel. The aldehyde R-group extends past Tyr-108 at the active site tunnel 
entrance, in close proximity to Leu-76. In contrast, the (R)-hemiaminal docked structure 
binds in the opposite arrangement, with the 4-HPAA R-group buried in the active site, 
in a similar manner observed with the 4-HPAA docking (Fig. 4.16B, Table 4.1). The 
hemiaminal moiety is close to the carboxylic acid residues, but the hydroxyl is deeper 
into the active site than the nitrogen. 
 
Table 4.1 Binding modes calculated from in silico docking. Predicted binding affinity and protein-
ligand interaction distances of docked reaction intermediates in the NCS active site (2VQ5, subunit A). 
Conformations predicted by AUTODOCK VINA. For full structures of intermediates and atom numbering 
information, see Fig. 4.15. Fig. 4.16, Fig. 4.17, Fig. 4.18 and Fig. 4.19 show the structures of selected 
binding modes. All binding modes described were the highest ranked by the software. Table adapted from 
Lichman et al.
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Ligand 
Binding 
affinity 
Heteroatom distances 
Residues 
    Tyr-108 Glu-110(O1)
a
 Glu-110(O2)
a
 Lys-122 Asp-141 
  
  
Atom on ligand
b
 
 
  N 6′O N 6′O N 6′O 8aH 3O 4′O N 6′O 
  kcal.mol
-1
 Å 
Dopamine -5.3 4.5 
 
2.9 
    
3.1 
 
3.0 
 
4-HPAA -5.2 
 
4.4 
 
3.0 
 
3.4 
  
3.1 
 
3.4 
(S)-hemiaminal -7.3 5.0 2.8 3.1 2.9 
   
3.2 
 
3.2 4.2 
(R)-hemiaminal -7.1 4.6 4.4 3.8 3.0 3.1 3.7 
 
>10 3.1 5.1 3.0 
Cis-iminium -7.5 4.0 
 
3.0 
 
3.2 
  
3.1 
 
3.9 
 
Trans-iminium -7.2 4.3 
 
3.8 
 
3.6 
  
3.2 
 
4.6 
 
anti-quinolinone -7 5.3 
 
4.3 
   
3.3 2.8 
 
4.0 
 
syn-quinolinone -6.8 8.3 
 
>10 
   
9.6 >10 
 
>10 
 
a
 Both oxygen atoms on the Glu-110 side chain are involved in docking interactions. 
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Fig. 4.16 Predicted conformations of substrates in NCS active site. A. Dopamine. B. 4-HPAA. 
Structures of ligands can be found on Fig. 4.15. More detailed information on protein-ligand interactions 
can be found in Table 4.1. Black dotted lines show predicted electrostatic and catalytic interactions. Active 
site residues carbons are coloured yellow; docked ligands carbons are coloured purple. Ligand accessible 
surfaces are represented by transparent purple. A section of the protein solvent accessible surface is 
represented in green. Conformations depicted are lowest energy predictions. Figure adapted from 
Lichman et al.
137
 
 
Fig. 4.17 Predicted conformations of hemiaminal intermediates substrates in NCS active site. A. 
(S)-hemiaminal. B. (R)-hemiaminal. Figure details described above in Fig. 4.16. Figure adapted from 
Lichman et al.
137
 
 
Fig. 4.18 Predicted conformations of iminium intermediates in NCS active site. A. Trans-iminium. B. 
Cis-iminium. Figure details described above in Fig. 4.16. Figure adapted from Lichman et al.
137
 
  
A B
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There are two possible iminium intermediates depending on the cis or trans geometry 
of the double bond (Fig. 4.15). Typically, trans double bonds are more stable due to 
steric effects; however, in the confines of an enzyme active site this preference may be 
reversed. Both isomers dock into the enzyme active site in a similar dopamine-first 
manner: the dopamine catechol binds to Lys-122; the nitrogen is in close proximity to 
Tyr-108, Glu-110 and Asp-141; and the aldehyde R-group is at the active site entrance, 
pointing out towards the solvent (Fig. 4.18, Table 4.1). The key difference between the 
cis- and trans-iminium intermediates is the chiral centre that would form in the next 
electrophilic addition step. The electrophilic addition into trans-iminium would be at the 
Re-face of the iminium, forming the correct (1S)-product (Fig. 4.18A). The cis-iminium 
conformation would result in a Si-face attack, causing formation of the incorrect (1R)-
isomer (Fig. 4.18B, also see Fig. 4.9). 
 
Fig. 4.19 Predicted conformation of anti-quinolinone intermediate in NCS active site. The syn-
quinolinone was not predicted to bind in the active site. Figure details described above in Fig. 4.16. Figure 
adapted from Lichman et al.
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The final reaction intermediate is the quinolinone. Again, there are two possible 
isomers of this intermediate (assuming an (S)-isomer product) (Fig. 4.15, also Fig. 4.9). 
For these intermediates the difference is the 8a-stereocentre. This second chiral centre 
is removed in the rearomatisation step, but its configuration is important for the 
involvement of the enzyme in this process. The two quinolinone intermediates are 
described either as syn, where both protons are on the same face of the molecule, or 
anti, where the protons are on opposite faces. Typically anti products are more stable 
due to steric and conformational effects. The docking of these two intermediates 
provides very distinct results. The syn-(1S,8aS)-quinolinone does not bind in the active 
site at all, but on the edge of the active site tunnel entrance. The anti (1S,8aR)-
quinolinone binds in a dopamine-first manner: the catechol is close to Lys-122 (< 3 Å) 
and the aldehyde R-group is at the active site entrance (Fig. 4.19). The positive 
nitrogen was further away from the carboxylic acid residues than with the docking of 
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other reaction intermediates, but there is a close interaction with Glu-110 and the 8a-
proton, which is removed in the final reaction step.  
A key factor in the biocatalytic utility of NCS is its ability to turn over a wide variety of 
structurally diverse aldehydes. These docking calculations provide a structural 
explanation for this observation: in the most favourable binding modes for reaction 
intermediates only the aldehyde R-group is partially exposed to the solvent. The poor 
tolerance of α-substituted aldehydes by NCS may be rationalised on steric grounds, as 
the α-carbon is buried in the active site. Large aldehydes (but with no α-substitutions) 
may be accepted as the R-group bulk can be in the solvent, away from the enzyme. 
The docking calculations also aid in understanding the mechanism itself by showing 
potential amino acid interactions with reaction intermediates and by demonstrating the 
different binding modes of reaction intermediate isomers. 
4.2.3 pKa predictions 
Predicted pKa values of titratable amino acids in the NCS active site indicate their 
protonation states at different points in the reaction mechanism (Table 4.2). These 
residues are Tyr-108, Glu-110, Lys-122 and Asp-141. All of these residues were 
identified as interacting with reaction intermediates on the basis of the docking 
experiments. 
Table 4.2 Active site residue pKa predictions. Acid dissociation constants (pKa) of TfNCS active site and 
reaction intermediate ionisable groups predicted by PROPKA, version 3.1
139
. The enzyme model was the 
X-ray structure 2VQ5, subunit A. Ligand conformations were predicted by computational docking of 
reaction intermediates into the enzyme active site with AUTODOCK VINA (Table 4.1). Table adapted from 
Lichman et al.
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  Residue 
  Tyr-108 Glu-110 Lys-122 Asp-141 Ligand N 
  pK
a
 
Typical
a
 10.0 4.5 12.5 3.8   
            
Ligand
b
           
None 15.5 8.1 7.9 6.7   
Dopamine 13.3 5.7 7.2 4.1 15.8 
(S)-hemiaminal 15.2 5.6 7.2 4.2 13.6 
Cis-iminium 16.4 5.1 7.1 6.8 11.6 
Trans-iminium 16.2 5.4 7.1 7.0 11.4 
Anti-quinolinone 16.3 6.9 7.4 5.6 10.5 
a 
Model pKa values used by PROPKA 3.1 at the start of calculations 
 
The phenol group of tyrosine has a typical pKa of 10 but is known to deprotonate in 
some reaction mechanisms. In the NCS active site it is predicted to have a higher pKa, 
ranging from 13.3 to 16.4 depending on the ligand present; this is too high for any 
significant deprotonation during the reaction mechanism. These predictions therefore 
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suggest that Tyr-108 does not play any active acid/base role in the mechanism, but 
may contribute electrostatic stabilisation or H-bond interactions. 
The carboxylic acid residues glutamic acid and aspartic acid are typically deprotonated 
and negatively charged (model pKa of 4.5 and 3.9 respectively). However, in the apo 
NCS active site both Glu-110 and Asp-141 are predicted to have a significantly 
increased pKas (8.1 and 6.7 respectively), suggesting a proportion of the residues are 
protonated and not charged. There would be repulsion between two negatively charged 
residues in close proximity in a hydrophobic active site, and the pKa is affected 
accordingly. It is possible that at pH 7.5 there is one negative charge (and one proton) 
shared between the two residues. The binding of a ligand with a charged nitrogen 
changes the predicted pKa noticeably—both residues are expected to be deprotonated 
and negatively charged to stabilise the positively charged nitrogen. There is a predicted 
increase in the basicity of Asp-141 when the iminium was bound, probably caused by 
the greater distance between the positive charge and the residue. There is also a 
predicted increase in basicity of Glu-110 when the quinolinone intermediate is bound. 
At this point, Glu-110 appears in close proximity to the 8aH proton, which is removed in 
the next reaction step (Fig. 4.19). This prediction points towards Glu-110 as the 
mediator of this deprotonation/rearomatisation. 
Lysine residues are typically protonated and positively charged (model pKa 12.5). In the 
hydrophobic confines of the NCS active site, this tendency for positive charge is 
removed, and the predicted pKa of Lys-122 accordingly is reduced to 7.9. This would 
result in a proportion of Lys-122 residues being neutral and non-protonated at pH 7.5. 
Upon substrate binding this effect appears greater and the pKa falls to 7.2-7.4 
depending on the substrate bound. This increased neutrality is in accordance with Lys-
122 catalysing the cyclisation step in the dopamine-first mechanism. In order for the 
lysine nitrogen to interact/bind to the 3-hydroxy group of the substrate, it must be 
neutral. The pKa2 of phosphate, which also catalyses this reaction, is 7.2, suggesting 
that this level of acidity/basicity is ideal for catalysing this mechanism. Therefore, the 
predicted pKa of Lys-122 with substrates bound is ideal for acid-base catalysis in 
enzyme mechanisms at pH 7.5.  
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4.3 Experimental analysis 
4.3.1 Selection of mutants and experiments 
In order to investigate the mechanism of NCS, the behaviours of ten enzyme variants, 
including wild-type (WT), were examined. Residues predicted to play a role in the two 
proposed enzyme mechanisms were mutated: Tyr-108 to phenylalanine, Glu-110 to 
aspartic acid and glutamine, Lys-122 to leucine, and Asp-141 to glutamic acid and 
asparagine. Residues were also mutated at the aldehyde binding site predicted by the 
dopamine-first mechanism. Leu-76 was mutated to alanine and valine, and Ala-79 was 
mutated to isoleucine. These aldehyde-binding mutations in particular were chosen to 
distinguish between the HPAA-first and dopamine-first mechanisms; it was proposed 
that, based on the dopamine-first mechanism, these mutations would have aldehyde 
specific effects. If the enzyme operated by the HPAA-first mechanism, mutations of 
these residues would affect activity in a manner general to all aldehydes, as they are 
not near to the proposed aldehyde binding site adjacent to Lys-122. 
All NCS variants expressed and purified successfully (Fig. 4.20). Melting and 
aggregation temperatures were measured (for all variants except A79I) to examine the 
effect of amino acid substitutions on thermodynamic stability. Biotransformation 
conversion yields were measured, along with enantiomeric excesses for enzymes 
demonstrating sufficient conversions. Enzyme activities were determined by measuring 
conversions after thirty seconds—this was within the linear phase of the reaction time 
course and thus a reasonable proxy for initial rate (Fig. 4.21). For selected variants, 
kinetic parameters were determined using the same method. In order to examine any 
aldehyde-specific effects from amino acid substitutions both 4-HPAA and hexanal were 
examined in enzyme assays (dopamine was always the amine used). 4-HPAA (the 
natural substrate for the enzyme) and hexanal have different aldehyde R-groups and 
so were expected to interact with the enzyme differently to each other. 
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Fig. 4.20 SDS-PAGE showing purified Δ29TfNCS mutants. From lane 1 to 8: WT, L76A, L76V, Y108F, 
E110D, E110Q, D141E, D141N. Mutants A79I and K122L were also purified in a similar manner. 
 
Fig. 4.21 Time course of reaction with 10 mM dopamine, 2.5 mM 4-HPAA and 20 µg.mL
-1 
WT- 
Δ29TfNCS. Time points taken at 30 sec, 1 min, 2 min and 5 min. Solid line describes fitted exponential 
decay, dotted line shows initial rate. This experiment demonstrates that a reaction time of 30 seconds is 
within the linear regime of the enzyme and thus is a reasonable proxy for the initial rate. 
4.3.2 General observations 
The, By using a method that analyses fluorescence spectra and static light scattering to 
define protein unfolding transitions, the melting temperature (Tm) of WT Δ29TfNCS was 
determined to be 60.7 °C (Table 4.3). A previous study, which used CD spectroscopy 
to determine melting temperatures, detected a Tm of 66 °C.
54 The difference between 
these two values is likely to be due to differences in method and sample preparation. 
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Table 4.3 Melting and aggregation temperatures (°C) of TfNCS variants. Data generated using an 
Avacta Optim instrument. Over a temperature ramp, Tm was calculated by observing changes in the 
intrinsic protein fluorescence spectrum; Tagg was calculated by changes in light scattering intensity. Table 
adapted from Lichman et al.
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Protein T
m
 T
agg
 
  °C 
WT 60.7 ± 0.1 60.8 ± 0.1 
L76A 54.9 ± 0.1 54.4 ± 0.6 
L76V 58.7 ± 0.1 59.1 ± 0.5 
Y108F 61.5 ± 0.3 62.4 ± 0.4 
E110D 57.2 ± 0.2 57.4 ± 0.5 
E110Q 66.0 ± 0.4 65.8 ± 0.1 
K122L 69.8 ± 0.3 67.9 ± 1.8 
D141E 62.0 ± 0.3 61.8 ± 0.2 
D141N 63.9 ± 0.1 62.8 ± 0.9 
 
Previous investigations into NCS had been adversely affected by the use of phosphate 
or Tris buffers (see section 4.1.4).57 To avoid these problem, HEPES buffer was used 
in all enzyme assays; this buffer exhibited significantly lower background reactions than 
phosphate and does not react with aldehydes.57 However, in order to solubilise the 
aldehydes, the reactions contained 10% v.v-1 MeCN, which may have been slightly 
detrimental to enzyme activities (see section 6.5.2 for more exploration of co-solvent). 
Under the conditions used for the biotransformation between dopamine and 4-HPAA, 
phosphate buffer exhibited 69% conversion, without enzyme being present. HEPES, on 
the other hand, showed just 5% conversion (Fig. 4.22). High substrate concentrations 
increase the non-enzymatic conversion; this ultimately limits the concentrations that 
can be reached in biotransformations, enzyme activity assays and kinetic experiments. 
Enzyme activities with both substrates at 10 mM were difficult to measure due to high 
background conversions, so activities were measured with one substrate at 10 mM and 
the other 2.5 mM. In kinetic experiments, one substrate was maintained at 2.5 mM, the 
varied substrate was tested varied up to 20 mM for dopamine and 15 mM for 
aldehydes. High concentrations could not be reached due to high background 
conversions and concentration dependent substrate degradation. 
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Fig. 4.22 Conversion yields of biotransformations. Enzymes and buffers were incubated with dopamine 
and aldehydes for 1 h at 37 °C. These conversion yields are the product concentrations at the end of the 
hour reactions. Both starting substrate concentrations were 10 mM, so that the maximum product 
concentration possible is 10 mM. Aldehydes: 4-HPAA (black bars) and hexanal (white bars). Conversion 
yields were obtained by HPLC analysis and quantified by comparison with verified standards. Values are 
the means of three separate reactions, error bars indicate SDs. Hepes background conversions have been 
minused from all enzyme samples. Figure adapted from Lichman et al.
137
 
Generally, conversions with 4-HPAA were higher than with hexanal (Fig. 4.22). This 
difference was observed also with the chemical phosphate reaction, so is not an 
enzyme dependent effect. Instead it is possibly due to intrinsic differences between 4-
HPAA and hexanal with respect to solubility, reactivity and propensity to exist in 
solution as hydrates. This difference in reactivity was also reflected in the activity data, 
and it was more apparent in activities than conversions.For WT, activity with 4-HPAA is 
three times that with hexanal, 426 and 142 nkatal.mg-1 respectively. This is observed 
because activity reflects initial rates rather conversions over time; with 
biotransformations, over time the hexanal conversion converges with the 4-HPAA 
conversion. 
Chiral HPLC analysis of the biotransformations showed that THIQ products produced 
by NCS were single enantiomers (Fig. 4.23). The enzyme products were compared to 
those produced by the racemic phosphate reaction: phosphate catalysed reactions 
gave two enantiomer peaks and a dopamine starting material peak. For all conversions 
above 10% the product peaks could be detected by chiral HPLC. For these 
conversions only a single product peak could be identified (>95% ee), demonstrating 
the chiral nature of the enzyme reaction, and also showing the successful repression of 
the racemic background reaction. For variants E110D, E110Q and K122L, which 
showed conversions below 10%, peaks on the chiral HPLC could not be identified and 
integrated with sufficient confidence to define the reaction stereoselectivity. 
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Fig. 4.23 Chiral HPLC analysis of enzymatic reactions. (A) Dopamine and 4-HPAA with WT. (B) 
Dopamine and hexanal with WT. Dopamine standard (black trace) appeared at 27 min. Phosphate buffer 
catalyzed reactions (blue trace) showed two equal sized peaks for the racemic products. Wild-type enzyme 
catalyzed reactions (orange trace) showed a single isomer peak (> 95% ee). (C) Dopamine and 4-HPAA 
with variants. Conversion with A79I not shown (but variant was shown to be stereoselective in plot D). (D) 
Dopamine and hexanal with variants. Conversion with D141N was too low to observe on chiral HPLC. 
For both C and D, conversions with E110D, E110Q and K122L were too low to observe. Arrows, from left, 
show (S)-product, (R)-product and dopamine. HPLC method 3 (see section 2.4.1). Figure adapted from 
Lichman et al.
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Due to the high background reaction at high substrate concentrations, enzyme 
activities were measured with one substrate at 10 mM and the other at 2.5 mM (rather 
than both at 10 mM as in the biotransformations). This resulted in two enzyme activity 
measurements for each substrate combination. In all cases, higher concentrations of 
dopamine resulted in higher rates (Fig. 4.24). Possible explanations for this (based on 
this data alone) is that 2.5 mM dopamine was not at a saturating concentration or that 
high concentrations of aldehyde could have been inhibitory. Subsequent kinetic 
analysis of WT with 4-HPAA or hexanal failed to show evidence of substrate inhibition 
and also showed that neither dopamine nor 4-HPAA or hexanal were saturating even 
at 10 mM (Fig. 4.25,Table 4.4). 
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Fig. 4.24 Enzyme activities. Initial rates of reactions between dopamine and aldehydes catalysed by NCS 
variants. 4-HPAA (black bars) and hexanal (white bars); Solid bars show 10 mM dopamine and 2.5 mM 
aldehyde, lined bars show 2.5 mM dopamine and 10 mM aldehyde. Values are the mean of three separate 
measurements, error bars indicate SDs. The Hepes background activity has been minused from all 
measurements.  
Kinetic experiments were conducted by keeping one substrate concentration at 2.5 mM 
and varying the other up to 15 mM (for aldehydes) or 20 mM (for dopamine). With WT: 
dopamine, 4-HPAA and hexanal did not reach saturating concentrations in these 
experiments.For two-substrate kinetics, the non-varied substrate concentration should 
ideally be at a saturating concentration. The fact that this was not achieved in these 
experiments prevents straightforward comparisons between kinetic parameters for 
dopamine and for aldehydes; this in turn prohibits satisfactory explanations for the 
effect of substrate concentrations on activity. It is possible, though, to compare the 
effect of different aldehydes and amino acid substitutions on kinetic parameters. For 
example, it is clear that reduction in activity caused by the use of hexanal instead of 4-
HPAA was manifested in 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝 rather than 𝐾𝑚
𝑎𝑝𝑝. Dopamine 𝐾𝑚
𝑎𝑝𝑝, as expected, did not 
change significantly, but the 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝 fell by over three-fold. Interestingly, although hexanal 
had a lower 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝 than 4-HPAA, it also had a lower 𝐾𝑚
𝑎𝑝𝑝. This was perhaps reflective of 
hexanal’s increased hydrophobicity and reduced solubility, which could increase affinity 
towards a hydrophobic enzyme active site. Taking into account the reduced chemical 
conversions observed with hexanal instead of 4-HPAA, it is possible that the reduced 
𝑘𝑐𝑎𝑡
𝑎𝑝𝑝 was a chemical reactivity effect rather than an enzymatic effect. The aldehydes 
exist in water in equilibrium with the hydrate, and it is possible that for hexanal the 
equilibrium is further towards the hydrate, reducing reactivity. 
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Fig. 4.25 Velocity/substrate concentration curves for wild-type (WT, black), L76A (orange), A79I (blue) 
and Y108F (red). (A) Varying 4-HPAA concentrations with 2.5 mM dopamine. (B) Varying hexanal 
concentrations with 2.5 mM dopamine. (C) Varying dopamine concentrations with 2.5 mM 4-HPAA. (D) 
Varying dopamine concentrations with 2.5 mM hexanal. All fits are Michaelis-Menten kinetics. Data points 
are the mean from three measurements; error bars indicate SDs of three reactions. For parameters, see 
Table 4.4. Figure adapted from Lichman et al.
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Table 4.4 Apparent kinetic parameters for TfNCS with 4-HPAA and hexanal. Corresponding 
velocity/substrate concentration curves can be found in Fig. 4.25. Table adapted from Lichman et al.
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Varied 
Substrate 
Constant 
Substrate 
Enzyme Michaelis-Menten 
      𝑉𝑚𝑎𝑥
𝑎𝑝𝑝
 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝
 𝐾𝑚
𝑎𝑝𝑝
 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝 𝐾𝑚
𝑎𝑝𝑝⁄  
   nkatal.mg
-1
 s
-1
 mM s
-1
.mM
-1
 
Dopamine
a
 4-HPAA WT 1150 ± 48 24 ± 1 22.2 ± 1.5 1.09 ± 0.08 
  
L76A 649 ± 22 13.6 ± 0.5 16.8 ± 1.0 0.81 ± 0.06 
  
A79I 1972 ± 95 41 ± 2 29.6 ± 2.1 1.39 ± 0.12 
  
Y108F 485 ± 13 10.2 ± 0.3 13.3 ± 0.7 0.76 ± 0.05 
Dopamine
a
 Hexanal WT 323 ± 7 6.8 ± 0.1 20.1 ± 0.7 0.34 ± 0.01 
  
L76A 196 ± 10 4.1 ± 0.2 17.0 ± 1.5 0.24 ± 0.02 
  
A79I 334 ± 11 7.0 ± 0.2 13.2 ± 0.8 0.53 ± 0.04 
  
Y108F 221 ± 8 4.6 ± 0.2 16.9 ± 1.1 0.27 ± 0.02 
4-HPAA
b
 Dopamine WT 893 ± 43 18.7 ± 0.9 18.1 ± 1.4 1.03 ± 0.09 
  
L76A 682 ± 24 14.3 ± 0.5 17.4 ± 1.0 0.82 ± 0.05 
  
A79I 2174 ± 429 46 ± 9 39.4 ± 9.9 1.16 ± 0.37 
  
Y108F 219 ± 16 4.6 ± 0.3 5.2 ± 0.9 0.89 ± 0.17 
Hexanal
b
 Dopamine WT 205 ± 16 4.3 ± 0.3 13.4 ± 1.8 0.32 ± 0.05 
  
L76A 150 ± 5 3.2 ± 0.1 13.4 ± 0.8 0.24 ± 0.02 
  
A79I 300 ± 21 6.3 ± 0.4 12.5 ± 1.5 0.50 ± 0.07 
  
Y108F 119 ± 7 2.5 ± 0.1 7.6 ± 0.9 0.33 ± 0.04 
a  
All kinetic parameters for varied dopamine were recorded with 2.5 mM aldehyde, and dopamine 
varied from 500 µM to 20mM 
b
 All kinetic parameters for varied aldehydes were recorded with 2.5 mM dopamine, and aldehyde 
varied from 250 µM to 15 mM 
4.3.3 Lys-122 
The exchange of lysine to leucine at position 122 (K122L) was designed to probe the 
role of the Lys-122 nitrogen. Leucine was selected as it lacks the amine moiety, does 
not have β-branching, and has no additional functionality or significant bulk that could 
potentially give rise to misleading results. Methionine may also be a reasonable amino 
acid to substitute at this position. The variant K122L was expressed and purified in a 
similar manner to WT. The K122L variant demonstrated essentially no activity or 
conversions above background with either 4-HPAA or hexanal (Fig. 4.24). This was in 
agreement with results from Ilari et al where no activity was identified with a K122A 
mutant (using Δ19TfNCS and the CD spectroscopy method, see section 4.1.4).43 This 
data confirmed that Lys-122 is necessary for NCS activity; it plays a key role in the 
enzyme mechanism. 
Interestingly, the K122L amino acid substitution caused an increase in the enzyme 
stability with regards to both the melting and aggregation temperatures (Table 4.3). The 
increase in Tm was fairly large: 9 °C. The destabilising effect of the Lys-122 is caused 
by the energetic cost of burying a positively charged residue in a hydrophobic region. 
Although Lys-122 is accessible to water from two directions, which can stabilise a 
charged residue, the adjacent amino acid residues are hydrophobic, and tend not to 
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form stabilising interactions with charged side chains. The exception to this is Phe-112, 
adjacent to Lys-122, which could form π-cation interactions with a positively charged 
lysine.140 
The destabilising effect of burying a charged residue was also manifested in the pKa 
predictions, in which Lys-122 is predicted to have a shifted pKa, increasing its 
propensity to be neutral (Table 4.2). The large change in Tm in K122L, however, does 
suggest that a large proportion of the residue is charged in the apo enzyme. There is 
presumably a balance between the energetic cost of burying a charge and the intrinsic 
basicity of the primary amine; at pH 7.5 this equilibrium allows the lysine to be primed 
for acid-base catalysis. There is also likely to be a mechanism for Lys-122 to gain or 
lose protons aside from interactions with substrates—access to a proton sink is 
required. This could be mediated by water via the tunnel next to Lys-122. Alternatively 
main-chain amide groups could provide access to the pool of protons on the protein 
surface. 
Both the dopamine-first and HPAA-first mechanisms propose acid-base catalysis for 
Lys-122. In the HPAA-first mechanism, the positively charged lysine initially activates 
the aldehyde and then catalyses the formation of the hemiaminal and then the loss of 
water to form the imine (Fig. 4.5).56 In the dopamine-first mechanism the Lys-122 
interacts with the 3-hydroxy group of dopamine to catalyse the electrophilic aromatic 
substitution step (Fig. 4.10).57 The data concerning K122L were insufficient to 
distinguish between the HPAA-first and dopamine-first mechanisms.  
4.3.4 Glu-110 
The residue Glu-110 is proposed to play the same role in both the HPAA-first and 
dopamine-first mechanisms: it catalyses the proton abstraction from the quinolinone 
intermediate to trigger rearomatisation and product formation. This step has been 
proposed to be partially rate determining.51 In order to separate the spatial and charge 
effects of the glutamic acid carboxyl group, two variants were investigated. The E110Q 
variant, with an amide in place of the carboxyl group, was intended to preserve as 
much structural and positional features of Glu-110 as possible, but with the charge 
removed. The E110D variant, on the other hand, maintained the original charge but the 
position of this charge was changed. Both variants expressed and purified in a similar 
manner to WT (Fig. 4.20). Both variants also showed no significant activity or 
conversions above background, except E110Q which demonstrated conversion with 4-
HPAA slightly above the HEPES background (Fig. 4.22, Fig. 4.24). There was 
insufficient conversion to measure stereoselectivity accurately with the chiral HPLC 
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method, so it was unclear whether this was an enzyme catalysed conversion. A 
tentative explanation for this increased conversion can be found later in this section. 
The two amino acid substitutions showed contrasting impacts on enzyme stability. 
E110Q had a melting temperature 5 °C greater than WT, whilst E110D destabilised the 
enzyme by just over 2 °C (Table 4.3). The explanation for this is similar to that for 
K122L stability changes: placing a charged group in a buried hydrophobic region of a 
protein exhibits an energetic cost. The variant E110Q loses the charge so is stabilised, 
whilst in E110D the charge is buried deeper in the protein, so increases the 
destabilising effect. It is also possible some interactions between Glu-110 and adjacent 
residues are maintained in E110Q but lost in E110D due to the change in functional 
group position—this could also explain the reduction in melting temperature seen for 
E110D. Again, as for Lys-122, this energetic cost of burying a charge was reflected in 
pKa predictions: in the apo active site the residue was predicted to be more neutral than 
charged at pH 7.5 (Table 4.2). When a positively charged nitrogen is placed near the 
residue, as predicted by the dopamine-first mechanism, the pKa of the residue is 
predicted to fall, and the residue would be predominantly negatively charged.  
The severe loss of activity with both E110D and E110Q shows that both the position of 
the residue and the charge of the residue are of utmost importance to the NCS 
mechanism. This suggests that the residue does not merely provide electrostatic 
stabilisation to the substrates and intermediates, but plays an active role in the enzyme 
mechanism. In both proposed mechanisms the residue acts as base, extracting the 8a 
proton from the quinolinone intermediate—the exact position of the residue determines 
the success of this step. The docking of the anti-(1S,8aR)-quinolinone in the active site 
shows the proximity of the 8a proton with the Glu-110 (3.3 Å to the 8a carbon) (Fig. 
4.19). This provides a structural insight into how this step may occur in the dopamine-
first mechanism. There was also, accordingly, a slight increase in the predicted pKa of 
Glu-110 at this point (Table 4.2).  
Data on Glu-110 variants are insufficient to distinguish between the HPAA-first and 
dopamine-first mechanisms, especially as both mechanisms have them performing the 
same main function. However, previous work on a Glu-110 mutant (E110A) by Ilari et al 
provides a very interesting comparison to the work here. Whereas no activity is 
observed with Glu-110 variants in this work, Ilari et al observed reduced, but significant, 
activity in the E110A variant.43 The kinetic assays were conducted using a CD 
spectroscopy method that detects specific formation of (S)-products. Importantly, the 
assays were conducted in phosphate buffer, which catalysed the racemic reaction. The 
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presence of activity with phosphate and not with HEPES (the buffer used here) 
signifies that phosphate must be catalysing the reaction step that Glu-110 typically 
catalyses. The fact that a chiral product was observed with E110A in CD experiments 
shows that chirality is not established by the Glu-110 catalysed step. The mutant 
K122A, on the other hand, showed no formation of chiral products, even though 
phosphate was present and could catalyse any Lys-122 catalysed step. This shows 
that chirality is established by the action of Lys-122. This may also account for the very 
slightly increased conversions observed from E110Q compared to K122L (Fig. 4.22).  
This understanding also provides insight into substrate binding in the E110A NCS 
active site, as in order for phosphate to catalyse the step typically catalysed by Glu-
110, either phosphate must enter and bind in the active site (in the Glu-110 position), or 
reaction intermediates must diffuse out of the enzyme into the buffer. In either scenario 
this suggests that the active site binds substrates fairly loosely. The high 𝐾𝑚
𝑎𝑝𝑝
 values 
determined through kinetic assays suggest this weak binding is a general feature of 
NCS (Table 4.4). 
The anti-(1S,8aR)-quinolinone can only be derived from the trans-iminium; it is 
inaccessible from the cis-iminium (see Fig. 4.9). Observations of Glu-110 mutant 
behaviours coupled with results from docking studies provide strong indication that the 
anti-(1S,8aR)-quinolinone is the reaction intermediate found in NCS. This, therefore, 
must also mean that the iminium is found in a trans configuration in the reaction 
mechanism.  
Docking investigations of dopamine, hemiaminal and iminium reaction intermediates 
suggest that Glu-110 is in close proximity to the intermediate nitrogen throughout the 
reaction mechanism (Table 4.1). This suggests that in the dopamine-first mechanism 
Glu-110 may play a role in the early steps in the reaction mechanism. It may help 
catalyse the initial nucleophilic attack to form the hemiaminal, and the subsequent 
dehydration to form the iminium intermediate.  
4.3.5 Asp-141 
In both proposed enzyme mechanisms, Asp-141 plays a minor role compared to Glu-
110. In the HPAA-first mechanism, it binds to the 4-HPAA phenol (Fig. 4.5).56 Substrate 
tolerance studies have shown this cannot be an important interaction for the enzyme 
mechanism as aldehydes without this phenol group are readily accepted.53,57,61 In the 
dopamine-first mechanism the residue is proposed to play a role in binding and 
stabilising the positively charged nitrogen of the substrate and intermediates. In a 
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similar manner to investigation into Glu-110, two variants of Asp-141 were studied: 
D141E probed the spatial effect of the charge and D141N probed the presence of the 
charge itself. Both variants expressed and purified in a similar manner to WT (Fig. 
4.20). The amino acid substitutions also caused a slight increase in melting 
temperatures (Table 4.3). D141N raised the melting temperature by 3 °C, as removing 
a charge from a hydrophobic active site increases thermodynamic stability. D141E 
raised the melting temperature by 1 °C: charges are more detrimental to stability when 
more buried. Again, pKa predictions reflected melting point observations: the pKa of 
Asp-141 was shifted slightly towards neutrality (at pH 7.5) (Table 4.2).  
Activities and conversions with all substrates were reduced as a result of the Asp-141 
amino acid substitutions. The removal of the charge (D141N) caused a greater 
reduction in activity than moving the charge (D141E). The variant D141N caused 
reduction in all activities by 90% or more; in contrast D141E retained 55% activity for 4-
HPAA and 40% activity for hexanal (dopamine 10 mM, aldehyde 2.5 mM) (Fig. 4.24). 
This effect was reflected in conversions, though it was not so pronounced (Fig. 4.22). 
Both variants retained stereoselectivity (Fig. 4.23), though D141N conversions with 
hexanal were too low to detect via chiral HPLC. Interestingly, the substitution D141E 
affected activities with hexanal more than activities with 4-HPAA (Fig. 4.26). The 
HPAA-first mechanism predicts Asp-141 binds to the 4-HPAA phenol; if so then it 
would be expected that aldehydes with this phenol interaction would be more affected 
by Asp-141 amino acid substitutions than those without. The opposite effect was 
observed—hexanal was more effected by the substitutions than 4-HPAA. The 
dopamine-first mechanism proposes a more general role for Asp-141 which is not 
aldehyde specific, so superficially this also cannot account for the slight shift in 
substrate specificity of D141E. However, the intrinsic reactivity of different aldehydes 
could account for the aldehyde specific effect: as hexanal is less reactive than 4-HPAA 
(as shown by reactions with phosphate) it benefits proportionally more from enzyme 
catalysis than 4-HPAA. When an element in the enzyme catalysis is lost (i.e. the Asp-
141 stabilising/charge interactions), the activity towards the less reactive aldehyde is 
reduced proportionally more. This explanation is speculative; kinetic experiments may 
be able to account for the aldehyde specific behaviour of Asp-141 variants. 
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Fig. 4.26 Relative substrate preference of variants. The value for substrate preference is obtained by 
dividing the activity or conversion with HPAA by the value for hexanal. The resulting value describes the 
magnitude of HPAA activity/conversion relative to hexanal. Therefore, higher values show increased 
preference for HPAA compared to hexanal, and lower values relative improvement in activity/conversion 
for hexanal rather than HPAA. 
The behaviour of Asp-141 variants cannot be fully accounted for by either the HPAA-
first mechanism or the dopamine-first mechanism. However, the severe reduction in 
activity (93%) observed with the substitution D141N and the substrate hexanal is 
completely incongruent with the proposed Asp-141 role in the HPAA-first mechanism 
(Fig. 4.24). It can, however, be rationalised with the dopamine-first mechanism, in 
which it does not interact with the aldehyde. 
The difference in behaviour between D141E and D141N is indicative of a residue that 
provides electrostatic stabilisation rather than base catalysis: for Asp-141 the charge 
was much more important than the exact position of the charge. This contrasts with 
Glu-110 variant behaviour, where the exact position and charge were both vital. 
Computational docking (supporting the dopamine-first mechanism) showed Asp-141 
stabilising the dopamine and hemiaminal positive charges at the first stage of the 
reaction, perhaps catalysing the initial nucleophilic attack and subsequent dehydration 
(Table 4.1). This behaviour would correspond to the experimental data collected. 
4.3.6 Tyr-108 
In NCS, Tyr-108 forms part of a narrow access tunnel to the large internal active site, 
restricting the entrance of substrates. It is also adjacent to the important Glu-110 
residue. In the HPAA-first mechanism it is proposed to H-bond with the dopamine 4-
hydroxy group, stabilising the quinolinone intermediate (Fig. 4.5). This proposed 
interaction, however, cannot account for successful activity observed when the 4-
0
1
2
3
4
5
6
Activity
10 mM dopamine
2.5 mM Aldehyde
Activity
2.5 mM dopamine
10 mM aldehyde
Conversions
10 mM substrates
S
u
b
s
tr
a
te
 P
re
fe
re
n
c
e
 R
a
ti
o
H
P
A
A
/H
e
x
a
n
a
l
WT
L76A
L76V
A79I
Y108F
D141E
Phosphate
130 
 
hydroxy group was not present.51,57 In the dopamine-first mechanism Tyr-108 may 
interact with the iminium cation, but otherwise no clear role is assigned.57 
Computational docking of reaction intermediates in the active site suggested that Tyr-
108 interacts with the hemiaminal hydroxy, and perhaps aids initial aldehyde substrate 
binding and subsequent formation of the hemiaminal and imine (Fig. 4.17A). 
To investigate the role of Tyr-108, the variant Y108F was expressed and purified (Fig. 
4.20). This amino acid substitution allowed specific interrogation into the role of the 
phenol, in terms of its H-bond and electrostatic interactions. The variant had a very 
slightly increased stability compared to wild-type (1 °C), probably because hydrophobic 
interactions were improved (Table 4.3). The variant showed a 50% loss of activity for 4-
HPAA and 30% loss for hexanal (dopamine 10 mM, aldehyde 2.5 mM) (Fig. 4.24). The 
amino acid substitution had a greater detrimental impact on 4-HPAA activity than on 
hexanal activity (Fig. 4.26). In order to investigate this aldehyde specific effect more, 
kinetic parameters for both substrate combinations were determined (Fig. 4.25, Table 
4.4). 
The variant Y108F showed a reduction in both 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝 and 𝐾𝑚
𝑎𝑝𝑝 for every substrate 
combination (Fig. 4.27, Table 4.4). The most significant reductions in 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝 and 𝐾𝑚
𝑎𝑝𝑝 
were observed with varying 4-HPAA concentrations. The decreases in 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝 and 𝐾𝑚
𝑎𝑝𝑝 
were proportionally larger when 4-HPAA was used than when hexanal was used; this 
was apparent both when dopamine and when the aldehyde was varied. Reductions in 
𝐾𝑚
𝑎𝑝𝑝 for all substrates with Y108F can be rationalised simply by the increased size of 
the active entrance allowing substrates easier access. This, however, seems to be the 
opposite result to what would be expected if the phenol binds to the aldehyde. The 
decrease in 𝐾𝑚
𝑎𝑝𝑝 was more prominent for 4-HPAA than hexanal as it is the bulkier 
aldehyde and its binding is impacted the greatest due to this change. The fact that the 
𝐾𝑚
𝑎𝑝𝑝 reductions were proportionally larger for aldehydes than dopamine perhaps can 
be best accounted for by the dopamine-first mechanism where Tyr-108 is part of the 
aldehyde binding site. In contrast, the HPAA-first mechanism predicts Tyr-108 to bind 
to dopamine, not the aldehyde, therefore it would be expected that Y108F would 
weaken binding (increasing 𝐾𝑚
𝑎𝑝𝑝) to dopamine—this is not what was observed 
experimentally. 
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Fig. 4.27 Apparent kinetic parameters for TfNCS with 4-HPAA and hexanal. Parameters found in 
Table 4.4. 
The reduction in 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝 with Y108F suggested that Tyr-108 plays a role in the mechanism 
of the enzyme. In the HPAA-first mechanism this role would be the binding to the 
quinolinone intermediate via the 4-hydroxyl group. In the dopamine-first mechanism 
this role is not as well defined, but based on its interactions with (S)-hemiaminal in 
docking calculations (Fig. 4.17A) it may aid with the initial aldehyde binding, formation 
of the hemiaminal and dehydration to form the iminium. The reduction of 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝 was 
greater for 4-HPAA than hexanal (Fig. 4.27). It was unclear, though, why the reduction 
in 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝 was not consistent with different aldehydes. An origin of this difference 
(according to the dopamine-first mechanism) may be that the Tyr-108 phenol group 
sterically constrains the intermediates during the reaction, encouraging them to be in 
conformations conducive to reaction progression. Hexanal is less affected by this loss 
of the tyrosine phenol as it is less bulky, and so is less sensitive to its presence. This 
explanation is, of course, speculative; presently there is insufficient information to 
explain the aldehyde-specific effects of Y108F. Ultimately for 4-HPAA there was a 
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greater reduction in 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝 than 𝐾𝑚
𝑎𝑝𝑝; this resulted in an overall reduction in 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝/𝐾𝑚
𝑎𝑝𝑝. 
Hexanal, on the other hand, had an equal reduction in these kinetic parameters, so 
overall 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝/𝐾𝑚
𝑎𝑝𝑝
 was the same as WT (Table 4.4). 
Interestingly, although Y108F demonstrated poorer activities with 4-HPAA than with 
hexanal (compared to WT), the conversions showed the opposite result (Fig. 4.26). 
The comparative quantity of 4-HPAA product compared to hexanal product was slightly 
increased. A possible explanation could be if there is a correlation of activity with 
product inhibition. This, however, has not been observed. 
4.3.7 Leu-76 
The residue Leu-76 was examined in order to identify aldehyde specific effects. 
Although the residue is not proposed to play an active role in either enzyme 
mechanism, it was selected for investigation as it is proposed to interact with 
substrates in a very different manner in each mechanism. In the HPAA-first mechanism 
it is not near either the dopamine or the aldehyde substrate so would not be expected 
to have any influence on the enzyme activity (Fig. 4.6, subunit B). Conversely, in the 
dopamine-first mechanism it contacts the aldehyde R-group (Fig. 4.18). If the 
dopamine-first mechanism were correct, it should be possible to mutate this residue 
and observe aldehyde specific effects on the enzyme activity. Two Leu-76 variants 
were selected, to examine a progressive change in the residue sidechain: L76V and 
L76A. These variant were expressed and purified (Fig. 4.20), and were shown to 
demonstrate reduced stabilities with respect to WT (Table 4.3). The reduction in 
stability correlates with loss of hydrophobic interactions: the progressive loss of each 
carbon resulted in a 2 °C reduction in melting temperature. 
The removal of methyl groups on the side chain of residue 76 (from leucine to valine to 
alanine) caused a reduction of activities and conversions (with 4-HPAA and hexanal) 
(Fig. 4.22, Fig. 4.24). For activities, the relative decrease in 4-HPAA activities was 
slightly less pronounced than the decrease for hexanal (Fig. 4.26). Strangely, 
conversions showed the opposite trend, with 4-HPAA conversions falling more sharply 
than those with hexanal. This was similar but opposite to the trends seen for Y108F, 
where activities showed a relative switch towards hexanal but conversions moved in 
the opposite direction. A tentative explanation for this observation is product inhibition. 
Increased activities may correlate with increased product inhibition which ultimately 
results in reduced conversions. More experiments are required to unravel these 
observations. 
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In order to examine the origin of the fall in activity with Leu-76 variants, kinetic 
parameters were measured for L76A (Fig. 4.25). If Leu-76 were to form part of the 
aldehyde binding site it may be expected that the loss of activity would be caused by 
increases to aldehyde 𝐾𝑚
𝑎𝑝𝑝. This was not observed: aldehyde 𝐾𝑚
𝑎𝑝𝑝 values were identical 
to WT. Dopamine 𝐾𝑚
𝑎𝑝𝑝 values were slightly reduced (Fig. 4.27, Table 4.4). The origin of 
the loss of activity was the reduction in 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝, which was observed for all substrate 
combinations. As observed with 𝐾𝑚
𝑎𝑝𝑝 values, changes in 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝 were larger when 
dopamine is the varied substrate. The impact of L76A on 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝 was unexpected, and 
suggests the residue is not involved in the initial binding of substrates but perhaps in 
the position of the intermediates as the reaction progresses. Overall, the L76A kinetic 
parameters demonstrate that there no clear difference in behaviour between 4-HPAA 
or hexanal.  
4.3.8 Ala-79 
Sequence alignments between TfNCS and CjNCS2 show differences in the constitution 
of loop 3 at the entrance of the active site. In TfNCS the sequence from 76 to 80 is 
LPGAF; CjNCS2 has an alanine inserted between 77 and 78, and an isoleucine in 
position 79: LPAGIF. The TfNCS variant A79I was examined to investigate the effect of 
having an isoleucine at position 79. The mutant was expressed and purified in a similar 
manner to WT. No melting point was recorded so the effect of the mutation on enzyme 
stability is unknown. 
The A79I showed increased activities (between 20-50%) with both 4-HPAA and 
hexanal (Fig. 4.24). The increased activities were proportional with all substrates: there 
was no aldehyde specific effect (Fig. 4.26). Kinetic experiments performed to examine 
the origin of the activity increase were unable to approach substrate saturation, so 
some parameters have large errors associated (Fig. 4.25), though all fits were 
statistically significant (p<0.05). The origins of the increased activities seem to depend 
on the aldehyde tested. For HPAA, both 𝐾𝑚
𝑎𝑝𝑝 and 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝 values became larger with the 
amino acid substitution (Fig. 4.27, Table 4.1). Hexanal activity was affected through 
slight reduction in dopamine 𝐾𝑚
𝑎𝑝𝑝 and an increase in hexanal 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝. The changed 
dopamine 𝐾𝑚
𝑎𝑝𝑝 when different aldehydes were examined is difficult to rationalise with 
the dopamine-first mechanism as dopamine binding would not be expected to change. 
This could support the HPAA-first mechanism, or could merely demonstrate the 
complexity of the kinetics in this reaction—𝐾𝑚
𝑎𝑝𝑝 does not simply correspond to 
substrate binding. 
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It is interesting that A79I affected activities with the two aldehydes in different ways. 
The difference between the aldehydes can be partially rationalised on the basis of the 
aldehyde bulk. The A79I variant may reduce affinity towards 4-HPAA as an increased 
side chain bulk disrupts binding. This additional protein bulk does not disrupt the 
hexanal binding has less bulk. Increases in 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝 may have been the result of increased 
restriction in reaction intermediates conformations. The isoleucine could also prevent 
intermediates from exiting the active site prematurely, or encourage the adoption of 
conformations that progress the reaction.  
4.3.9 3,4-Methylenedioxyphenylacetaldehyde 
Studying the activities of variants with dopamine and the aldehydes 4-HPAA and 
hexanal led to the observation of some aldehyde-specific effects (Fig. 4.26). D141E 
and L76V showed proportionally greater losses of activity for hexanal than for 4-HPAA; 
Y108F demonstrated the opposite effect, with proportionally greater losses in activity 
for 4-HPAA than hexanal. The amino acid substitution A79I had similar overall impact 
on both 4-HPAA and hexanal activity, but the kinetic origins of these changes were 
different (Fig. 4.27). 
In an attempt to draw out more aldehyde-specific effects, especially for variants of the 
dopamine-first aldehyde binding site (Leu-76, Ala-79, Tyr-108), the activity of variants 
with a large substrate was examined. The substrate selected was 3,4-methylenedioxy-
phenylacetaldehyde (Fig. 4.28A), which had not been previously tested with NCS, but 
was expected to be turned over based on substrate studies.53,57 The methylenedioxy 
group attached to the aromatic ring results in a bicyclic ring, similar to the previously 
tested 1-naphthylacetaldehyde substrate. 
Activities with 3,4-methylenedioxyphenylacetaldehyde were between 10-30% lower 
than with 4-HPAA (Fig. 4.28B). L76A and Y108F showed the smallest reduction in 
activities relative to 4-HPAA and A79I the largest (Fig. 4.28D). According to the 
dopamine-first mechanism, these relative changes could be related to varying steric 
clashes due to the increased bulk of the aldehyde. However these differences are 
small: overall, the pattern of activities for the different variants compared to WT was the 
same as for 4-HPAA. No clear aldehyde-specific effects were observed and so no 
further assays were conducted with this aldehyde. 
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Fig. 4.28 Activities and conversions with 3,4-methylenedioxyphenylacetaldehyde. A. Structure of 
3,4-methylenedioxyphenylacetaldehyde and (S)-THIQ product with dopamine. B. Enzyme activities. Solid 
bars show dopamine 10 mM, aldehyde 2.5 mM. Lined bars show dopamine 2.5 mM, aldehyde 10 mM. C. 
Conversions, 10 mM dopamine, 10 mM 3,4-methylenedioxyphenylacetaldehyde. D. Substrate preference 
for activities (activity with HPAA divided by activities with 3,4-methylenedioxyphenylacetaldehyde). 
 
4.3.10 Citronellal 
Clear aldehyde-specific effects were observed with the variant L76A and the aliphatic 
aldehydes (S)- and (R)-citronellal (Fig. 4.29A). L76A demonstrated increased activities 
compared to WT for both citronellals (with dopamine) (Fig. 4.29 B and C). With 10 mM 
dopamine and 2.5 mM citronellal, activities with (R)-citronellal increased by 30% and 
activities with (S)-citronellal more than doubled. In contrast, activities with hexanal, also 
an aliphatic aldehyde, fell by 40%. The fact that the two citronellal enantiomers 
demonstrated different activities with WT and L76A is a strong indication that the 
effects observed are enzymatic/structural effects rather than just due to general 
chemical reactivity.  
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Fig. 4.29 Activities and conversions with (S) and (R)-citronellal. A. Structure of (S) and (R)-citronellal. 
B and C. Enzyme activities. Black bars are WT, white bars are L76A. Solid bars (B) show dopamine 10 
mM, aldehyde 2.5 mM, lined bars (C) show dopamine 2.5 mM, aldehyde 10 mM. D. Conversions, 10 mM 
dopamine, 10 mM citronellal. Black bars are WT, white bars are L76A.  
The HPAA-first mechanism cannot account for these results, as Leu-76 is not 
especially near the proposed aldehyde binding site. Docking calculations of imine-
citronellal intermediates in the WT active site (Fig. 4.30) predicted a dopamine-first 
arrangement of the intermediate, with the dopamine portion in close proximity to Lys-
122. Notably, the aldehyde R-group is predicted to be in contact with Leu-76. The 3`-
methyl groups of the (S)- and (R)-citronellal occupy positions in the active site tunnel 
around 3.65 and 3.75 Å away from Leu-76 respectively. Whilst the 3`-methyl from the 
(S)-citronellal points away from the enzyme bulk, the (R)-citronellal 3`-methyl points 
into the enzyme, towards the residues Leu-72, Phe-80 and Met-97. Although the 
substitution L76A frees space near this methyl group for both citronellal isomers, there 
remain more steric restrictions on the (R)-citronellal. This could account for the different 
effects between the aldehydes.  
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Fig. 4.30 Predicted conformations of citronellal iminium intermediates in the NCS active site. A. 
Docking of (S)-citronellal-trans-iminium. B. Docking of (R)-citronellal-trans-iminium. Black dotted 
lines show potential steric or hydrophobic interactions between the intermediate methyl groups and L76A. 
Active site residues carbons are coloured yellow; docked ligands carbons are coloured purple. Ligand 
accessible surfaces are represented by transparent purple. A section of the protein solvent accessible 
surface is represented in green. Conformations depicted are lowest energy predictions. Figure adapted 
from Lichman et al.
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Kinetic assays were conducted to explore the origin of the aldehyde-specific activity 
increase with L76A (Fig. 4.31, Table 4.5). For both WT and L76A, dopamine 𝐾𝑚
𝑎𝑝𝑝 
values with citronellal were lower than 𝐾𝑚
𝑎𝑝𝑝 values in assays with 4-HPAA or hexanal. 
WT had a slightly lower 𝐾𝑚
𝑎𝑝𝑝 than L76A in these reactions. For these assays, where 
dopamine concentration was varied, the origin of the activity increase in L76A was 
manifested in 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝, rather than 𝐾𝑚
𝑎𝑝𝑝. The kinetic plots for varying citronellal 
concentrations (Fig. 4.31) are very different to plots with 4-HPAA or hexanal (Fig. 4.25). 
When interpreted with Michaelis-Menten kinetics the 𝐾𝑚
𝑎𝑝𝑝 values are an order of 
magnitude lower than any other recorded NCS 𝐾𝑚
𝑎𝑝𝑝: 400-600 μM, compared to the 
next lowest, 5.2 mM for HPAA and Y108F (Table 4.4). The 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝 values for citronellal 
isomers are also an order of magnitude lower than those previously recorded. The 
origin of the L76A increased activity with citronellal appears to be entirely due to 
improvements in 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝, rather than reductions in 𝐾𝑚
𝑎𝑝𝑝. The L76A substitution may not 
affect initial binding of the aldehyde (which is perhaps directed more by Tyr-108) but 
may affect the behaviour of reaction intermediates. Removing the steric bulk close to 
the citronellal methyl moiety may enable the intermediate to more easily occupy 
favourable conformations that are conducive to reaction progression. 
A B
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Fig. 4.31 Velocity/substrate concentration curves with citronellal for wild-type (WT, black) and L76A 
(orange). (A) Varying dopamine concentrations with 2.5 mM (S)-citronellal (circles) or (R)-citronellal 
(triangles). (B) Varying (S)-citronellal concentrations with 2.5 mM dopamine. (C) Varying (R)-citronellal 
concentrations with 2.5 mM dopamine. Nonlinear least-squares fits: solid lines Michaelis-Menten kinetics, 
dashed lines substrate inhibition kinetics. Substrate inhibition equation: rate = Vmax.[S]/(Km + [S] + ([S]
2
/Ki)). 
Data points are the mean from three measurements; error bars indicate SDs of three reactions. For 
parameters, see Table 4.5. Figure adapted from Lichman et al.
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Table 4.5 Apparent kinetic parameters for TfNCS with (R)- and (S)-citronellal (citron.). Corresponding 
velocity/substrate concentration curves can be found in Fig. 4.31. Table adapted from Lichman et al.
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Varied 
Substrate 
Constant 
Substrate 
Enzyme Michaelis-Menten 
      𝑉𝑚𝑎𝑥
𝑎𝑝𝑝
 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝
 𝐾𝑚
𝑎𝑝𝑝
 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝 𝐾𝑚
𝑎𝑝𝑝⁄  
      nkatal.mg
-1
 s
-1
 mM s
-1
.mM
-1
 
Dopamine
a
 (S)-citronellal WT 153 ± 8 3.2 ± 0.2 13.8 ± 1.0 0.23 ± 0.02 
  
L76A 368 ± 19 7.7 ± 0.4 15.3 ± 1.0 0.50 ± 0.04 
Dopamine
a
 (R)-citronellal WT 115 ± 3 2.4 ± 0.1 10.3 ± 0.4 0.24 ± 0.01 
  
L76A 138 ± 5 2.9 ± 0.1 11.0 ± 0.6 0.26 ± 0.02 
(S)-citronellal
b
 Dopamine WT 22 ± 1 0.46 ± 0.02 0.38 ± 0.10 1.20 ± 0.31 
  
L76A 45 ± 2 0.93 ± 0.05 0.59 ± 0.09 1.57 ± 0.25 
(R)-citronellal
b
 Dopamine WT 17.9 ± 1.4 0.37 ± 0.03 0.53 ± 0.14 0.71 ± 0.20 
  
L76A 26.4 ± 1.6 0.55 ± 0.03 0.49 ± 0.11 1.13 ± 0.27 
   
Substrate Inhibition
c
 
   
𝑉𝑚𝑎𝑥,𝑆𝐼
𝑎𝑝𝑝
 𝑘𝑐𝑎𝑡,𝑆𝐼
𝑎𝑝𝑝
 𝐾𝑚,𝑆𝐼
𝑎𝑝𝑝
 𝐾i,SI
𝑎𝑝𝑝
 
   nkatal.mg
-1
 s
-1
 mM mM 
(S)-citronellal
b
 Dopamine WT 27.4 ± 1.8 0.57 ± 0.04 0.64 ± 0.12 37 ± 11 
  
L76A 64.1 ± 9.6 1.34 ± 0.20 1.06 ± 0.25 23 ± 11
d
 
(R)-citronellal
b
 Dopamine WT 33.9 ± 4.8 0.71 ± 0.10 1.42 ± 0.31 13 ± 4 
  L76A 41.9 ± 6.6 0.88 ± 0.14 1.09 ± 0.29 15 ± 6
e
 
a  
All kinetic parameters for varied dopamine were recorded with 2.5 mM aldehyde, and dopamine varied 
from 500 µM to 20mM 
b
 All kinetic parameters for varied aldehydes were recorded with 2.5 mM dopamine, and aldehyde varied 
from 250 µM to 15 mM 
C 
Substrate inhibition equation: 𝑅𝑎𝑡𝑒 = 𝑉𝑚𝑎𝑥. [𝑆] (𝐾𝑚 + [𝑆] + ([𝑆]
2 𝐾𝑖⁄ ))⁄  
d 
Calculated p-value > 0.05 for this coefficient (0.081) 
e
 Calculated p-value > 0.05 for this coefficient (0.054) 
 
  
A B C
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The plots for varying citronellal concentrations also seem to show evidence of 
substrate inhibition (Fig. 4.31, dotted lines). Although substrate inhibition equations 
appear by eye to fit the data better than the Michaelis-Menten equations, the Michaelis-
Menten fits are slightly more statistically significant. For both L76A plots the substrate 
inhibition 𝐾𝑖,𝑆𝐼
𝑎𝑝𝑝 term has a p-value>0.05. Furthermore, typically the simplest possible 
model (with fewest parameters) should ideally be used to interpret data (Occam’s 
razor)—in this context this is the Michaelis-Menten fit. More data points would be 
required at higher substrate concentrations to fully distinguish between these two fits. If 
substrate inhibition with respect to the aldehyde were present, it would fit with the NMR 
observation that dopamine did not bind to the enzyme subsequent to aldehyde 
binding.54 With the dopamine-first mechanism aldehyde substrate inhibition is 
straightforward to imagine: the aldehyde binds deep in the active site, preventing 
dopamine binding and the reaction progressing. There is no evidence, however, for 
substrate inhibition with 4-HPAA or hexanal. 
(R)-Citronellal and (S)-citronellal demonstrated strikingly different kinetic parameters 
than 4-HPAA and hexanal: an order of magnitude difference for both 𝐾𝑚
𝑎𝑝𝑝 and 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝. 
This is slightly surprising, given that citronellal and hexanal appear structurally more 
similar than hexanal and 4-HPAA. It is also notable that the citronellal concentration 
with maximum rate was 2.5 mM, which was the concentration of dopamine in the 
experiments. It appears that citronellal binds to the enzyme more tightly than other 
aldehydes tested. This may be a result of its increased hydrophobicity. It would be 
interesting to determine if this reduction in 𝐾𝑚
𝑎𝑝𝑝 is a gradual effect caused by increasing 
hydrophobicity or there is a cut-off where 𝐾𝑚
𝑎𝑝𝑝 reduces more suddenly. A more sudden 
change would be indicative of a shift in kinetic mechanism or of the rate determining 
step. This could be examined by testing various related substrates with increasingly 
long alkyl chains.  
Overall, the increased activity with citronellal caused by the amino acid substitution 
L76A is evidence in favour of the dopamine-first mechanism. Although the actual origin 
of this activity increase cannot be defined based on activity and kinetics data alone, the 
computational docking data shows the close proximity of Leu-76 and the citronellal R-
group in the dopamine-first mechanism. Furthermore, the fact that the (R)- and (S)-
citronellal behaved differently despite having the same chemical reactivity proves this 
was an effect caused by the enzyme.  
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4.4 Discussion of mechanism 
Overall, computational and experimental data provide more support for the dopamine-
first mechanism than the HPAA-first mechanism. The key evidence supporting the 
dopamine-first mechanism is the increased activity of L76A with citronellal. The effect 
of this amino acid substitution on activity with citronellal can be partially rationalised on 
the basis of the computational docking. 
4.4.1 Electrophilic aromatic substitution 
Due to the corroboration between predicted binding modes and experimental data, the 
mechanism of the final electrophilic aromatic substitution step in the reaction seems 
clear (Fig. 4.32). Electrophilic addition occurs on the Re-face of the trans-iminium 
cation, establishing the 1S chiral centre. This step is catalysed by the interaction of 
Lys-122 with the 3-hydroxy group of the catechol. In order to achieve the correct 
(neutral) protonation state to catalyse this step, Lys-122 can exchange protons with the 
solvent via an adjacent water channel. The electrophilic aromatic addition forms the 
(1S, 8aR)-anti-quinolinone, defining the product chirality, and the 8aR proton is then 
removed by Glu-110, causing rearomatisation and formation of the (S)-THIQ.  
 
Fig. 4.32 Electrophilic aromatic substitution. Final steps of NCS mechanism.  
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4.4.2 Iminium formation 
The first step in the reaction mechanism is the binding of dopamine in the active site 
with the catechol adjacent to the Lys-122 and the nitrogen interacting with Glu-110 and 
Asp-141. The mechanism of the next steps, the formation of the iminium intermediate, 
is unclear, both with respect to the specific identity of the reaction intermediates and 
the roles and protonation states of the enzyme residues. The aldehyde must bind: 
candidates residues for binding to the aldehyde moiety are Tyr-108 and Glu-110. The 
aldehyde is then attacked by the dopamine; the face of the aldehyde attacked 
determines whether the intermediate formed is the (S)- or (R)-hemiaminal. Docking 
calculations show a strong preference for the (S)-hemiaminal intermediate compared to 
the (R)-isomer but there is no experimental evidence to validate this. Overall, one side 
of the active site entrance (around Tyr-108) is more hydrophilic than the opposite—this 
difference may indicate a tendency for forming the (S)-hemiaminal. 
If dopamine is positively charged, it must be deprotonated to enable nucleophilic 
attack—this can be catalysed by a negatively charged Glu-110 or Asp-141. The 
electrophilic aldehyde then requires a proton to neutralise the resulting oxyanion. In 
solution mechanisms this proton is obtained via exchange with the charged nitrogen 
(Fig. 4.33). This is possible in the enzyme mechanism, but the exchange may instead 
be mediated by a residue, probably Glu-110, based on the docking conformations. It is 
also possible the aldehyde may enter the enzyme active site as a hydrate. In this 
scenario, dehydration of the hydrate to form an activated (protonated) aldehyde would 
require a proton. This could also be taken from Glu-110. Thus regardless of whether 
the aldehyde enters as a hydrate or an non-hydrated aldehyde, one proton is required 
from the enzyme (probably Glu-110) to form the hydroxy. 
 
Fig. 4.33 Imine formation. Typical acid-catalysed mechanism for imine formation in solution. An important 
step is the protonation of the hemiaminal to form a good leaving group (water). 
142 
 
 
Fig. 4.34 Enzymatic trans-iminium formation. Proposed mechanism for trans-iminium formation. Prior to 
the steps drawn here, the dopamine must be deprotonated. The aldehyde may enter as a hydrate – the 
outcome would be identical. The small bond rotation depicted prior to formation of the iminium double 
bond is required to establish the trans-isomer of the iminium. It is possible that this is not part of the 
mechanism but rather a matter of depicting the intermediate in a clearer manner. 
In the solution mechanism for formation of a Schiff base, elimination of water from the 
hemiaminal to form an iminium first requires protonation of the hydroxy group to form 
water, a good leaving group (Fig. 4.33). The docking of the (S)-hemiaminal shows the 
Glu-110 oxygen less than 3 Å away from the hydroxy group, and this residue is 
therefore the best candidate for protonating the hydroxy group (Fig. 4.34). But, as 
described above, the Glu-110 is likely to be deprotonated, having donated a proton to 
the hydroxy group (or by dehydrating the aldehyde hydrate). A proton can be provided 
to the hydroxy group by the adjacent protonated secondary amine. This proton 
exchange may be modulated by Glu-110 or direct exchange with the amine may occur. 
In all reasonable mechanistic scenarios, the amine is deprotonated prior to formation of 
the iminium. The presence of a lone pair on nitrogen at this point in the mechanism 
indicates that no base is required at the elimination step, as electron donation will come 
directly from the nitrogen lone pair. The neutral nitrogen is also able to invert its 
configuration, and is able to have optimal overlap with the C-O σ*-orbital at elimination 
(Fig. 4.34). 
The prediction that Glu-110 or the oxyanion deprotonates the secondary amine means 
Asp-141 does not catalyse the elimination step, despite its close association with the 
(S)-hemiaminal nitrogen. Mutational investigation into Asp-141 showed that the 
chemistry/charge of the residue’s side chain is influential in the reaction mechanism, 
but its position and H-bonding is less important. Its charge may stabilise reaction 
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intermediates and modulate Glu-110 pKa.  The only possible catalytic role Asp-141 may 
play is catalysing the initial nucleophilic attack of dopamine to form the hemiaminal. 
There is an entrance to the active site on the other face of Tyr-108 to the main 
entrance. This tunnel meets with the main active site between Tyr-108 and Glu-110. It 
is lined with hydrophilic residues: Glu-103, Tyr-131, Tyr-139, Thr-159 and Asp-141 
(Fig. 4.35). This is a water channel, and waters are present in this channel in the 
crystal structures. In the docking studies, the (S)-hemiaminal hydroxyl group is 
perfectly positioned to leave through this water channel when formation of the iminium 
occurs. 
 
Fig. 4.35 Water channels in NCS active site. A. Main substrate binding site (showing (S)-hemiaminal 
intermediate docked, purple sticks). B. Route of water channel, around Tyr-108, lined with hydrophilic 
residues. C. Water channel near Lys-122, allowing exchange of protons. Side chains depicted as yellow 
sticks. A section of the protein solvent accessible surface is represented in green. Taken from PDB file 
2VQ5, subunit A. 
 
The exact protonation states of Glu-110, Asp-141 and the substrate nitrogen at the 
start of the mechanism are unknown: there are eight potential arrangements (23). It is, 
however, only possible to draw reasonable mechanisms from five of these starting 
points based on key mechanistic requirements: Glu-110 protonation of the hemiaminal 
hydroxyl leaving group and Glu-110 deprotonation of quinolinone intermediate (Fig. 
4.32). It is not possible to fully differentiate between these mechanisms based on the 
present experimental evidence. The only differences between the mechanisms are the 
overall protonation state of Asp-141 and the initial exchange of protons to ensure a 
neutral nitrogen nucleophile and a protonated Glu-110 (Fig. 4.36).  
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Fig. 4.36 Productive protonation states of active site. Different possible stating states of active site 
generated by varying Glu-110, Asp-141 and dopamine protonation states. Arrows show exchange of 
protons required to reach active site state conducive to reaction progression. Three other possible states 
exist but reasonable mechanisms for them cannot be drawn. Leftmost state is that predicted by 
computational predictions: Glu-110 neutral, Asp-141 charged and dopamine protonated.  
 
4.4.3 Conformational change 
The predicted conformations of the (S)-hemiaminal and the trans-iminium in the active 
site showed a crucial difference. Whilst in the (S)-hemiaminal binding mode the 
nitrogen occupied a position near Glu-110 and Asp-141, in the iminium conformation 
the nitrogen moved away from Asp-141 and towards the catechol ring (Fig. 4.17A, Fig. 
4.18A). This change was enabled by a bond rotation in the ethylamine part of 
dopamine. The ethylamine in the (S)-hemiaminal was in a staggered conformation, but 
in the iminium had a pseudo-chair conformation (Fig. 4.37). Mechanistically, this 
conformational change is crucial for enabling the electrophilic aromatic substitution 
step, and it is remarkable that the docking investigation revealed this in the binding 
modes. It is worth bearing in mind that this proposed bond rotation is not as extreme as 
the rearrangement required in the HPAA-first mechanism (section 4.1.2), and, 
furthermore, the aldehyde R-group that moves does so in the relatively wide active site 
entrance. Nevertheless, the apparent movement of the aldehyde R-group in this step is 
extremely interesting—the group appears to move further towards the residues Leu-76 
and Ala-79, suggesting closer interactions in the iminium than the hemiaminal. 
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Fig. 4.37 Proposed conformational change in Trans-iminium.  The thin black arrows show either 
movement of electrons or bond rotation. The clear block arrows show the movement in the aldehyde R-
group during the reaction mechanism. This uses the aldehyde 4-HPAA as an example. 
 
It is likely that this rearrangement plays a role in the enzyme mechanism as a pseudo-
chair conformation of the intermediate would be the lowest energy conformation of the 
iminium at the intramolecular cyclisation step. Inclusion of this step in the reaction 
mechanism may aid rationalisation of some kinetic parameters, especially those for 
L76A. The activity changes caused by the L76A substitution are primarily due to 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝
 
and not aldehyde 𝐾𝑚
𝑎𝑝𝑝 values, despite Leu-76 being in the proposed aldehyde binding 
site. The mutation, though, may have greatest influence not on the initial substrate 
binding, but on this conformational change. The increased ease of this conformational 
change would result in an increased 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝. The substitution L76A may therefore stabilise 
this conformational change for the bulky citronellal iminium intermediates. 
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4.4.4 Mechanistic unknowns 
Based on computation and experimental data, it has been possible to propose a full 
mechanism for NCS (Fig. 4.38). Despite this, there remain many uncertainties about 
the NCS mechanism. Structural information with ligands (e.g. dopamine, reduced 
iminium) would test the veracity of the dopamine-first mechanism, which currently relies 
heavily on computational docking. Testing enzyme activities over different pH values 
may reveal the real pKa values of active site residues; this can be compared to pKa 
predictions (Table 4.2).  
The specific roles of numerous residues are unknown. For example, based on 
structural, computational and experimental data it is expected that Tyr-108 and Phe-
112 are expected to be somehow involved in the enzyme mechanism. Preliminary 
screening results with the Phe-112 variant F112L shows activity was present, but 
reduced compared to WT (see section 6.6). More in depth investigation into this 
interesting residue is required to understand its role in substrate binding, its interaction 
with Lys-122 and its apparent dynamic nature. This screening also showed that Met-97 
has an influence on the enzyme activity; some Met-97 variants had improved activities 
with certain substrates (section 6.6). The residue Tyr-108 occupies a crucial position in 
the enzyme active site—it helps define the shape of the active site entrance and the 
water channel. It was also predicted to bind to the aldehyde and hemiaminal. The 
kinetics of the variant Y108F showed a reduction in 𝐾𝑚
𝑎𝑝𝑝
 for the aldehydes HPAA and 
hexanal. This could not be rationalised simply, and the precise role of the residue 
remains unclear. 
A key prediction of the dopamine-first mechanism is the binding order of substrates: 
dopamine binds in the active site before the aldehyde. A verification of this would be 
more evidence for this enzyme mechanism. Attempts to determine the binding order of 
substrates using product inhibition and Hanes plots were unsuccessful, primarily due to 
the background reaction and high substrate concentrations. Alternatively, the 
observation of substrate inhibition with the aldehyde may also add to evidence for the 
dopamine-first mechanism. Reactions with citronellal possibly show substrate 
inhibition, but clearer data with a variety of aldehydes is required to prove it is a feature 
of the enzyme kinetics. 
 
147 
 
 
Fig. 4.38 Proposed dopamine-first mechanism for NCS. The roles of Tyr-108 and Asp-141 are unclear 
but suggested interactions are included as an hypothesis.  
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4.4.5 Kinetic challenges 
Overall, the kinetic data has proven to be difficult to rationalise in terms of the 
dopamine-first mechanism. This is influenced by a range of factors including the high 
background reaction, the complexity of the mechanism and the remarkably high 𝐾𝑚
𝑎𝑝𝑝 
values. It is important to note that when dealing with a bimolecular reaction 
mechanism, the apparent Michaelis-Menten parameters 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝 and 𝐾𝑚
𝑎𝑝𝑝 are collections 
of numerous rate constants and as such the parameters cannot be interpreted as they 
can for simpler reactions. The fact that the substrates kept constant were not at 
saturating concentrations is very detrimental to analysis of the kinetic parameters—
using a saturating concentration of substrate is vital so the effects of varying one 
substrate can be observed clearly.  
The kinetics of the Pictet-Spengler reaction catalysed by NCS is exceptionally complex 
as the reaction has multiple reversible steps, numerous possible intermediates and 
reaction steps that can occur outside the enzyme. There is also some tentative 
evidence of substrate and product inhibition, and that reaction intermediates are able to 
diffuse in and out of the active site. For example, the first step in the NCS mechanism, 
iminium formation, occurs readily in solution around neutral pH, so it is possible that 
these intermediates could diffuse into the active site from the solvent. The iminium may 
be more favourable in solution for some aldehydes than others so different substrates 
may have different kinetic mechanisms (this is a possible origin of the kinetic 
differences of HPAA/hexanal and citronellal). 
The effect of the co-solvent on NCS activity is currently unknown. In order to solubilise 
the aldehydes, all enzyme activity assays contributing towards the kinetic parameters 
contained 10% v.v-1 MeCN, The presence and concentration of this organic solvent 
may have affected the kinetic parameters, perhaps contributing to the high 𝐾𝑚
𝑎𝑝𝑝
 values. 
Investigation of different aldehydes and ketones as substrates for NCS demonstrated 
that co-solvent can be very influential for activity, but its affect differs with the substrate 
investigated (see sections 6.5.2 and 6.6.4). The degree to which the co-solvent 
influences the enzyme stability, substrate solubility and imine formation is unknown, but 
it probably plays a role in all these factors. Further exploration of the NCS activity and 
kinetics must include a thorough investigation on the effect of co-solvent.The 
combination of very high 𝐾𝑚
𝑎𝑝𝑝 values with large background reaction rates at high 
substrate concentrations is a major problem that prevents kinetics experiments from 
reaching saturating concentrations. At high substrate concentrations there would be 
increased formation of imines outside the enzymes and possibly increased catalysis 
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from dopamine itself. Improved experimental methods such as quenched flow or CD 
stopped flow may enable the collection of improved kinetic parameters. 
4.4.6 Catalytic inefficiency 
Despite the challenges experienced in collecting kinetic data, the apparent kinetic 
parameters collected may still be indicative of the enzyme behaviour. The parameters 
describe an enzyme that is catalytically inefficient. For its natural reaction NCS 
exhibited an apparent kcat/Km of 10
3 s-1.M-1 (varied HPAA). In a global analysis of kinetic 
parameters, where thousands of kinetic enzyme reactions were compared, the median 
value for kcat/Km was determined to be 10
5 s-1.M-1. NCS appears to be amongst the 
least efficient enzymes, operating with two orders of magnitude lower catalytic 
efficiency than the median values.5 The origin of this comparative inefficiency is the 
𝐾𝑚
𝑎𝑝𝑝 value, which was in the region of 20 mM (the median is 0.13 mM). The 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝 
(around 20 s-1) was, on the other hand, above the median value of 13.7 s-1. 
The high 𝐾𝑚
𝑎𝑝𝑝
 means that high substrate concentrations are required for the enzyme to 
demonstrate turnover that approaches its fastest rate. In Thalictrum flavum, NCS was 
present in the roots and rhizomes,141 and in Papaver somniferum, it was found in the 
sieve tube elements of the phloem.44,69 The concentration of NCS substrates in 
Thalictrum flavum are unknown, but metabolomics studies in Papaver somniferum and 
Papaver bracteatum offer some insight into the absolute metabolite concentrations in 
alkaloid producing plants.142,143 In a low-alkaloid P. somniferum strain tyramine (the 
precursor to dopamine) accumulated to 5 mM in the latex (NMR analysis). Other 
metabolites which do not accumulate (e.g. amino acids) were in the approximate range 
0.5-10 mM (NMR analysis). In P. somniferum and P. bracteatum dopamine was found 
at concentrations of 1 mg.mL-1 (5 mM) in the latex.144 This surprising abundance of the 
NCS substrate dopamine in alkaloid producing tissues will enable NCS to have a 
reasonable turnover despite a high 𝐾𝑚
𝑎𝑝𝑝. Subcellular trafficking of NCS and its 
substrates will also play a role in regulating turnover. 
NCS catalyses the first committed step into the benzylisoquinoline alkaloids, and, as 
such, it is vital for alkaloid production.44 It is abundant in alkaloid producing tissues: in 
P. somniferum stems NCS is the most abundant protein of all in the morphine pathway, 
and it is in the top thirty of all proteins present.69 The position of NCS at the entry to 
alkaloid pathways allows it to control the metabolic flux through these pathways. 
Assuming in vitro kinetics are similar to those in vivo, the high 𝐾𝑚
𝑎𝑝𝑝 of the enzyme will 
ultimately result in entry to alkaloid pathways being proportional to the concentrations 
of its precursors. The substrates dopamine and 4-HPAA are tyrosine derivatives and 
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therefore are closely linked to primary metabolism. In times of stress, when primary 
metabolites are relatively scarce, it would be undesirable for the plant to deplete the 
primary metabolites in order to produced specialised chemicals that are not vital for its 
survival. The high 𝐾𝑚
𝑎𝑝𝑝 values of NCS prevent significant flux through the alkaloid 
pathways when dopamine or HPAA concentrations are low. The NCS kinetics may 
result in the enzyme acting as the gatekeeper to the BIA pathway—any change in 
substrate concentration will elicit a corresponding change of flux into the BIA pathway. 
The high 𝐾𝑚
𝑎𝑝𝑝 values therefore prevent complete depletion of substrates that may be 
required in other pathways. 
4.4.7 Enzyme engineering 
Plant secondary metabolism enzymes often display low catalytic efficiency, perhaps 
due to low selection pressure, or, as is possible in the case of NCS, requirement for 
metabolic control.5,145 Although the enzyme may be optimised for its particular task in 
the plant, it may not be fully optimised for its actual catalytic activity. It may be desirable 
to improve the enzyme catalysis for use in in vitro biocatalysis, in vivo metabolic 
engineering or even in planta genetic modification. Recombinant NCS has been used 
in alkaloid producing microbial systems. However, in a number of these systems, NCS 
does not appear to be active.72–74 In a yeast system that produces (S)-reticuline from 
glucose, PsNCS3 was shown to be active, but the inefficiency of the step caused a 
228-fold drop in yield.45 In another yeast system, two copies of the NCS gene were 
required to increase yield.21 
The variant A79I is evidence that it is possible to increase the catalytic efficiency of 
TfNCS towards its natural substrate through mutation. This variant had an overall 
increased apparent kcat/Km, but also increased 𝐾𝑚
𝑎𝑝𝑝s. Variants with reduced 𝐾𝑚
𝑎𝑝𝑝 values 
also had reduced 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝s (and overall reduced apparent kcat/Km). In order to generate 
significant improvements in the NCS catalytic efficiency then a separation of the 
correlation between 𝐾𝑚
𝑎𝑝𝑝 and 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝 is desired. Ideal variants for metabolic engineering 
applications are those with reduced 𝐾𝑚
𝑎𝑝𝑝 values and increased 𝑘𝑐𝑎𝑡
𝑎𝑝𝑝
 values. It is 
possible, though, that the mechanism of the reaction places a speed-limit on the 
enzyme kinetics. The high 𝐾𝑚
𝑎𝑝𝑝 may be a necessary result of the deep substrate 
binding site, and the fact that substrates may enter in the wrong order or orientations 
and block activity.146  
The activity of the TfNCS variant L76A with (S)- and (R)-citronellal is the first 
demonstration that the NCS substrate preference can be modified through mutation. 
The rationalisation of this change with the dopamine-first mechanism signifies that it is 
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possible to design mutations based on this mechanism to engineer changes into the 
enzyme. This can lead to the future generation of NCS variants capable of catalysing 
the stereoselective formation of diverse tetrahydroisoquinolines. 
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 Chapter 5: Biotransformations and cascades 5
5.1 Introduction 
The THIQ moiety is a “privileged scaffold” for drug design.92 Privileged scaffolds are 
small organic structures that have shown significant precedent for modulating biological 
systems, through their presence in numerous bioactive natural products and/or their 
prevalence in synthetic drugs (Fig. 5.1). The THIQ moiety is found in numerous plant 
BIAs with biological activities, such as glaucine (antitussive),147 norcoclaurine (anti-
HIV),148 and tubocurarine (anesthetic/poison) (see section 1.1.2).149 Non-ribosomal 
peptide derived THIQs are produced by micro-organisms and include saframycin88,89 
and trabectedin150 (both have anti-cancer properties) (see section 1.7.4). The THIQ is 
also present in synthetic drugs such as almorexant (anti-insomnia),151 and solifenacin 
(antimuscarinic).152 The (S)-THIQ CKD712, known to be a product of TfNCS,53 has 
recently been shown to have a number of bioactivities, including inhibition of cell 
signalling pathways153 and wound-closing effects.154 
 
 
Fig. 5.1 The THIQ moiety in natural products and drugs. THIQ moiety highlighted in red. 
Compounds with privileged scaffolds are considered good targets for drug discovery, 
and therefore they are common targets for synthetic organic chemistry. Discussion of 
synthetic approaches to THIQ can be found in section 1.8. To summarise, recently, two 
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catalytic methods for the facile PS formation of THIQs have been developed. The first 
uses a calcium hexafluoroisopropoxide catalyst in organic conditions (and can also 
accept ketones, see section 6.6).93 The second, developed by Hailes and co-workers, 
uses phosphate buffer in mild aqueous conditions.59 A chiral method based on the 
phosphate catalysed reaction has also been developed, by a different group.95 In the 
last decade there also been numerous advances in methods for forming chiral THIQs 
via hydrogenation155 and non-classical asymmetric approaches.156 
Enzymes are exceptional catalysts for use in sustainable organic chemistry.157 They 
exhibit high chemo-, regio-, stereo- and enantioselectivities and operate in mild, 
aqueous conditions. Developments in directed evolution means that enzyme properties 
can now be modified relatively easily—changes to substrate scope, thermostability, 
solvent tolerance and even reaction selectivities are regularly reported.107–111 It is also 
becoming possible to construct whole syntheses using enzymes,158 and use them in a 
single pot (see section 5.4.1).159 The chiral THIQ is an ideal target for biocatalysis. 
As described in section 1.8, a number of enzymes have been used for the biocatalytic 
formation of chiral THIQs: BBE, IRED and MAO.104 Crucially, these methods all require 
prior synthesis of THIQ or the 1,2-dihydroisoquinoline moiety before the biocatalytic 
step. This means that using these methods still requires a considerable synthetic effort. 
NCS, on the other hand, performs the whole PS reaction, converting an arylethylamine 
and an aldehyde to a (S)-THIQ. The synthesis of the THIQ and formation of the chiral 
centre is concurrent. Furthermore, the enzyme does not require cofactors or 
regeneration. 
There are four publications describing preparative scale  production of chiral THIQs 
using NCS. The first, in 2010, was a gram scale synthesis of (S)-norcoclaurine, using 
hypochlorite to generate 4-HPAA from tyrosine, and TfNCS as the catalyst.58 A recent 
study has expanded this method to halogenated compounds.60 The other studies have 
used CjNCS2 to produce a variety of (S)-THIQs including 1-alkyl substituted 
compounds.57,61 
This section describes efforts to use TfNCS and CjNCS2 in biotransformations. This 
involved the measuring of specific activities, the investigation into different conditions 
for biotransformations and, finally, the establishment of a multi-enzyme cascade 
method. 
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5.2 Specific activities 
Specific activities of purified Δ29TfNCS and CjNCS2 were measured by incubation of 
the enzymes with 10 mM dopamine and 10 mM 4-HPAA at 37 °C (Fig. 5.2). Enzyme 
concentrations in these experiments were 0.11 mg.mL-1 for Δ29TfNCS and 0.08 
mg.mL-1 for CjNCS2. Enzyme activities plateau well below full conversion (10 mM): the 
fitted curves suggest maximum conversions are 5.9 mM and 6.6 mM for Δ29TfNCS 
and CjNCS2 respectively. This plateauing is perhaps due to product inhibition, enzyme 
instability or degradation of substrates/products. For both enzymes data points at 30 
minutes are lower than the expected value; this, again, was possibly due to product 
degradation. 
 
Fig. 5.2 Specific activity of NCS. Δ29TfNCS (black) and CjNCS2 (orange). Points are the mean of three 
measurements values, error bars are one standard deviation from mean. Lines are equations: =  
𝑽𝒕
𝒕+𝑲
 , the 
fits have been weighted (to 1/SD
2
). Enzyme concentrations are 0.106 mg.mL
-1
 for Δ29TfNCS and 0.08 
mg.mL
-1
 for CjNCS2.  
Conversions were measured after 2, 5, 10, 15 and 30 minutes. The specific activity of 
CjNCS2 can be estimated by assuming the first three points of the time course 
(including zero) are linear and calculating the gradient of the straight line. This was the 
method used previously by Pesnot et al to calculate the specific activity of CjNCS2.57 
Using this method here to calculate the specific activity of CjNCS2 provided a value of 
6.32 U.mg-1. This was in the same order of magnitude as the value of 4.4 U.mg-1 
quoted in Pesnot et al.57 The difference between these specific activity measurements 
may be in the conversions from the raw data (HPLC peak area) to product 
concentration, and the presence of TFA in the chemical standards (see section 5.3.5). 
If a TFA counterion was accounted for in the Pesnot et al calculations then the CjNCS2 
activity rose to 6.25 U.mg-1, very similar to that calculated here. 
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Assuming linearity in the first few points in a time course is not appropriate in many 
cases. When rates are particularly fast, as with Δ29TfNCS, there is no section of the 
curve which is approximately straight: the rate is constantly changing as the substrates 
are consumed (Fig. 5.2). One solution to this is to use lower enzyme concentrations to 
obtain time courses that are approximately linear. However, it is also possible to use a 
non-linear regression fit to calculate the initial rate numerically. The fitted equation can 
be differentiated and the gradient calculated at any given time. Unsurprisingly, with this 
method the gradient varies significantly depending on which time point is selected. 
Strictly, specific activity should be calculated from the initial gradient, at t=0, which for 
CjNCS2 gave a specific activity of 8.75 U.mg-1 (Table 5.1), around 40% larger than that 
calculated with the linear rate method. 
Table 5.1 Slope of time course (rate) at different time points calculated by differentiation of fitted equation: 
𝒄 =  
𝑽𝒕
𝒕+𝑲
. Derivative function: 𝑹𝒂𝒕𝒆 =  
𝑲+𝑽
(𝒕+𝑲)𝟐
. Raw data in Fig. 5.2. 
NCS Time (min) 0 0.1 0.5 1 2 5 
Tf Rate (mM.min
-1
) 2.66 2.43 1.77 1.27 0.74 0.25 
Tf S.A. (U.mg
-1
) 25.1 22.9 16.7 12 6.98 2.36 
Tf S.A. (nkatal.mg
-1
) 418 382 278 200 116 39.3 
Cj Rate (mM.min
-1
) 0.7 0.68 0.63 0.57 0.48 0.3 
Cj S.A. (U.mg
-1
) 8.75 8.5 7.88 7.13 6 3.75 
Cj S.A. (nkatal.mg
-1
) 146 142 131 119 100 63 
 
The specific activity of Δ29TfNCS (using numerical method at t=0) was 25.1 U.mg-1. 
This value was in accordance with activity measurements for Δ29TfNCS in the 
mechanism studies, though those experiments used lower concentrations of substrates 
and a different experimental method (Chapter 4). In the mechanism investigation, the 
specific activity of WT Δ29TfNCS with 10 mM dopamine and 2.5 mM HPAA was 
determined to be 426 ± 22 nkatal.mg-1 and with 2.5 mM dopamine and 10 mM HPAA, 
348 ± 12 nkatal.mg-1 (see section 4.3). These values were in reasonable agreement 
with the value determined here, with both substrates at 10 mM: 418 nkatal.mg-1. 
Δ29TfNCS had a larger specific activity than CjNCS2 but also experienced a sharper 
plateauing of activity through the time course. This was reflective of the high Km values 
calculated for Δ29TfNCS (section 4.3); the poor binding of substrates means that high 
substrate concentrations are required to maintain good activities. There was also a 
possible effect of product inhibition, though this has not been verified. 
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5.3 Biotransformations 
5.3.1 CjNCS2 and ortho-product 
A biotransformation was performed with purified CjNCS2, dopamine and hexanal. The 
reaction was conducted in 85 mL HEPES buffer (50 mM, pH 7.5), with 10 mM 
dopamine, 15 mM hexanal and 0.014 mg.mL-1 protein. After 3 hours (at 37 ˚C) the 
reaction was quenched with acid, filtered, and purified by preparative-HPLC. Two two 
fractions were obtained. NMR analysis confirmed the first fraction was the expected 
para substituted product and the second fraction a mixture between the ortho product 
(66%) and para product (33%). The major para product was obtained with overall 57% 
purified yield (170 mg). Comparison of the purified para compound with a racemic 
standard by chiral HPLC showed the major biotransformation product had an ee of 
78% (Fig. 5.3). This was inadequate for a chiral biotransformation and showed the 
presence of the competing racemic chemical reaction in these conditions—a simple 
way to improve the ee would be to have increased the enzyme concentration. 
The ortho product was also analysed by chiral HPLC, and although a verified racemic 
ortho-standard was not available, comparison of the data with the racemic para product 
suggested that the ortho product was racemic. The production of the ortho-THIQ as a 
minor product in a biotransformation was reported by Pesnot et al (with heptanal rather 
than hexanal) but chiral analysis of this product was not performed.57 The analysis 
presented here suggests that the product was not chiral and therefore not likely to be 
derived from enzyme activity (Fig. 5.3). The chemical Pictet-Spengler THIQ synthesis 
reaction typically produces a mixture of ortho and para products but the enzyme 
reaction seems to exclusively produce the para.94 The presence of ortho in this 
biotransformation was indicative of a high background reaction, which was also 
represented in the relatively low ees. 
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Fig. 5.3 Biotransformation with dopamine and hexanal. Top: formation of ortho and para product. 
Bottom: chiral HPLC analysis of products (method 3). Dotted line: chemically verified racemic para-
product. (S)-isomer RT: 13.2 (R)-isomer RT: 17.0-17.5. Dashed line: purified para-product (ee = 78%). 
Solid line: ortho-product (containing small quantities of (S)-para-product) double peak at 13-14 is (S or R)-
ortho and (S)-para and peak at 16.2 is the other ortho enantiomer. Therefore ortho-product appears mostly 
racemic. Magnitudes of absorbance adjusted to enable comparison. HPLC method 3 used for ees (see 
method 2.4.1). 
5.3.2 Enzyme loading  
The quantity of purified enzyme required to achieve high enantiomeric excesses (ees) 
in biotransformations was investigated (Fig. 5.4). Purified CjNCS2 at 0.014 mg.mL-1 
was shown to give inadequate ees of 78% (Fig. 5.3). Different concentrations of 
CjNCS2 (diluted in HEPES buffer) were used in biotransformations (with dopamine and 
hexanal) and the ees of the conversions were measured. Even at the lowest 
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concentration tested (0.16 mg.mL-1), ees were high (97%) and satisfactory for 
biotransformations.  
 
Fig. 5.4 The effect of enzyme concentration on the ee of a reaction between dopamine and hexanal. Bars 
show the quantities of the S and R enantiomers produced, in HPLC peak area. Measurements are means 
of triplicate experiments, error bars show one standard deviation from the mean. The dashed line shows 
the ee of the reaction, as a percentage. Reaction conditions are 10 mM dopamine and 15 mM hexanal. 
HPLC method 3 used for ees.  
Additionally, two types of biotransformation were investigated: the ‘batch process’ and 
the ‘step process’. In the ‘batch process’, all substrates were added simultaneously (10 
mM dopamine and 15 mM hexanal), whilst in the ‘step process’ they were added 
gradually so the concentrations of substrates did not reach the same maxima. In the 
step reactions approximately 20% of the final substrate concentration was added every 
15 mins. There was no observable difference between the two reactions, both had 
similar conversions and excellent ees of >99%. Both biotransformations showed 
superior ees than reactions attempted previously (e.g. Fig. 5.4, maximum ee >98%), 
despite lower enzyme concentrations (0.1 mg.mL-1). This is likely to be because water 
was used to dilute the reactions, whilst previously HEPES was used. Although HEPES 
buffer catalyses the chemical PS reaction to a much lower degree than phosphate 
buffer, it still has a minor catalytic effect, greater than that of pure water.59 Thus HEPES 
very slightly reduces ees compared to water. There is likely to be a compromise to be 
made between the buffering strength required in the reaction and the background 
reaction caused by the buffer.  
5.3.3 Buffer choice 
For maximum ees the ratio of enzymatic conversion over the background must be 
optimised. The type and concentration of buffer used in the reactions was investigated. 
The concentration of buffers was varied between 10 and 50 mM. Due to the previous 
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success with using HEPES at pH 7.5, only similar Good’s buffers (MOPS and MES) at 
pH 7.5 were investigated.  
 
Fig. 5.5 Biotransformations in different buffers. Data points are averages of triplicate raw peak areas. 
Error bars are one standard deviation from mean. Numbers above buffer type refer to concentration (mM). 
‘Background’ measurements are those recorded without enzyme present. ‘Lysate’ is activity in soluble 
fraction after lysis with BugBuster. ‘Boiled’ is activity in lysate after 30 minutes incubation at 100 ˚C. 
‘Phosp’ is activity in phosphate buffer. NC = norcoclaurine. HPLC method 3 used for ees. The product 
concentration of the boiled control was too low for ee detection. 
The product formation and substrate consumption, both with and without purified 
CjNCS2, was measured for 1 hour reactions (Fig. 5.5). Not surprisingly, non-desired 
background reactions were greater with higher concentrations of buffer. However, 
conversions with enzymes present were also slightly raised, and as the ees did not 
appeared to change between different concentrations of buffers, it appeared that there 
was a slight increase in enzyme activity with higher buffer concentrations. The buffers 
HEPES and MOPS, which have similar operational pH ranges, provided similar results. 
MES had marginally greater conversions than other buffers, both with and without 
enzymes. However, it was subsequently realised that pH 7.5 lies outside the buffering 
range of MES (pH 5.2-7.2), so this was likely to be a pH effect rather than an effect on 
MES. It was decided that the reasonably low background conversions and high ees in 
50 mM HEPES pH 7.5 was sufficient for biotransformations.  
5.3.4 Lysate reactions 
Enzyme purification is costly in terms of both time and resources. It is desirable to 
develop reaction conditions where the enzyme does not require purification, so the 
reaction can be performed as either a whole cell conversion or in crude lysate. The 
ability to use crude lysate also means that screening for enzyme activity with diverse 
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substrates and mutants can be achieved much more cheaply and quickly (see section 
6). The use of crude lysate is typically a problem with NCS as phosphate (present in 
the cell lysate), catalyses the background reaction.59 The correct controls must be put 
into place to ensure that any observed activity or conversion is enzymatic. The most 
sensitive method to use would be chiral-HPLC, but very long run times make this 
method impractical. 
It was possible to remove much of the background reaction in the cell lysate by 
desalting. Desalting removes small molecular weight molecules from the lysate. These 
include phosphate itself, as well as other phosphate containing molecules such as ATP 
and sugar-phosphates. It did not reduce the background reaction to the extent that a 
full purification does, but it reduced it sufficiently to enable the effective use of lysate in 
some screens and biotransformations (Fig. 5.6). Although purification of a His-tagged 
enzyme is generally fairly straightforward, and would reduce the background reaction 
effectively, desalting avoided the use of the expensive nickel resins. Furthermore, 
elution of proteins from nickel columns typically used high concentrations of imidazole, 
which inhibited the enzyme.  
 
Fig. 5.6 Lysate Reactions. SN: supernatant, DS: Desalted, pET = empty vector. Signal to BG is the 
enzyme catalysed reaction divided by the background reaction observed. Δ19TfNCS used.  Conditions: 
60% lysate, 0.5 mM dopa, 2.5 mM PAA.  
A number of different biotransformations were attempted with CjNCS2 desalted lysate 
using different substrates and different loading quantities (Table 5.2). A 35% loading 
was sufficient to provide excellent ees for phenylacetaldehydes. Hexanal, a substrate 
less well accepted than the phenylacetaldehydes, has a slightly lower but nonetheless 
acceptable ee. Decreasing the loading to 9% reduced the ee of the hexanal reaction to 
below 90%, which was inadequate. 
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Table 5.2 Lysate reactions. CjNCS2 desalted lysate reactions with different substrates and with different 
loading concentrations. HPLC method 3 used for ees. Reactions: 10 mM dopamine, 15mM hexanal. PAA 
= phenylacetaldehyde. HPAA = 4-hydroxyphenylacetaldehyde. Dopamine and product peaks described as 
raw peak areas from chiral HPLC analysis (AU
2
). 
Substrate Loading Dopamine (S)-isomer (R)-isomer ee 
 % AU
2
 AU
2
 AU
2
 % 
HPAA 35 30.7 250.0 3.0 >97 
PAA 35 21.0 135.0 0.5 >99 
Hexanal 35 37.3 84.7 3.5 92 
Hexanal 9 62.2 41.4 3.1 86 
5.3.5 Identification of TFA salt 
In measuring some biotransformation conversion yields by HPLC, some yields were 
calculated to be over 100%. The origin of this error was in the conversion of HPLC 
peak areas to concentrations, which was governed by calibration curves. These curves 
were obtained running HPLC measurements of verified chemical standards with 
different known concentrations. These standards were obtained by performing a 
chemical or enzymatic reaction, quenching the reaction with acid, and then purifying 
the products by reverse phase preparative-HPLC. The HPLC solvents used are acidic 
and contain trifluoroacetic acid (TFA). Under acidic conditions the secondary amine 
product will be protonated, and trifluoroacetate was the most likely counter ion. After 
isolation of products by preparative-HPLC, the solvent was removed in vacuo. Two 
methods were used to remove excess TFA and isolate the pure product: either 
repeated addition and evaporation of methanol (as performed by Pesnot et al57) or by 
freeze drying in small quantities of water. For oxidation sensitive compounds the latter 
method was preferred as it avoided heating the products. 
The dissolving and evaporation steps with methanol were proposed to remove TFA 
from the sample, leaving neutral products.57 Although this process removed excess 
TFA via an azeotrope, it does not necessarily leave the product as a free base, but 
may leave it as a trifluoroacetate salt. Similarly, repeated freeze drying removes excess 
TFA, but still leaves the product as a cation with a trifluoroacetate counter ion. 
Basification of the protonated product, which has a pKa of around 10-11, would typically 
require the addition of a base with at least a similar pKa (e.g. bicarbonate).
160 After 
neutralisation, the product can be extracted into an organic solvent. The pKa of 
trifluoroacetate ~ 0 and so is insufficiently basic to extract the product proton. Although 
the protonation state of a compound is at an equilibrium, here the energy barrier 
between the protonated product and TFA is probably too high to allow exchange. 
The presence of TF-acetate in these compounds was confirmed by carbon-13 NMR. 
The TF-acetate ion gives carbon-13 peaks with low signal intensity, due to the 
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muliticipity (splitting by F19) and the fact they have no protons attached. Repeated NMR 
scans were required to increase signal-to-noise and revealed TF-acetate peaks in 
purified biotransformation products. By taking into account the additional TFA 
molecular weight in the purified compounds, the concentrations of the standards were 
revealed to be lower than originally determined. Thus, when the calibration curves were 
recalculated, the product concentrations for enzyme conversions were reduced to 
reasonable values, below 100%. 
5.3.6 Demonstrative biotransformations 
To demonstrate the scope of reactions possible with NCS, two fully characterised 
biotransformations were performed. Both used dopamine as the amine, but differed in 
enzyme, enzyme preparation method and aldehyde. The first reaction used a purified 
Δ29TfNCS mutant (L76V) turning over hexanal and dopamine, whilst the second used 
CjNCS2 desalted lysate and phenylacetaldehyde (Fig. 5.7). Both these 
biotransformations had novel elements: the former was the first NCS reaction to report 
the mutant and the latter the first to use lysate. The mutant L76V was chosen for use in 
the biotransformation due to preliminary data which suggested that was superior to WT 
at turning over aliphatic aldehydes. Unfortunately, this initial observation was not 
subsequently verified, and the mutant was determined to perform the reaction equally 
as well as WT, but no better.  
 
Fig. 5.7 Biotransformations. Two demonstrative biotransformations using different enzymes, 
preparations and substrates. Conversion describes the quantity of product at the end of the reaction in the 
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crude mixtures. Yield refers to the quantity of purified product isolated. Both products were isolated as TFA 
salts. HPLC method 3 used for ees. 
The reactions were performed at milligram scale, using 40 mg of dopamine starting 
material (with 1.5 molar equivalents of aldehyde) and obtaining 40 mg and 33 mg of 
product for the hexanal and phenylacetaldehyde reaction respectively. Both the 
reactions provided excellent ees and good conversions, but relatively modest purified 
yields. 
Steps can be taken to improve the purification process. Although the ees cannot be 
improved, both the conversions and yields could ideally be higher. It was apparent that 
much of the product is lost during the preparative-HPLC purification. Furthermore, with 
increased reaction scales (>100 mg) this purification method is not practical. In a 
reported biocatalytic synthesis of (S)-norcoclaurine with NCS, chromatographic 
purification was avoided by using activated carbon from which the substrates and 
products were eluted.58  
Recent work by Maresh et al has demonstrated that it is possible to drive the reactions 
to completion and simultaneously avoid chromatographic separation by the use of 
excess dopamine.60 The tetrahydroisoquinolines can then be extracted into an organic 
ethyl acetate layer, separating them from dopamine. Removal of solvent should result 
in the pure product. The purity of the product will depend on whether the reactions go 
to completion and whether there are numerous side products. Addition of the 
antioxidant sodium ascorbate into the reaction mixture may help prevent the oxidation 
and degradation of substrates and products.58,60 This reaction and organic extraction 
method was adapted and used for biotransformations described in section 6.6.9 
(methods section 2.6.3). 
Although the methods developed here resulted in the production of single enantiomer 
products with reasonable yields, it may be worth investigating other strategies and 
purification methods for biotransformations in the future. 
5.4 Multi-enzyme cascades 
The majority of the following work can be found in Lichman et al.161 
5.4.1 Introduction  
Enzymatic cascade reactions enable the combination of numerous biocatalytic steps in 
a single pot, bypassing isolation and purification steps, and providing complex chemical 
transformations in an efficient manner.162 The formation of these cascades is greatly 
aided by the fact that enzymes generally operate in very similar conditions (pH 6-8, 20-
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50 ˚C, aqueous).163 Furthermore, the increasing emphasis on environmentally benign, 
non-toxic synthesis methods has led to a greater interest in the potential for enzyme 
cascades in organic synthesis. 
The variety of enzymes now available enables various combinations of enzymatic 
transformations and substrates. It is now possible to consider a ‘biocatalytic 
retrosynthesis’ approach and construct syntheses in a purely biocatalytic manner.158 
Similarly, the concept of ‘systems biocatalysis’ is to use multiple enzymes in vitro 
creating an ‘artificial metabolism’ that can be carefully and deterministically 
controlled.159 Systems biocatalysis has a similar aim to synthetic biology/metabolic 
engineering (the ‘biological’ production of valuable chemicals) but has a significant 
difference in methodology: the former operates in vitro and the latter in vivo. Using 
enzymes in vitro makes reaction control relatively simple—for example, to slow down a 
reaction step rate, just add less enzyme. In contrast, in vivo approaches would require 
genetic manipulation of ribosome binding sites or promoters to achieve the same goal. 
The in vitro systems biocatalysis approach enables the establishment of specific 
cascade designs that enable recycling of co-factors and shifting of equilibria.162–164 
There has been considerable focus on the use of NCS in in vivo synthetic biology 
systems, but few attempts at in vitro cascades.21,45,72,73,76 The exception is the formation 
of aldehydes in situ from amino acids using hypochlorite prior to addition of NCS; this is 
an example a sequential chemoenzymatic cascade (see section 1.5.1).58,60 When using 
NCS, the high non-enzymatic background PS reaction must be controlled to obtain 
high ees. This is more manageable in vitro where enzyme concentrations and buffer 
components can be modified. However, despite the challenges of the background 
reaction, recent work has demonstrated NCS activity is possible in vivo.21,45,76 
There are numerous biocatalytic steps possible both before and after an NCS 
catalysed step that could be combined in an in vitro cascade. The available options 
are, of course, exemplified by natural BIA biosynthesis. Dopamine could potentially be 
formed enymatically from tyrosine via a 3-hydroxylation and decarboxylation. 
Enzymatic modifications of the BIA moiety may be achieved for example through 
methylation, methylenedioxy bridge formation and aromatic oxidative coupling (Fig. 
5.8). 
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Fig. 5.8 Possible biocatalytic steps preceding or following the NCS reaction. Dopamine can be 
formed from tyrosine via (a) decarboxylation catalysed by tyrosine/DOPA decarboxylase, and (b) 
hydroxylation catalysed by tyrosine hydroxylase or tyrosinase. Modification of hydroxyl groups is possible 
through (c) methylation catalysed by methyltransferases and (d) methylenedioxy bridge formation, 
catalysed by CYPs. Modification of the carbon skeleton may be possible through aromatic oxidative 
coupling (e), also catalysed by CYPs. Routes to aldehydes are discussed below in Fig. 5.9. 
The large aldehyde substrate scope of NCS led to the decision to focus on cascade 
designs enabling the in situ formation of aldehydes.53,57,61 Aldehydes are very reactive 
and relatively difficult to synthesise, so the in situ formation of these intermediates 
would be very valuable for the NCS reaction and may ultimately allow for the one-pot 
synthesis of diverse THIQs. An aldehyde synthesis method could potentially be useful 
for other biocatalytic reactions requiring aldehydes. There are a number of enzymes 
that can form aldehydes. These enzymes include: alcohol dehydrogenases,165 
carboxylic acid reductases,166 laccases167 and transaminases (Fig. 5.9).114 
 
Fig. 5.9 Possible biocatalytic routes to aldehydes.  
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5.4.2 Aim 
The aim was to construct a biocatalytic cascade using a transaminase (TAm) and NCS. 
The TAm can catalyse the formation of an aldehyde from an amine. The aldehyde 
would then be a substrate for NCS in the formation of a THIQ. NCS also requires an 
amine substrate, and although it may be possible to use two different amines as 
starting substrates (and select enzymes and substrates with no cross-reactivity), it was 
decided to use the same amine as substrates for both enzymes. 
The amine compound chosen was dopamine. Dopamine was expected to be converted 
into the aldehyde 3,4-dihydroxyphenylacetaldehyde (3,4-DHPAA) by a TAm. This 
aldehyde can be combined with dopamine in a PS reaction catalysed by NCS, forming 
the chiral THIQ (S)-norlaudanosoline ((S)-NL, also known as tetrahydropapaveroline, 
THP) (Fig. 5.10).25 It was also hypothesised that the addition of formaldehyde to 
norlaudanosoline could trigger a second PS reaction, forming a tetracyclic 
tetrahydroprotoberberine (THPB, also known as a berbine) compound.168 
 
Fig. 5.10 Proposed biocatalytic scheme. 
5.4.3 Target compounds 
The key target compound of this cascade is norlaudanosoline (NL). It is a BIA found in 
mammals, where neurologically it is acts as a depressor and has been shown to have 
roles in Parkinson’s disease169 and drug addiction.170 Perhaps unsurprisingly, 
considering its formation from dopamine, it has been shown to regulate dopamine 
levels in the brain.171 Intriguingly, it has been shown to be the precursor to 
‘endogenous’ morphine, which is produced in mammalian brains.172–174 The proposed 
mammalian morphine biosynthesis route, via NL, provides a fascinating counterpart to 
the plant biosynthesis route, which is shown to proceed via (S)-norcoclaurine (though 
was originally thought to proceed via NL).25,30–32 The presence of a morphine 
biosynthesis route in mammals is a remarkable example of the convergent evolution of 
the formation of very complex molecule. There is also evidence that only the (S)-isomer 
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of NL is present in mammalian brains; this points towards the presence of a 
mammalian BIA Pictet-Spenglerase.173,175  
Synthetically, NL is a versatile compound and can serve as a precursor to numerous 
BIAs with biological activities. NL has also been employed in synthetic 
biology/metabolic engineering routes to BIAs and in a number of cases it serves as a 
vital feedstock.64–66 Typically these systems are fed with rac-NL, which results in an 
immediate 50% loss of material due to the (S)-selectivity of downstream enzymes.68 
For synthetic biology, medicinal chemistry and natural product investigations, a 
stereoselective synthesis of (S)-NL would be valuable. 
The tetrahydroprotoberberine alkaloids (THPBs, also known as berbines) are a 
subgroup of BIAs closely related to berberine, a compound with anticancer and 
antimicrobial activities.11,176,177 They are found in both plants and animals174 and include 
compounds such as canadine178 and spinosine.179 Although in plants they are typically 
formed enzymatically via the berberine bridge enzyme,18 in vitro they can be accessed 
chemically from norlaudanosoline via a PS reaction with formaldehyde (Fig. 5.11).168,179 
The products of this reaction have potential in cancer chemotherapeutics.129 The 
expected regioselectivity of this formaldehyde cyclisation is the least sterically hindered 
product (major product: 10,11-dihydroxy). This contrasts with the regioisomerism of the 
9,10-dihydroxy-THPBs formed by BBE.101,103 
 
Fig. 5.11 Tetrahydroprotoberberine production from norlaudanosoline with formaldehyde. 
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5.4.4 Transaminases 
Transaminases were chosen for this cascade as they can convert amines to 
aldehydes, and could potentially accept dopamine as a substrate. The Ward and Hailes 
groups have considerable expertise in using TAms, and the Ward group has a large 
library of TAms available to screen. TAms have been extensively studied in 
biocatalysis, both in one-pot reactions and multi-enzyme cascades.163 In a case often 
considered a landmark in biocatalysis, a TAm was engineered to accept a very bulky 
substrate and contribute to the industrial synthesis of the commercial pharmaceutical 
sitagliptin.180 
Transaminases catalyse the conversion of a carbonyl moiety to a primary amine, and 
vice-versa. Typically the carbonyl in question is a pro-chiral ketone and the desired 
product is a chiral amine. The reversed reaction, from an amine to a carbonyl, is 
possible but less typically desired as it may involve the destruction of chirality. 
Superficially, the reaction appears to be a reductive amination, but instead of a 
reducing agent the reaction utilises a co-substrate which exchanges its amine/carbonyl 
function group with the substrate. The co-factor pyridoxal phosphate (PLP, vitamin B6) 
is vital for the reaction mechanism, essentially acting as an electron sink (Fig. 5.12). 
 
 
Fig. 5.12 Transaminase mechanism. Half the reaction is depicted—in order for the PLP to regenerate 
the reverse reaction must occur with the co-substrate. PLP: pyridoxal phosphate; PMP: pyridoxamine 
phosphate; Pi: inorganic phosphate. 
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Due to the reversible nature of the reaction, TAms often suffer from problems relating 
to the equilibrium of the reaction—the isolated reaction will not typically go to 
completion. These unfavourable equilibria can be helped by numerous cascade 
designs.163 Methods for shifting equilibria include: excess co-substrates,180 removal of 
the co-products,180 enzymatic181 or chemical182 consumption of the (co)product, and 
cascades to recycle the co-substrate.183,184 Cascades with TAms must be designed 
with shifting the equilibrium in mind. 
5.4.5 Cascade design 
 
Fig. 5.13 ‘Triangular’ cascade design. Figure adapted from Lichman et al.
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The overall reaction design described here is a one-substrate, two-enzyme, one-pot 
cascade. This three sided design can be described as a ‘triangular’ cascade (Fig. 
5.13). 
Similar cascade designs had previously been achieved using monoamine oxidase 
(MAO) to convert dopamine to 3,4-DHPAA in the first step. MAOs convert amines to 
imines using molecular oxygen. The imines are then hydrolysed by water to form 
aldehydes. Originally the dopamine-MAO cascade forming racemic NL (THP) was 
observed using mammalian tissue extracts containing MAO.70 Subsequently 
Aspergillus niger was shown to have sufficient MAO activity to enact the same 
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transformation.29 More recently, a stepwise fermentation method was developed to 
produce racemic NL de novo using two E. coli strains, one containing dopamine 
biosynthesis genes and the other overexpressing a MAO.71 In these three preceding 
examples, the PS reaction between dopamine and 3,4-DHPAA occurs spontaneously, 
and thus a racemic product is formed. 
There is precedence for NCS accepting 3,4-DHPAA as a substrate in place of the 
natural substrate 4-HPAA.25 Some in vivo synthetic biology approaches to BIAs have 
attempted to add NCS to the dopamine-MAO cascade, in order to form (S)-NL at the 
key branch BIA point.72–75 However, it is not clear that NCS is fully active in these 
systems; the reported formation of (S)-BIAs such as (S)-reticuline may be a result of 
(S)-selective enzymes downstream of NCS. More recently, in vivo approaches to BIAs 
have eschewed this MAO route and focussed on the natural biosynthetic route via 4-
HPAA.21,45,76 
There are significant advantages to using a TAm rather than an MAO in this triangular 
cascade. The requirement of a co-substrate for TAms allows for stoichiometric control 
of the reaction. As the PS reaction requires equimolar quantities dopamine and 3,4-
DHPAA, the TAm co-substrate can be limited to ensure exactly half of the original 
dopamine is converted to 3,4-DHPAA. This control is not possible with MAO as oxygen 
is the ‘co-substrate’ and controlling oxygen concentrations is more challenging. This 
exacting stoichiometric control is a feature of the in vitro systems biocatalysis 
methodology—such control would not be possible in an in vivo system. The triangular 
cascade design also solves problems with the TAm equilibrium. The PS reaction 
consumes both the starting material and product from the TAm reaction. Assuming the 
PS catalyst is stable and sufficiently active, the actual TAm equilibrium position is 
unimportant and the reaction progression should be determined by the limiting quantity 
of co-substrate. 
5.4.6 Transaminase screen 
The initial stage towards the formation of the triangular cascade was the screening of 
various TAms to identify an enzyme that could efficiently convert dopamine into 3,4-
DHPAA. Ten TAms were chosen for screening from the in-house TAm library in the 
Ward group (see methods sections 2.1.5 and 2.3.4). These were selected partly as 
activities had previously been detected with these enzymes. Analysis of lysed cells 
post-induction showed all constructs demonstrated overexpression of TAm (Fig. 5.14). 
Only two homologues appeared to be insoluble, and the remainder demonstrated 
soluble expression of recombinant protein with the expected size. 
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Fig. 5.14 Expression of TAms. P = pellet, S = supernatant. Enzymes: 1 = empty vector, 2 = BSU_09260 
(1), 3 = BSU_09260 (2), 4 = CV_2025, 5 = Dgeo_1416, 6 = KPN_00255, 7 = PP_0596, 8 = PP_3718, 9 =  
SaV_2612, 10 = SaV_4551, 11 =  VF_JS17. Of the two BSU_09260 constructs, only the one producing 
soluble protein (2) was taken on for further investigation. Figure taken from Lichman et al.
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The TAm screening reactions were conducted in phosphate buffer, which catalysed the 
in situ formation of racemic norlaudanosoline from dopamine and 3,4-DHPAA. 
Therefore, the reaction progress was tracked on HPLC by formation of 
norlaudanosoline. Following the relatively stable norlaudanosoline was simpler than 
tracking the formation of the reactive aldehyde, which, unless shepherded into the PS 
reaction with dopamine, would probably be degraded by native E. coli enzymes 
present. The TAm co-substrate pyruvate was present in the reaction at half the molar 
concentration of dopamine, thus overall allowing the TAm to convert only half of the 
dopamine present. 
The enzymes CV2025 (Chromobacterium violaceum)114 and PP_3718 (Pseudomonas 
putida) demonstrated significant activity in these screening conditions, with 21% and 
15% conversion respectively (Table 5.3, Fig. 5.15). The enzymes PP_0596 (P. putida), 
SaV_2612 (Streptomyces avermitilis) and VF_JS17 (Vibrio fluvialis)115 displayed trace 
activities. The well-studied enzyme CV2025 exhibited the greatest conversions and 
was used in the completed cascades. 
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Table 5.3 TAm mediated synthesis of rac-norlaudanosoline from dopamine. Table adapted from 
Lichman et al.
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Entry TAm Organism 
Uniprot entry 
name 
Gene name Conv. %
b
 
1 Empty vector    n.d.
 c
 
2 BSU_09260 Bacillus subtilis YHXA_BACSU yhxA n.d. 
3 CV_2025
114
 Chromobacterium violaceum Q7NWG4_CHRVO CV_2025 21 
4 Dgeo_1416 Deinococcus geothermalis Q1IYH3_DEIGD argD/lysJ n.d. 
5 KPN_00255 Klebsiella pneumoniae A6T537_KLEP7 gabT n.d. 
6 PP_0596 Pseudomonas putida Q88Q98_PSEPK PP_0596 Trace 
7 PP_3718 Pseudomonas putida Q88GK3_PSEPK PP_3718 14 
8 SaV_2612 Streptomyces avermitilis Q82JZ2_STRAW SAV_2612 Trace 
9 SaV_4551 Streptomyces avermitilis Q82ER2_STRAW SaV_4551 n.d. 
10 VF_JS17
115
 Vibrio fluvialis F2XBU9_VIBFL JS17 Trace 
50 mM dopamine, 25 mM pyruvate, 1 mM PLP, 10% v.v
-1 
TAm, 37 °C, 4 h. 
b
 Concentration of rac-
norlaudanosoline, determined by analytical HPLC. 
c
 n.d. = not detected. See Fig. 5.15 for reaction time 
course. 
 
 
Fig. 5.15 Progress curves charting the accumulation of rac-norlaudanosoline over time with 
different TAms. The final measurement at 4 hours was performed in triplicate (error bars are one 
standard deviation). Loss of product between 2 and 4 hours is likely to be due to the instability and 
oxidation of the product. Only TAms showing activity towards dopamine are represented here. Conditions: 
50 mM dopamine, 25 mM pyruvate, 1 mM PLP, 10% v.v
-1 
TAm, 37 °C, 4 h. Figure adapted from Lichman 
et al.
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5.4.7 Optimisation 
To enable the formation of (S)-norlaudanosoline from dopamine, the racemic PS 
reaction was minimised by changing the buffer from phosphate to HEPES and purified 
Δ29TfNCS was added to catalyse the (S)-selective PS reaction. The optimum reaction 
conditions for the cascade were investigated with the aim of maximising the conversion 
and ee. The factors that were varied were the starting concentrations of dopamine, 
NCS and TAm. The molar concentration of the TAm co-substrate pyruvate always 
remained half of dopamine. It was hoped that this optimisation would enable the rates 
of the two enzymatic steps to be approximately matched. If the TAm rate were 
considerably faster than the NCS step then a building up of 3,4-DHPAA would occur 
and result in an increase of non-productive side-reactions (including the non-enzymatic 
PS), ultimately reducing the yield and ee. 
Time courses of product formation were recorded under different reaction conditions 
(Fig. 5.16). The factors varied were dopamine concentration (20 and 50 mM), lysate 
concentration (10 or 30% v.v-1) and NCS concentration (100 or 500 μg.mL-1). 
Unsurprisingly, higher concentrations of enzyme led to greatest and fastest 
conversions. With dopamine at 50 mM it was clear that the limiting step was the 
transamination;an increase in TAm concentration greatly increased initial rates. Overall 
it seems that the initial rate was determined by TAm concentration, but the point at 
which the conversion plateaus was partially determined by NCS concentration.  
Conversions and stereoselectivities (after three hours) were measured in a similar 
experiment (Table 5.4). The component concentrations were varied: dopamine 
concentration (20 or 50 mM), lysate concentration (10, 20 or 30% v.v-1) and NCS 
concentration (100 or 500 μg.mL-1). 
 
174 
 
 
Fig. 5.16 Reaction time courses. A: Dopamine depletion from 20 mM. B: Product formation from 20 mM 
dopamine. C: Dopamine depletion from 50 mM. D: Product formation from 50 mM. Diamonds, large 
dashed line: 10% v.v
-1 
TAm lysate, 0.1 mg.mL
-1
 NCS. Squares, dotted line: 10% v.v
-1
 TAm lysate, 0.5 
mg.mL
-1
 NCS. Triangles, short dashed line: 30% v.v
-1 
lysate, 0.1 mg.mL
-1
 NCS. Crosses, solid line: 30% 
v.v
-1
 lysate 0.5 mg.mL
-1
. Data points are means of triplicates, error bars of one standard deviation are 
smaller than the markers so were not depicted. 
Table 5.4 One pot synthesis of (S)-BIAs. Table adapted from Lichman et al.
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Dopamine CV2025 NCS Conv. ee 
mM % v.v
-1
 µg.mL
-1
 %
b
 %
c
 
20 10 100 74 (74) 99 
20 20 100 86 (89) 99 
20 30 100 82 (93) 99 
20 10 500 77 (82) 99 
20 20 500 87 (92) 99 
20 30 500 84 (95) 98 
50 10 100 36 (42) 98 
50 20 100 55 (66) 97 
50 30 100 70 (78) 99 
50 10 500 42 (48) 98 
50 20 500 65 (73) 98 
50 30 500 72 (85) 96 
General reaction conditions: 2 equivalents dopamine, 1 equivalent 
pyruvate, purified Δ29TfNCS and CV2025 lysate, 50 mM HEPES pH 7.5, 
37 °C, 3 h. 
b
 Determined by analytical HPLC. Conversions in brackets refer 
to depletion of dopamine. 
c 
Determined by chiral HPLC of the crude 
product, method 2 for dopamine. 
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Stereoselectivities were determined by chiral HPLC of the crude reaction. Product 
peaks were identified by comparison with verified chemical standards. Chromatograms 
of reactions contained some small peaks that could not be identified. The major (S)-
norlaudanosoline product was easily identified due to its size and retention times. 
However, based on the chemical standard alone, it was not immediately clear which 
peak in the crude reactions represented the minor (R)-norlaudanosoline: there were 
two small peaks around the correct retention time that were possible candidates. 
Enantiomeric excesses were calculated for both peak options, and were all found to be 
>95%, regardless of the (R)-norlaudanosoline peak selected. By plotting calculated ees 
against NCS concentration it could be seen that with the (R)-norlaudanosoline as peak 
1, ees fall with increasing NCS concentration. On the other hand, if ees are calculated 
with peak 2 they rise with increasing NCS concentration (Fig. 5.17). As NCS is only 
known to make the (S)-isomer, increasing NCS concentration will increase ees. 
Therefore, peak 2 and not peak 1 must be the (R)-isomer. By establishing this, it was 
then possible to calculate the ee with greater accuracy. This peak identification 
problem would have also been solved by doping a run of the chiral HPLC analysis with 
racemic NL. 
 
Fig. 5.17 Enantiomeric excesses when calculated with peak 1 as (R)-isomer (A) or peak 2 as (R)-isomer 
(B). Each different shape marker represents different reactions condition: 20 or 50 mM dopamine, 10, 20 
or 30% v.v
-1
 TAm lysate. Solid lines connect identical reaction conditions (except NCS concentration, 
which is represented on the x-axis). Notice the gradient of all lines in A is negative and in B is positive. 
HPLC method 2. 
The optimum conditions resulted in 87% conversion of dopamine to (S)-
norlaudanosoline with an ee of 99% (Table 5.4). The reaction contained 20 mM 
dopamine, 500 µg.mL-1 NCS and 20% v.v-1 CV2025 lysate. The highest concentration 
of NCS, together with the lowest concentration of substrates, resulted in the maximum 
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conversions and yields. Similarly, increased TAm concentrations always resulted in 
increased dopamine consumption, though this did not always translate into increased 
(S)-norlaudanosoline concentrations. At 50 mM dopamine the maximum TAm 
concentrations (30% v.v-1) resulted in greater conversions, but at the lower dopamine 
concentration (20 mM), the lower TAm concentration of 20% v.v-1 was optimal. This 
difference was probably due to aldehyde side reactions, as the aldehyde was being 
produced more rapidly than NCS can turn it over. There was also marginally poorer 
stereoselectivity with 30% v.v-1 lysate—the chemical composition of lysate and the 
increased concentration of reactive aldehyde resulted in increased racemic PS 
chemical conversion. In terms of conversions, NCS concentration had more of an 
impact when higher concentrations of dopamine were present. 
5.4.8 Modifying the amine 
The scope of the triangular cascade is limited because the arylamine must be a 
substrate for two enzymes, and the TAm product must also be a substrate for NCS. 
Due to the large library of TAms available, and the broad substrate scope of these 
enzymes, the limiting enzyme is unlikely to be the TAm. The NCS, on the other hand, 
has very specific substrate requirements, especially regarding the amine substrate. 
Though the 4-hydroxy group of dopamine is superfluous, the 3-hydroxy is vital for the 
reaction progression.51,53,57 Bulkier chiral amines such as metaraminol are substrates 
for NCS, but the TAm products would be ketones, and as such unlikely to be suitable 
carbonyl substrates for the enzyme (see sections 6.3.2, 6.5 and 6.6).   
As described, the simplest modification of the reaction cascade that could be applied 
was to use 2-(3-hydroxyphenyl)ethylamine in place of dopamine. This compound is 
essentially dopamine with the 4-hydroxy group removed. Using the optimum conditions 
determined for dopamine, the compound 2-(3-hydroxyphenyl)ethylamine was 
successfully turned over by the cascade, producing a novel (S)-BIA (Fig. 5.18). The 
conversion of 56% and ee of 90% were considerably lower than for dopamine, and this 
is perhaps reflective of either the poorer affinity of NCS to 2-(3-
hydroxyphenyl)ethylamine or the corresponding 3-hydroxyphenylacetaldehyde 
compared to dopamine and 3,4-DHPAA. 
177 
 
 
Fig. 5.18 Cascade performed with 2-(3-hydroxyphenyl)ethylamine. Conditions: 20 mM amine, 10 mM 
pyruvate, 20% v.v
-1
 CV2025, 500 µg.mL
-1
 Δ29TfNCS, 50 mM HEPES pH 7.5, 37 °C, 3 h. Conversion 
(formation of product) determined by analytical HPLC, ee measured by chiral HPLC method 3. 
 
5.4.9 Tetrahydroprotoberberines 
Norlaudanosoline can be converted into a tetrahydroprotoberberine (THPB) through a 
second PS reaction with formaldehyde. Formaldehyde can be added to the cascade 
reaction after the reaction has gone to completion. The formaldehyde destroys the 
enzymes present and reacts rapidly with the norlaudanosoline. In an analogous 
manner to the preceding PS reaction, the 3-hydroxy group on the 3,4-DHPAA is crucial 
for this cyclisation. 
Under optimised conditions, the cascade for the formation of (S)-norlaudanosoline from 
dopamine reached completion after approximately 3 hours. Formaldehyde (in 
phosphate buffer) was added to the reaction at this point and allowed to react for 30 
minutes. Analysis of this reaction revealed the formation of two THPB products, the 
para-cyclisation product (10,11-dihydroxy) and the ortho-cyclisation product (9,10-
dihydroxy) in a ratio of approximately 7:1 (Fig. 5.19). Based on previous studies and 
steric effects, this is the expected distribution of product.168 The second (formaldehyde) 
PS step occurred with 74% conversion (64% and 9% for major para and minor ortho 
product respectively); overall from dopamine this is 64% conversion (56% and 8%). 
The chirality of the product is established enzymatically by NCS, and the addition of 
formaldehyde does not affect the ee. Only the (S)-enantiomer of the major product was 
observed by chiral HPLC, though the HPLC method used was of insufficient sensitivity 
to determine the ee of the minor product. 
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Fig. 5.19 One-pot chemoenzymatic synthesis of tetrahydroprotoberberines. Reaction conditions: (a) 
20 mM dopamine, 10 mM sodium pyruvate, 500 µg.mL
-1
 NCS and 20% v.v
-1
 CV2025 lysate, 50 mM 
HEPES pH 7.5, 37 °C, 3 h. (b) 40 mM formaldehyde, 1 M sodium phosphate, pH 6, 30 min, 37 °C. HPLC 
method 2 used for ees. Figure adapted from Lichman et al.
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THPBs are formed biosynthetically by the berberine bridge enzyme (BBE), a flavin 
dependent oxidase. This enzyme catalyses the formation of exclusively (S)-THPBs en 
route to berberine, and typically forms products with 9,10-dihydroxy regioselectivity.101 
The enzyme has been employed in kinetic resolutions and deracemisation cascades 
for the biocatalytic production of 9,10-dihydroxy-(S)-THPBs.99–101,103 The formaldehyde 
method developed here produces the alternative 10,11-dihydroxy isomer, and can 
therefore be seen as complementary to the BBE approach—there are now different 
chemoenzymatic routes to both 10,11-dihydroxy-(S)-THPBs and 9,10-dihydroxy-(S)-
THPBs. Interestingly, using a fluorinated substrate led to a switch of the typical BBE 
regioselectivity.102 Similarly, it has been shown that modification of pH168 or buffer 
concentration60 may shift the regioselectivity of the non-enzymatic PS reaction.  
5.4.10 Scale up 
Two demonstrative preparative biotransformations at milligram scale (0.2 mmole) were 
performed using the cascades, demonstrating the scalability of the system. The 
syntheses were performed on a 0.5 mmole scale, using identical reaction conditions to 
those used at the micro-scale. The products were isolated and purified by preparative-
HPLC. The cascade for the synthesis (S)-norlaudanosoline was completed in 2 hours, 
with 86% conversion; the pure compound was obtained with 62% isolated yield and 
>95% ee. The 10,11-dihydroxy-(S)-THPB was formed from dopamine within 2.5 hours 
with 47% conversion; the pure compound was obtained with 42% isolated yield and 
>95% ee. The product identities were confirmed by NMR spectroscopy (see methods 
section 2.6.2 and for NMR spectra see Appendix B section 9.1).  
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5.4.11 Summary 
In summary, a novel ‘triangular’ cascade for the synthesis of BIAs has been 
established, using the enzymes TAm and NCS. Although similar cascades have been 
designed with MAOs, the cascade developed here is unique due to the use of a TAm, 
and the stoichiometric control of conversions afforded by the triangular cascade 
arrangement. The stereoselectivity of the process is also unique. The syntheses 
demonstrate that with chemoenzymatic cascades it is possible to obtain remarkably 
rapid increases in chemical complexity with high atom economy. For example, the 
major THPB product is formed from a low-cost starting material, in under 3 hours and 
the reaction involves the formation of 2 C-N bonds, 2 C-C bonds and a chiral centre.  
5.4.12 Future work 
In order to make these systems truly scalable, methods for facile purification must be 
developed as preparative-HPLC is not practical for scales of over 1 mmole. 
Furthermore, the loss of material at the purification step would ideally be reduced. 
Possible purification options include adsorption to resin58 or extraction into organic 
solvent.60 In order for purifications to be most effective, very high conversions are 
desired, to minimise contaminating substrates and side products. 
Subsequent to the work on the triangular cascades, NCS activity was examined with 
different substrates (Chapter 6). In this study, an organic extraction method was 
developed capable of purifying secondary amine NCS products away from starting 
materials without the requirement of chromatography (see section 6.6.9 and methods 
section 2.6.3). This method could be easily applied to the multi-enzyme cascade 
synthesis of THIQs and THPBs described here. This would enable further reaction 
scale-up. 
The scope of the triangular cascade reaction with respect to the starting substrate has 
been demonstrated through use of 2-(3-hydroxyphenyl)ethylamine. Other 
phenethylamines with a 3-hydroxy group are likely to be potential substrates also. For 
example, norepinephrine, L-DOPA and metaraminol may be suitable substrates, as 
may some halogenated dopamine analogues. If CV2025 does not turn over the amine, 
it will be possible to screen the numerous reporting TAms for activity. Therefore, the 
limiting factor in this system is likely to be acceptance of substrates into NCS. 
It is also possible to use different aldehydes instead of formaldehyde for the second 
cyclisation step. As this is not an enzyme catalysed step, many different aldehydes can 
be used in this step, potentially forming numerous 8-substituted THPBs. Modifying the 
aldehyde vastly increases the possible compounds that can be produced by this 
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cascade. Similar 8-substituted THPBs have previously been chemically synthesised 
from the oxidised berberine by attacking the electrophilic 8-position with Gringard 
reagents.185–187 The resulting compounds have been examined for antimicrobial 
properties,185 and show promise especially against Mycobacterium tuberculosis.186,187 
In contrast to the fully oxidised berberine derivatives, the addition of an R-group onto 
the THPBs produced here will result in the formation of a new chiral centre at the 8-
position. It is possible that the first chiral centre, established using NCS, will determine 
the isomer formed in the subsequent chemical cyclisation (Fig. 5.20). Whether or not 
this is the case, the characterisation or separation of products from such a reaction will 
be challenging.  
 
Fig. 5.20 Proposed stereoselective formation of 8-substituted-THPBs. The (S)-stereocenter set up by 
NCS could influence the stereoselective of a subsequent PS reaction, forming a THPB with two 
stereocenters. For simplicity, only the more favourable para-cyclised regioisomer is considered here. For 
the THPB products, it is assumed that the trans-bicyclic conformation will be more favourable than the cis 
conformation, so only the trans is considered here. The Re-face attack of the imine by the catechol results 
in the R-group in a pseudo-equatorial position, whereas a Si-face attack results in the R-group being in a 
less favourable pseudo-axial position. A 3D depiction of the THPB is shown in the box. The expected 
major products are the pseudo-equatorial (1S,8S)-THPB. The ratio of the diastereomers formed may 
depend on the size of the aldehyde R-group. 
Although the triangular cascade has elegance in terms of the single starting material 
and the TAm equilibrium position, it is ultimately a ‘dimerisation’ cascade and so is very 
limited by the NCS mechanism requirements. A simple modification to the cascade 
would be the use of different amines for NCS and TAm. The crucial step here would be 
181 
 
the acquisition of a TAm that did not accept dopamine as a substrate. It would then be 
possible to introduce different amines that could be converted in situ to aldehydes, 
which, in turn, would combine with dopamine in a PS reaction catalysed by NCS. This 
system would have challenges with respect to the cross-reactivity of substrates, but 
considering the large array of TAms available to screen this would be a sensible next 
step. 
In order to diversify NCS cascade products further, other multi-enzyme systems must 
developed. As described in section 5.4.1, formation of aldehydes can be catalysed by 
alcohol dehydrogenases, laccases or carboxylic acid reductases (Fig. 5.9). Dopamine 
itself can be formed from tyrosine with a combination of enzymes (Fig. 5.8). THIQ 
reaction products can be modified with methyltransferases and various different CYPs. 
In all, there are an incredible number of possible cascade designs centred on the NCS 
Pictet-Spengler reaction. The formation of these will allow the biocatalytic, green 
production of diverse molecules. 
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 Chapter 6: Screens and substrates 6
6.1 Introduction 
6.1.1 NCS engineering 
It has been demonstrated that it is possible to engineer NCS towards increased 
activities for both natural and unnatural substrates (section 4.4.7). The poor kinetic 
parameters for NCS suggest it may be possible to improve the catalytic efficiency of 
the enzyme, especially with respect to the 𝐾𝑚
𝑎𝑝𝑝—the mutations A79I and Y108F 
showed that modification of kinetic parameters is possible. The substrate promiscuity, 
especially with respect to the aldehyde, also confirmed that the enzyme has the 
potential to catalyse the formation of diverse chiral tetrahydroisoquinolines (THIQs). 
Notably, the mutation L76A demonstrated that activities towards specific substrates 
can be significantly improved.  
Using directed evolution methods, it may be possible to develop a ‘toolkit’ of NCSs. 
This would consist of numerous enzymes, each evolved to specialise in the synthesis 
of a particular chiral THIQ. Directed evolution would consist of accumulating multiple 
mutations onto NCS; these mutations could result in new desirable activities. 
There are numerous methods for mutating enzymes in directed evolution experiments. 
These include error-prone PCR, site-saturation mutagenesis, recombination, 
phylogenetic and combinatorial methods.107–111 The choice of mutation method 
depends on the desired outcome of the evolution, but also on the information available 
on the system being investigated. The data presented in the project has indicated that 
NCS operates with a dopamine-first mechanism (section 4) and therefore it is now 
possible to mutate NCS in a rational manner. For example, the mutation L76A altered 
aldehyde specificity, and Leu-76 was selected for mutation as it is in the aldehyde-
binding site. 
There are a number of exciting potential avenues for evolving NCS activities. This 
includes the aforementioned modification of kinetic parameters and aldehyde substrate 
specificity. There are also certain aldehyde substrates that are currently poorly 
accepted by NCS: in particular α-substituted bulky aldehydes. Furthermore, it may also 
be possible to turn over ketones. There could be potential for the modification of the 
amine tolerance, but this is perhaps more challenging than modifying aldehyde 
specificity because the amine is bound deep into the active site. It may also be 
conceivable to modify the stereo- or regio-selectivity of the NCS reaction, providing 
access to valuable (R)- or ortho-THIQs respectively.  
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6.1.2 Screening requirement 
In directed evolution investigations a crucial limitation on the experimental outcome is 
the quantity of mutants that can be screened. Screening activities with purified enzyme 
and HPLC provides excellent sensitivity, but is often too low-throughput for effective 
directed evolution. More rapid screening methods are desired for the effective directed 
evolution of NCS. This section describes attempts to develop experimental methods 
suitable for the future directed evolution of NCS. 
The best methods for directed evolution are selection methods, where genotype and 
phenotype are linked and only active variants survive to the next evolution round.188 
Unfortunately, developing a selection strategy for NCS activity would be a considerable 
challenge and this was not pursued. A similar excellent option is a colony based assay, 
where screening reactions can occur on the agar plates and a colorimetric change is 
observed. Again, no plate based assay for NCS was considered, mostly as in these 
methods the high background reaction would be difficult to control.  
The background chemical Pictet-Spengler reaction is promoted by cell lysate, even 
without the presence of recombinant NCS. The use of purified enzymes enables the 
greatest control of the background reaction. However, purification of enzymes is costly 
in both time and resources. Furthermore, NCS activity is inhibited by imidazole, so if 
NCS is purified with nickel and eluted with imidazole, an extra desalting step is required 
for optimal expression. It was discovered that it is possible to significantly reduce the 
background reaction in cell lysates that had been treated with a desalting step, without 
the requirement for purification (see section 5.3.4). This desalting method for enzyme 
preparation is reasonable to pursue in screening methods as a compromise between 
enzyme purification and use of cell lysate. 
A screening method was developed by Pesnot et al using fluorescamine to detect 
primary amines.57 Fluorescamine reacts with primary amines to form a fluorescent 
product. This method detected the loss in dopamine concentration associated with a 
successful reaction. The secondary amine THIQ product does not form fluorescent 
products with fluorescamine. However, fluorescamine also reacts with proteins to form 
a fluorescent product. Therefore, this method is effective for screening a single purified 
enzyme with multiple aldehydes, as with a purified enzyme the protein concentration 
can be controlled and minimised. It would be less effective for screening cell lysates of 
multiple mutants, where protein concentrations are unpredictable. 
Alternative screening methods for NCS activity were sought which would be more 
compatible with unpurified cell lysate. A method which could specifically detect 
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secondary amines would be ideal as this would enable product formation to be followed 
rather than substrate depletion. With this in mind, the chloranil test was investigated. 
This test is often used for detecting amines on peptide synthesis resins. Chloranil 
appeared to be insoluble upon mixture with aqueous solution, and no readable output 
was possible. This mixing with water is necessary as the enzyme reactions occur in 
aqueous solution—therefore the chloranil method was not explored further. 
6.2 Purpald® 
6.2.1 Proof of concept 
The compound Purpald® reacts with aldehydes to form a purple coloured product (Fig. 
6.1).189 This method is often used to detect formaldehyde production. In a recent 
directed evolution study, Purpald® was used in an enzyme coupled assay for the 
detection of methanol.190 Purpald® was investigated as a screening method for NCS. 
Although this method detects loss of substrate rather than formation of product, it was 
thought that it would be more appropriate for screening mutant lysate reactions than 
fluorescamine as it would not be sensitive to proteins present. 
 
Fig. 6.1 Mechanism of aldehyde detection with Purpald
®
. Purpald
®
 reacts specifically with aldehydes to 
form an intermediate complex. Oxidation of the complex in air over a few minutes will give rise to a purple 
complex. It is possible to use an oxidant such as NaIO4 to accelerate oxidation. 
Test reactions were prepared to probe the behaviour of Purpald® with different 
aldehydes (Fig. 6.2). Hexanal, heptanal and phenylacetaldehyde (PAA) were 
investigated: all showed reasonable sensitivity between 0.25 and 10 mM aldehyde, 
which is suitable for NCS reaction screening where aldehyde concentrations are 
around 1-10 mM. Aldehyde concentrations above 10 mM caused saturation of 
absorbance detection. Absorbance at 550 nm and 595 nm was monitored, with 550 nm 
showing greater values. The sensitivity of the assay depended on the aldehyde 
investigated, with PAA giving double the absorbance of hexanal which, in turn gave 
twice the signal intensity of heptanal. 
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Fig. 6.2 Purpald
®
 reaction with different aldehydes. A: Picture of increasing aldehyde concentrations 
from L to R: 0, 0.01, 0.1, 0.5, 1, 2, 5, 10, 15, 20, 50, 250 mM. B: Calibration curve. Absorbance 
measured at 550nm. Aldehydes: Phenylacetaldehyde (circles, solid line), Hexanal (diamond, dashed) and 
Heptanal (square, dotted line). Each measurement is mean of duplicates, error bars show one standard 
deviation. Reaction conditions: 30% v.v
-1
desalted boiled lysate, 10 mM dopamine, 0-10 mM aldehyde, then 
1:1 combination with Purpald
®
 (10 mg.mL
-1
 in 1M NaOH). 
The absorbance spectrum of the Purpald® complex with PAA was measured, showing 
a peak at 527 nm (Fig. 6.3).  
 
Fig. 6.3 Purpald
®
-PAA complex. Sample conditions:  20% v.v
-1 
desalted lysate, 50mM PAA, 50% v.v
-1 
Purpald
®
 (10 mg.mL
-1
 in 1M NaOH). All diluted 1:100 in MES pH 7.5. 
6.2.2 Time courses and amine reaction 
A number of experiments were conducted in order to investigate the behaviour of 
Purpald® and to optimise conditions for its use in screening assays. It became evident 
that it was possible to track the consumption of aldehyde in a reaction using a standard 
curve to convert absorbance values into concentrations (Fig. 6.4). The pET control, 
without NCS, however, was observed to show consumption of 50% aldehyde perhaps 
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due to background Pictet-Spengler reaction or consumption of aldehyde by other 
processes. 
 
Fig. 6.4 Time course reaction using Purpald
®
.  Sample conditions:  20% v.v
-1 
desalted lysate, 10mM 
dopamine and 10 mM PAA. Reactions quenched at time points with 50% v.v
-1 
Purpald
®
 (10 mg.mL
-1
 in 1M 
NaOH). WT is squares, solid line. pET control is diamonds with dashed line. Aldehyde concentrations 
calculated using standard curve. Measurements are triplicates, error bars show one standard deviation. 
It was also noticed that Purpald® formed a yellow colour when incubated with 
dopamine, even without the presence of aldehyde. This was confirmed by measuring 
the absorbance of different samples containing control pET lysate and combinations of 
substrates at 10 mM (Fig. 6.5). PAA-Purpald® produces an absorbance peak at around 
530 nm, whilst dopamine-Purpald® gave a smaller peak at around 410 nm. When both 
dopamine and PAA were present in the sample, both peaks were observed. The 
aldehyde peak was reduced in size, but the dopamine peak seemed to become much 
more intense. The reduction in the size of the aldehyde peak may be due to the 
consumption of Purpald® by dopamine or due to formation of non-reactive imines 
between aldehyde and dopamine. Purpald® also reacts with secondary amines in a 
similar manner to primary amines. The identity of the amine-Purpald® reaction product 
is unknown, but may involve nucleophilic attack from the amine onto Purpald®. Overall, 
this previously unobserved reaction between amines and Purpald® reduced the 
sensitivity of this method for the detection of aldehydes. 
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Fig. 6.5 Spectra of Purpald
®
 products. Dopamine (dotted line), aldehyde (solid line), both (dashed). All 
substrates at 10 mM. 
Despite the reaction between amines and Purpald®, it was still possible to effectively 
track the aldehyde consumption with Purpald®. Comparison of Purpald® readings with 
HPLC product detection showed that (with dopamine, PAA and WT desalted lysate) 
aldehyde consumption mirrored product formation (Fig. 6.6). However, there remained 
a large decrease in aldehyde concentration with pET controls, due to the consumption 
of aldehydes or background Pictet-Spengler activity. This suggested that although 
Purpald® detection can follow successful reactions well, it may not be ideal for the 
detection of unknown activities. 
 
Fig. 6.6 Time course of reaction. Squares, dashed line: PAA with WT (Purpald
®
 detection). Diamonds, 
solid line: THIQ product with WT (HPLC detection). Triangles, dotted lines: PAA with pET (Purpald
®
 
detection). PAA detection with Purpald
®
 at 522 nm and converted to concentration with standard curve. 
Measurements are means of triplicates, error bars are one standard deviation. Reaction conditions: 80% 
v.v
-1
 desalted lysate, 10 mM dopamine, 10 mM PAA. Then dilution 1:1 with Purpald
®
 (10 mg.mL
-1
 in 1M 
NaOH). 
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6.2.3 Optimisation 
A screen of TfNCS mutants with various aldehydes was conducted using Purpald® as 
the detection method (Fig. 6.7). The selections of mutants are discussed below 
(section 6.3.1). Although reasonable activities were identified with HPAA and PAA, high 
background readings or low activities for all other aldehydes prevented useful data 
being collected. It was known that WT has significant activity with hexanal compared to 
background, but in this screen this activity was not evident, therefore it was clear that 
there were problems with the assay. The origin of this could have been the very high 
loading concentration of lysate (80% v.v-1). 
In order to optimise the screening conditions, the optimum lysate loading concentration 
was investigated. Hexanal was used as the aldehyde as this showed poor sensitivity in 
the previous assay. Reactions with different desalted lysate concentrations were 
measured, comparing WT to a pET control (Fig. 6.8). Surprisingly, losses in aldehyde 
in the controls were shown to be consistent regardless of lysate concentration. This 
suggested that the aldehyde was intrinsically unstable or perhaps was forming imines 
with dopamine. The best condition to detect activity over background was after 5 
minutes with 50% v.v-1 lysate loading. In all lysate loadings, after 30 minutes aldehyde 
consumption was greater in controls than with enzymes. Although it is possible to 
detect activity with the Purpald® assay, the small dynamic range, and high background 
conversion suggests it was not be suitable as a general method. 
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Fig. 6.7 Aldehyde Purpald
®
 screen 1. HPAA: 4-hydroxyphenylacetaldehyde, PAA: phenylacetaldehyde, 
CHCA: cyclohexanecarboxaldehyde, 3-HBA: 3-hydroxybenzaldehyde, cinnam: cinnamaldehyde, BA: 
benzaldehyde. Conditions: desalted lysate 80% v.v
-1
, 10 mM dopamine, 10 mM aldehyde. Then dilution 
1:1 with Purpald
®
 (10 mg.mL
-1
 in 1M NaOH). Aldehyde concentrations determined by standard curves. 
A final attempt at using Purpald® to screen mutants with various aldehydes was 
conducted, using purified enzymes rather than lysates, and doubling the concentration 
of Purpald® used for detection. In constructing standard curves, there appeared to be 
very little Purpald® response to benzaldehyde and 3-hydroxybenzaldehyde. This 
suggests that Purpald® is not generally applicable in screens with all aldehydes. 
Activity was observed with HPAA, PAA, Hexanal and (S)-citronellal. Overall, despite 
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efforts to optimise reaction conditions, it was clear that Purpald® was not a good 
detection method for NCS reactions. 
 
Fig. 6.8 Lysate loading examination. WT (diamonds, solid line), pET (square, dashed line), difference 
(triangle, dotted line). Conditions: 10 mM dopamine, 10 mM hexanal, varying lysate concentration. Then 
dilution 1:1 with Purpald
®
 (10 mg.mL
-1
 in 1M NaOH). 
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6.3 Substrate screens 
6.3.1 Mutants 
Mutants of TfNCS were screened with a variety of substrates. The mutants can be split 
into two main categories. The residues Leu-76, Ala-79 and Phe-80 are all in the region 
of active site where aldehydes R-groups are expected to bind based on the dopamine-
first mechanism (Fig. 6.9). The other residues investigated in this section were Tyr-108, 
Glu-110 and Asp-141. All of these are ‘mechanistic’ residues, that are expected to play 
a role in the mechanism of the enzyme, rather than just substrate binding. They were 
targeted when amines were varied, especially when the substrates require more 
extreme modifications of activity (e.g. N-methylated amines). Formation of mutants is 
described in method section 2.1. 
 
Fig. 6.9 Residues targeted in screening assays. Green sticks:  residue side chains. Green surface: 
solvent accessible protein surface. Purple surface: solvent accessible ligand surface. Purple sticks: docked 
structure of (S)-aminol to demonstrate dopamine-first mechanism interactions. See section 4 for more 
details on mechanism. 
6.3.2 Fluorescamine and aldehydes 
Fluorescamine was used to screen mutants with aldehydes in a method similar to that 
reported by Pesnot et al.57 This method requires the protein to be purified. The first 
attempt using a fluorescamine screen, with a 1 hour reaction time, provided low 
signals—WT TfNCS with HPAA showed only about 40% conversion. To improve 
signal-to-noise, reaction times were increased to three hours. 
The enzymes Δ29TfNCS WT, L76A, L76V, A79F, A79I and F80L were examined, 
along with CjNCS2 (see section 2.1.2 for creation of mutants). In the reactions, the 
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amine used was dopamine. No activities were observed with acetaldehyde, 
cyclohexanecarboxaldehyde (CHCA), cinnamaldehyde, 3-hydroxybenzaldehyde (3-
HBA), benzaldehyde (BA) and the ketone 4-hydroxyphenylacetone (4-HPA). This is in 
line with previous observations that α-substituted aldehydes and ketones are poor 
substrates for NCS.57 Activities were also not observed with 3-methoxylbutanal, 
pentanal and cyclopropanecarboxaldehyde, though these three compounds were not 
freshly distilled prior to use and may have oxidised. 
Activity was observed with 4-hydroxyphenylacetaldehyde (HPAA), phenylacetaldehyde 
(PAA), hexanal, heptanal, decanal, (S)-citronellal and (R)-citronellal (Fig. 6.10). When 
this reaction was initially conducted, activity with hexanal,  decanal and citronellal had 
not previously been identified. 
 
Fig. 6.10 Aldehyde mutant fluorescamine screen. Conditions: 100 μM dopamine, 1 mM aldehyde, 25 
μg/mL purified enzyme, 3 h incubation then addition of fluorescamine (10 mM in MeCN 0.25x volume of 
reaction).  
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For all substrates, except for (S)-citronellal, CjNCS2 showed less fluorescence than 
any TfNCS mutant. Although it is clear that CjNCS2 had activity for all these aldehydes, 
direct comparison with TfNCS mutants was difficult as the background fluorescence of 
the proteins were different. The purified protein CjNCS2 had less than half the 
fluorescence than purified WT-Δ29TfNCS at the same concentrations. 
It is possible to compare TfNCS mutants with each other, as they demonstrate similar 
fluorescent responses. The mutant A79I showed increased activity compared to WT for 
HPAA, PAA and hexanal. This was observed in kinetic assays and discussed in section 
4.4.3. The mutant L76A showed increased activity for both citronellal aldehydes and 
decanal. The response of L76A to citronellal was discussed in section 4.3.7. The 
increased activity with decanal had not previously been observed but, as for citronellal, 
can be accounted for by steric effects. The mutants L76V, A79F and F80L showed 
similar activities to WT, and did not show any significant improvement in activity with 
any particular aldehydes. 
6.3.3 Fluorescamine and amines 
Primary amines were screened with a different selection of mutants (Fig. 6.11). These 
mutants included aldehyde-binding mutants known to cause changes in activity (L76A 
and A79I), and mutants further inside the active site near to where the amine nitrogen 
is expected to bind: Y108F, E110D and D141E (see section 4). The amines screened 
(with PAA) included dopamine and metaraminol, which was previously shown to be 
turned over by CjNCS2.57 More unusual amines tested were 2-bromo,5-
hydroxyphenylethylamine and 3,4-dihydroxyphenylpropylamine.* In the bromo amine, 
the bromide blocks the typical cyclisation position in the Pictet-Spengler reaction, so 
the intention here was to force formation of an ortho-product. The latter, a propylamine, 
would form a seven-membered ring in a Pictet-Spengler reaction. 
Activities with dopamine were similar to those expected from studies of the mechanism: 
activity was knocked out with E110D and reduced with L76A, Y108F and D141E. 
Metaraminol activity was observed but only for WT and A79I. Notably, it is known that 
CjNCS has some activity with metaraminol, but this was not observed in this assay. 
This suggests the sensitivity of this assay was poor. No activities were shown with the 
brominated amine. Strangely, the propyl amine did not give a fluorescent response at 
all, even in the HEPES background. 
                                               
* These compounds were synthesised by Dr Eleanor Lamming 
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Fig. 6.11 Amines with fluorescamine. Conditions: 500 μM amines, 1 mM HPAA, 25 μg/mL purified 
enzyme, 3 h reaction time then addition of fluorescamine (10 mM in MeCN 0.25x volume of reaction).  
6.3.4 Purpald® and secondary amines 
Secondary amines were tested for activity with the same set of mutants as section 
6.3.3. As the compounds tested were secondary amines, fluorescamine could not be 
used, so a Purpald® assay was conducted instead. The aldehyde used was PAA, 
which in the Purpald® assay performed relatively well (see section 6.2). A standard 
curve was used to convert absorbance values into concentrations; however it was clear 
that there was a large background reaction (Fig. 6.12). Regardless, it was possible to 
see that the results for dopamine matched very well with the fluorescamine results (Fig. 
6.11), so the assay could certainly identify some activities. Despite this, no activity was 
observed for the secondary amines: N-methyl-3-hydroxyphenethylamine*, 4,N-
dimethyldopamine* and isoprenaline (Fig. 6.12). This was not especially surprising 
considering the nitrogen-enzyme interaction is vital; disrupting this interaction by 
adding alkyl groups is detrimental for NCS activity.  
                                               
* These compounds were synthesised by Dr Eleanor Lamming 
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Fig. 6.12 Purpald
®
  amines. Conditions. 45 μg/mL purified enzyme, 18 mM amines, 9 mM PAA. 1 hour 
incubation then 1:1 addition of Purpald
®
 (20 mg.mL
-1
 in 2N NaOH).  
6.4 Regioselectivity screens 
6.4.1 Introduction  
Two different regioisomers are possible in the Pictet-Spengler reaction with dopamine, 
depending on the orientation of the catechol ring at the electrophilic aromatic addition 
step. In the chemical phosphate catalysed reaction the major product is the para-
regioisomer (tetrahydroisoquinoline-6,7-diol) and the minor product is the ortho-
regioisomer (tetrahydroisoquinoline-7,8-diol).  Recently, a number of ortho-substituted 
THIQs have been shown to have superior antibiotic activities than similar para-THIQs 
for inhibiting Mycobacterium tuberculosis growth.94 To date NCS produces exclusively 
para-THIQs (see section 5.3.1). Enzymatic formation of ortho-THIQs is known: the 
biosynthesis of the antibiotic saframycin for example involves an ortho-Pictet-Spengler 
cyclisation step, though the mechanism of this non-ribosomal peptide associated 
enzyme is not known (see section 1.7.4).89 
An enzymatic route to ortho-THIQs would enable the facile production of interesting 
bioactive compounds and would thus be very valuable. It would also be beneficial if the 
products could be single enantiomers. NCS was rationally engineered with the intention 
of producing ortho-THIQs. The engineering was based on the dopamine-first 
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mechanism. The key electrophilic addition cyclisation step that establishes the 
regioisomer of the product is catalysed by Lys-122. By repositioning the catalytic lysine 
in the active site, it was hoped that the cyclisation directionality could be adjusted, and 
form ortho-THIQs preferentially to the typical para-product (Fig. 6.13). The substrate 
nitrogen position is dictated by the carboxylic acid residues Glu-110 and Asp-141, so it 
was hoped that moving the lysine residue would only affect the catechol position and 
not the entire substrate orientation.  
 
Fig. 6.13 Cyclisation step of NCS reaction. A. The Para-cyclisation step in dopamine-first mechanism. 
B. Proposed ortho-cyclisation step in engineered NCS. 
An alternative strategy for engineering the enzyme towards the formation of ortho-
THIQs may be to attempt to modify the chemical mechanism of the cyclisation, and 
encourage the formation of a spiro intermediate (Fig. 6.14). This intermediate could 
then undergo a C-C bond migration to form a bicyclic compound that shares a C-C 
bond, before losing a proton to form the product. The spiro intermediate could be 
formed if, rather than the 3-hydroxy group of the dopamine providing the key electron 
density, the 4-hydroxyl group could be more dominant. This would be encouraged by 
removal of the 3-hydroxy group (i.e. tyramine) or by methylation. The subsequent C-C 
migration would be controlled by the electron donating nitrogen, but two products 
remain possible. A similar spiro-mechanism has previously been observed for the 
related Bischler-Napieralski reaction.191 
A B
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Fig. 6.14 Theoretical spiro-mechanism. Nitrogen is an electron donating atom so would dictate the bond 
that migrates. 
Both strategies for altering the regioselectivity of the enzyme catalysed reaction are 
extremely speculative, but the former ortho-cyclisation approach is probably the best as 
there is clear precedent in the phosphate catalysed reaction. The dopamine-first 
mechanism was used as a guide to engineer the enzyme. 
The strategy for this engineering was first mutation of the Lys-122 to a non-active 
hydrophobic residue (leucine or phenylalanine). Then, by mutating a different residue 
to a lysine, the catalytic nitrogen would be moved around the active site. The best 
candidate residues for this are those near an ‘ortho’ position: Ala-69, Leu-72, Ile-85 and 
Leu-95 (Fig. 6.15). The residues near the faces of the catechol—Phe-112 and Met-
183—were also tested. The residue Met-126 was also examined despite its 
considerable distance from the catechol. Of course, the catalytic Lys-122 in the typical 
mechanism has evolved to be in a particular environment to optimise catalysis. This 
includes modification of the pKa and position of a water channel (see section 4.3.3). 
Any activity observed in these double mutants would be extremely small—subsequent 
directed evolution would be required to make the enzyme a useful biocatalyst. Due to 
the very small activities expected the screening was conducted with HPLC detection, 
as this has best sensitivity and reliability. 
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Fig. 6.15 Residues modified to lysine in regioselectivity screen. Lys-122 was mutated to leucine and 
phenylalanine. Glu-110 was not changed but is depicted to demonstrate active site orientation. 
The single mutants tested in this study were K122L, K122F and F112K. To the K122L 
mutant background the mutants A69K, L72K, I85K, L95K, F112K, M126K and M183K 
were added and examined. The double mutant K122F F112K was also investigated.  
6.4.2 Phenethylamines 
In order to speed up the enzyme preparation, a rapid, small scale method was 
developed. Pellets from small scale cultures (2 mL) were lysed (200 µL BugBuster) and 
centrifuged. Nickel agarose suspension (50 µL) was added to the supernatant and the 
mixture incubated. The Ni-agarose was isolated, washed (40 mM imidazole) and the 
protein eluted (50 mM EDTA) (Fig. 6.16). EDTA was used for elution rather than 
imidazole as imidazole inhibits the NCS reaction. 
 
Fig. 6.16 SDS-PAGE of Lysine mutants. Lanes: 1, pET control; 2, WT; 3, K122L; 4, K122L-69K; 5, 
K122L-72K; 6, K122L-85K; 7, K122L-95K; 8, K122L-112K; 9, K122L-126K; 10, K122L-183K; 11, K122F; 
12, F122L; 13, K122F-F112K. Purified from small scale cultures. 
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Fig. 6.17 Compounds tested with Lys mutants. Assay conditions: 12.5 mM amines (except D, 5mM), 
Aldehydes 10 mM. 20% v.v
-1
 enzyme, 1 h, 37 °C. Reactions analysed by HPLC. PAA: 
phenylacetaldehyde. Compounds 3-hydroxyphenethylamine, 3,5-dihydroxyphenethylamine, 3,4-
dihydroxyphenylpropylamine and 2-bromo,5-hydroxyphenylethylamine were synthesised by Dr Eleanor 
Lamming. 
The purified enzymes were tested for activity with a variety of amines, with the intention 
of observing either novel or unusual activities (Fig. 6.17).* Of those tested, WT NCS 
was known to have activity with dopamine, metaraminol and 3-hydroxyphenethylamine. 
HPLC analysis of the reactions showed WT activity with the expected compounds: 
dopamine (A, B), metaraminol (C) and 3-hydroxyphenethylamine (D). The 3,5-
dihydroxy-phenethylamine (E) has very high reactivity so conversion was observed in 
all samples including the pET vector control. WT did not appear to have activity with 
compounds E, F and G. All mutants (including F112K) had no apparent activities with 
any amines. There were three exceptions: new peaks were observed for WT with 
isoprenaline (H), F112K-K122F with B (dopamine and hexanal), and F112K-K122L with 
E. 
These hits were re-tested to eliminate false positive data—reactions were replicated 
and analysed by HPLC. All three of the hits observed in the screen were not observed 
in the replicate and thus the original screening results appeared to be false positives. 
Control reactions with dopamine and hexanal were performed for mutants F112K- 
K122F and F112K-K122L. Although the originally observed peaks from screening were 
not observed, these two mutants appeared to catalyse the typical para Pictet-Spengler 
reaction.  
                                               
* Compounds 3-hydroxyphenethylamine, 3,5-dihydroxyphenethylamine, 3,4-dihydroxy-
phenylpropylamine and 2-bromo,5-hydroxyphenylethylamine were synthesised by Dr Eleanor 
Lamming. 
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Although no novel activities were noted, the fact that some activity is maintained upon 
moving a key catalytic residue is surprising and interesting. The Phe-112 side chain 
does point towards the catechol, so a lysine here can perhaps interact with the 3-
hydroxy group. The position of Phe-112, next to Lys-122, means that both are in a 
similar local environment. Therefore a lysine in position 112 may have similar 
properties to one at 122. 
6.4.3 Other Pictet-Spengler reactions 
The set of lysine mutants were tested for activity with different Pictet-Spengler 
reactions (Fig. 6.18). The reaction mechanisms for tryptamine and histamine Pictet-
Spengler reactions are similar to that with dopamine; all require the formation of an 
iminium intermediate before electrophilic aromatic cyclisation. The key differences are 
the aromatic rings and the nature of the electrophilic aromatic substitution step. The 
residues that are thought to be involved in the formation of the iminium and the final 
deprotonation step (which is conserved in all reactions) are Glu-110 and Asp-141, and 
remain unchanged in these mutants. The Lys-122 interacts with the catechol ring on 
dopamine, so it was thought that different aromatic rings may require different positions 
of Lysine, or perhaps an absence of this residue. 
 
Fig. 6.18 Pictet-Spengler reactions tested and their corresponding products  
To screen mutants in a rapid manner, reactions were conducted on 96-well microtiter 
plates coated with nickel sepharose. These types of plates are typically designed for 
ELISA assays, which do not require large protein loadings. Due to this, many 
manufacturers’ plates did not show sufficient protein binding for observable enzyme 
catalysis. However, HIS-Select® high capacity plates from Sigma-Aldrich demonstrated 
sufficient loading for NCS reactions to occur (using the fluorescamine assay detection, 
see section 6.3.2) (Fig. 6.19). Unfortunately the reaction damaged the plates, rendering 
them single use only. 
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Fig. 6.19 Assay using nickel coated plates. Clear bars – pET control, Solid bars – WT. Fluorescence 
shows presence of amine normalised to maximum amine concentration (1 mM). Reaction: dopamine and 
PAA. 
It was thought that the presence of 10% v.v-1 organic solvent in the reaction mixture 
may damage the nickel coating of the plate. The solvent is required to solubilise the 
aldehyde. Different solvents were tested with the plates to determine which was most 
compatible (Fig. 6.20). Upon addition of the reaction mixture to the nickel coated wells, 
all solutions became cloudy, except for those with MeCN. This cloudiness was possibly 
detachment of the coating from the well wall caused by the solvents. In terms of the 
fluorescence response, the best solvent was MeCN. This solvent was used in future 
work with the nickel coated plates. Elution of protein from the nickel coated plates with 
varying concentrations of imidazole or EDTA was examined, as this may enable 
multiple reactions with a single purification. However, purification from the plates was 
not possible, and the best activities were observed with the enzyme immobilised on the 
well surface. 
 
Fig. 6.20 Solvent compatibility with nickel plates. Clear bars – pET control, solid bars – WT, grey bars 
–difference (pET-WT). Fluorescence shows presence of amine normalised to maximum amine 
concentration (1 mM). All solvents except MeCN caused cloudiness/precipitation. Propanol only caused 
small amount of cloudiness, whilst for DMSO the precipitate settled at the bottom of the well.  
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The nickel plate method was used to detect activity with the lysine library and amines 
(Fig. 6.18). Fluorescamine was used to screen for a reduction in amine present. As 
expected WT and phosphate activity was detected with dopamine but no mutant 
demonstrated a clear loss in fluorescence due to activity. Tryptamine alone showed a 
very low fluorescent response, suggesting a problem with the assay for this compound. 
The histamine fluorescent response was similar to dopamine, but activities were not 
observed for any enzymes, except a slight reduction of fluorescence was observed with 
phosphate. It is not clear whether this background reading was due to lack of a protein 
signal in the phosphate control (which will cause reduction in signal regardless of 
activity) or genuine activity. Phosphate catalysed Pictet-Spengler reactions with 
histamine have not previously been explored, so it may be worth verifying this signal.   
The fluorescamine assay is not especially sensitive, and does not seem appropriate for 
the observation of very low level promiscuous activities in enzymes. Therefore the 
same samples as analysed by the fluorescamine assay above were also analysed by 
HPLC. The chromatograms were examined for the presence of new peaks. 
Unfortunately the histamine samples did not seem to run well using the typical HPLC 
method. This is perhaps as they are too polar for the method which is optimised for 
THIQ analysis. The HPLC traces showed a few unknown peaks but these peaks were 
considered too small to warrant further examination. 
Overall, the lack of positive results for the lysine mutants was not unexpected. Larger 
mutant libraries and more sensitive assay methods (i.e. MS) would increase the 
chances of finding a hit. Regardless, such extreme rational engineering is ambitious; it 
would require large efforts in directed evolution and a considerable dose of luck for a 
successful novel enzyme to be generated in this manner. 
6.5 α-Substituted aldehydes 
6.5.1 Identification of activity  
The WT Δ29TfNCS was screened with 3-hydroxybenzaldehyde (3-HBA) and 
cyclohexanecarboxaldehyde (CHCA), using a nickel coated plate and a fluorescamine 
assay. Activity with these substrates was detected. Only trace activities with WT NCS 
had ever been previously observed for these substrates, and therefore this result was 
explored further by HPLC analysis.57 
Reactions with purified WT TfNCS using dopamine with 3-HBA and CHCA were 
analysed by HPLC. Both dopamine consumption and new peaks in the expected region 
of THIQs were observed (Fig. 6.21). Phosphate catalysed reactions also formed the 
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same potential product peaks. The phosphate reaction was greater than the enzyme 
reaction for 3-HBA. The 3-HBA product peak was verified with a chemically 
characterised standard. For CHCA the phosphate reaction seemed to form very little 
product compared to CHCA, so the product peak at the time was unverified. 
 
Fig. 6.21 α-Substituted aldehyde product formation. Open bars: Phosphate, solid bars: WT NCS. 3-
HBA: 3-hydroxybenzaldehyde. CHCA: cyclohexanecarboxaldehyde. Conditions: 1 mM dopamine, 10 mM 
aldehyde. 1 mg.mL
-1
 purified WT TfNCS. 3-HBA product peak verified with characterised standard. CHCA 
product peak unverified. Peak areas are not standardised so comparing different products directly is not 
possible. 
6.5.2 The effect of solvent  
A profound impact of solvents on the NCS reaction became apparent during lysate 
experiments. The aldehydes used in the Pictet-Spengler reactions are typically not very 
soluble in water, and so are solubilised in an organic solvent at 10% v.v-1 of the final 
reaction mixture. Reactions with dopamine, PAA and crude lysate showed that the use 
of DMSO as a co-solvent greatly enhances enzyme activity (Fig. 6.22). Heptane, even 
though it is not miscible in water, was slightly superior to MeCN as a co-solvent. Both 
were inferior to DMSO. Adding neat aldehyde with no co-solvent showed poorest 
conversions 
 
Fig. 6.22 Solvent effects with crude lysate. Open bars: pET control, solid bars: WT TfNCS. Conditions: 
Dopamine 10 mM, PAA 15 mM, 5% v.v
-1
 cells, 15% v.v
-1
 solvent, 2.5 h incubation. Peak area of dopamine 
shows a similar trend. 
0
2
4
6
8
10
12
14
16
18
3-HB CHCA
6.056 5.662
P
e
a
k
 a
re
a
 (
A
U
2
)
3-HBA
0
20
40
60
80
100
120
140
MeCN Heptane DMSO Neat
P
ro
d
u
c
t 
p
e
a
k
 a
re
a
 (
A
U
2
)
Solvent
204 
 
6.5.3 Verification of activity 
The aldehydes phenylacetaldehyde (PAA), benzaldehyde (BA), 3-hydroxy-
benzaldehyde (3-HBA) and cyclohexanecarboxaldehyde (CHCA) were tested with 
purified WT TfNCS, dopamine and with MeCN or DMSO as a co-solvent. Activity above 
background was observed with PAA, BA and CHCA (Fig. 6.23). There seemed to be 
slight activity above background for 3-HBA. CHCA and BA strongly favoured MeCN as 
a co-solvent whilst PAA showed a slight preference for DMSO. The product peaks for 
PAA and 3-HBA peaks were validated with verified standards. The product peak for 
CHCA was isolated by collecting the analytic HPLC eluent and its identity was verified 
by high resolution mass spectrometry ([HRMS ES+] found [M+H]+ 248.1653, 
C15H22NO2 requires 248.1651). The product peak for BA was unverified, but in the 
expected region of THIQs. It was notable that the enzyme has superior activity for 
CHCA than the phosphate reaction.  This suggests that the enzyme provides catalytic 
rate enhancement in a different manner to phosphate—some substrates that are poorly 
turned over by phosphate may be good substrates for the enzyme. 
 
Fig. 6.23 α-Substituted aldehyde product formation. Conditions: Dopamine 1 mM, aldehydes 10 mM, 
50 µg/mL purified WT TfNCS, 10% v.v
-1
 solvent, 3 h, 37 °C. PAA: phenylacetaldehyde, CHCA: 
cyclohexanecarboxaldehyde, BA: benzaldehyde, 3-HBA: 3-hydroxybenzaldehyde. MeCN/DMSO refers to 
solvent used. PAA and 3-HBA peaks validated with verified standards. CHCA peak was subsequently 
purified and analysed by mass-spectrometry. The BA product peak was unverified. 
In the previous experiment (Fig. 6.23), the activity of the enzyme with 3-HBA was just 
above the control HEPES reaction. To verify that the small increase in peak area was 
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an enzyme mediated effect, the reaction was replicated with higher concentrations of 
NCS. The data showed the reaction was indeed enzyme catalysed (Fig. 6.24). 
Surprisingly, the enzyme reaction clearly favoured DMSO as a co-solvent, which was 
the opposite of the results observed for the very similar substrate BA.  
 
Fig. 6.24 3-Hydroxybenzaldehyde activity. Conditions: Dopamine 1 mM, ketone 10 mM, 93 µg/mL 
purified WT TfNCS, 10% v.v
-1
 solvent, 3 h, 37 °C. MeCN/DMSO refers to solvent for aldehyde. 
The BA product identity remains unverified. In the future, it will be necessary to purify 
larger quantities of these novel products in order to analyse them by NMR and chiral 
HPLC.  
6.6 Ketones 
6.6.1 Chemical synthesis of 1,1-disubstituted-THIQs 
The 1,1-disubstituted-THIQ moiety is found in numerous natural products, and it is an 
attractive synthetic target for active pharmaceutical intermediates (APIs). Analogously 
to 1-monosubstituted-THIQs, these disubstituted moieties can be formed via a PS 
reaction between a phenethylamine and a ketone. Ketones are generally less reactive 
than aldehydes and consequently whilst there are many methods for the synthesis of 1-
monosubstituted-THIQs, general methods for the disubstituted compounds are more 
unusual. For example, the facile phosphate catalysed formation of a THIQ from 
dopamine and an aldehydes does not extend to ketone starting materials.59 
There are a number of methods for the synthesis of 1,1-disubstituted THIQs (Fig. 6.25). 
Some methods rely on using specific ketones, which limit the reaction scope.192,193 
Other more general methods require unique catalysts: including a zeolite catalyst,194 
titanium catalysts195,196 and a calcium catalyst.93 There are also few methods for 
formation of 1,1-substituted tetrahydro-β-carbolines via PS reactions with ketones. 
These include the use of microwaves197 or unusual solvents such as 1,1,1,3,3,3-
hexafluoro-2-propanol (HFIP)198 to increase the slow rate of the reaction. There are 
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currently no general methods for the construction of chiral 1,1-disubstituted THIQs.156 
Some chiral applications are possible with a lithiation-substitution method that turns the 
THIQ 1-position into a nucleophile (Fig. 6.25G).199 Other methods involve chiral phase 
transfer catalysis, in which chiral ligands stereoselectivity catalyse alkylation or 
hydrolysis in biphasic systems (Fig. 6.25H).200,201 
 
Fig. 6.25 Chemical syntheses of 1,1-disubstituted THIQs. A. Synthesis via enaminones
192
. B. 
Synthesis with diethyl oxomalonate
193
. C. Zeolite catalysis
194
. D. Titanium (IV) catalysis
195
. E. ‘Umpolung’ 
synthesis with titanium (III) catalysis
196
. F. Calcium catalysis
93
. G. Lithiation-substitution reaction, using 
chiral starting materials
199
. H. Asymmetric alkylation/hydrolysis of Reissert compounds forming chiral 
products
201
. 
Through reactions with ketones, NCS may be able to produce 1,1-disubstituted THIQs. 
Based on its catalysis with aldehydes, it is possible that these reactions could occur in 
a chiral manner. Verified activity with ketones would make NCS a very valuable and 
unique catalyst, able to produce chiral 1,1-disubstituted THIQs. 
6.6.2 Biosynthesis of 1,1-disubstituted-THIQs 
There are BIA subgroups which contain the 1,1-disubstituted-THIQ structure. The 
spiro-BIAs202 are formed in planta from the protoberberines,203 and in turn are 
converted into the azepine BIA subgroup (Fig. 6.26A). The tetracyclic erythrina 
alkaloids204 are biosynthesised from the BIA (S)-norreticuline, through a rearrangement 
of the carbon skeleton via a 9-membered ring intermediate (Fig. 6.26C).205  
207 
 
The complex biosynthesis of these compounds derives ultimately from the 1-
monosubstituted-THIQ (S)-norcoclaurine, with the PS step between dopamine and 4-
HPAA catalysed by NCS and extensive elaboration required to reach the 1,1-
disubstituted molecular skeletons. It may, however, be possible to access similar 1,1-
disubstituted compounds directly via a PS reaction with a ketone. Direct access to the 
spiro-BIAs from a PS reaction (perhaps catalysed by NCS) would require conversion of 
ketones similar to 2-indanone (Fig. 6.26B). Tetracyclic erythrina alkaloids may be 
accessible through reaction with a cyclohexanone derivative (Fig. 6.26D). Formation of 
the final 5-membered ring can be achieved by cyclisation onto the nitrogen, which will 
require a 2-substitutent on the cyclohexanone. 
 
208 
 
 
Fig. 6.26 Biosynthetic pathways to BIA subgroups and metabolic short-cuts via NCS. A: proposed 
biosynthetic route to spiro-BIAs and benzindanoazepine alkaloids from protoberberines.
203
 B: Pictet-
Spengler shortcut to spiro-BIAs. C: Biosynthetic route to erythrina alkaloids via norreticuline and a 
morphinan-like CYP step and 9 membered ring intermediate.
205
 D: Pictet-Spengler shortcut to erythrina 
alkaloids. LG = leaving group. 
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6.6.3  Identification of activity 
Wild-type Δ29TfNCS was tested with 4-hydroxyphenylacetone (4-HPA), the ketone 
most similar to the natural NCS substrate 4-hydroxyphenyl-acetaldehyde. A 
fluorescamine assay seemed to show some activity with 4-HPA. Analysis of the 
reactions by HPLC showed the presence of a new peak with a retention time similar to 
other THIQs. 
Purified WT TfNCS was tested for activity with dopamine and 4-HPA and 2-hexanone. 
The effect of co-solvent on these reactions was also examined. The predicted 4-HPA 
product peak observed in the initial screen was observed again in this experiment, with 
DMSO greatly enhancing the amount produced (Fig. 6.27). This product was not 
observed in the phosphate reaction. For 2-hexanone, a very small peak was observed 
in the THIQ region. This peak was larger when MeCN was used as a co-solvent, and 
there was some evidence of this peak in the phosphate reaction. The reactions were 
repeated with double the concentration of enzyme, and an identical trend was 
observed. This suggested these new products formed were not merely side-products or 
contamination but indicative of a real enzymatic effect. 
 
Fig. 6.27 Ketone product formation. Conditions: Dopamine 1 mM, ketones 10 mM, 50 µg/mL purified 
WT TfNCS, 10% v.v
-1
 solvent, 3 h, 37 °C. 4-HPA: 4-hydroxyphenylacetone. MeCN/DMSO refers to solvent 
for ketone solubilisation.  
6.6.4 Verification of activity 
The very low or zero conversions observed for the phosphate reaction with ketone 
substrates suggested that clarified cell lysate could be used in place of purified 
enzymes without concern of a high background reaction. Accordingly, ketone reactions 
(4-HPA and 2-hexanone) were conducted with 50% v.v-1 clarified cell lysate loading, 
simplifying the reaction preparation. The choices of co-solvent, enzyme and substrate 
proportion were also investigated. For both 4-HPA and 2-hexanone, conversions 
appeared greatest with DMSO rather than MeCN, with TfNCS rather than CjNCS2, and 
with dopamine in excess rather than the ketone (Fig. 6.28). The enzyme CjNCS2 
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showed no activity for ketones. The use of DMSO rather than MeCN increases 
conversion of 4-HPA by over 4-fold, and for 2-hexanone around 3-fold. In contrast, for 
both ketones, the background reaction with phosphate or pET seemed to be larger with 
MeCN than DMSO. The preference of the 2-hexanone conversion for DMSO was not 
expected based on previous reactions with pure enzyme, where MeCN seemed 
preferable (Fig. 6.27). The improved conversion observed with excess dopamine has 
been shown previously,60 though the 5% v.v-1 less solvent present in these reactions 
with dopamine in excess may also have an effect on conversions. 
 
Fig. 6.28 Ketones and lysate. Conditions: Dopamine 10 or 15 mM, ketones 10 or 15 mM, 50% v.v
-1
 
lysate, 10-15% v.v
-1
 solvent, 3 h, 37 °C. 4-HPA: 4-hydroxyphenylacetone. MeCN/DMSO refers to solvent 
for ketone. Dopa/Ketone refers to which substrate in excess. Clear bars, phosphate; dark grey bars, pET; 
black bars, TfNCS; light grey bars, CjNCS2. 
The optimum reaction conditions were explored further. In a single experiment, the 
effects of DMSO, enzyme preparation and ascorbate were investigated (Fig. 6.29). 
Ascorbate is a common additive to NCS reactions—here the addition of ascorbate 
prevented the reactions turning a brown/black colour, and increased the product 
yield.58,60 Dopamine is prone to auto-oxidation and polymerisation; ascorbate is an anti-
oxidant and prevents this side reaction from occurring.206 Without ascorbate no 
conversion at all was observed with pure enzyme. Generally, pure enzyme was 
observed to be an inferior catalyst compared to cell lysate. Although the conditions 
were not controlled with respect to absolute enzyme quantity in lysate, the quantity of 
pure enzyme used here was typical for a biotransformation (80 μg.mL-1). The addition 
of DMSO did not serve to improve yields when using pure enzyme, but did when lysate 
was used. For lysate, the optimum DMSO concentration tested was 10% v.v-1, with 
yields falling to zero as concentration was increased to 50% v.v-1. 
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Fig. 6.29 Reaction conditions for conversions of ketones. Conditions: 20% v.v
-1
 Δ29TfNCS lysate or 
80 μg.mL
-1
 pure Δ29TfNCS, 5 mM ascorbate (except in ‘no ascorbate’ reaction), 10 mM 2-hexanone, 15 
mM dopamine. All data points are averages of triplicates; error bars show one standard deviation from the 
mean. No activity was observed for controls lacking substrates, an empty vector lysate control and for pure 
enzyme reaction without ascorbate present. The peak area used was the predicted product peak area. 
To verify the reaction products and HPLC signals, high resolution mass spectrometry 
(HRMS) analysis was conducted. The predicted THIQ product peaks for dopamine with 
4-HPA and dopamine with 2-hexanone were isolated by collecting the analytical HPLC 
eluent. These purified peaks were then analysed by high-resolution MS. The 4-HPA 
product was verified as the expected product ([HRMS ES+] found [M+H]+ 286.1457, 
C17H20NO3 requires 286.1443). The 2-hexanone product HRMS data was not 
satisfactory because only very low concentrations of the product were available. 
However, the m/z value strongly indicated the product was the expected product 
([HRMS ES+] found [M+H]+ 236.1245, C14H22NO2 requires 236.1651). Overall, this MS 
data verified that TfNCS is capable of forming 1,1-disubstituted-THIQs via a Pictet-
Spengler reaction with dopamine and a ketone. 
6.6.5 Mutant screen 
The range of ketone substrates that could be accepted by NCS was probed (Fig. 6.30). 
All available NCS mutants were screened for activity with dopamine and four different 
ketones. 4-HPA and 2-hexanone, with which activity had already been verified, were 
screened. The α-ketoacid α-ketoglutarate (α-KG) was examined—NCS activity had 
been observed for the α-ketoacid 3-hydroxyphenylpyruvic acid25,46 and 1-carboxylic 
acid THIQs were historically proposed as key intermediates in BIA synthesis.207,208 
Cyclohexanone (CH) was investigated as representative cyclic ketone. The screen was 
conducted using clarified cell lysate, 10% v.v-1 DMSO, excess dopamine and analysis 
by HPLC. 
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Fig. 6.30 Ketones screened with all NCS mutants. 
Conversions (with verified HPLC peaks) were observed with both 4-HPA and 2-
hexanone, with the greatest turnover demonstrated by mutants A79I and M97F 
respectively (Fig. 6.31). Activity was observed with α-KG, again with A79I and M97F 
showing the highest conversions. Conversions with CH appeared to be very high—
analysis of dopamine concentrations suggested conversions were greater than 80% 
(for WT TfNCS). It is important to note that the product peak for α-KG has to date not 
been verified by MS or NMR. The identity of the CH product has since been verified by 
MS (see section 6.6.9 below) but its retention time has not yet been confirmed. These 
are priorities for future work. 
The behaviour of different mutants in these ketone substrate screens provides some 
interesting information regarding NCS. It is clear than CjNCS2 cannot turnover 
ketones; this is consistent with previous substrate screens.57 The mutant F112L (not 
previously examined) had 10-20% activity of WT for all substrates. This showed Phe-
112 is important for activity—probably for controlling the position and pKa of Lys-122—
but it is not necessary for the enzyme reaction to occur. Improvement of activities with 
the mutation A79I has been observed previously and seemed to impact a variety of 
substrates (section 4.3.8). The reduction in activities with the L76A mutation is perhaps 
greater than would be expected based on previous work (section 4.3.7). The Met-97 
mutants have not previously been tested; here for 4-HPA, 2-hexanone and α-KG they 
show the same trend, with activities increasing from M97V to L to F, with M97F having 
greater activities than WT. For CH this trend was not observed and M97L activity was 
equal to WT, with M97F and M97V showing lower conversions. The CH conversions 
have relatively high background reactions, so activities observed for mutants that are 
typically inactive (i.e. the K122 mutants), may not be a real enzymatic effect. 
Mutants that appeared to demonstrate good conversions with ketones were then 
examined with a greater range of substrates.   
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Fig. 6.31 Mutant ketone screen. Conditions: Dopamine 15 mM, ketones 10 mM, 45% v.v
-1
 lysate, 10% 
v.v
-1
 DMSO, 3 h, 37 °C. 4-HPA: 4-hydroxyphenylacetone, CH: cyclohexanone, α-KG: α-ketoglutarate. 
Solid bars are product peak areas. For 4-HPA and 2-hexanone peaks were verified by mass spec. For CH 
and α-KG peaks are not verified. For CH plot, crosses show consumption of dopamine. AltNCS is WT 
Δ29TfNCS without C-terminus His-tag used in crystallisation trials (pQR1855).  
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6.6.6 Alkyl ketones 
NCS activity with the alkyl ketone 2-hexanone had been partially verified by MS 
analysis. The screen showed that a number of mutants had greater activity for 2-
hexanone than WT, in particular A79I, F80L and M97F. A variety of alkyl ketones with 
different chain lengths were then investigated (Fig. 6.32).  
 
Fig. 6.32 Alkyl ketones examined. 
Alkyl methyl ketones of C3, C4, C5, C6, C7 and C10 length were examined. Activity was 
observed for all of these compounds except for acetone, the most volatile (Fig. 6.33). 
The mutant A79F showed highest conversions at short chain lengths, and this seemed 
to decrease as chain length increased. The mutants A79I and F80L showed the 
opposite trend: increased conversions as chain length increased (up to C7, 2-
heptanone). These trends seem to correspond with increasing or decreasing bulk at 
the active site entrance to compensate for the substrate chain length. When the ketone 
becomes 10 carbons long activity is reduced for all mutants, probably as the solubility 
of the ketone becomes very poor. It is unclear with the standard HPLC methods 
whether activity is present with acetone. No activity was observed with the symmetric 
3-pentanone, probably because the ketone functional group becomes more difficult to 
access due to increased bulk of the ethyl group rather than methyl substituent. 
In the previous screen the M97F mutant appeared to turnover 2-hexanone with the 
greatest efficiency. This result was not replicated in this screen; here M97F generally 
appeared to have poorer conversions than WT. The differences between these two 
screens may be due to the slightly different conditions: the concentration of lysate is 
halved and reaction times are extended. There may also be differences in expression 
levels of mutants between the two experiments. 
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Fig. 6.33 Alkyl ketones. Conditions: 20% v.v
-1
 lysate, 37 ˚C, 6 hours, 15mM dopa,10 mM ketone, 10% 
v.v
-1
 DMSO. All product peaks are unverified, except for 2-hexanone. No data present for L76V with 2-
heptanone. These products are expected to have similar absorbance coefficients so peak areas are 
comparable. 
6.6.7 Bulky ketones 
A variety of ketones with bulky cyclic R-groups were examined (Fig. 6.34). These 
included the phenyl methyl ketones phenylacetone (PA) and 4-hydroxyphenylacetone 
(4-HPA), the cyclo methyl ketones cyclohexylmethylketone (CHMK) and 
adamantylmethylketone, and the aromatic ketones acetophenone and propiophenone. 
No activities were observed with the conjugated ketones acetophone or 
propiophenone. For either substrates this is probably because of the increased stability 
of the ketone through conjugation, and for propiophenone the increased bulk of the 
ethyl adds another steric challenge for the enzyme. The adamantylmethylketone was 
not turned over by any enzyme, probably due to its extreme bulk, resultant steric 
clashes and inaccessibility of the ketone. 
 
Fig. 6.34 Bulky ketones examined. 
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Activity was previously observed and verified with 4-HPA and so it was not surprising 
that phenylacetone (PA), a very similar compound, is also turned over (Fig. 6.35A). 
Conversions were observed but were low with cyclohexylmethylketone (CHMK). The 
seemingly lower conversions were probably due to accessibility difficulties with the α-
substitution present (Fig. 6.35B). 
Compounds 4-HPA and PA showed highest conversions with A79I, around double the 
WT values. Variants A79I and A79F had slightly increased conversions for CHMK. 
Potential explantions for the improved activity with Ala-79 mutants can be found in 
section 4.4.3. Briefly, increased bulk in this position may prevent the intermediates 
leaving the active site and may also encourage the reaction intermediate to adopt 
conformations condusive to reaction progression. 
 
Fig. 6.35 A. Phenyl ketones. B. Cyclohexylmethylketone. Conditions: 20% v.v
-1
 lysate, 37 ˚C, 6 hours, 
15mM dopa,10 mM ketone, 10% v.v
-1
 DMSO. PA: phenylacetone, 4-HPA: 4-hydroxyphenylacetone, 
CHMK: cyclohexylmethylketone. All product peaks are unverified, except for 4-HPA. No data present for 
L76V and A79F with 4-HPA. Products in A are expected to have fairly similar absorbance coefficients so 
peak areas may be comparable. 
6.6.8 Cyclohexanones 
The high conversions observed for NCS with cyclohexanone (CH) was unexpected and 
rather remarkable considering that the cyclic ketone is structurally very different to the 
natural NCS 4-HPAA substrate. A variety of different substituted cyclohexanones and 
related compounds were investigated with a selection of mutants (Fig. 6.36). 
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Fig. 6.36 Cyclic ketones examined. 
The conversions with different cyclohexanone derivatives seemed to be influenced by 
the steric bulk of the substrate. Substituents in the 2-position were not accepted (e.g. 
tert-butyl or methyl), probably due to steric clashes. There was possibly a very small 
product peak with 2-methylcyclohexanone and A79I, but a larger peak would need to 
have been observed to give this observation any confidence. Substituents in the 3- and 
4- positions of cyclohexanone were generally accepted (Fig. 6.37), except when 
numerous substitutions were present (e.g. the trisubsituted 3,3,5-
trimethylcyclohexanone). The size of substituents in the 4 position seemed to slightly 
affect conversions, with the smaller methyl group substituent showing larger product 
peaks than the phenyl and tert-butyl groups. The 4-PhCH and 4-tBuCH substrates 
showed very similar conversions, but the 4-phenyl showed generally slightly larger 
peaks (though this could have been due to differences in absorbance). 
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Fig. 6.37 Cyclohexanones. Conditions: 20% v.v
-1
 lysate, 37 ˚C, 6 hours, 15mM dopa, 10 mM ketone, 
10% v.v
-1
 DMSO. CHCA: cyclohexanecarboxaldehyde, CP: cyclopropanone, CH: cyclohexanone, 3-
MeCH: 3-methylcyclohexanone, 4-MeCH: 4-methylcyclohexanone, 4-PhCH: 4-phenylcyclohexanone, 4-
tBuCH: 4-tert-butylcyclohexananonehydroxyphenylacetone. All product peaks are unverified, except for 
CHCA. No data present for M97F and M97L for 3-MeCH. Products are expected to have fairly similar 
absorbance coefficients so peak areas may be comparable. 
Cyclopropanone seemed to show considerably lower conversions than cyclohexanone. 
This was probably a general non-enzymatic feature of cyclic ketone reactivity. Attack of 
the ketone by a nucleophile and change of hybridisation from sp2 to sp3 will result in a 
change of the torsional strain in the ring. For the six membered ring, this strain change 
is favourable: in cyclohexanone the carbonyl is partially eclipsed with neighbouring 
hydrogens; after attack, all bonds can be in staggered arrangements. This is not the 
case for cyclopentanone, where the change in strain is unfavourable as bonds become 
more eclipsed upon attack (Fig. 6.38). 
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Fig. 6.38 Reactivity of cyclic ketones.  
The effects of mutations on the conversion of cyclohexanone derivatives were fairly 
general: A79F and A79I tended to show increased conversion compared to WT. 
Deviations from this were observed for 4-tBuCH, where L76V showed equally high 
conversions as A79F. For 4-MeCH, F80L seemed to be the best performing mutant. 
The origin of these improvements was probably shape complementarity between the 
substrate and active site binding region. 
 
Fig. 6.39 Enones examined 
The cyclic enones cyclohexenone and isophorone were investigated and neither 
appeared to be turned over by NCS. There were some small extra peaks present with 
2-cyclohexen-1-one with the mutants A79F and A79I but these were too small to 
indicate conversion with any confidence. The lack of activity with these compounds 
was likely to be due to their reduced reactivity caused by the conjugated system 
present.  
6.6.9 Biotransformations 
Larger scale biotransformations were conducted for selected substituted 
cyclohexanones and Δ29TfNCS mutants. The aim was to purify and fully characterise 
the spiro-products. Based on the screening data, substituted cyclohexanones and 
mutants selected were: CH (A79F), 4-tBuCH (A79F), 4-PhCH (A79I), 4-MeCH (A79F), 
CP (A79F), 4-HPA (A79I) and 3-MeCH (A79F). The biotransformations reactions were 
performed in a volume of 5 mL, with 50 mM HEPES pH 7.5, 20% v.v-1 clarified, filtered 
lysate, 5 mM ascorbate, 10 mM ketone, 15 mM dopamine and 10% v.v-1 DMSO. The 
reactions were incubated for 6 hours at 37 ˚C. At this point the samples were frozen 
until further processing. 
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Previously, preparative-HPLC was used to purify biotransformation products. However, 
preparative-HPLC is not especially convenient for large scale reactions, and alternative 
purification methods were explored. Recent work described that at around pH 7 it may 
be possible to extract THIQ products into ethyl acetate whilst leaving excess dopamine 
in the aqueous phase.60 This extraction method was attempted with the cyclohexanone 
reaction. The THIQ product successfully extracted into the ethyl acetate, and all 
dopamine remained in the aqueous layer. A number of brine washes were required to 
remove protein and other cell debris from the organic layer. However, upon removal of 
the solvent, the product was not sufficiently pure—the yield was calculated to be over 
100%, and proton NMR verified impurities were present. High resolution mass spec 
analysis verified that the expected product was present ([HRMS ES+] found [M+H]+ 
234.1497. C14H20NO2 requires 234.1494). In subsequent attempts to purify THIQs in 
this manner, significant amounts of the ketone starting material were found to co-purify 
with the THIQs product. When extracting into ethyl acetate, any remaining ketone (or 
aldehyde) will move into the organic solvent along with the product. Thus, this method 
is only appropriate when 100% conversion is known to have occurred. 
A second extraction step was added to the procedure to remove ketones. After removal 
of the ethyl acetate, the material was resuspended in a 1:1 mixture of dichloromethane 
and 0.1 M HCl. The acid conditions protonated the THIQ. The charged THIQ 
partitioned with the aqueous phase whilst the neutral ketone remained in the DCM. 
After washing the DCM with more dilute HCl, the aqueous layers were combined and 
water was removed, initially by rotary evaporation and the last few millilitres by freeze 
drying (this prevented overheating of the product). The compounds purified by this 
method were obtained as hydrochloride salts and were pure (as analysed by NMR). 
The purified yields were reasonable, ranging from 33-60% for four different 
compounds. The range was perhaps related to slight variations in the extraction 
procedures, or the pKas of the products. The conversion yields for these reactions are 
presently unknown.  
The establishment of this purification method is significant as it should be general to 
most NCS reactions: typically a primary amine combines with a neutral 
ketone/aldehyde to form a secondary amine. It will allow the scale up of reactions and 
remove the requirement for preparative-HPLC purification. There is also scope for 
improving the method further, for example more concentrated acid can be used to 
ensure full protonation of the THIQs. Also, it is probably possible to acidify the ethyl 
acetate directly, protonating the THIQ at this earlier stage. This would forgo an 
evaporation step. It may be apposite to add a third final extraction step: basifying the 
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aqueous layer and neutralising the THIQ, moving it back into a low-boiling point organic 
solvent. Removing organic solvent by evaporation to yield the product would be quicker 
and more energy efficient than removing water. It is worth noting that these acid-base 
extraction procedures are classic methods for extracting and purifying alkaloids from 
natural sources. 
6.6.10 Spiro-THIQs 
Four novel cyclohexane-spiro-THIQ products have been purified using the extraction 
method. They have been characterised by 1H and 13C NMR, and high-resolution mass 
spectrometry has also confirmed their elemental identity (see methods section 2.6.3  
and appendix B, section 9.2). Typically, five characterisation methods are required for 
novel compounds, therefore melting points, infra-red absorbance spectra and/or 
retention times/Rf-values will be measured for these compounds to complete their 
characterisation. 
Three of the four compounds purified by this method are symmetric and non-chiral. 
They each have a substituent on the 4-cyclohexane position (Fig. 6.40). 
 
Fig. 6.40 Synthesis of 4’-substituted-spiro-cyclohexane-1,1-THIQs. Reaction conditions: 50 mM 
HEPES pH 7.5, 20% v.v
-1
 filtered lysate, 5 mM ascorbate, 10 mM ketone, 15 mM dopamine and 10% v.v
-1
 
DMSO. The reactions were incubated for 6 hours at 37 ˚C. Purification was achieved by organic then acid 
extraction. See methods section 2.6.3 for more details. 
Though these compounds are not chiral, the 4’ position on these compounds is a 
stereocentre. This stereoisomerism arises due to the configuration of the 4’ substituent 
relative to the THIQ moiety. Although the reaction could theoretically provide either 
stereoisomer, the outcome has a significant steric consequence. When depicted in 
three dimensions it is possible to see that, assuming the cyclohexane is in a chair 
conformation, the 4’ substituent can either be in an axial or equatorial position. 
Theoretically the spiro-fused ring system can ring-flip, changing the axial/equatorial 
distribution, but one conformation seems much more favourable (Fig. 6.41). The 4’ 
substituent is expected to favour an equatorial position due to steric effects. 
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Fig. 6.41 Conformations of cyclohexane-spiro-THIQ. The two ring-flip conformations that can be 
occupied by spiro-THIQs. The axial/equatorial positions of 4’-substitutents are depicted (R1/R2). The LHS 
conformation is expected to be favoured as it has fewer steric clashes. The RHS conformation has 
considerable steric clashes, shown circled. For 4’-substituents the LHS R1 equatorial position/conformation 
is most favoured. 
The predicted stereochemical and conformational outcome of these reactions was 
confirmed by NMR spectroscopy—all three products had purely equatorial 4’-
substituents. The crucial NMR experiment for assigning the configuration was nuclear 
Overhauser effect spectroscopy (NOESY), which identified the relative position of 
protons through space (Fig. 6.42). NOESY correlations between the isoquinoline 
aromatic proton (Hb) and cyclohexane protons (Hf) verified the dominant conformation 
of the molecules. The correlations from the 4’ R-group to adjacent protons confirmed 
the equatorial position. 
 
Fig. 6.42 NOESY correlations. These interactions verified the equatorial conformation of the 4’-
subsituent. Due to the plane of symmetry through the cyclohexane ring, not all protons are depicted. If the 
4’ substituents were axial, then correlations between the 4’ R-groups and Hf would be expected: these are 
not observed. Furthermore, correlations between the 4’ R-groups and Hg would not be present if the 
substituent was axial. Arrowheads show the directionality of the correlation; correlations with the tBu group 
could only be confirmed in one direction. For complete 
1
H and 
13
C NMR assignment see methods section 
2.6.3 and for NMR spectra see appendix B section 9.2. 
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6.6.11 3-Methylcyclohexanone 
A reaction was conducted with A79F-Δ29TfNCS lysate, dopamine and racemic 3-
methylcyclohexanone (Fig. 6.44). In a similar manner to the 4-subsituted 
cyclohexanones, the most sterically favoured product would have an equatorial 
configuration. However, because the starting material is chiral, but used as a racemate, 
there are four possible products. If the substituent is in an equatorial position, then two 
possible enantiomers can be formed (Fig. 6.43). These enantiomers have two chiral 
centres, the 3’-centre defined by the starting material and a new centre at the 1-
position. If the yield is over 50% then the enzyme must accept both enantiomers of 3-
methylcyclohexanone, though it is possible one may be more favoured than the other. 
The nature of the products formed is determined by the whether the 1-position or the 
3’-position dictates the reaction progression. If the 1-position dominates (i.e. through 
enzyme control—only the (1S)-THIQ is formed) then the two products will not be 
enantiomers, but diastereomers. One of these will have an axial methyl group. If the 3’-
position defines the reaction progress (i.e. through substrate/steric control) then the 
products will be enantiomers and the enzyme will produce both an (S)-isoquinoline and 
a (R)-isoquinoline in one reaction. 
 
Fig. 6.43 Rac-3-Methylcyclohexananone products. If the more sterically favoured equatorial products 
are formed (substrate/steric control), two enantiomeric products may be produced. If ‘enzyme control’ 
dominates, and the 1-position controls the reaction, then (R)-3-methyl-cyclohexananone would form a 
product with an axial substituent. 
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The product was obtained with a purified yield of 60%, showing that both 3-
methylcyclohexanone enantiomers are accepted (Fig. 6.44). NMR analysis showed 
only a single compound was formed, suggesting two enantiomers are formed.  
  
Fig. 6.44 3’-Methylcyclohexane-spiro-THIQ formation. Reaction conditions: 50 mM HEPES pH 7.5, 
20% v.v
-1
 A79F-Δ29TfNCS lysate, 5 mM ascorbate, 10 mM ketone, 15 mM dopamine and 10% v.v
-1
 
DMSO. The reactions were incubated for 6 hours at 37 ˚C. Purification was achieved by organic then acid 
extraction. Product mass was confirmed by HRMS. For more details see methods section 2.6.3 and for 
NMR spectra see Appendix B section 9.2. 
The NMR spectra were fully assigned, and this confirmed the identity of the 
enantiomeric 3’-methyl equatorial product(s). Again, the NOESY was vital in confirming 
the identity of the compound (Fig. 6.45). 
 
Fig. 6.45 NOESY correlations. Solid lines (LHS) show strong correlations, dotted lines (RHS) show 
weaker correlations. There is probably correlation between Hg and Hk but signals are very close so appear 
positive on spectra (correlations are typically negative). Due to similar shifts, it is also difficult to distinguish 
between Hf and Hk, so some correlations could not be assigned. Arrowheads show the directionality of the 
correlation; correlations with the Me group are only described in one direction. Crucially, no evidence of 
correlation is observed between the 3’-methyl and Hn, Hm, Hl or Hk, which would be present if the 3’-methyl 
group was positioned axially. For more details and NMR assignments see Methods section 2.6.3 and for 
NMR spectra and more detailed assignments see Appendix B section 9.2. 
 
The relative proportions of the (1S,3’S) and (1R,3’R) products are unknown, and it is 
possible the enzyme prefers one 3-methylcyclohexanone enantiomer over another. 
This distribution could be investigated with chiral HPLC or derivitisation of the products. 
Comparing this racemic reaction with an enantiomerically pure 3-methylcyclohexanone 
reaction would also be informative.  
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This reaction is notable for being the first demonstration of the formation of a (1R)-
isoquinoline by NCS, though admittedly this is more a quirk of nomenclature than a 
novel reaction. Nevertheless, the fact that these equatorial products are formed shows 
that, with respect to stereochemistry, these substituted cyclohexanone reactions seem 
to be mostly controlled by substrates/sterics than the enzyme. 
6.6.12 Docking studies 
Preliminary computational docking studies into the cyclohexanone reactions have been 
conducted in order to understand how the substrates may fit into the NCS active site. 
So far, only the 4-tert-butylcyclohexanane-iminium intermediate has been investigated. 
The most favourable binding modes for this compound fit precisely with the expected 
conformation according to previous docking studies and the dopamine-first mechanism 
(Fig. 6.46) (see section 4.2.2). The intermediate binds in a dopamine-first conformation, 
with the catechol bound to the Lys-122. The iminium is in a trans configuration, with the 
nitrogen near Tyr-108 and Glu-110. The cyclohexane is in a chair conformation, with 
the tert-butyl group equatorial, and points directly out the active site.    
 
Fig. 6.46 4-Tert-butylcyclohexane-dopamine iminium docking. The imine intermediate of dopamine/4-
tBucyclohexanone docked in TfNCS active site (see methods section 2.2.3). This is the most energetically 
favourable binding mode. The nitrogen is in close proximity to Tyr-108 and Glu-110, as predicted by the 
dopamine-first mechanism (see section 4.2.2). 
Here it appears that the alternative axial conformation of the tert-butyl group would not 
be tolerated—it seems, therefore, that the general chemical sterics of the reaction 
match the enzyme steric requirements. This model also shows how substitutions on the 
cyclohexane 2-position would be sterically unflavoured in the context of the enzyme. 
This matches experimental observation (section 6.6.8). Similarly, the origin of the 
failure to convert 3,3,5,trimethyl-cyclohexanone seems clear—an axial methyl group on 
the 3-position would be sterically unflavoured. 
A B
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There appear to be relatively close interactions between residues at the active site 
entrance and cyclohexanone: Leu-76, Ala-79 and Phe-80. These residues were 
targeted in the past for modification of aldehyde substrate specificity. The mutations 
A79I, A79F and F80L had a positive impact on conversions with cyclohexanone (Fig. 
6.37); though data was not normalised to protein concentration. It is possible that these 
mutations modify the shape of the cyclohexanone binding site, increasing shape 
complementarity. Nevertheless, it does seem counter-intuitive that increasing bulk at 
the active site entrance (A79F/I) can have a positive impact for bulky substrates such 
as 4-phenyl- or 4-tert-butylcyclohexanone as docking seems to show there is no space 
for the larger amino acid side chains. It is possible to account for increased activities by 
proposing that the bulky residues do not contribute to the initial ketone binding but to 
the subsequent reaction progression. The increased bulk could stabilise conformations 
of the imine intermediate that enable the crucial cyclisation step. This hypothesis is 
discussed  in section 4.4.3.  
The A79I mutation was originally designed as CjNCS2 has an isoleucine in position 79. 
Yet, in TfNCS A79I appears to improve conversions with cyclohexanones whilst 
CjNCS2 has no activity with ketones at all. The difference in activity is possibly the 
arrangements of loops around the active site entrance. Although there is generally 
strong sequence identity between CjNCS2 and TfNCS, there is some variation on the 
make-up of loops, especially the positions of proline residues. These could severely 
affect the active site entrance interactions, removing promiscuous activities to ketones. 
An alternate explanation would be that the catalytic machinery in CjNCS2 is somehow 
‘weaker’ and it cannot react with the more stable ketones, regardless of the initial 
binding. Modelling the CjNCS2 active site would greatly aid understanding of why the 
similar enzymes behave so differently. 
6.6.13 The origin of activity with ketones 
Aside from the differences between the two NCSs tested, the other key unknowns are 
the effect that the organic co-solvent has on the reaction, and the preference for lysate 
rather than pure enzyme. The reaction appears to proceed efficiently with 10% v.v-1 
DMSO, but does not proceed with 10% v.v-1 MeCN. There are two possible origins to 
this observation. The co-solvent may affect the formation of the imine intermediate 
outside the active site, or it may alter the activity of the enzyme itself. Recent work on 
Δ29CjNCS2 also described the positive effect of DMSO on reaction conversions, 
though this was for aldehydes and pure enzyme, rather than ketones and lysate.61 
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The PS reaction can be split into two parts: imine formation and cyclisation. For 
ketones, imine formation may be possible outside the enzyme active site, but the lack 
of reaction with the phosphate buffer catalyst suggests that cyclisation is definitely not 
possible outside the enzyme active site. It is known that the co-solvent can significantly 
affect imine formation in aqueous media. In a study of the related Mannich reaction 
between an amine, formaldehyde and butyraldehyde, it was found that DMF and 
DMSO were the best co-solvents due to their ‘homogenising’ effect.209 Higher 
concentrations of these solvents provided improved rates. In a similar study of aqueous 
imine (and enamine) formation via a fluorescent reaction reporter, DMSO and DMF 
were again found to be most effective co-solvents. MeCN demonstrated far inferior 
rates.210 A related hypothesis for NCS is that the presence of DMSO (rather than 
MeCN) dramatically shifts changes the equilibrium between amine/ketone, imine and 
enamine enabling enzymatic reaction progression.  
The effect of organic solvents on enzyme activity is widely acknowledged: stability, 
rate, stereo-selectivity and regio-selectivity can be modified positively with the addition 
of organic solvents.211 There is a particular precedent for the action of DMSO on 
enzymes. For lysozyme, the addition of small quantities of DMSO (<5% v.v-1) increases 
the rigidity of the enzyme, reducing non-productive conformations and increasing the 
rate.212 DMSO has also been shown to improve the enantioselectivity of some 
lipases.213 The co-solvent may be affecting the NCS structure enabling it to catalyse 
the formation of more challenging (both sterically and energetically) products. 
The results have some implication regarding NCS in plant metabolism. The enzyme 
appears to demonstrate significant promiscuity with respect to its substrate. The 
observed activity with ketones does not quite qualify as catalytic promiscuity as the 
reaction has not changed. However, turning over ketones is certainly more 
energetically demanding than aldehydes; this is demonstrated by the fact that the 
phosphate cannot catalyse this reaction but turns over aldehydes. The observed 
activity with ketones is not merely substrate promiscuity, which is generally based on 
steric and not energetic requirements.214 It is interesting that the enzyme seems to 
have ‘extra’ catalytic ability compared to its natural reaction, as it may be expected that 
evolution would maintain only the necessary catalytic power in the enzyme. The ketone 
reactivity does not necessarily co-evolve with aldehyde reactivity, as demonstrated by 
CjNCS2. It is not known whether the conditions in plant vacuoles, where NCS is 
expected to reside, are condusive to the ketone activity, or whether this activity is only 
revealed in vitro. However, the promiscuity of the enzyme may explain partially why 
conversions of 4-hydroxyphenylpyruvate were previously observed with NCS 
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enzymes,25,46 and why 1-carboxylic 1,1-disubstituted THIQs were observed in plant 
extracts and believed to be BIA precursors.207,208 
6.6.14 Future work 
The ability of NCS to turn over ketones and form 1,1-disubstituted-THIQs is 
remarkable, but more data is required to complete the investigation. The products of 
the reactions with the ketones cyclohexanone, cyclopentanone, phenylacetone, 4-
hydroxyphenylacetone and 4-methyoxyphenylacetone will be purified and 
characterised, using the extraction method described above. The products of the α-
keto-acids 4-hydroxyphenylpyruvate, phenylpyruvate and 4-methyoxyphenylpyruvate 
will also be purified and characterised, though these compounds will exist as 
zwitterions so may not purify using organic extraction methods; preparative-HPLC may 
be used instead. Purification of the (R)-3-methylcyclohexanone product will provide an 
interesting comparison with the racemate. Enzymatic conversion data for these 
reactions will be measured by calculating dopamine consumption via HPLC: samples 
have been saved for this analysis. This will also give a good indication of the efficiency 
of the purification procedure. 
The stereochemical characteristics of the methyl ketone reactions are unknown. Once 
obtained and purified, the products will be analysed by chiral-HPLC to determine their 
enantiomeric excess. The reactions with methyl ketones could also be performed with 
a chiral arylethylamines, such as metaraminol or L-DOPA, causing formation of a 
diastereomeric product which can be analysed via NMR. However, NCS activities are 
low for these substituted amines. So far the purified compounds are all solids: it may be 
possible to obtain a crystal structure of a compound, which will enable the assignment 
of an enantiomeric product without the requirement to form a diastereomer. 
Conversions with aliphatic methyl ketones are currently insufficient for product 
purification and characterisation. Conditions producing higher quantities of product will 
be determined prior to preparative scale reactions. 
As described above (section 6.6.2), it may be possible to access natural BIA subgroups 
with a ketone PS reaction, catalysed by NCS. The spiro-BIAs and erythrina alkaloids 
may be accessed with 2-indanones or 2-substituted cyclohexanones respectively. 
Presently there is no evidence for successful activity with 2-indanone or 2-substituted 
cyclohexanones, but similar ketones such as cyclopentanone and 3-substituted 
cyclohexanones show turnover. Targeted mutations of NCS may enable modification of 
substrate tolerance and allow access to the more challenging cyclic ketones, eventually 
providing a ‘metabolic short-cut’ to the spiro-BIAs and erythrina alkaloids. 
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6.7 Conclusion 
NCS is an excellent candidate for directed evolution but unfortunately no reliable high-
throughput method has been established for rapid screening. The high background 
reaction, instability of the aldehyde substrates and variety of possible products formed 
by the enzyme has proved problematic in the formation of such a method. The 
fluorescamine screen remains the most reliable but is not ideal for lysate screens or 
variable protein concentrations. The method that has proved most fruitful for screening 
NCS activities has been HPLC analysis. This is the most sensitive method and will 
produce fewer false positives or negatives than more rapid methods. It enabled the 
identification of activities with α-substituted aldehydes and ketones, activities which 
were largely undetected by other methods. 
Directed evolution benefits not just from rapid screening methods but also from the use 
of small, smart libraries.109 The knowledge of the enzyme mechanism enables design 
of combinatorial rational mutation libraries specifically targeting particular enzyme 
activities.215,216 These smaller libraries require less screening effort and so lower-
throughput, more sensitive methods like HPLC can be used. 
The identification of activities with ketones demonstrates the potential of the NCS for 
the synthesis of more diverse isoquinolines. Mutations with improved activities towards 
unusual substrates have already been identified. Directed evolution could improve 
these activities further. Another excellent target for directed evolution is the kinetic 
parameters of NCS for its natural substrates. NCS appears to have fairly low catalytic 
efficiency (see section 4.4.6); an improved NCS would be useful for biocatalytic and 
synthetic biology routes to THIQs. Ultimately a toolkit of NCSs, each a specialist at a 
particular PS THIQ reaction, could be produced through multiple directed evolution 
experiments. 
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 Chapter 7: Conclusion and future work 7
7.1 Mechanism and kinetics 
7.1.1 Dopamine-first mechanism 
The overall aim of the project was to explore the use of NCS for biocatalysis. The first 
step was to confirm the mechanism of the enzyme; this would provide a starting point 
for future enzyme engineering. Computational and experimental data collected during 
this study have provided considerable evidence in favour of the dopamine-first 
mechanism for NCS (Chapter 4). Roles have been proposed for catalytic residues in 
the enzyme active site, and the positions of the substrate binding sites have been 
established. The successful rational engineering of the aldehyde substrate profile 
demonstrated the veracity of the dopamine-first mechanism. Based on all current 
understanding, a detailed mechanism for NCS has been proposed (Fig. 4.38). 
7.1.2 Kinetics 
There have been considerable challenges in achieving a full understanding of NCS 
reaction kinetics, but some progress has been made (section 4.4.5). A new method for 
measuring kinetics was developed which avoided problems associated with 
incompatible buffers. Based on this method, it has been possible to compare the 
kinetics of different mutants and substrate combinations, though it has not always been 
possible to fully rationalise the observed effects. The presence of an organic co-solvent 
in the enzyme assays may also have affected the kinetic parameters calculated. 
The apparent kinetic parameters derived from this work describe an enzyme which 
requires high substrate concentrations (very high apparent Km values) to achieve high 
turnovers. It is possible that in vivo this sensitivity acts as a gatekeeper into BIA 
biosynthesis: only when there is high substrate concentrations are present will 
metabolic flux be diverted into this secondary metabolism pathway. This could prevent 
energy/material from being misdirected in the plant metabolism. The high apparent Km 
values may also have impacted efforts to use NCS in microbial systems, though recent 
work has shown this in vivo activity is possible.21,45,76 The kinetic assays were found to 
be extremely sensitive to substrate concentrations, mostly because of the non-
enzymatic background reaction. Despite the effort made to establish a good method, 
ultimately significant compromises were made. Overall it has not been possible to 
obtain a satisfactory understanding of the enzyme kinetics. 
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7.1.3 Future work 
Most work on the NCS mechanism, kinetics and structure has been conducted with 
TfNCS. It would be interesting to examine other NCSs and see how they compare. In 
the final section of this study it was shown that TfNCS and CjNCS2 have considerably 
different substrate tolerances (section 6.6.5); the origin of these differences could be 
examined. There has also been recent work showing significant differences in the in 
vivo activities of different NCSs.76 This may be due to their kinetics—perhaps only 
TfNCS is ‘inefficient’, the other NCSs may have different kinetic properties. 
The complete exploration of NCS kinetics is ultimately very important to fully 
understand the enzyme mechanism. However, the system is not easy to control, and 
there are many factors to deconvolute. Perhaps first, a kinetic understanding of the 
chemical phosphate catalysed PS reaction is necessary before tackling the enzyme 
kinetics. Also, before the complex kinetics is examined, there are many basic questions 
to be answered about the enzyme mechanism, especially regarding the steps lead to 
the formation of the imine. 
A structural examination of NCS and its mutants would significantly aid any further 
investigation into the enzyme mechanism and would also be invaluable for enzyme 
engineering efforts. Currently, the effort to establish NCS crystallisation conditions for 
X-ray structural analysis has not yielded fruit, but for now this work is continuing. It is 
hoped that a new structure would correct some ambiguities in the previous structure, 
such as the orientation of Phe-112. An NMR structural investigation would also provide 
interesting data to this regard, but NMR studies require significant time and resources 
to establish.  
It may even be possible to examine NCS using a biophysical method, such as intrinsic 
tryptophan fluorescence. There is tryptophan in within 7 Å to the interesting Phe-112 
and Lys-122 residues. Once other tryptophans (and perhaps tyrosines) are removed by 
mutation, it may be possible to track the movement of Phe-112 and substrate binding 
through changes to tryptophan fluorescence in single molecule experiments. This 
would provide a dynamic picture of NCS. 
Finally, there is still much to understand about in planta NCS behaviour. The full 
functions of the N- and C-termini are unknown (section 3.6). Furthermore, there is the 
intruiging possibility of functional aggregated NCS inside plant cells. There are also 
experiments that can be done to examine the hypothesis that NCS is inefficient due to 
metabolic flux control. 
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7.2 Biotransformations and cascades 
7.2.1 Biotransformation methods 
Methods for biotranformation procedures using NCS have been improved over the 
course of the project. Significantly, (desalted) lysate was shown to be a suitable 
method of enzyme preparation, despite the background reaction. The first use of 
mutants for biotransformations was also demonstrated. Despite this, most NCS 
biotransformations demonstrated in this project were not superior to previous 
examples. The use of preparative-HPLC was not ideal for the purification of products 
from larger scale  conversion (>100 mg), and concentrations of substrates used are far 
too low for any industrially relevant transformations. 
However, the biotransformations conducted with substituted cyclohexanones have led 
to significant improvements in biotransformation methodology (section 6.6.9). The 
adoption of the anti-oxidant ascorbate, use of excess dopamine and development of an 
extraction method has led to a cleaner, quicker and more scalable biotransformation 
protocol. The use of ketone substrates, which do not suffer from the background 
reaction, will enable much higher substrate concentrations in the future. 
7.2.2 Triangular cascade 
A multi-enzyme cascade was developed for the synthesis of (S)-norlaudanosoline and 
an (S)-tetrahydroprotoberberine (section 5.4). During the optimisation of the cascade, 
seven previously unreported transaminases were examined.  The one-substrate, two-
enzyme, one-pot ‘triangular’ arrangement was a novel method to pull the TAm 
equilibrium reactions to completion. Overall, with the additional formaldehyde chemical 
step, these cascades demonstrate a remarkable increase in molecular complexity over 
a short time: one chiral centre, two C-N bonds and two C-C bonds can be formed 
within about 3 hours. 
7.2.3 Future work 
Although the triangular cascade is limited with regards to its substrate/product scope, 
there is potential for scaling the reaction. Conditions can be modified to improve the 
regioselectivity of the final step. The newly developed extraction protocol can be used 
for product purification, rather than preparative-HPLC. 
The extension of the cascade reaction that can be worked on as soon as possible is 
the use of different aldehydes in the final chemical step. This will increases the possible 
range of products significantly. The stereocentre set by NCS could influence the 
subsequent PS reaction, resulting in products with two chiral centres.  
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There are many more enzymes that can be use with NCS to build cascades both in 
vitro and in vivo. For example, a different TAm can be used, which does not turn over 
dopamine—this will allow the use of two different amines as starting materials for 
THIQs. Other enzymes that form aldehydes can be explored: alcohol dehydrogenase, 
carboxylic acid reductase, etc. Enzyme can be used to form dopamine (e.g. tyrosinase 
and decarboxylase) and can be used to modify the THIQ product (e.g. CYPs). The 
newly discovered NCS ketone/cyclohexanone activity could be combined with enone 
reductases.  
The incorporation of the complete BIA pathway into microbes is currently a particularly 
exciting area, with significant progress being reported on an almost monthly basis.19–
21,45,65,76 However, biosynthetic pathways do not have to just be copied from a natural 
product producing organism into microbes. Instead, novel biosynthetic pathways can 
be constructed, using promiscuous enzymes from various sources. This will enable the 
production of novel and non-natural chemicals in vivo. 
7.3 Screens and substrates 
7.3.1 Screening methodology 
Screening methods were developed with the intention of using them for screening 
libraries of NCS mutants in an enzyme engineering/directed evolution effort. Although 
the fluorescamine screen for NCS activity had already been developed, it was not 
suitable for lysate or non-purified enzymes, so different methods were investigated. 
The investigation into Purpald® did not result in a good screening method. Aldehydes 
are readily consumed by native E. coli proteins so there is little reliability in detecting 
aldehyde concentration. Also, Purpald® was found to react with amines. Some 
improvements were made with regards to increasing the throughput, by using small 
cultures and nickel coated plates. Ultimately, however, no significantly improved 
method was developed. Ultimately, the low-throughput HPLC proved most useful 
screening activities.  
7.3.2 Screening results 
NCS activity was observed with a range of aliphatic aldehydes, which had not been 
investigated beforehand. Especially interesting was the activity with the citronellals. A 
number of mutants were found to have improved activities, including L76A for (S)-
citronellal and A79I for numerous aldehydes including the natural substrate. No 
activities were identified with N-alkyated amines. Furthermore, there was no success in 
the effort to switch enzyme regioselectivity. However, the double mutants F122K-
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K122F/L showed native activity, suggesting a certain robustness to the enzyme 
mechanism. Activities were observed with the α-substituted aldehydes 3-
hydroxybenzaldeyde, benzaldehyde and cyclohexanecarboxaldehyde.  
7.3.3 Ketones 
The identification of NCS activity with ketones is probably the most significant results of 
this entire project (section 6.6). It is especially remarkable how high the activities are 
with derivatives of cyclohexanone. Furthermore, there is considerable intrigue with 
regards to the solvent dependence of the reaction, and the lack of activity with CjNCS2. 
The novel spiro compounds generated are also of interest—there are very few 
methods to synthesise them. This discovery is of wide interest, with potential impact 
within enzymology, synthetic biology and chemistry. 
7.3.4 Future work 
Future screening and engineering is likely to use HPLC for maximum sensitivity. 
Although a rapid screening method is useful, if a relatively small number of mutations 
need to be screened, then sensitive methods are preferred. Mutations will be site 
directed, and informed by the dopamine-first mechanism and docking investigations. If 
directed evolution is to be attempted, libraries will be rationally designed, small and 
smart to maximise hits and minimise screening effort.109,111 
A toolkit of many different evolved NCSs can be generated, each specialising in a 
particular substrate. It may be worth evolving the seemingly catalytically inefficient 
enzyme towards improved kinetic parameters. Activities with aliphatic compounds and 
α-substituted compounds can be significantly improved. 
There is scope for considerable improvement in the use of ketone substrates. The 
aliphatic methyl ketones seem to have very poor yields—these can be improved 
through evolution. The products of these reactions are likely to be chiral: (1S)-1,1-
disubstituted-THIQs. This will be one of the only methods, chemical or enzymatic, for 
the formation of such compounds.156 Finally, other ketones currently not accepted by 
NCS may be accepted by evolved enzymes—finding an NCS that turns over the 2-
substituted cyclohexanones and/or 2-indanone will provide a metabolic short cut into 
the erythrina and spiro isoquinoline families (section 6.6.2). 
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7.4 Perspective 
Ultimately the project fulfilled its key objective: to improve the understanding of the 
NCS mechanism via mutation and then to use this knowledge to engineer the enzyme 
activity. This was most clearly achieved with the improved activity of L76A for (S)-
citronellal.137 The aim to explore the biocatalytic potential of the enzyme was also 
achieved, especially with the development of a novel triangular cascade method.161 
The most significant result of study was the observation and verification of NCS activity 
with ketones, in particular substituted cyclohexanones. Interestingly, in contrast to the 
project’s objective, the discovery of this activity was not a result of the mechanistic 
understanding of the enzyme. Instead, it was achieved through a mixture of chemical 
intuition (the ketone-aldehyde relationship), serendipity (the use of DMSO) and, 
perhaps most importantly, a willingness to ‘follow one’s nose’ (i.e. recognise promising 
preliminary results and follow them up). Many aspects of the ketone activities are 
completely unpredictable: the effect of the solvent, the preference for lysate, and the 
differences in activity between closely related enzymes.  
Why does the reaction occur? There is no clear evidence for these types of reactions 
occurring in plants. It appears, through the behaviour of NCS homologs, that the NCS 
ketone activity does not necessary co-evolve with the aldehyde activity. One would 
expect, through genetic drift, promiscuous reactions such as the ketone reaction to not 
occur. Though it is possible that the formation of 1,1-disubsituted-THIQs by NCS is a 
purely in vitro phenomenon, there are historic reports of 1-carboxylic acid THIQ 
derivatives in Papaver species.207,208 It is possible there are undiscovered 1,1-
disubsituted-THIQ natural products in Thalictrum flavum and other BIA producing 
species formed by NCS.  
NCS may also play a role in other biosynthetic pathways. CjNCS2 has been shown to 
turn over dihydrocinnamaldehyde, forming a THIQ similar to those on the biosynthetic 
pathway to colchicine.57,61 The Pictet-Spenglerases forming the ipecacuanha alkaloids 
remain unknown; an enzyme closely related to NCS could catalyse these reactions. 
The Pictet-Spengler reactions with dopamine form at least three branch points of plant 
secondary metabolism; all these pathways may have diverged from a Pictet-Spengler 
reaction producing various THIQ products, catalysed by a promiscuous NCS ancestor. 
Intriguingly, certain enzymes, especially those involved in secondary metabolism, may 
have evolved to be promiscuous. When a change in the (chemical) environment of an 
organism occurs, these promiscuous enzymes would be able to respond by producing 
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mixtures of novel compounds. If one of these compounds has a positive impact on 
survival, its formation would be selected for: enzyme expression would be upregulated 
and the enzymes would acquire ‘specialising’ mutations, increasing their catalytic 
efficiency. This is when the classical biosynthetic pathways would arise. Yet underlying 
these upregulated pathways, there may still remain low-level, plastic, promiscuous 
metabolic networks able to produce novel compounds in response to new 
environmental conditions.3 Regardless of specific evolutionary mechanism, there are 
certainly countless enzymes in secondary metabolism with promiscuous activities that 
have not yet been explored. 
As this work demonstrates, there are aspects of enzyme behaviour that are not easy to 
rationalise and certainly very difficult to predict. Despite this, there are bold efforts to 
design novel enzymes from scratch using computational methods.217,218 Typically, 
these designed proteins are inferior to extant enzymes and are considerably improved 
by directed evolution, thereby demonstrating both imperfect design methods and the 
blind power of evolution.219,220 An alternative approach to developing ‘new’ enzymes is 
to use a combination of chemical intuition and directed evolution.108 By exploiting the 
existing catalytic machinery in extant enzymes and harnessing the power of (directed) 
evolution, it is possible to develop enzymes with novel activities.221–223 This is similar to 
how nearly all enzymes have come into existence. This approach shows an 
appreciation that there remain significant mysteries in nature—unknowns in enzyme 
mechanism, promiscuity and evolution. By attempting to unravel these mysteries novel 
methods and materials for industrial biocatalysis and synthetic biology will be revealed.   
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 Appendix A: Molecular Dynamics 8
8.1 Introduction 
8.1.1 Protein dynamics 
In solution, proteins are dynamic structures: bonds stretch, surfaces are buffeted by 
solvent molecules, loops flex, side chains rotate and, in some cases, whole portions of 
a structure move relative to each other. Overall, these motions contribute enormously 
to the function of a protein, though there remains much debate about the exact roles 
motions play.233 On a very simplistic level, the overall conformation of an enzyme 
structure—its tertiary fold, secondary structures, side chains and loops—will determine 
its ability to both bind a substrate and catalyse a reaction. In some cases these two 
prerequisite events of catalysis may require different protein conformations.234 
By considering the vast possible structures an enzyme amino acid sequence can 
occupy it becomes immediately clear that only very few conformations would be 
conducive to substrate binding or catalysis. Therefore limiting the accessibility of non-
productive conformations (reducing conformational entropy) is vital for efficient 
catalysis.235 This is generally achieved by increasing the rigidity/stability of a productive 
conformation, or at least severely limiting the number of easily accessable protein 
conformations.146 By considering that impact of flexibility, stability and conformation in 
catalysis, the role of residues beyond the enzyme active site becomes clearer: 
generally, the active site conformation determines the catalysis, the overall fold 
determines the relative positions of the active site residues and amino acid networks 
control the exact conformations of the active site residues.236,237 Altogether the 
combination of these interactions result in an active enzyme. 
8.1.2 Molecular Dynamic Simulations 
The motions within proteins determine the major structural conformations and therefore 
activities; in turn, these motions will impact experimentally observable phenomena.  
Despite this, protein motions are very difficult to detect directly. This is partly due to the 
fact that most experimental techniques deal with ensemble measurements and not 
single molecules, but the small size- and time-scale of the changes also limits their 
detectability. Experimental methods such as NMR and single molecule FRET can 
detect exchange/motion between different protein conformations. 
Using computational simulations it is possible to ‘observe’ protein motions. Presently, 
computational simulations can offer hypotheses which can then be verified 
experimentally. Simulations can also be used to provide explanations for experimental 
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observations. The former hypothesis-generating approach is more scientifically 
rigorous and therefore preferable. 
All-atom molecular dynamics (MD) simulations are typically used to compute protein 
behaviour over a few hundred nanoseconds. This time period can detect fast motions 
such as bond fluctuations and sidechain conformations. It is also possible to observe 
coupled motions between residue networks and loops. Longer scale motions, such as 
conversions between secondary structures and motions between domains are typically 
of larger timescales so must be examined with coarse-grained models or a 
‘metadynamics’ type approach. 
8.1.3 NCS  
Norcoclaurine synthase (NCS) was considered a good candidate for MD simulations as 
it is a relatively small (21 kDa) single domain protein, with a high resolution crystal 
structure available.43 Despite the high-resolution of the crystal structure, there were 
concerns about the interdomain N-terminal interaction and the impact this may have on 
protein conformation. Furthermore, there appeared to be a difference in the active site 
conformation in the two protein subunits—the rotamer of the Phe-112 was different 
(see section 4.1.3). This rotamer was expected to have a significant knock-on effect on 
catalysis as it is adjacent to the vital Lys-122 residue. Docking studies, which proved 
vital for establishment of the dopamine-first mechanism for NCS, were severely 
affected by the Phe-112 conformation (section 4.2.2). In subunit A, where the Phe-112 
points into the active site, docking produced excellent data which enabled the 
establishment of the new mechanism. In subunit B the Phe-112 was modelled pointing 
away from the active site, in a seemingly non-favoured position (as determined by 
MOLPROBITY).121 The docking for subunit B, on the other hand, provided very 
different data—substrates, when bound, were very deep in the active site and in 
arrangements that did not appear conducive to catalysis. The active site cavity 
revealed by the Phe-112 rotameric configuration significantly modified the docking 
results. Finally, there was also the suggestion in the X-ray electron density that in 
subunit B the Phe-112 could be observed in two conformations, one similar to that in 
subunit A. 
These interesting observations, coupled to a general interest in protein motions and 
dynamics, led to the decision to conduct MD simulations for NCS. Of primary interest 
was the motion of Phe-112 in the active site. 
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8.2 Method 
8.2.1 Preparation of NCS 
The crystal structure of holo Δ19TfNCS (2VQ5) was selected in favour of the apo 
(2VNE) courtesy of its superior resolution (2.1 Å compared to 2.7 Å).43 The A and B 
subunits were separated into separate files. Water molecules, ions and ligands were 
removed from the structure. The N- and C-termini were truncated, with the protein 
starting at Ser-40 and ending at Lys-197. This ensured that only the main globular 
domain was observed in the simulations.  
8.2.2 MD Commands 
The commands for the MD simulations are described, numbered, below. The outputs 
for a single simulation of subunits A and B are described. The two other simulations for 
each subunit were conducted in an identical manner and provided similar results. 
1. pdb2gmx -f 2VQ5A.pdb -o 2VQ5Ap.pdb -water tip3p -forcefield charmm27 
Simulations were conducted in GROMACS using the CHARMM27 forcefield.116,117 
Enzyme protonation states were left unchanged: Glu-110 and Asp-141 were negatively 
charged and Lys-122 was positively charged. Although this may not be the catalytically 
active form of the enzyme, this is likely to a major form of the enzyme in solution and it 
is likely that this form of the enzyme binds the substrates. 
2. editconf -f 2VQ5Bp.pdb -o 2VQ5Bbox.pdb -c -d 1.0 -bt cubic 
The protein was centred in a cube and positioned at least 1.0 nm from the edge.  
3. genbox -cp 2VQ5Abox.pdb -cs spc216.gro -o 2VQ5Asolv.pdb -p topol.top 
The box was solvated with water. The Tip3p explicit water model was used for this as 
this is appropriate for use with CHARMM forcefields. 
4. grompp -f ions.mdp -c 2VQ5Asolv.pdb -p topol.top -o ions.tpr 
5. genion -s ions.tpr -o 2VQ5ions.pdb -p topol.top -pname NA -nname CL -np 8 
Counterions to the protein charge were added. In this instance sodium positive ions 
were added to counter the overall protein negative charge. Water molecules were 
replaced with the ions. 
6. grompp -f minim.mdp -c 2VQ5Aions.pdb -p topol.top -o em.tpr 
7. mdrun -v -deffnm em 
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Structures with solvent and ions were energy minimised. Minimisation was stopped 
once Fmax reduced below 250 (Table 8.1). 
Table 8.1 Energy minimisation output. 
 Subunit 
Potential 
Energy  
Max force     Norm of force     Steps 
A -6.49E+05 2.4399084e+02 (atom 310) 8.02E+00 2980 
B -6.50E+05 2.4718457e+02 (atom 310) 7.556655 3239 
 
8. grompp -f nvt.mdp -c em2.gro -p topol.top -o nvt.tpr 
9. mdrun -v -deffnm nvt 
NVT equilibration for 100 ps. This phase involves a constant Number of particles, 
Volume and Temperature. It is known as “isothermal-isochoric” or “canonical”. 
Temperature is expected to stabilise once equilibration is complete, which it was 
observed to do in all simulations (Table 8.2). 
Table 8.2 NVT equilibration output. 
Subunit 
 
Potential 
Energy 
(kJ/mol) 
Kinetic 
Energy 
(kJ/mol) 
Total 
Energy 
(kJ/mol) 
Temp 
(K) 
Pressure 
(bar) 
A 
Average -528020 103228 -424792 299.62 -791 
Err.Est. 370 76 450 0.22 15 
RMSD 5795.74 1200.11 6225.53 3.48335 345.121 
Tot-Drift 2331.66 506.323 2837.98 1.46961 110.578 
B 
Average -528932 103144 -425788 299.643 -768 
Err.Est. 390 68 460 0.2 13 
RMSD 5830.16 1218.17 6289.27 3.53893 330.21 
Tot-Drift 2512.69 429.182 2941.88 1.24682 76.8577 
 
10. grompp -f npt.mdp -c nvt.gro -p topol.top -o npt.tpr 
11. mdrun -v -deffnm npt 
NPT equilibration stabilises the pressure and the density of the system. Number of 
particles, Pressure and Temperature are kept constant in this step. It is known as the 
“isothermal-isobaric” ensemble. Similar to the NVT step, this was conducted with a 100 
ps simulation. The density was expected to converge on the value 1000 kg m-3, the 
experimental value for water. In all simulations this convergence was observed (Table 
8.3). 
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Table 8.3 NPT equilibration output. 
Subunit Energy 
Potential 
(kJ/mol) 
Kinetic 
(kJ/mol) 
Total 
(kJ/mol) 
Temp 
(K) 
Pressure 
(bar) 
Density 
(kg/m
3
) 
Volume 
(nm
3
) 
A 
Average -533970 103354 -430616 299.986 -0.79143 1005.13 415.737 
Err.Est. 64 24 74 0.071 3.1 0.38 0.16 
RMSD 797.369 460.299 904.811 1.33603 135.949 4.01689 1.7122 
Tot-Drift -261.715 4.77326 -256.943 0.013855 1.27769 2.3275 -0.99008 
B 
Average -534642 103220 -431422 299.865 4.39353 1005.03 415.435 
Err.Est. 110 16 110 0.047 5.8 0.39 0.17 
RMSD 835.758 469.415 950.211 1.3637 133.957 4.03061 1.71255 
Tot-Drift -253.287 -37.1174 -290.403 -0.10783 1.16311 1.33054 -0.5769 
 
12. gerun mdrun_mpi -deffnm md_100 -cpi -cpo -cpt 1 
Three 100 ns simulations were run for each subunit (Table 8.4). The overall 
computational efficiency for each simulation was 22 ns/day.  
Table 8.4 MD simulation output (100 ns). 
 Subunit 
 A B 
Energy Average Err.Est. Tot-Drift Average Err.Est. Tot-Drift 
Pressure (bar) 0.921108 0.13 0.407032 1.08316 0.09 -0.41284 
Potential (kJ/mol) -534699 14 26.7634 -535491 4.5 0.667088 
Total Energy (kJ/mol) -431341 15 31.0167 -432226 5.1 4.93421 
Temperature (K) 300 0.0035 0.012346 299.995 0.0026 0.012396 
Density (kg/m
3
) 1004.76 0.1 -0.39464 1004.66 0.014 0.065392 
Kinetic En. (kJ/mol) 103358 1.2 4.25354 103265 0.9 4.26691 
Constr. Rmsd 6.40E-11 6.40E-11 -3.84E-10 6.11E-11 6.10E-11 -3.67E-10 
Volume (nm
3
) 415.886 0.041 0.163388 415.584 0.006 -0.02689 
 
Post processing was performed to ensure protein was whole throughout the simulation, 
and in the centre of the simulation box. 
13. trjconv -s md_100.tpr -f md_100.xtc -o mdA_100A.xtc -pbc mol -center -ur 
compact -skip 10 
14. trjconv –s md_100.tpr –f mdA_100A.xtc –o mdA_100Bfit.xtc –fit rot+trans 
The “skip 10” command resulted in only one frame being obtained out of every ten. 
This made the output file a more manageable size, speeding up subsequent 
calculations and processes. 
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8.2.3 Calculating bond angles  
The behaviour of the Phe-112 residue was examined by tracking two separate angles 
(using the ‘angle’ function). See section 4.2.1 for more details. Briefly: the rotation of 
the phenyl ring was tracked through the changing dihedral angle between the Cα, Cβ, 
Cγ and Cδ1 atoms (Fig. 4.11). The position of Phe-112 relative to the entire protein was 
tracked by the angle formed between the Phe-112 Cα, Cζ (at the tip of the phenyl ring) 
and the Cα of His-106, which was on the same β-strand as Phe-112 but at the other 
end of the protein (Fig. 4.13). The distributions of these angles were measured both 
over time and as frequencies (Fig. 4.12, Fig. 4.14). 
8.3 Results  
8.3.1 General observations 
The pressures, temperatures, densities, constrained RMSDs, volumes and energies 
(potential, total, kinetic) of all six simulations (three for each subunit) were stable over 
the 100 ns duration. No large motion or unfolding was observed for the simulations, 
except for the C-terminus, which was very mobile (Fig. 8.1, backbone RMS fluctuation). 
Subunit B appeared to be slightly more stable over the 100 ns, with fewer sharp peaks 
in RMSD (Fig. 8.1, backbone RMSD). 
 
Fig. 8.1 Backbone root mean square deviations and fluctuations.  Simulation 1 shown. Simulations 2 
and 3 provided similar data. 
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8.3.2 Phe-112 dynamics 
As described in section 4.2.1, the Phe-112 side chain appears to be flexible in the 
enzyme site. In all simulations, the residue aromatic ring flips, suggesting packing is 
not especially tight. More importantly, in all three subunit B simulations the Phe-112 
residue rotamer changes conformation, adopting the conformation observed in subunit 
A. Subunit A simulations show no changes in Phe-112 rotamer conformation. Overall, 
this data suggests that the conformation seen in subunit A (at around 65°, Fig. 4.14) is 
the most favourable in solution. It is unclear whether the starting subunit B 
conformation (110-130°) is a crystallographic artefact or a conformation actually 
accessible in solution. If it is the latter, then it would be expected that the exchange 
from conformation A (65°) to conformation B (110-130°) can occur, but this was not 
observed in subunit A simulations. Longer simulations may reveal this exchange. 
8.3.3 Phe-112 mutations 
The mutant F112L was designed to investigate the Phe-112 residue. Full examination 
of this mutant has not yet been conducted, but it was included in substrate screens 
(section 6.6.5). This screen showed that the mutation F112L does not completely 
remove NCS activity, but significantly reduces it. The effect of the mutation on enzyme 
stability is unknown. Interestingly the mutants F112K-K122F and F112K-K122L show 
some NCS activity, but at very low levels (section 6.4.2). 
The position of Phe-112, adjacent to the catalytically important Lys-122, means that 
although it has no direct role in the enzyme mechanism, it influences the positioning 
and environment of Lys-122. It is conserved in all known NCSs. It is likely to help 
maintain the pKa of the lysine site chain, which is vital for the reaction progression. 
Based on preliminary data from mutations, however, its role does not appear to be so 
vital to make it a necessary residue for the NCS reaction. 
8.4 Discussion 
8.4.1 Phe-112 conformations 
If the two different Phe-112 conformations are real features of the enzyme in solution, 
then they would have significant impacts on the enzyme activity. Docking investigations 
on the two different subunits demonstrated that the different Phe-112 conformations 
cause very different binding modes. Preliminary experimental mutation data suggests 
that Phe-112 is a very important residue for the enzyme mechanism, if not vital. 
It has been demonstrated that NCS has relatively high apparent Km values for its 
natural substrates (section 4.4.6). Non-productive/non-binding active site 
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conformations would result in high Kms—there is a possibility Phe-112 conformations 
could impact on this value.146 If this were to be the case, then many questions would be 
raised regarding the role of residue and its conservation. Perhaps the high apparent Km 
is favoured due to in planta metabolic control—if so, the unfavourable conformations of 
Phe-112 could be evolutionarily favoured. Alternatively, perhaps no other amino acid is 
tolerated in its place (adjacent to the important Lys-122), but the unfavourable 
conformation is a necessary but unflavoured consequence of this. It is also may have a 
role in controlling the water channel adjacent to the residue. 
8.5 Conclusion and further work 
The MD simulations successfully demonstrated that the Phe-112 observed in subunit B 
of the Δ19TfNCS crystal structures (2VNE and 2VQ5) are not stable in solution and 
decay to the more favourable conformation seen in subunit A. It remains unclear, 
however, whether this conformation B is crystallographic artefact or a real feature of 
NCS in solution.  
If the alternative Phe-112 conformations are real, they would impact substrate binding, 
as suggested by docking studies. If this were the case, in order to improve the 
enzymes’ apparent Kms, the Phe-112 residue could be targeted for mutation. First, the 
alternative aromatic residues tyrosine and tryptophan can be investigated in the 112 
position. Secondly, improving the packing of the Phe-112 side chain by mutating 
adjacent residues can be attempted—hopefully fixing the side chain into the favourable 
conformation.  
The motion of the Phe-112 remains a hypothesis based on MD simulations; the only 
tentative experimental data for this is the X-ray crystal structure electron density. 
Experimental data for the residue motion could be obtained through NMR 
spectroscopy, perhaps through specific labelling of phenylalanine residues. These 
NMR experiments are not trivial, and would require significant time and resources. 
Slightly more straightforward experiments could use fluorescence methods: either 
intrinsic fluorescence (perhaps from Trp-61, which is 6.5-7 Å from Lys-122 and Phe-
112) or from FRET probes. Ideally these experiments would be done in a single 
molecule manner, to identify discrete conformational states. 
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 Appendix B: NMR spectra 9
9.1 Triangular cascade products  
From methods section 2.6.2 and section 5.4.10. 
9.1.1 Norlaudanosoline 
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9.1.2 THPB 
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9.2 Spiro-1,1-THIQs 
From methods section 2.6.3 and section 6.6.9. 
9.2.1 4-Methylcyclohexane 
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9.2.2 4-Phenylcyclohexane 
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9.2.3 4-Tert-butylcyclohexane 
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9.2.4 Rac-3-methylcyclohexane 
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